var title_f36_32_37376="Osler Weber Rendu";
var content_f36_32_37376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral telangiectasias in Osler Weber Rendu syndrome (Hereditary hemorrhagic telangiectasia)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 339px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFTAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDoLicrIisQd77MnsKtEKpcAh1A6+oxVW4Vmlz5nzjnGB+lS27pLtwfnxzgdK83U+mYiyvFKnl5Iz0B6/5FXoysjyEZCEZPQYPtWVaHacYHDYBIODWgZykrLtGxzkD6D19KEKWhf80CAKVDBWDbh6UyNzgqchOMk+vaoJWXyJBuZM4+7xnnpUZnYADcC4AYAdParMlEW4xbOgj3B5Dj5RkD3PtTQxO50O/YOue9SSXUccUbOvzPw+TkCmAYiZYUbbyc/Wga8ySLq77zlgMD0p0NwwDFQCmOw71XDyxFPLG2PoQ5596lZtzlYhhO/apvYGriuiGVJGUdeDWispP3ADxxj1qksZABQiQdx6GpUBPVdvHJAoQPUuxykLu+8MdhxTXZpRlRkY5zSIoVAu75W5xmlfaF5BA7Yp3ZFikZDGxLuoyeAo7e/wDkUm0SE59MkDoaJCrS4K5NS2zAuQQAPQ0jW1kKiIFQkYwOB0p2dpyQMdBz0p6AMOV5FNSNhk5JYnv6UEDGUDJyD6tQVJdMKWDdwKlCAqRnkGlRSOCTkfrVBchTcq5MeGz39KlVggct1zgAUMScZGcmoiBvwfvelJuw7XJBcKZBHnJx6c055sEhA3TFMVdrE4PqfenCYMpPoKWoWRWZyzHd09KjZd0mB90VPNIpIOMDFQo6DHAxS2K1Gn5SDnkdDT9xIzz1psjAsNpx9akaRSFUcfSmgaGSYwAVJ57dvrVW6Zt646dx7VaZiQdq8djUfyH2YcUXuJaFWSCCRcg4I5xinENJyANoHA9amdYw+Vzk1LE6gFXIK44GOlWmDbKtoEjnAEbdc5xj8KkZRJdBnOAWyalEw8z90qk7cAk96rCQSOWOSo6npS6C1buQ3CeUJDGWOW6HpmoBMz+YPLOWIViOhqxdAsyomAAMnJzk1FbsIgRIQ2MlsHvQWthtvIyuyMcL2zxipdzR4jibdwTn0qi21phvcbG5I64zVpljeTEbnA7D0ouMmMpZtrBdoAGBQHREO3JOeOOh7CkkkCsWA+bOAoOeKggeSRmLjZErZBI60mwRcVjtCyLtZh06ZqB2AlVm3BwNrNupJXIjJLHJOF7mo4WLfOy7MZyCc80hk0jlhzICQdufXH+NV5NqPKpOCBuHXn8ajG6dCd5XYwJLcA/SlfYEiQspO0luOQc96dykrEyXambbgggg5Hc45FFQwxoXBD5ZRknPT2ortwkpJOxEkixGV+UsoBBznr9acDEk6nbsBPJPTBPX1NVXDFZGAQEY5OeQfSooZmAdHcgpghT39vpXCNo0VgDAorNlSeOmPTH/ANenRypFbogkj45VgOTjrWSLlUkVAxBwSMdPwFPgu8qZAjBi/wDDjp0NOwmjWlcSREjIc9OfWq0a5bcH8lDkFe4NV/MlXCKv3V+px6U4u9uytcsDx0VcjH4UWZCaRZRWjLIvz/MDtIzn3qSBpomXdICq8lemBVSS9hCeZvaMDlTjmpIZzOF8t8KRk71xx70gvpqWL67iG1jll7FOQfrUsT7YV8tQSOQSeCarwtGMrAoGTjBq1C2wAMVweg9Keu4m0lYsW+5VV2Byep96swFnLAnOeMVUWXYhReQPWmm6wDtHzEdqdmTozQIUqRuFRTSeYQDwV96rwTMyFioGPSkDMW3FPxNTqUrdRJUbquQD1p8a7huBxQck/TkCo0kK8A8+1GqKumtC7a5J+fHIxSMdrbe+cg1WSYjJ4yOtNnn3jIXk0XZKSuWWcs2BgcYpQ/l4JOST35xVJHYDcRjFK8jMh6bj3p6lWiaMgLKCDgdarcKTu5x2qp9sdflYZ4pkl2AuKQ0jUzkDOMdqhJWPJ3Dn3rEudbjQ7D1HoayZNaMsjbD245oZpGk2dZJHv2ksAAOMUksPyfL94dxXPwasQfmJ3YxirCa0FcEnI6AU7dxcjRfaJwMsOR37UhzgYzmqp12GVSmMntirVvfWsjLGMBgKVkDut0TrIxjwe3ekVeQSMGpUePaefrTJXRFBAOPSqs0Z3QgTK7ufpTGQhCFPfIJqvLdGNPlJ3fpSLddMZP8AjSY1EmG5XGQoJplw0iKjQhTj7yinxSo+4MDxznNRkR4LAHrnHrQri06kZVpFYlcJ1qnOgL5jLBu2Oh/GrM8+9wiF9v8As0SOCpEfHHzE9qNxrQrGBmT+FcjLBTzxSojGBPLOM8HNKgRSkjtgn07/AFp0Uw3+YR8vTPoaRVxVV4oy0pDFhgtjtTx5aQ7gTsB4DcZpks+GJi+ZVGCWHFUgqsTJPNwP4ATg0+hO5d+RQAGXluh6jvTGnXLKVMkmOuOOfeqySAqFUDc3Vj6UyRyqEiQfe+8O+PekmXZFuS5CJh8kY6AZ+b2qveTtKo8leSAA3HXvx+VN80yJK/zADlAx5xTLdkRAi4Dk7iM8jPai40ki9DGkJ2OpBJzxzRRGolPyPubO360VrSnKK0V/v/RkyfmNlk3tuYbc/wAQ5qGW6DBAZBkrtPHYdKZdhlHDOMj5SOh9qzBK8yhZN2UztA9vb3rIrlurjpC/24nA2EAbl9f8alEc1rc+dE6uqn7hOSQR60y3kSWPzQpZR94Hn9aVTGgV4eGTrkn1/WmJvoaiSeZEr5CHbtY5yQR2psaTR27fvvO2ZJ3Dk1DFJJ5iERBmkHzLn19qfHgSMokcf3QOVouY2LMU32gIu3ynVeM9xVlhuXlOg9MVTjXylIIBwTg1cE25gHbcuPTrQvMT8h8ZSRcr1QcjGPrVkndBv446Y7VUUKrfJx3ANSlwkZycd/Y1SJaJS+08DnGTULSiKHJI55NUrzVI7WHJkBJ6CsiTU1eEsT8ueO9K5rCm2b0Work44zV+C9iZSSQCK4ZbpklBzlR05qQagyyEZwW9qWxrKhc7mW4QKNrY71FCyHPzLk9M1xbao4BDNUEOsSLLkSdKbkCwzsdwMl8EYB/Wr2ENvkYGOM1x6a2zFckHuTUsutvGmAcr6Z6U4siVCTN+5lUIQzDavSsK51ZYZQEOR61i6prhlj2qcZ9KwZLlyhJJ9uaR0UsPp7x1D69um2N0PpVe51pwpQHJrmBJnn9KdJOzsM4AoN/YxWxdubzzHYlzk81BBcHaeckmq8YBc7jweaVgABwBmlYvTYvi7cPwQR0zU5leTbg4NZiEY5YVbSVd2N2cVSRnK3QlimZJgjsB3zUpuJFkLxNzWeZw0hPXPHSnLclEIOAD0Ipcq2FY6qw1cbUBY7j1ya1l1KORQpXaa86F2VlBHY1ci1MtNxnPeqv0MpUE9TuFdJpflfGO1ORvlVhggcEVzFtdgTDcRtrUivsuFU7QaDGVNo1d2G4DZz2p7PIOOBx0qOGUM22PkjHFSMF3KzHLDHFKxi9yKNF2/MOfUVBcLHjC5AHJAPWrBLbc4HHPJqBf3m4Ywc5zSZS7jmhV4yqH5mXnPaoNrICgGcd6n3s2Cyjj+VJgeYsiuME5yaTQrkM0rK20jYAMhetVWidgVOFbPTsatztG6lMkk98VGsTQRqjSKxH4YoGiusIaViZCARwe9MWMQAtIgIPKljgfWryx9yctzgj0qE2qsMFi6jqSeQaVh8xAI2kdhGcE43A9KCqpMd2SgHOOme3NOKLFdBmZthHJx1Poar3Mji4WNgAjnC+nPTNVbqF7liCZpZI/I2iLO3g4zRTIS3mpEgjVAeSBndzzzRW1GKle7S9f+GZTbQryNE5STOByp6g1DKwEseV2u2WJXpzio/vhSGIDYBXFMi+8fN5ZDwGHb6Vz20NGWhEImUJHkfex2p++JlUSMrEAHA/rTXnbymMDDOTsXPFUXYv5ciDYxwfShuxmlfc0fM8w4QHbuwGUcH/61WolYwjGflyGPTPsKq2rssK4AZSOR3Bqz5jo6/KNjDjuaF3ZDXRCxMQmZF2M44C84qwsz/KhKDb0AGKrXXZclS3TFKh+QDKgsOSaYW6l+aQ7lZ8IDx9KyNS1IbiqH7vTmqdxfvGHDMfTJ5rmLvUGNxsHK0nI1pUdTQ1G4dyxUfL6VXgZhAcnioBIZU5+nNOjcBCW4xRy9Tp2Vi4ZG2Ahh6c8UOoYEkneOlU3nTZwSSOaje5D8sRx2qgVyzI7DGfTk1CHw7YGfpUMlzgcnPFVJbjDEluvpSsaRLpu9rZGala6JGD0PSsFpyeValWc7QeCRTL5S7dTtzz3qJZSY87sVHI5kizVQSMoIbpTHfQ0BOVTKtgnjApZJjtTJzn0rLR8jJ6A1MJsleOAaBM0opQc7u3SjzlUgMfpVKORsnHApCS8gB6UCsaaDc24fdHelic7j83WqTSFY2II/pUf2nYN2R0pkWNDPzfexjpSGU7gHxx3HeqCXIcDPX1FS+aDJnqBUjSJ25AGc84FPhKhvl5bpVeSTa6lT9c1JHMNx4x7VSGTiU+cMMcjrVx9S2MgY52jHFUFIX5gelQMcsGXpS6Csmdnp+pKRvU4B4xWva3e9gSyn8a4azkATJJUY6VPBdskgKMCM5+lDZzypXeh3rPgsOCOvHU1UWRfMbaSD1rKttRY4JK9MVZt7mMktld+OQaLmHI0aW8NhV7dqdFE7SnccAfdWo1lyMbsDruFMnnDrhmPIwfakRYFhDTAq3AGeO9SGNFQKRnJ9elRxEIoVc7iBge1SlcM5Y9ffmpE9xjNsUhR9WqGKQjllKEnknjNTIjM5bdlT61WmhWZ2DOAQMnnpRuCsQXPO9VOCRjDdCagtwVZVk/esxwQOwx0z+tMad1d4JBtUkYz3pYBhWZSQxxj0p3NLWRahkjV1jK7T2HJB9qKjjZ5JhtXgLknpz7UV00KkYp3E0VQxc7DwwPamqkvnAMdwb+InJJpWWNdzKzMxPGRx9aZ5jdFJIQgkHqfSuQ1dyxbwqWLEfLyAQelTRxqduZOCOF9v/10yDa2zaSR1IHUepz3qUqCMYKgdGHUf/Wp2MmyeJQi5BXJGAPWnb8oNp5HX/8AXUZBcgYODxn096GAj291I6nk0IS7iTTmVowuVK/pVbUboRRBAVOOBSX0kaxlUGCawLmVg5DdPc9KGaxjcbdXLNkjI7GqMgDNwORSSzZkIY8UxJMnjqKaRutCRrgRAA8/Sk84MmcnJ79KrO3BJxiq7SBDgdKYxZZGRzg0zzfm5OPSqk9xzt6D1qu9wWHP4HNNIrmNF5DsZQefWoPNdh8wIqvDdbjyQGFSibLbD0p2BSDeN/ynr2p0Mg2OT1FVrhWjbcBxSNIBHlTwRRYrmuW7W4JQqc4pjnBYnpWdBcGNmU8ipGuSykcc8UWDmJklBBI9amRwIyxrLRiuR2NS+eSu3oKGgUjWilYjAHXvT7mbayBeCRzVKKdBDjOGqtLcEy5LdBxzSFc05JdgUE8Gopp1KfL3NZc0+4glulQtIWcZPFVYTkbSSgDkjOKsQyqGHIyeuawY3IbJJqx5x25/WlYaZqtPiUADOKmSYAA+9Y0EuXy3NWGulGBiixVzVab5W29PSnRSblx71mpMjtw3HepYZgJCF60gNbzF4APyjqKmiYKGIHFZaycYzj1NTxscYzgds0yTUjutmNucd6uW9xsdWf5mPO2sBZMMR6frVi3nIJJHPSkS4naWV4JVZWO1R0yashlPBBCn0rk7K4ypXdjHfNbNlcrsKOpYA5J71NzmlCxqwDZIxjyT0ye30qaaNuCG5x3qnbugXI6Dpz3q0JRs7ZHBosZu9xV2xws2PnIycnp71TknQA5cM4HemzSB7eVd7bzyMDpWWoaaFsFuBzgZxR6DjDuPb/SpCqgcnJOOT9KvQyR27kuDlePemwWQj8oo3mBjnaRnnFPLxRj5gofOB70IJNPQDdFHw6kAjAIOevtRSRRblEjIWXPRqK3oyir81vn/AMMyrFMkpKFRmJUDOR2p7RM6EjncxLHuKhhuZZVOxsKG4BWrXmSE7WGcDqo6Vz6BK6RBuMMS7DycZB/nWra826qzDYeh9DVCSLK4xxnPpmrEQVQu3cQRkg9qNtTN6lpU2e5HII71BeSBoSfusOmOuaexOwKDg9jWbfz+XEQTgHnH9aEEVdlG5lyvXGO1ZFxLuY8nPelupiMshzz61T84BiWPJpo6YohlY793qOajaXaMYFOmbgkng1S3jfg800aE7TZQjt3zVSSYnpyBUdw+9iAcEVVaSTB46U7C2HTNye/tVSViOhz7U7zA3XioJCTnYOfWrRMnYUSknI4IqYXBIBY4I6GsVrgtcPHuOR1x0pNz5xk/nV8pzfWF0Oma7WWMAsM4qk0mzODxWfCrEjJNWoo2IHBJqLWNVWv0HZJqSJPMkVSwUMQNx6D3qVISCatw2xYdOtJtCc5GVq0c9mkwyAyfjkVFZSNNbxuxyW61s6xAJYH458vBHuBWD4ccPHJEf4TkfStN43OZ1ZKqlfdGlsJUHn6UkkJxx1rfgst8KtjjFRmBCSO/pWdzo533ME25wPWo2hI7kVr6jLb2Ue6aRR7E8muYvNZ3yN5Efydi/WtIpy2MalaFP4mWyzoc5BpVugvDAisR7+4b+PH0FQNLI2dzsfxrRUu5zvMEvhOgXU4OQHHFH2+CRuJAK5yk/Gn7JEf2lU6pHWR3SnGxxVmG4KkHOTXFhiOhI+lXLa/li4b5h71Do9jop5mm7TVjt4rwFuOTVmK5yMH8a5KDUYpON2w+/FX4bkJg7s5rKUGj0IVoTV0zofNBB6gfWpYpiM8/SsZboFc5xTlu8Ec1FjW6Z0tvJgg9vrWnFcFV2g9RXMWt1nknmr0F1hlJ6VJEo3Out5yFVc8d/atJ23xgJ0J6+/vXL2swfaF71sx7tgAI+Xrj+VNM55RL6o64yu59uOB2qaJdsLEEiNuSo7E+9NgKhOu5yuAemKA+fl3luOAKRD1KiTFVdWZcJwGx1qRLdSu92APGAfXqDUs1msrI27JP3sVN5O9QgyGYdu3vSSBtdBUOEAcFlIIxRUULbfmlXJ6D0JooXmVr0KBhCAiM5TOD7CnTSlGTJAz0Jyc1COMlWOCTkEdKnlX93GuQSPU0bikMZjvG9Cyk8GpFl2syjkD0o2l/vDYUPQ1CXUPnjigzRNJJwHVunrWRq0wkzsPuQO1XJmAUgN05xmsHUJCpIB4Pb0osXBamfK5wRzwapSvnOWqSaQgHdWfJIw3nOc8E1Z0on88ZIbOMYzjvVSadVbCHPtUMkvzDjHtVZySxYgkU0gZLIwYc5U1XaTYD83FQ3FwsCkucD3NYN5fSXDcEqg6AGtIwcjmr4qFFa7nRKm475ZVVeyk1VvtSggiKwMskh4GOQPc1zhJPU5pOlaqiup5tTHykrRVi7p2ZLhy3JxkmtDyjvX0NYkTtGwZGIYdxVxdTnCgEIfcrTlFt3RNCvCMeWRvQRcjvWpa24zyR+NccNUuQOCoPrig6re9p2X6ACsnRkzoWOprozvhAoycjiprR4w20446V5rJe3UmfMuJWz/tGofNf++//AH0aSw76smWYLoj0HWr63toJmaRPMKkKgIJJ6dK4fTbxrO6WUDI6MB3FVCeaK3jBRVjjqYiU5KS0sdzF4xtIrYIIJmccdhWBqHiK7uZD5OIEzwF5P51iijNEacUEsTUlpckkleVy8rs7HuTmkNMFL3rQwbvuOpKKSgQtNpaTrQAtFJRQMX0qWGeWJsoxHt2qGl+tFrjjJxd0zUh1UgAOuPcVoQXiyD5XBrnO9GcHIPNZummdlPH1I/FqdjBcdgau290w+8a4iK9niPD5Hoa1dOv/ADWw/wAr+nrWMqTR6VDHQqPl2Z31ldFQNnBGK3obtWgwG+c4HpXCWt1hRyc46Vv6ZdoSpGT9e1c70OtpM6+G4BOGHCnPXrV9CzSFgcLjIrHsmEmc5A6E5rVWT94DkDAxnHWkYSL4UCIDGTxkkH+lMiBjlZlbchHIPAqFJNsmMk5460TkGBiud38qZmWGaKOJTtCg9OMUUsBUjyiDyMls5NFK5psZcEJ+z56s3JqQtiQB0AI9uTVGxmO1xOCrhj06Yq1cgkY6qw/EU0TJEknMbbs+n0qpc5AUZ6ADFWsB4RlshfxxWbKSDjIOPWhoiO5BfOASO5rBvZeSMk1p3kh2fw1gXr5JYdKaRvBFaeQ457+9Zs7Y9afcPyOT6cVVZuTuNWkailiwJz06g1mX96IE4PzHoM0uo3aRKfmDMegArBmleaQvI24n1ranTvqzz8Xi/ZrljuE0rzOWdtxqOlOKQ1ueK227sTNFLSUALQKKUdKYCUUUUAFFFHegAPSjtR1ooAKBRRQIXvQTzSUGgB2eKKQUpximAUmaKSkAvegUUDrQAClpO9FAC0Z4pM0UAIacjlGDKSCOQab3ooC9jUg1OZmVWVT7jiuq0S63Beepri7Fd0h9q6fQn2uyA4PBBrmrRVtD28BVnL4nc9K0rLxAiRCOOCcc1tcMw+b/AL5PH681z2hnKgY3nqM10KKO57jKciuRbHVPcmmDRkEEZB5C1JDeRxqHYg8c4/8Ar0yOEljyoB7k4IpkdugkRpSCqHJB5z9KdzOyNKxdJPnIAB55/wAaKkmETlQC4THOT298UUrlaMwzGoCYwGOevBNPlBaMbRgDg5HemTt5t6FAwjdP8KlniaMGM8N161SYS2IhwNhbauM/Ws+6yHwoOQKvHc8Z3ZwO+OKqSDGTjk9DTYkYl2xRWB79qwbyXGRnK/zrc1Dh3ByT61zt4CCcdT2NJM6Iozp8E9wDzVC5kCJnA3dhV2ZsDHJNZt0jMjk+lbxIqtpaGDM5klZmOSajNOYYYim11I+ak23dhRSmkNMkKSl7daXFAxO9LS4pdhxSHYbSVIEyM0ojPpRcfK2RUoGamEXFOEZFK5SpshCE0ojqyicipPKpcxqqN0UtlIVxV3yucVHJHihSFKi0VPakPrT5FwabVnO1YBS4pB+tPVSe1AJXEAo21Kqe1LtouUoMg2mgCpttIRxSuNwIsUhxTyuelNIpkNCYpcUmKWgQmKSn80BdzADucUAX9MiPllj3re0ZQLtSTjtVO0h2xKB6Vu6JaF51IBODkiuWpLc+hwtHkikd3oZZkUMDwMdBkCugttkiMZGbdnuAKyrO2ZYA4RSQM9MGrokKPGiKSZB06Vy7I1nq9DTIVkZSmxgOcnB/nUKbnlJO7IGRnjpUtsGZ/mI49/vU6aJvNVgG9xngUzHYWRGVlZC7AryAOPyoqXzHJ9GxyB2opWvsaLzM2KAO3UZHPNTXCfuVc4LDgg96jClZGGclT1pJZXZsLj3FUiJpkRP7s5C7ceuKoXJDBcZ5HFaEiK0Xz/e7dqzPKLOcudp9untQ2KJlahD8pO7n0rnb1ChLDqBjkV111AShAIPvWHqVqwVieaF5nVDY5Yxk5J/WoJY8g+netF0Pphc1A6ckHpWqYmjj9Ri8q5YdjzVWtnX4cFXA9qxq6oO6Pn8TT5KjQHkUmKXpRVnOGKeq5NKq56Vbhh6epqW7G9Ok5ESoAMkVMIjgelXordnUhAOnNSrbkjaOtZuR2QoGesBPQCpVtyK0ktyCOAam8nAxjvWfOdEaCMn7MeTjgUGLGOK2PJwuMUfZRjPWlzl+xRlx2+RkCnNAQeBWg0WMAdaGhKtxyMU+YfszO8gqpbjGagmi3DIFaUi8f0qvsbDHacDr7VSZnOC2MWcYqDHWrd4PnNQRxlzxW6eh5NSPv2QRKfSp1QVNDAWIUCrQsyOo59qhyOmnh2UgvOKPL9RWtDp7lhgAZoexZWYZ5B9KjnNvq7MgqQelIY/WtU2pxypzSNZOe2PY0+cl4dmO0fpTSvFXpoCnaq7KRVpnNOlYrMKTGKlamn3q0c8o2GGrmlW5muM4+Vapnmup0KzMVsC4+d+SKzqS5UdWCoe1q67IsQQdOgHvXTeHLQm4RgTkHAGcZrOghGcY7V1nhu1Mc8eON3TJ6muOTPorcsTr7SNliC5HBzuA6imyW5lmDgZKjnj9KuwlXjIIIPGcHv3p8kWOIwm085PFQ9jgvZjI22qNvUAYxzio2LFiWL5HONp/yatIoSMLuHHQZxTPMjlblyX4B47+lCEMTa0Gw/K5xxjH40VdNqGy6/exwM4xRS5TXm7HNQyn7SyA8jrSXRZGVgecVKsWy5aRQMsMH2okZATyOPWhaDlYbaSbyGKYPTmkkTz3wIx0xwMVHBIGPOAM5IPerayiThz8yrgZ9KdzO1ncoTWsmNqlSucE54FY2pWoUsudzYxwDXRS4HJBZM4P1rOukwuSSS2eAKSZ0QZw00JXII5z0qrLGMcZzW9c2u4u4HfAFZ9xCVJ4rRG1rnL65BvtnwOlcsVAAJIz6eld5epmJhiuJu0C3LqB0PSumjLoePmNOzUyA05Bk0hFWbSFnI4rZux51OLlKyHwQk9a17S0+ZCwbDVZ0vTjNIoxle9dda6YFiQKikK2d39K5pTPZpUFFGLBYZYgLgEZz0pgt/LJGPXkV0/2KRxgDCZ+lOmtcxiNYgoBrJyOqMUc3FbnA3fd605oVB+7gH0rWaxYBiQVIOPrUktjEqxmMtuxlt3c0rl8phNb4xlTk/rT47ZcfOSpraNu9xLhFw6jHFR3lqxcbyAyjGfWkhWMURYOOv1pjwZIC1o+S20u2Ao461RlfnAwKtEWKcioqsrfeFZ88xjidFY4Ycird6wG4E1BpViL25JnyLcdx3+laLzMp66Ixkt5Ll8ICRkDOO9bUOiSx3YjjTcwHY5FbNjpSJLtUbEB610NlawREhfmbuT/AEpSqdiIYVQ1e5ykGluM/uypHWrv9lhUXY4Yt2xzXSRW5dn6qAccjrSyWxjAQ/Oo54rJyZ1KKRgRWBQ9Of5Uw2DySnblmPNdDHbPnKo4ZRgd6fDYnIEhEfpnj8KE2Fkc2dNYMVZRkUstgSvQED1rqFtAGOFCnuTU8enqvysoIJB6d6E2S7HAXVj8jMeCO2Kwru329BXouoWYBYBQQT9a5PVLYqzAr+IrWMmYzpqSOUkUg1ERV64iOTUMFu9xOsUYyzdK3UjzKlJqVkifRLI3NzuZcohyfc12lvb5wAMAe1M0fTktIAvty2OpretE2FlVRJu7Y61zVJ8zPbwuH9hTt16le0s2kZW2legz2rvdAtoltQWIO7gggcY96wbC2MuzG1U6gN6+ma6PSoDAP3jFVzn5eRzUPuOtK6saUcSBDycjue4qTCgh87hjB4poO8rxhM/cAp5JBCqCpHAb/H1qTjY0qWBDYODxwKj2EsAzMqFuhOMGpSmDxKxx1zTQN+MgbgOQaNxkoBbau5hx0B/lRTo8hgZPun6DmiqhT5jRmCr4LF+o/WoJizXGQvA6Y/nVwRYYuACMVVkyJ2J43elZoJEdrH5c+ZOQ2cHPT8Kvqkb4Ofl+nWoo5IlypOR1BqaSRCi4OBjrinZIzbbY4xKCPl46HmoriySaJmjBV8A5zjFR+dtk67lPerkZUsHGSBx060r30LV0cjdwSI0gkUfKcZWs2WAso3DLHnFdtfQ5y2Aqe4zmuYnQeeTnOc4NXFW0OmMuY5i+tvkbA5rgNYjKXrcYzXrlxDgMNoJx6Zrzrxda+XNvA6Hmt6TtI5cfT56Ta6HNkc1vaNb+YVGODWHEu6VV9TXpHhLTBKysw44xWlaVkcGAhduRqaHppVUYLwRwcV0tvYmRQqgKo7k1PHHHAixggE+grRhjRUB4y3QD/PNcyR6bbZSWyWOFux4JNTRacu1Tnf37H86sBUcYmjZhxlegz7+1XISoIVEA7hV4AosJtoyX0+Lncxbnj5cVk3Wno82Qrso4AU4rpd8bu22XoeQvP60ssAIyw3jHGTxj6U2ilJo437M8cu1SRj0HaqcyYuHyGcA/MoGc12U9vuQ7k2nrhTioRBFEjFIm3MMFie9Jo0TuctJpnmzkx7gp52sORUV5occq5WMBgMfKTmuvKlQ24JhhgseMVn3s0mn3UexlMj4IA5HXijbUN9Eed+IdI+zpbywo6RMdjljk5re03TsWVoiJweFGznnvnvWv4g01JbuNmnaQPzIgXH5VqRBv3ZQEbQAFAxgD0pt9BKKWqMn7DJaQOkcaOGPJYfN+Xanabo80hE7lVCsMKWxmuht7ZXw7lVVsttAzg981aRNqERomM53YGc+1K1xc1jOFiiFpJhhm5AXp7VKlnGQowdh43E/57Vct2mIZnQBw3yHqMemKsoVj2h/vE9P60WRLbM2awjikXyyhOfvK3I4qE25379x3Aghsd61mUZJRV5+UZGDg9/51EkhEm4LgZyu7t/jTsK5nvFKreZhC+PTg+vFRPFhyzYXJ52nIz/SrtxMSC4H3ieDxVOUIAH3IRjB6Z9utO2o7GbfuqIRINo5GQOtcdqmGXPTnoa7C+kBjzIOvygVx+qHaWDYOehoKhE5e7jUscDH0rd0PSHiCPgBmGXJ6/SpdI0Z7mdZ5lxEDlR6+9dnb2GFAUKoAyWY4xSlLSxdOkoy52UWsI0tyJSu0rkA5zn0+taOi26vuZkI3DGMAVYEMx2BrcPg8yDr+XStIqDEkmMg8bewpJXLnPSxJaWgk2g5UcE4GRjPpW4yLHGqhsqPu44/nVSwRFBLL9CDyfw/Kr1xKrTooRipGenAolocU227EUURB+ZidpxwKeZFZWO4cHHP8qMlTlQnLfQVIIRIeijvgCoJv3IMkFhjn7y5xyKiV2icqWyxP04x1NWpEDH5RnnHTpVV8M7Lzxznrj/CkVHUvWxE/yjl+jEGim2WVZSpGSeCcj6CitKMOdPQc7p6GQPl3bulQyIA+5jj2p7ncofgEelRrIHDZPAODmskKWxGSWcFUGMdabzI7BSMDtT7dGTgNkA8cVOD8+VGM9eKCb2IISiqS4PAxj1PvVqBtyLtBCnpx0pqgsMHH0I71JGv3gSDt6ihIq46+CtbjGW44H9TXN3EEbXQaaT5c4ITsK6MZ24wAuMnHX8K5/UVk2NtTABJFao3o9jPuIl3uYS2wnChuuPeuS8T2XmxMcZ45rsY4nC4k4wMkGqF/AjRsvXPtTXc2lFSXKzy/T9Ob7WARuOeAO9eweFbERRKHABAzgiuJgtBa6gj44zxmvRdOmR1BGBkD8MVUnzPU5Y0FRjyxNW1hjRTIyAnB+c/yqw4jDLJOw3Y4VTxj0qpJdEQRhOmcDjtUaXDM6jjLHaBwRikNQb1NHYJUOQdpGMDpQztgBlKpgjOM59KSRnKbpSQoY/Ki4I/CoJjI8Zli5j4XcT1OOn6UAoksa5iXO0EnqB1/H8KjDMrBsevy45H/AOuobDc4X7RKVkBxgLk/4VdiaL52LMzcbl+8T6nPagpq2hBJE7To7uUIyNueBn1rNh1GVtTeLb93gMF+WtSd1ly7l1jA/hHcdAD6VAQhZQPkOCGJH8X9aC1tqiK7CtGQwzE3r0way0sVvdRURN58cOCxJOF9AavzqzTLG7oRymFHCe4xTvKjheKGCTzFwdz7cAGh6jWi0ItVjUxqqypJnkqq42juAasGQSOI7RHEeFAz1Jxz+FQo6SJIkcRMynlmPGAOcfjUdhdussckAdHVt2SMkfhUsFF2NaGHy2VCvzBTk5yKWPIZd+ZBjnLYwPf0qCOdReELIDLICSG6Ed8VKrrKWRChdvlZu2PTmqM+V9S220SbEK9eQD+tRTqhwCSvlnOWHQ/SqckYGVkkxIvGV7DHWngMiQ+YTIV+8xILH+hoYuW2zJQysHK/LwMs3P1xVV2++FX5HbKgjketRXDfKPLBZ9wwCcck80v2Vp4ZWBzJnBIboOn86CrJase06tK7kY4GABzj/IrOmn8mbzIlJUrkbx972qZ7JYLPzZrlth4wT8/4/wBKwL7UMQGNUBO7OTwSPT86HpuVGCexHqFwCrlX+XaCeM1nW1it1IHlVmU/dB/matW0D3Em6c4BP3e341txiK1UMxUe57UmzZRsOsrQKhRSN/uO9X5IJjJEYPLJVAvyjr9c1SXUohcpG0gU544/WtUTRmPcJAB1JHX8u9SkmyZ3RAIH8okj92OOnQ59KdbSBHVJGz2GTginxpI3zCQNH1DYwMe4okhK/f6ltyg9APr3qzJ9malkB5XHJA4Off8AWrOQMhuCepzz+FUNNYxfu2zk9eM4q/wXAc5wcge1RJnPLRjmVQBtbJwep70/BMaA5VvU0zDAKyREsSAPoafNGTP6qeo5xmoEVpmeOTgA9vkBqRPmK7gPLbqQO9K+zYWQ4TuFpyBVZUDMcevPNIdxzvgoHXaN2VHFFEkIADEDK88niiu/BuVnb8i35HPgFl4x7dqRWVN44z6ZpqZAwB1PpVaXdEzdwT1rz0Jq6LR80xAxkYJ645Ap8cqABdp3d6iMzRgcjpSBNwU9yc8VTISL2QV3Dr1pkAyS+Tz1pIWWMbWBYHoKsEoUzGhxnk0D2I/7/IHpz1rPmLsp4wMnoetX7gLHEWz8xHGaoHdsMhJUYyeMkD6VUX0NqfcpXYVYwQ2Zjyy9gvY1my4JPQk9627O5MbukaIXYYPGcZ/max7oFJGQKeDjmtHsdMN7GReQRkE5yf5Vs6FN51uIFwrMR87dsVSlgLKAeMjkVUSQ2cy+h4+lLYc48y0OsjuSYZI8HIJRWB7dzSWs7Wzxyx8OgwNwBAPY1WhO+wacAnBwXB+6T2PuRmpJ0WKKN/MwWO1k7/WmZJLY1dMW+1GSW3XLFwTJKRkqOp/HBHSn2unTQagLC3njuGb7zLjgYz19am0Cexks3jW1uPtAO1pjwDn+H27c9eDT9Dl+w6gJPLzL5gCN5mBnjgkfyoS0MpSkuZJE95ZEbV2DYuWcqclsHH8yKoraSRrLcEOqqdmO+PU/ga27+ZzrTpeXDMqlOQnylc5OR6dfzqbVLcXXNmkkyRqu2SQbVcHnp6kYH4VXLdmUarja/U5mV4zas0l1xklYhwSTwf5DiqNy8q3bRNFmJEGJ0bGSRnke1Xb2AI08wBkhUrhgDtZj9emKgkSee2hVZERIVJk+U5PPBz3zjGKlo6otbleO4zMuZBCp25Y89vamXsU9wjiFo8xKX5Yg4B6fWq+pWQvokKI6Ijjc6n5QPT68VbghN1MqKCwCHDEY2gdSR6YFLfQ10XvEFqcRHAZkwAeRjNWdMfM0gihcPJwWlPTHORj+VTrFALWVluPlVgAhUDJ6cfSqV9azpLFLbzTYbnONo46jPSlYV09C2syeYV3RtKxyWA5HqB6U+ORo7u4JXELA7cADr0z71RRXjuVkEqIPmIwOhOM0+V8RnyycjAOeh+lUS4okvdRggSMu4Qv8oVRn8cVo2NkJYj5txFFt4VmBOfXGKxbaO3N2HnGHAACj0712eoXWjadohlMgnumhITYoKqST1U/xc5qorXUxry5LRindnJXsUkF8ELukUn3JucMvrSR3zadGypJHLDL1UHnI6f8A6qvx3Fnerare38cVmoykABIB43FicHJ7cHmotb+xXTtILM2qRSboPn3eap/iII47cflRbqgUrtRa/r+uxiarfzX0hcoQ/A4Py4/HvVK2ssNvclm9T2+lX5GQs7HGFGcDtVSS73REwqSc9GqJHXCFlZF0qiRjb1pwiaVfmUFR37msy3e4kcI4wwOCe351s25dAgilV8dwODSS7hJcpUsLGGO4jaVBuOdsZatC4tVZ0aIfVR2zTxtm3rNGBIP7o6HtUznMKSjC5Uo8eOc+taWMpTbdwt18txs4UYwGPOO9aSCKVGULypPH8/51k28jFog5bAPzZ6/nWrBGONigqe3+etJmEySHKJtClVDE4I/lV07k5BySegH+cVG5EYVWAKHhaRmBCkZ2r0Oc1izF6k53LtUHhRnIPQ0GU+X8inGepPeoWc5GAdhHpimEkkKCD1zz1pAkLLJ5kI25DHHy+gpInKkeUcOeCfaojmJASWO3klcdPT2p0eWVXUnrk5osVYulg4UEDr1z0oquszbh6A8ACiuzCKbT5VcctDKxhwF/Diq8xDMY2B2k5z6VJNnywY+e4qukhddzD5h2rjIZKIBKcMxGO4qFd8E5hbn0Jq1G+1A3GT71WumMkoYL044NK5UexfiwSNwBx696nySh6g+lZ8Ehj2hhuWpluFVwoGST16GncLE8ieaq5Bzxk461Uu0jZlUruweeep/wrRYh0ZScZ9e1Z11iKIs7AEnAI7D/ABpx3HB6mc3mQIxhP7xwQxzgD0qo0RiQPhhGeAT/ABetXJdxjyOFX7vpR5U+pT29uWJmY4wBhUGOmPWtDqUrFLAdckfKB0NVbqJHLBgCDVzU7c2twYROj7fvFD90+n1qg7t04Pv3obsax11Q2KSe3iMcZIikOHz6Vbe4MLRnDy8/eI+XI6iqiKTyc49qljIEq7vceuARg0rhKPU1xfKkHnQGOEFgC4c4OMHpTpvEn2m+TzkWOJRtcxgqX5yST6nHXFQ2FpbyWd7dahL5MKOsMCRqX3M3TIHb3rK0uBL6J7iNzIN2wRkY2uWwq+59sU3foc6dO7Ut0dlpt22p3OyYkoQSsagZA/hGDwasR6itqZLea5VWGMmPBAI6D0NcjdR3NrNDbsGjvEG5lJxgDufSra+VO374M0mwESBuc+/r3pptCdOL9Dfu9TglNqLZWHlL80RJ2sMk8g9+amjmtDbNPNKJ5iDDtJ2bcgE5GM8VzOUhZWe53/MD0xn3qFW3XpuZUDDO9wCMvz/WjmY/YK2jL7KtxAYIEZnaXadrcMO1aGowGK1VlVmlYYfZ0X0Xp6ZrDtb5o4JDFGpXzPvn8eM1pPfF7ItG8qsceZg/Kfw/CmmXKMrogWYIAERTEF+4V6k+/r/hU51GQ2ItGf8AdxtuQHnaeeB6Vj3stz5Lw2ZKJOwYM4yTjsDTI5GeLEjZkyMAdPelexbgmrstiUE78KNqnPPejyLhY7cRphrltiEc9TUEaRSStFNIkQZcrI5wFORz+HPFXotRh0a5C2N19ulicNHcKCoAxyBnrn/JpkTb2juVNesL/Q7uK3u0KyyYIz2J75H8qteILazFlbW9vHIt0gVppHfPboO2OhH1rKu5lu5VeT5mQbVySx655J6nmkUM2Gbt6UNpbFRpydnJ6onNysihIIzFGihVDsXOO/J59ePelibL5bBApgwy4PH1p0Y2nKkYPFS2zTlS2JZfLKYRQAeaqwWQll+TIJ7epp88qwgsAdv9496pQX8st/HHtATPJz/Wi7Y0nbQ6EWdvHCFK75FPzsTgH2x/WqiXCpcGMRYUHAweRUu1wCIgZUXh16kD1HtUIhiZ/NRizMeQTgA5qzJeZbeU72QMd6jIyPvD+tCMyqoRfvccN0P+NV5CqSKJ5G3xjOBjhf60y3c/a4vJPQZBPr6mmyLGqgfy2U7hz09D71dtZZDEGKAs2R/hmsGCG/jvxIX4LEkk9QfWujtWVYzlj/ePHQe3rWcmYzVvMGfa4TB6cGpSGKgjayjoSO1QbCw3MwCN0B71YRlVsq7KBwDWRmxk+6QNjCkYwSetNMLkr83K8tzVedjJJj7gyM4OM1biUBeGZgTnGMYo3HsgLqsbDkk9u2KiV1MiAHa56D/69Rb2Ks33B37mmrtfLIQdp49SKBpFvc+8L0x1GeSPWimK2940jTHPBPWiu3BpWd3+FypGbEXI98VXPmgnIHX2qU7gQVPbmgPtfLVxIxYiMxO4En2xSxqfNOPunsKUfKzBc8jp2qWI5Xng0ikDgBgxGRmoZIi0m5TjHfGKlUl2AJwBmrEbK4+bigd7DoRxncDjio50juICrjodxGffirEITGMZX+tIwUDgEZPJqkyb6mHeSBAPl2jHB/vH1qpavdQ4WKRo3kHzMOwq/qSeZIzL91RnGfyFU44pJGTzOGAJO0/pWiOqDVigx866KQf3tq9iT71ZudOnt7dLi5CxxbigwwLMw6gDPbuaVJo7CeO6A3XER3Ko6FsnnPtWbc3Ul1cyS3Dl5HOScY/Kk7I2jzN6bEq4AVicgdRT/kfJIIHao4Y94IPIxwKlMakbTgL159KSfc1dh6ZiQje21uw7iptPnawm8y2O0A7sHpnHX61X8xNuFzt7AdaWRlVQCcbugI60X7EuCloyzatbSatPeaosszzAKzo/zAAADGenQc0jRu8RNqAkjS/d3cJEc8e54A47k1VUMc4FOSSWFlZWZWU5V1OCD7U09DN0bfCzP8QWcNj5rWeqW140D7JliJBjPrz1HbPrWfaawzkKjbiccdSTV7U4LW6VvOijBcYZkGw/jjrWdBokEcqSQyTAryOlJqL2Kh7VK0tTdZwVQBDEMAkMMHnvzVqxAuHaNZ4kU55dgBVFbeSRpHlnlYvwzM3X/PtSLZwRgAvu74JJpjs2jUvDDaxPGsyXDr8zOGwmPQZ61mQ3fmxSbY2Rj91m+7+I608PGExsU46YHSqiNI2crtGc8UX7DjTdtSUv5xTepwo2gdsfSpQhkx2z2FKke0Bj0qzaL5jDBzjmhl2S2GxxOGACjjvT54ynCn8PSrcoEZAJyOtRSNGybkII6cUMlMqTOUQn+6M1W02eW6dl9OuOgHrU80jI+DHuiP8AEOcfWtLRIEkikjSIBsnfI52qo7fWmlcJS5Y3JLaNI4T5m+VsY+5kD3rOgtVWRUADB2wrlsAGtdbIWpLRT7nbqBnj8KypYlkuWt5CwbqqjqT6VpayMoyu3ZmhciSEKQrI8JCsoOCfXkVBdSQGVDD8hRuSerA+o9qpwTGKNlcM23ghuwqG5nUsrxquSozx3/Gk2JR1LF3J5rSIm5y7bgwHTFWtPjZZFLKXkC4Y1BaMjxLzyWyATwp/rWzFst1BjBSRsnIqH3Ik7aFufYUDHcDj1696dH84U7vk24IxSW8ZdVDAKzAEeozzUpXY6qpx/eI4z/nms27mD00Jkj3fOcgehqGRcRlipB/2asKSIw3HPPTnFQvKkzOxU5zz9KCFe5GQZV53ZPPTHNPJZVAYtJj/AA55ox+8DZwjDNI7/KNzM3rg9PakUNdsZOVC8YQDOarzv5pVY2AByxBGKe7ISyodxHp1z3qtIWDoq8c4Iz+mKVy4rUt27c/exnoR1FFRhCAD05wT6UVtRhKSdkn9xcii8mV74P44pYxu6k+1K0ZRizdqjVjvO3gdc+9ZI5Gy4uByOlISHTDYqOCULGMnJJqZgozjoRSGmOO0ICp5Heno24H3xmmOpIBXnPHJp0bbZUDcD+dMq5YRgmT0HepQQ6HI4PGaiC7ZNxwyfpUwYZwvC4yKSIbMW/TZISgDHPA75qhJ8khVSwKjHzev/wCqt28jIVXJBweRWFPuZmJbA3BTnt/kVomb05XIlhLoiOcFyQSOw71mTwLFdhFcMoHUevpW3KEWQTOm6PdgqSRwMcfrWYzRbjK6qqklQq9cdqq2h0Qmx0EbGQKgYtjOPp149qkl5VQ7YGfyFSW9lJdXltaqrRsXAbb1BPbP9K7O70TTJLWeW2AWaCJAqhsl3Jx0PP8A9ehR5rinWUGr9TkZNPsGtFn06/dp1+/HIu38s81WggRnBlbLAdT2rS1TS5LSUwkHcFDbWHK+1ZTk26FfvMe5PSptys2hLmWjuW2jCsCnbvSyRAqDwMDJNR2FxAHaK9kaJXQkSIoZgew5p4/1aiEtJHj7zDBp7oHdMz7m3SRlbrtORTfJAXapx6kGtHaY5sBc5GRntVxdNaS188bfmbaMnGfpRa4+dJamNb25AUZJ980/YN7Y5NXDGYlYMNrDpVZA5kby/wB5gc4p2BSuQXKYwp4zxkVUUFTwDtBwea2BZtd3CwwEvcFdyqP1zVjS/DrzyzxTTeTLCu8pjO5fXNLldyvaRirtjLS2nuIJoImJSUb8AD5sc02KymtoyJAY2H8J9K6jw7GkehIZYlYHeqOV5yD/APXqPXboXEFlD5eJUj2vIOS31+lXyq12c3tnz8qWhyeoF3CIqEg8M3pVaKFoFKgEx5zzXQjTyZmV3G0Hn0qO+jt7RwFPmjgtgZzRyXNFWWyMlnuFRPLxs27gMZP1q74ctZWtGeVgyKScEcsfamW8VzmK5kMYjLsdpHA+v4VraXcR20kwb7pPOBwD7VaRnUm+VpFloopbJntiUIGM5yc1zOohkmjlAKzL3rT1e48l3+zZUPy4HQe9ZF3JG9krpIWnJ2uD9eMUSfQmlda9ypc3QldZBzkfMPemvFvjALYUZbZ049j69qrQk5kBAJznHoK0rS2eREuCAUBwS3T8BWTZu/dL2k2zeQR5fy9vX3rYgiV9oYnCLjPtVO0mkcGNuSSFUnsK1kiKgAdFOSD6/wD6qhvscs5a6i2kZVQNoBHJ4PIq3NChwwzkdPWoxIvm49Bmn+a2QCuRkY7YHNIwk23ckaIAHdxu4yahWMowBGd3PIxxRNJ5mwtnIbJ9akdpDGd2FBPp1pC1IZRvYgZBHUL6VDIQpQMd4BwB6ZqQgeWcMW3E8CoJI2d1JIXucnmlcuLKx3G+lRQFRI1fPckk/wCGKkUIZBgYep4ljWR8AFyvJx1pjpvmGFwcdDTfcqL1sIVeSRSOFX8qKVMmU54UdTjOaK3oU3NNps0bKkgbBz0HvUCn5SMgValYqQABk8c1TXAc4/CsEcj1RPCP3eDmpg2AD1HrVaJ237SuRjrUqNuJB6DgUAmWV27cNnk8+9HWQ8Fsdu9Rxv8ANtb5lPrTNpRmUcg9aCkWkyoYEjaeoBqWORlQjAwR19aphjklSeRjNPt3YEBzx79xQDRZkDyhhwp9u1Yd/F8xLKfQ1thwfu42nqKq3oDFs8kcEUxwdmc/dMRGw3ktgY9KiWJY5Yd4BVeST3PaproMAoAJHTHrVWcmMuXUkqBkH2qzqizV0qeO1lLyL5k6vvG9v4h92trR9RfUNake5LRpEoMu085zx1+tcjHOzyRMOpXnIyOlaWhuttETuxNIxDA5zj/6/SqTFOCab6noYjXeklw8VxCFIK4GcHnk/wD6q4/XYdPTVraBA727y/Pt4IGegzUb6rJGxt4pMQhPnwMYPWsya83XcLlS7hhgE9e9Oc9LGdGk4u9y5c+G7mGSURQmVQcrwMlcZwcd8VVjt2e7gto/MUv90OuPeuosdb8qwjXym8185fH3VJ6+1Z8dyH1W2ukZAVJX5uST7fhUytbQ1jUnqpGTqjxwFA0YjOACEPGffNFlftA8DXUEn2Qs21/bGDjt1xWxcwwf2kJ5ow5cblXOeea56+jmOLVIwUiy2SeF75osXGSkrMszX0ZtzAVyCxMcgA3YPr9Kq2knlw8OApPMm35vofaotPjSa0EgYhmjc57A4PArU0+0S40hMbYvKQM5P8Ro1ZTcYqxoeHrCC7nkdSNqnKuOD07fjWrcTwNJcPAQ9yqFJAp5x6AVyltZ3dvd5tJguxgSc8MOtJblrfUbhpHJjyVBA6HrxVJuxlKHM73NiC7lltHhh6R/PsA6VXhd1xuzuXJB9j2qDS9QMKQyxRmWaUssmD0GayrzVJW1KYRgqinaq+gp9BqLbaRsnUY0glDcKgIx3JrJ0vUxLpl/lA11H/q891/+tUU+ZJZ+c7gHxWdG42tHEoUuw3N7Ci5SgrGraamqabbIGy8jMX3D8MVWt7+UXrLvCRg7s5OD+FZU78IA/wB0krjpg0kU+H4JJINLyK5FqzodW1xLhlEEQiZuHZe4rDYs7EKrEDk4qANvJ5PsBVu3jLsUYlR02Dv9aGwjFQVkSWtsZZPnzknnA6e9bsMQWA+YuFXjBOSfwqCztGQEuG2n34/KtRLRZFQs3zH+VZNmU5ofpkHIlwQB0PoK1ldgQH6HgkjrVQBY1CoePQVOkjvGy8gY+9U7HPJ8zuKXKMWVfm/zzT1LANuIC9Bg/nzTVBXGe3ORQ0rxscsMH+IqOAf5UE7kjJhMnr3y2PSgDI2uuPQN+gxTCdxb5tsY9BzmnjY0mSwBxyCaZIBdhLhto9RTCFZWMmfm75xT94Y7txJ+lQzS8bGGSeeuM1I0Ee3y885HGSf8+9RJJtdkGCSeD1wKhdmVyvPHof8AOakKl9gjUZ9fSi5aWpLIWQFVwAwxx1JopAWWbL/njrRXZhISknZv8f0Lk7EJQMx5BPeqk2N+McipYnYMef1pkql2JHJHauQ5RozuBOMDrinMNqHbxmoUdgGG0HHr60LJKAQRgc54qhIkiBCAsSSD1pS27BBz7VGGzgsQTUjKWXAOMd6k0THRyAHkZHp0qzvXgKMDHSqi4IAP5VZjVfLK5zxgUDZNEQGVRny8ZyKS54DOTkjHbtUUcojXa2BzgVNv5JBIBHNNCejMq6gVido56jn9KxJtwmlVsnfyC3rmupZQVAPB6gkVkahab97J1AOFzwTVI1hPWzMy2l8loC43bMgrQ9yyyxMcblPIqoS2N8mVbqQRSOzDarD+I496o6Uaf2graTZCZZiSx6/QVHBMY76JgvyqrHJ9cVGkkbs5wUjA3Y649aQnynMoztICjjvQNM2TPJiTa7RybQpVhw3t/wDWpkAlzEGkCzrIGHbOf5VmfaZJJVJc8HGfenNcxxyKuWkk5Zj1ApkqLNSS9I1F5I2OQc8HsKohGnupQSQsuQBnIA96rLPiSU4PzADPrUiysqs4O0kY+tCK+HYubFi091jBGFBXirGm/vruK2DuqSKFxnpxzVVndImGSylcGneetpf2M0TFdqByT3OM02RdtM32iS0029uVVo0ziJmPJPTNci1xNcwCRjtYyYYAdMDirN7qM091teQGMnO0dBVLzvJl2sAVLAkdqGx00477lS0ll06cyMzmInJUd62r7yrmNZYItp2hgc8uO9ZM0kbmQHOCMAVXOoMtnDFHx5blsn3pGkved+pZSdkvVIYj5SOe1UbqX/SXVWGw88etMuL1ZWR2Ubs/NjvVR5FLZ/i7UMa7seM7OCeTzmlh3HbtGT3zTFAK9SW9BV+1bcAu3C+3egbY2MNuAd+nTHatjS7YuiylcDP/AH1VKK2LsCE+UnBJrehCqirkgKOgFQ2YznZWRZjyRhQxWr5IjIAwBwOOcVRU4KgnKnk4NThn2989M4zUs53qAUkgkkDoeatAKyKA+APT096iDMVI4bcM5Axg0xsq2GOcjHy/55pCLi7CyEtuQfwgnHsPrT32FDvyiLwcc/r9KrpIiBvmwzccgMR/hQRnOxwMcE4oEP8AM+TaSWz90kYyKlX5m5XoMAHA7dcVEibRtUYUjtx9PwpwOw5JyG4zjmhiJy21WV8EjvwKgf5s4445AGKkjH7vC7iD7VE2X2qAFBP3sYpMSGOVHMf3fXoaZb+b5zlicnnippNsSZGCO3vVeFfNmOSAx7UbFotJK8hAYgDPp1opViTzAsbZI4OBRXRQqOCetvvHJoylY5GD9KnhfdgcH3NY2lXfnwK27t2rVhQkg4/+tWVrHMxZo/44+lRnlCCRjFTyEJk5696rEHIwAAetCAiVfMBHOVqxuCxg/hUTSBJAAPypryHdz93rRYpEzy4PQHPQ1Ism75c8fSq5I2Dvjp70oAKjHBNSadC45E8ew9V7+lTwsPLyc7u5PrVFXKyds4x9alBAYHgZ7Zpg0TvgrgioLiLK4A+YVLLKDH1PPSomdgD5mCo+UZNUiNUY15bZjZo1LEjJH+FY9wDHg/wE/KR0rpbtFIwcbscHPWsyVI2BRxtPr700zeFS25kzNgjAwvT6VJDO6W7ZJIBzgnjNOu7bDfK2eM81Vk+XKt/EO1M6E0ywsgOxgTwTkD3pI7gxcswBIIOBVMsyw7lYZHHJ/pUEsm5lJHQ5zQWtTTjmRXBPIODj2q5Lcx/IQ43dWJ6AelYIk3DIPQ9aGuN0W08570IbSZtz3hlTEbjYTziobm5ZoYwzEmMbAfasyOXy49q4ximSTk5DNknmi4lFInecYBLEmmvO5XJYHb6+lU2clflB56GondtwOflx0oLuiwbjLZzUbuSWUg4zxUEYPQnI7VNtywyOtMTaETaysCcehNTQxFuoH1pY7c7t2AF6j2q+JY4MEvuOO1JszlNIZBbEZK4+taNrbLGuSdzZ59qppc7gAq4+nartqzYBzgHrUNmUptl2MkjHGB2qdjtjGR0OeDmqyMCeOP50pZSQBnOecUjLctJPkjcfl6AY61ahbIwW+U+9UQiLIrk/hViKRVz/AHTwMetJDZbLYTEbHjqOtIXZW2AgAjncecVWDY3FWwD6dak3MG2uBtHPIGfxoFYm8wo2ZcAYyOPap0ullUBYgvHLDOWqtMVb5VHAGMMTiiOPhQMjnJJPNFhGispYCND8oxjHGKaWkMu5gSnPVu1RpvZgI8nu3Hb1p5QbyH9OgxyKCRJJjtKKS3bjipoZN5KgIABnnrTX8tCd3zYGcE4OKhdmSJmACkdDzkUhpXCeReSowRwQTmiLlRkLuxu3eoqCPMkxUHg/pU5MXLZT2AzzTKtYerx2x38kn9aKrTseC3K9NntRWtOcYqzBwvqcF4O1MOixk8jpXfWxHl5OOe9ePeG2ZJAyivUdMnLwLu4IAp1I2Zw05c0Vc0yN7DgD8KhuMD5R0FPEhVfWoA/mNz0NZo1IWQK3J5+tPTBOSPzpNirLnrnqKezEE5AHHbrTYxFGCR27e1OU7TyuecZ9KFACAnvUqgMrcdeuaktMrNuaRueP4T61IxIjweeeaRsozDBPofSgb9rbjyKEaDxIQpByFHB9qYzkqcdKCdoOMc00tnPAHrTJZE7OykdBjniqMiByQeTVuRwx6AY4z61TmyhyvIHP0pXCxVnRkAC8j0b+lVHeLPzKcjqKvzvuUEfgRVK4UFcHAzVJjUmirPGrKfLKbT0weRVV03Acc+9LMu3np9KpO5B4Yk1RqqzRKEYAjGB70LxuyOc1RZnJ6nio3eTs7U7A65rIBnlsYprhQRkj8Kx2kmBGXb86aGkLYyTRyi9v5GxvQAktzVdriEHknPtVIKXIHLE8Ad6QxMDyMY7ChRE60uhc+2qBwpx27Upv2ZtqoOPWqbQkqME1NFAc4brVWRPPJlkTyPjdwKnjwMbuc+9RLEQR+lSoG655qGxovQnAGMD3rQiIH3XJHoazY2xjAPA6H1q1FKNgYrjn0rNjNJSDk7tuOakT5QcYPQ1QSQ4UKARU4dFiHJyKQ7GgziVsFdxx2PFBcDGACAOlULdg67d/PbmrKDB5POPXpQGxehLFgUX7w5wKa7Os2crs4465ptuV/jAyed3YU2Q4lKj5lB684FDJW5Ksh3EMwHUc9TVxM7QQfrjqapwqNzscsSc8+tWkGcuQfTJNAMsowJPJ54bOOB7VLJhMO3y9skdaphlyo42DqM9/rT3ZZVBO456c0CsKf3pDsQc9gcflUczcffxjjHcn0qVAp+UKAAOSBVWVSzcH5R0pItEqoORnBHp60+4XBUIgx90+1VukwHU+grQidBHtcnn5cgZxT3B7lcOFfaF69cUVLEgiDsxDgc8iisalSMPidhb7HkvhlR6d67/TRg47cUUV2VfiOGl8CNeLkDPrSBQsZIGCSRRRUxKK7qBI2B61IwA3EDoaKKClsI46fU1IvQfSiis0UGA0gU8gAcfhUQ5yT60UVSNESRRqXII425qmB+9YdttFFLoC6kUv3TVOQnYOevWiikUQTkiFscdelVHGVbOfXrRRVpCWxR+8W3ZPGetUXAJOexNFFNA9yPaNx47VBOo3AY4NFFUT1GIo+fjpinADFFFUJhGB8vHerc8axtGEGAUVj7kjmiigBCBtBxzmpolAcYFFFT0LROgHNJcIoiRgMMSBxRRSL7E3YDtxUxGJMdsUUVmNbj4vlLY470OStxgE4xnFFFHQZMgwwI9K0VG1AR/eI/SiipBk8ZLBM4446e1OHRD3x1oopIlk8YyATyetSKMAkZ7d6KKrqJbD0UGVMjqwqaVQs0YXIDDJGetFFLoESe8HlxkR/KDngVTBIU470UU2VHYW1UZDY+bnn8KM5nZj97nkfSiigXUkiAKITzlsGiiioqQjKzkrkN2P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Osler Weber Rendu syndrome (also known as hereditary hemorrhagic telangiectasia). Note the multiple 1-2 mm, discrete, red macular and papular telangiectases on the lower lip and tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color Atlas &amp; Synopsis of Clinical Dermatology, 4th ed, McGraw Hill Medical Publishing, New York 2001. Copyright &copy; 2001 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37376=[""].join("\n");
var outline_f36_32_37376=null;
var title_f36_32_37377="Dermatitis herpetiformis knees";
var content_f36_32_37377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules and vesicles are present on the knees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37377=[""].join("\n");
var outline_f36_32_37377=null;
var title_f36_32_37378="Evaluation of weight loss";
var content_f36_32_37378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 633px\">",
"   <div class=\"ttl\">",
"    Evaluation of progressive unintentional weight loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 613px; height: 750px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bouras, EP, Lange, SM, Scolapio, JS. Rational approach to patients with unintentional weight loss. Mayo Clin Proc 2001; 76:923.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37378=[""].join("\n");
var outline_f36_32_37378=null;
var title_f36_32_37379="SCCA columella";
var content_f36_32_37379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    SCCA of the columella",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Parsons JT, Stringer SP, Mancuso AA, Million RR. Nasal vestibule, nasal cavity, and paranasal sinuses. In: Million RR, Cassisi NJ (Eds). Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: J.B. Lippincott Company, 1994. Copyright &copy; 1994 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37379=[""].join("\n");
var outline_f36_32_37379=null;
var title_f36_32_37380="High blood pressure treatment in adults";
var content_f36_32_37380=[" <h1 id=\"patTopicTitle\">",
"  Patient information: High blood pressure treatment in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/32/37380/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37380/contributors\" id=\"au8109\">",
"       Johannes FE Mann, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/32/37380/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37380/contributors\" id=\"se5420\">",
"       George L Bakris, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/32/37380/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37380/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/32/37380?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIGH BLOOD PRESSURE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hypertension is the medical term for high blood pressure. Untreated hypertension increases the strain on the heart and arteries, eventually causing organ damage. Hypertension increases the risk of heart failure, heart attack (myocardial infarction), kidney failure leading to dialysis, and stroke. Fortunately, treatments to lower blood pressure are usually easy to take and can help prevent health problems.",
"    </p>",
"    <p>",
"     This topic will review the treatment of essential (also called primary) hypertension. Essential hypertension does not have a known underlying cause. Other topics about hypertension are also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"      \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"      \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      LIFESTYLE CHANGES",
"     </span>",
"    </p>",
"    <p>",
"     Making lifestyle changes is an important first step in the treatment of high blood pressure. In some patients, lowering sodium and alcohol intake, keeping weight in the ideal range, engaging in regular aerobic exercise, and stopping smoking may be sufficient to control high blood pressure. As an example, most professional societies suggest that sodium intake should be less than 2.3 grams (2300 milligrams [mg]) per day. Such lifestyle changes can lower blood pressure as effectively as therapy with one blood pressure-lowering drug. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"      \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, many patients also require one or more medications to lower the blood pressure. The following is an overview of the different types of drugs that may initially be prescribed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HIGH BLOOD PRESSURE MEDICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     There are various medications that are commonly used to treat high blood pressure.",
"    </p>",
"    <p>",
"     Some people will respond well to one drug but not to another. Therefore, it may take time to determine the right drug(s) and proper dose to effectively lower blood pressure with a minimum of side effects.",
"    </p>",
"    <p>",
"     Although generally well-tolerated, high blood pressure medications can cause side effects; the side effects depend upon the specific drug given, dose, and other factors. Some side effects result from lowering of the blood pressure, usually if the blood pressure lowering is abrupt, and therefore can be caused by any high blood pressure medication. These include dizziness, drowsiness, lightheadedness, or feeling tired. They usually subside after a few weeks when the body has adapted to the lower blood pressure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Diuretics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Diuretics lower blood pressure mainly by causing the kidneys to excrete more water and sodium, which reduces fluid volume throughout the body and widens (dilates) blood vessels.",
"    </p>",
"    <p>",
"     The diuretics used to treat high blood pressure are thiazides (chlorthalidone, hydrochlorothiazide, and indapamide). In some cases, a potassium supplement or a potassium-sparing diuretic (amiloride, spironolactone, or triamterene) are given in combination with a thiazide diuretic because the thiazides can cause potassium deficiency since increased amounts of potassium are excreted in the urine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Side effects are uncommon with low doses of thiazide diuretics. Weakness, muscle cramps, and other symptoms can occur as a result of decreased sodium, potassium, and water level. Other symptoms may include reversible impotence and gout attacks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      ACE inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Angiotensin-converting enzyme (ACE) inhibitors block production of the hormone, angiotensin II, a compound in the blood that causes narrowing of blood vessels and increases blood pressure. By reducing production of angiotensin II, ACE inhibitors allow blood vessels to widen, which lowers blood pressure and improves heart output.",
"    </p>",
"    <p>",
"     The available ACE inhibitors include benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some patients, ACE inhibitors cause a persistent dry hacking cough that is reversible when the medication is stopped. Less common side effects include dry mouth, nausea, rash, muscle pain, or occasionally, kidney dysfunction.",
"    </p>",
"    <p>",
"     A potentially serious complication of ACE inhibitors is angioedema, which occurs in 0.1 to 0.7 percent of people. People with angioedema rapidly (minutes to hours after taking the medication) develop swelling of the lips, tongue, and throat, which can interfere with breathing. These symptoms are a medical emergency, and the ACE inhibitor should be discontinued.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Angiotensin II receptor blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;The angiotensin II receptor blockers (ARBs) block the effects of angiotensin II on cells in the heart and blood vessels. Similar to ACE inhibitors, ARBs can widen blood vessels and lower blood pressure.",
"    </p>",
"    <p>",
"     The available ARBs include azilsartan, candesartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The main difference between ARBs and ACE inhibitors is that ARBs do not produce cough. Some people who take ARBs experience headache, nausea, dry mouth, abdominal pain, or other side effects. Angioedema is less common with ARBs than with ACE inhibitors.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Calcium channel blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Calcium channel blocker drugs reduce the amount of calcium that enters the smooth muscle in blood vessel walls and heart muscle. Muscle cells require calcium to contract. Thus, by inhibiting the flow of calcium across muscle cell membranes, calcium channel blockers cause muscle cells to relax and blood vessels to dilate, reducing blood pressure as well as reducing the force and rate of the heartbeat.",
"    </p>",
"    <p>",
"     There are two major categories of calcium channel blockers:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Dihydropyridines, including amlodipine, felodipine, isradipine, nicardipine, nifedipine, and nisoldipine",
"      </li>",
"      <li>",
"       Nondihydropyridines, including diltiazem and verapamil",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The side effects of calcium channel blockers vary with the specific agent used. Patients who take dihydropyridines may develop headache, flushing, nausea, overgrowth of the gum tissue (gingival hyperplasia), or swelling of the extremities (peripheral edema).",
"    </p>",
"    <p>",
"     Nondihydropyridines can occasionally cause the heart rate to slow too much. Other side effects may include headache and nausea with diltiazem or constipation with verapamil.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Beta blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beta blockers block some of the effects of the sympathetic nervous system, which increases the heart rate and raises blood pressure with stress",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     activity. Beta blockers lower blood pressure in part by decreasing the rate and force at which the heart pumps blood.",
"    </p>",
"    <p>",
"     The available beta blockers include acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, nebivolol, pindolol, propranolol, and timolol.",
"    </p>",
"    <p>",
"     Some beta blockers have combined activity, blocking both the beta and alpha receptors (see next section). These include labetalol and carvedilol.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beta blockers may worsen symptoms of asthma, other lung diseases, or blood vessel disease outside the heart (such as peripheral vascular disease). As a result, they normally are not prescribed for patients with such conditions. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=see_link\">",
"      \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In addition, beta blockers may mask symptoms of low blood sugar (hypoglycemia) in people with diabetes who are treated with insulin. Beta blockers can also cause fatigue, insomnia, strange dreams, a decreased ability to exercise, a slow heart rate, rash, and cold hands and feet due to reduced blood flow to the limbs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Alpha blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alpha blockers relax or reduce the tone of involuntary (ie, smooth) muscle in the walls of blood vessels (vascular smooth muscle), allowing the vessels to widen, thereby lowering blood pressure. An increase in blood vessel diameter is known as \"vasodilation.\" The available alpha blockers include doxazosin, prazosin, and terazosin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alpha blockers can cause dizziness, particularly when standing up, and particularly with the first few doses, low blood pressure when standing, or other side effects. They also may increase the risk of developing heart failure. For these reasons, they are not frequently used as a first-line treatment of essential hypertension. A possible exception is in an older man with symptoms related to enlargement of the prostate; such symptoms may be relieved by alpha blocker therapy. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"      \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Direct vasodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Direct vasodilators relax or reduce the tone of blood vessels. The two drugs in this class are hydralazine and minoxidil. Minoxidil is typically used in only severe or resistant high blood pressure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Side effects associated with direct vasodilators include headache, constipation, swelling in the lower legs, and rapid heartbeat. These effects are usually minimized by combining the vasodilator with a beta blocker. Minoxidil also may cause excessive hair growth. Rogaine, which is used to treat baldness, is a form of minoxidil that is applied to the skin.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      THE PROPER HIGH BLOOD PRESSURE MEDICATION FOR YOU",
"     </span>",
"    </p>",
"    <p>",
"     A healthcare provider will take several factors into account when determining which antihypertensive drug should be tried first. In addition to considering the effectiveness and potential side effects, he or she will consider the person's general health, sex, age, and race; the severity of the high blood pressure; any additional, underlying medical conditions; and whether particular drugs should not be used.",
"    </p>",
"    <p>",
"     Certain antihypertensive drugs are specifically recommended for the treatment of particular conditions, even if the person does not have high blood pressure. In many cases, a person with one of these conditions also has high blood pressure. As examples:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       An angiotensin-converting enzyme (ACE) inhibitor is recommended for people with diabetes mellitus who have increased levels of protein in the urine (proteinuria), heart failure, or a prior heart attack. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=see_link\">",
"        \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Beta blockers are recommended for people with heart failure or a prior heart attack. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"        \"Patient information: Heart failure (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12100?source=see_link\">",
"        \"Patient information: Heart attack recovery (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Beta blockers or calcium channel blockers are recommended to control symptoms in people with angina pectoris, which is temporary chest pain caused by an inadequate oxygen supply to heart muscle in patients with coronary artery disease. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/1/31766?source=see_link\">",
"        \"Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There are also certain antihypertensive agents that are not recommended in some people. Some examples include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       ACE inhibitors and angiotensin II receptor blockers (ARBs) (and many other medications not used to treat high blood pressure) are not recommended during pregnancy.",
"      </li>",
"      <li>",
"       Diuretics can worsen gout. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/57/24467?source=see_link\">",
"        \"Patient information: Gout (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Thus, it is important to mention all current and previous medical problems to the healthcare provider to determine which medication is best.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Combination drug therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a person has very high blood pressure (eg,",
"     <span class=\"nowrap\">",
"      160/100",
"     </span>",
"     mmHg or higher), then combination therapy with two drugs at the same time rather than monotherapy with one drug may be the",
"     <strong>",
"      initial step",
"     </strong>",
"     in blood pressure treatment. In addition, some people who are first treated with one drug do not have an adequate response with good control of the blood pressure. If this happens, a second medication may be added. Other options include raising the dose of the first drug or substituting a different drug, since some people will respond to a different type of high blood pressure medication.",
"    </p>",
"    <p>",
"     Adding a second drug, particularly as a single-pill combination, may be:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       More effective than increasing the dose of the first drug.",
"      </li>",
"      <li>",
"       Associated with fewer side effects, many of which occur more frequently with higher doses.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194141101\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194141108\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=see_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/56/40835?source=see_link\">",
"      Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=see_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/53/28498?source=see_link\">",
"      Patient information: Preeclampsia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=see_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/37/36435?source=see_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/6/37987?source=see_link\">",
"      Patient information: Heart attack recovery (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/27/21940?source=see_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21156?source=see_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/40/39554?source=see_link\">",
"      Patient information: Lowering the risk of having another stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/20/37186?source=see_link\">",
"      Patient information: Renovascular hypertension (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27539?source=see_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/31/37363?source=see_link\">",
"      Patient information: Glomerular disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194141116\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=see_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/1/40980?source=see_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12100?source=see_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/1/31766?source=see_link\">",
"      Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/57/24467?source=see_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194141124\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18068?source=see_link\">",
"      Can therapy be discontinued in well-controlled hypertension?",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=see_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36728?source=see_link\">",
"      Definition, risk factors, and evaluation of resistant hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link\">",
"      Overview of hypertension in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23828?source=see_link\">",
"      Patient adherence and the treatment of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33046?source=see_link\">",
"      Perioperative management of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44677?source=see_link\">",
"      Prehypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35256?source=see_link\">",
"      Treatment of resistant hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/highbloodpressure.html\">",
"      www.nlm.nih.gov/medlineplus/highbloodpressure.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung &amp; Blood Institute (NHLBI)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/Hbp/HBP_WhatIs.html\">",
"      www.nhlbi.nih.gov/health/dci/Diseases/Hbp/HBP_WhatIs.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBloodPressure/About-High-Blood-Pressure_UCM_002050_Article.jsp\">",
"      www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBloodPressure/About-High-Blood-Pressure_UCM_002050_Article.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.hormone.org/\">",
"      www.hormone.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/32/37380/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/32/37380?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37380/abstract/1\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37380/abstract/2\">",
"      MacMahon S. Blood pressure and the risk of cardiovascular disease. N Engl J Med 2000; 342:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37380/abstract/3\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37380/abstract/4\">",
"      Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37380/abstract/5\">",
"      Brown MJ. Matching the right drug to the right patient in essential hypertension. Heart 2001; 86:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37380/abstract/6\">",
"      Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f36_32_37380=[""].join("\n");
var outline_f36_32_37380=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIGH BLOOD PRESSURE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           LIFESTYLE CHANGES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HIGH BLOOD PRESSURE MEDICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           THE PROPER HIGH BLOOD PRESSURE MEDICATION FOR YOU",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f36_32_37381="Acute pancreatitis with pseudocyst formation";
var content_f36_32_37381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Acute pancreatitis with pseudocyst formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 389px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGFAfQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKXFACUUuKMUAJRS4oxQAlFLijFACUUuKMUAJRS1IkE0hASKRiegCk5oAiorSh0LVZhmLT7pvpGamXw1rTZ26Xdn/ALZmgDHorci8J69LIETSrrcfVMfzq7b+A/EVwoaPTzg8DLqP60ActRW/deD9etjh9OmY/wDTPDY/KoP+Ea1r/oF3f/fs0AY9Fa7eG9ZUEtpl2APWM1Vn0u/gUtNZ3CKO5jNAFKipPJk/55v/AN8mmYoASilxRQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAopaQUtABRRRQAUUVPZWlxezrBaQvNK3AVBmgCCpbW2nuphFaxSTSN0VFJNdjD4UstLTzfEN2rsyZW3tmyQ3ox7fQVLP4lkgtVttKs47GPlSYk5cdiT60AZ+n+CrySNZtSubewhJGfMbL4/3RV+LS/DFlnfJdX8qgnqERj9OtV9O0vV9WYPGJH2DlX7g10C+EIoo1lu51VDjcD1BoAzrfXrG2BSy0SyjyMqHj8whvqasXHivVAUFu3lLtwgVB8p962LTSdLjvs7C68EAfxj0rrrfTLeWKSS0sgcAFSy/pQB5ZLq+rzSBXmlD8N0xmq8uq6r5mxZpQwPOTzXrkltZGXZdWgU4/iXGKp3+maYpSVIIy4OMqeo9DQB5adU1cNEyzzAFsZyambVdRiYbbiZSpxwx/OvSh4b09pN5RdgG4xlsdfSmzeENKaXzOdh7h8/hQB5g+pak0gYXco/vfMeaams6jGxKXMnHOSxPFenP4N0sshSGTjGcHtS3Hg/SkYKqsF3blJPQelAHmya7qc0TMLiQY5wOpqyfE+rxRgLO3I4BHT2r0FPCWlwsGy3POB609vCOmSujkyhSckE0AcPD4y1EuGZInDLjYyD86mi8Q29wpEuj2En95/KG7+Vdk/g7STJ8oOxTuGT2qsPCunxA7Sq7jgEsOlAHMyX3hu5H+laJAvzbfk+X8eKglt/CDLIG02SM9AUkP8AU10WoeEbMFjHMuOvBzWTd6HaxJ5BlDSdRhsigDKXRPBzoXM2ooPQMD9e1OuvC/hgQi4hu74RNyobBJ/StZvCkVwo2XaBsD5c1YvfCzeQqrdr8nAB7CgDm4/DnhmXBF5eoo+9naT/ACqNvDnhkYxqV5gH5jsBrUfwndohC3MTynnp0FQT+EpUhVhMrueCO2aAM5fD3hvdhtUu8f8AXMU2Tw94eAUpqd0VPVjGBitCbwrqKoCse8dAc1Uu/D+oeQuLWRyPvEdKAIR4Y0NpExrM4iYHLGAcH86T/hFdIPC67g/7UH/16cNFvBGFMMo43jI9KrvYM8e5g8ci8YIPWgBX8GKXX7PrOnujchmLL/SpJPAN4EzFqOmyn0WQg/qKqTWzJEAzbs9cHoaH3MgZQx28kKT07UAOk8Ba6uTHBDKg/ijmUisifw/q0G/zNPuQF6kISP0rZhuruMDa8oTI43GrVvrmowJiO4lDZ7nOaAONaCVc7o3XHqpqOvRW8X6gRsnMcqg/OWUHIpTq9hdI6Xei2jhh95E2EflQB5zijFeiXGk+EbqMbJLmxl25LBtyA+4PNZl74EvTA1xpE8OowDoIztfH+6aAOOxRiprm3mtZTFcxSRSL1V12moqAExRilooATFGKWigBtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKKWkFLQAUUAZOK7zQvDVtpNtHqPiVV3yrm1tSf4uzOPT2oAydA8Ky3kC32qObPTARlyPncf7I/rXRTa1BYW39n+H7VYLd/lMqnMkvuT61Kq6n4l1GK3lUxvGB5W0YXb6emK7PRfh8CqLeqvmbshl9aAPN10ia5LS4eXzuTjOc/413PhLwUY7oSTW5lhAHyOK9M0rQ7XT0hjMKeYhwxI4J963rhYwqjAU7spIvHNAHN2vhy2jtmZH8sK3G0YIrnvFPhmJ9OedJnZl++B3967XV722s7TdcTqoOfmB/pXn+sazd6mHi0+BhCowJQflcUAcLLeNbApCMyA5yetbOl+Mb+2iEsEYdD8rgjlSKVtFjttOluL2FvPZ8ow6qfX6VFqFvLLFaPZIu/dskK8BqAINd1vWNXgUwvsC+g5z9ahtv7STaZJlAfG81Wu9OvoGll8wrCDymfmH0rl/FdzdgQWsTSGAx7225+ZvQ/SgDttb1ZbJom1S9VFPyr5XzFh68VHpvifSVBitr1n3dVlBX8ie9eS5o5oA9lbxdPab1K5CHGSe3rUcvi65nQsNgQ8Z6mvNtI1d4GEVzmWM8Lnqv/1q6qxNlLa/IXDk5wORQBsR+JL8uT5keD0yOlQv4g1dWOJ4wDndn+QrLiJ8xgpBUNlSe/tWwL63vLPyRaKz8fOo5yO1AFdrzUysfmXWI3PQHB596oSvMUAnu5DsY/xHnmrB84gqYMYOQarTI7HPOATkYoAkikllikCvIV7HcRkVXlkQJhVkVs/eJycVG0pDALJg45X0zU0bxINkYMjSfxEdKAJ4ZGU5ikcZHG3k5phvpVmkSWafC460kF8bJ2cxqdgyrDiq13dy3lw00ioAegAwT70AaKalmNtl1IrE5ye1ImsXyMFWZZMHKgdTWZGBKpU4JHUZ5PuaFjXYSDtPTPpQB1dv4uuA2Li3WQ9PkNalr4sspYmSMSRN1PmfdzXEQFhtUY3D7xNWFdXc9CgGCF70AelWOq2F4n+th3r1Bx+VaBs7K6XzPJhcEZIABryUpGuSEZSOSR1NaFtqUsRX7O8iEjkg8mgDv5/Demzrua3UAj0xVD/hEdMkI2yGPccEL39qyrTxO88KxXRfGNpAODitzStW0qaFcTlWJxh+MUAUpPBVqFdlmwM8ZHSqo8B2ocO0rHcd3ToK6a5s5LwmayvFUfwgHr7mmyWOqxKz+fHIzJtAPegDmF8C2pkSVpG+9jGODU0vgeDYQJCDjOMVLqw1yFfK8guqc5U5Na/hO9N7AlvdoYnUFSX4JNAHC3nglss0bKGHr/FXPvp+raZcOYywQHhkzX0DcaTbTxqA5bjBKnpVO78MjydsLbkAOd1AHi8niOK+T7N4hs0vI1+QOQA6D1Ddaoar4LhuLaS98NXa3UI5+yvxKo9vWuz8T+E45JV+zgxXA5J7GuRmt73Sn32y7CvO7PU0AcJLG8UjRyoySKcMrDBH4U2vSpn07xHbpBrISDUzjZewgAsfR/UVxniLw/faBcrHeoDE/MU8fKSD1BoAyKKSloAbRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACilpBXd+CtAgt7I69rWEhU/6JDIOJm/vH2FAFnwxosWg2EGu6nHFcXbHMFk/VR/eYfyrZ07Rr7X717m/TMMh3bD6e1Jomn3Guap/aN8T5J+UY6A56fSvYNE06O38pnBQj7v8AdPsKAI/DXh+CC0SJIxGUIKb/AOL6GuidBHc42BVJ5U8En1pkssNqhZyxizyvQr+FYes6k9/KbOXdHDnMUoPzH2oA0NS1m1tU3SsN+SGBGM475rl9Q8UTXey30mCRmB+U7cjJ9a6OTwVcy+FZL24mWZycwwluM9ixrndM1TVImGmWVpbQ7RtNwF/j7ge3vQBPaeD727ikuNSmxI3BVjkIT0OPStf4ReFtZ0t9Tg8WXmnS2DORbqoDNjuRxwMdqz0vp7PEDXfm3mS2yRvv461pvM7WCzNJsl2F2VT098UAZ2qeEPE48R6gYLqxuPDJIMKg/vIh2BHX1rkvGEGo6Vpbt4dgFze7wo8tN+PUgetd54A1ubXdbuNMiG9jEytMDyBjrVj4d+BdR8ORajpurzGcyyvJDKvJAJ6UAeI+CfBGqXGrRat4nvTbor7/ACHk3PI3owHAFes6LoYv9VupobUWwYDGFARvp9afL4Sk0zxMDcziWyb5lTvu759qmsfEH2fWf7OuHKRMSVHpzwaAPNtd+DFzr2tXk/h29sbdmclrS4JTDd9px0+tcvcfA7x1DKEOmQNzjctzHj+dfR0bvZ6/Fc4jaF1+baf4vWum1PTJbuCK5tJQ+/Hy7vlx6n3oA+aPDfwE8TNqML6jdaZZrEwZ0aXexHttGD+dYPjT4feIPCl5Ne6K8l/pZYhbi1BbZ6hl6j619YanYPoOmXd3DcxybYWdozz0FeC6J8Q5727S+t932YORPHn/AFa57igDzTQ77UNbtL+OVI3lsbVplIj+YhexxXOr4g1NP9VdNH6bABivq3w54R0vVdUv/EcZEYlszCbe3UKJi3JZvWvlvxzob+HfFOoacwARHLRY5BQ8j/PtQBkvfXbsWa5mLE5J3mtHSdYuhLHbS3H7h3ALPyR+NY1FAHYNv8xvK/eEAhsfXtSq+YzCyMufVsYNP8COgmaS5PyhCozU07rdX8riREAbaNvORQA63tZ77Z5Cb8EDaOd1dFqHheCy0dZ7iURXpHEYPJNav9oW/g3w8LhUQedz5h+/KfRR2+teV+IvFN7rEzHPkwE/KinJH1brQBqSpFajdc3USSYJI3At+QqexuNCn8tZNV8h8/xQttH1NcLRQB6XaHQhqZE+tQyL0zghWH1rUk0KKUNc6NJDfW2fmFvIGKfUV5BVnTr+6025W4sLiS3mXoyNj/8AX9KAO7Mbx3rRBWV3OAHGMCrr6ZLHHJLhZMf8tVPy4rO0fx7HdXKr4mtUmVuPtUK7XX3I/i/StTVrKL7IbrSbz7Rp78hkJIBPYjt+NAFaOHysOsmUByR3zWzo0VjquLdyYLnkhgeGrnLM7pY4iXLMMD61YeKWzvFRyY5E+YOO59KANNkudKu5GjdvlOFPNSxeLNQhkIZhJgdCalt5DqSxwlv9KIxtU/e96xdW0+azlQOiiN8kvj07UAdXZ+OJFIW4tAccsynrWrbeLNLuZFE2Ydxz864z+NcQLIW1tFNO+1ZRnA7LWbqIVCFV/NBI2t3AoA9osNRh3wrZ3Ubxpk7Qep961p9YPlMsqg4OSy9K+ehfSWUnmQuyy4x16+9dFofi+4QFLg+ZvP3sfdHvQB12pXK6rqawQ/JKxITB6iodS8PTraPBMNwzxIB0qKxlsr6SO9tZNtzEOYx/GK9G0i5h1XT48hMkbWXqePWgD5+1zQTbTny13DGSc4FGmaxCyjS9Yhe8sHHRv+WZ9VPY17brPhi0vWIhBCLnePWvLfEvhfyWZbU+WAPTke1AHB+LvDL6NILi0k+06XKf3cy87Cf4W9DXNV6To+o/2eZtN1CDz7C44libnI9c9q5rxj4bbRJ457VxPptxkwyjnH+wT6igDmaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorS8P6RPreqRWdtgFuWdjhUUdSaANbwR4fTVZ5b3UG8vSbPDXDjq3oo+tdZcfafEetQ20cYGkqAIXi+6ijtioNRVZmttD0hGFjApX5eGdz1Y+td/oWmx6Np0CBS/yfvCRhgaANDRhZ6cIbOQYgJ/1iD9a7ZZlW3CR7LiNhwy8Vw+n6btvGv7mRvsx+4uccd6v3yXUs+zSnWK3ZQWZmwQPagCLxXrqac5cObi5QZEWau/Bq2Xxh4lubm9kaKKJCRE3Tf6e3Fc7Z+ErJ5ZBdalL9pbPJ5Ge1dR8JxdeFfE9xBeBHs7lAnmIMjdng0AepeOLdNN8KfZoSqxP8jL3AHfNeTWYK6dIse5JJeUYcg89RXrvinQn1fQLi1Z3S6Vt0ZXoP/rV5rYaTdXGlxWMCAXltK2ecbh70AeaWKpo+oXOq6ol1cxQbgWHIGTyR9Ku654/8Mz/YfJ1Nxsy4dImJUf3GFekeGvCV7eyajDf2skMDADbLHmMk96o3nwY8DafqlvPfWM+4NmW2Sc+UR6+uKANb4U3XhG5gk1zQ5ZPtk4MckpUqFYf7JroB4n+yeMoEmmVmZSfQEnpx61zGpiztCYdBtIrK0hXYIYl2qR61538RPFGm6ULVNQ86W74eLySN2PegD3y70xbm6jvJgqTKCC2flx2zXzr4umul+IF/bXkrQQrIqxhePpg+ldZ4P+J0F1DD9nmNxCSEkhlOGX2I/rWzrVl4b8Q6rFJezYbp5ucFB70Abs1ssemadK0oDyKNp7OfQ1vacdRtdWjt4bUGxeJZNxb7r+w9K5a+v7S5XT9M0+U3C2bBVbH3/r71Z1/x69jZvp9zGIL9I/lWI5ZVPQUAdb4xaN9EvhIRIsqAMEHI9a+ONO0S8tr7UpUu/JinkaMIvO9STyR7V6XqfxZvdN1e306+j8yynUK7ryyZ7/Wu+i0bRvEGlG70ywWZIwvzRD5yx60AN+COm3MdkbWaYyoE3qp/nXDfG74a3uuXz6loCG5vYSY5bcY3OvqPXFe3eHPCVj4f1JNVguLq4P2b7KYd/wAq855X196ltFtodeud0qRoeQZDzyelAHw9qHgrxNpyBr7QdSgU5wXt2Gf0qCx8N6rdsf8AQp4o15Z5UKqB+NfYXi/xPZ2Dr9klaW5ikOVzuXb9a8n13WLzXtU83UbgLAGGEQ5yPQ0AeYpp0ltbhF3YTALY7+lXbOG30zTptXvIlMEbBEhY486T0rfmtEutRFqodoDJwvoK4n4j6mLrWzYW+1bOxHlIE6M3dj79vwoAw9a1a71i7M97KWPREHCoPQDsKz6SigBc0ZpKKAFzRmkooAXNb/hHxCdCviZovtFjMNs8J7j1HoRXP0UAesamli0MGr+H5DNBnd8w5jbuCPWsd715n8xvmcnlmrN+Hl+i6k+mXchW2vRsXJ4WTsf6flU2s6ZNp101tJuVQxw5PBoA0o2eOczRuyyj5ty8YqdtaluLcLdL5iEnLN61maPqEMTSRXYLLIpVSOoxTJUmaD7TEu+AHG3uaANK4knn2mSTK4+QenpVSeSC1R5XbOwbiWPU+gqudQO8I21AxBHPNc7rs7yXbqxO30zQA++1hp2by4wpJzk0y11OTzFWQ4U8HFZtA60Advol9eQTh7fIbJOGPGK9H8IaxLHMtzZy742/10Z4IPqK860+2mlsYbghnuHTGwcbR7iremS31hK0v3WVshOlAH0Lp14LuPIfajctnimajpcF3E+yMb8feI7Vw/hHxLbaiiKFEV7GOVbgMPWuzOrokRW5DIQOSOc0AeV+M/DpLvIvHljog5xXMaPexyW76FqsebK5Pys3WM9iK9X1C6S5upJDtEUvCY6kV554y0P7JObq3jZYHOQxHegDzjxJo1xoOrzWN1yUOUcdHU9GFZVeo3dmnivQms9w/teyUyQu3WVe6f4V5gwKsVYEEHBB7UANooooAKKKKACiiigAooooAKKKKACiiigAooooAkhiknlSKFGeRztVVGST6V6bYww+HdDfSIXh/te9wbmXGcL2jB7Y/nWV4Rsf7B0k+JLxB5zgpZIw6H/np/hXQeD9EfVrwXt6wZWO4se5oA6HwNoT2Nu1w4DSlThG6iuvSFWYGXiOQYYZwR7g0trbPKwWMoNowOemO1WZZ4FhlhvIyu0AgY4ZvagCndOsjLHLkW6/cyMbiPX2qpNMksxwGjK8mMHgj2qN5gJcSOxTPG4ZApotySzxED02nIFACtKBDMUHmRgHr1Gav6ZqM1qkMkLhkAAaNupHtWW0jLJIh/dPjoejfUUwysilo4uU525+8PagD2XQ/GloTHNfSyLCy+W4POB6mte38UeGmvtyzQyycqkyEBlHoR3rwuzuXhP3g6yA7o2GCKxfEemzQK19pqEIxyyE4I91oA9+vviAsCPAhiuIiShZOorkrzUZp3NwxE2ThX9F9DXjmh65dy6xbRSNgggFGHLfjXbeIPE2k+FZ7JtRnmxdttEcYDFAD94juKAOpU20UbXVzOsMCgs5k+6o6nPtXy/8UNYstc8bale6SzNYswWIkYyAOw9M19JePWsPFfwv1HT/AA7cxtqU6rPGiqVZkU5KZP8AeFfKN1o2p2k4hudPuo5T0VomBP04oAZpF3NZX8MtuQHzjBOM5r3Dw9qem3mlzLq5eO76RyA/dXt+Oaq/BX4V3N8BrGvWBNueIYJRgkd2IPSr/wAfdNsPCemabFoCOWn+drkN9z1UigDZ8M6pbaTqcMzENE5+8DkNz39DXqdx4X0DxKG1eWVYsoCAGHUcde9fKPhzxZbXcbWPiAmLK/uruLghh0DD0PrWtqlzrlgg8m7uVtRyEJO189xQB7ReeALTRtasbhZdOvbFm3XhuOTt9F9Kg1j4i6HozypoCrawFtpMY6kV4JcarqF6kiyajOwK42lzuX2pbCyuJpFEUTSiQASHH3T9KAPX0+LWsz3AtdKjjgRz888g3cHvXK+Lb+eK8+TWZZbpzvwj5Un1B7VzF5ZX+mQ4QFdxHC5Bx6VmySPBIXA3RsBuJ9f6UAb0GrySOXv3llYKVKgnk+pNNe+tdP07y4WaW4ck5Y54/wAayZLyMQ+Vbbo0bln6jPvWxoHh19RsXu7kbIU4C4zuPsaANXwIBM89y7SbhG204/irxq+843s5uc+fvYvnruzzX0ppdtb6fo1nawxYlXh5V/jJ6A14t8WrCKw8aXMcXDOiyOB2Yjn+lAHGUUuKMUAJRS4oxQAlFLijFACUUuKMUAKpIYFSQwORj1r2vUtA1DU/DWn3FxFuuxArncMHdjqa8UUlWBHUc19IaXqMjx6UZjIUv7RZsY+RCR0oA8dk06RZpVPN2eGI6D2FMlS5tP3cscsMe0sSQcH6V6Bq4h0jxBHdNbK9uzgSMRx9a9utfCukappaG/ghmtHQPkDk/SgD5Ka1kvIRNZkAsdpyOaxr2zmtiBMjB84JPevY/iB4Nl8Naxt00ONNuZMxKi5KD3NZeseGLuJvtFy8VwFQMFXqox39DQB5QYZBJ5ZRg/8AdxzWrY6Ysavc3zbY4vmKDqa3NQsNu2eM7Vxyo5YGqGsrLJoMLpExRH/ev6HtQBjTajdPIWWaRBngKxGBU1prV9btgzvJGT8yOc5/E1m96KAPQILp7mwF9ajbEDjC8shH9413PhPxlFPCtnqigscATE8MPSvHfDmty6NPJ8nm2sw2ywk8MOxHuK6CMJIkcsTYgk5Djr9PwoA9e1ixVpVvoefL5RF+6q+3rUzIL+zAuNrh1wPauP8ACHitbKRLG+Ba3Pyq7HOK6m6Q2kpnhx9jlO445Iz3oA8+1i3uPDetxz2Cu5D5EjdKxPiJpKTCPxDYYeC6OLkJ0jl+nYH+dep67piavYNkMzhSUPauE0KYxtdaRqw8rT7zMbKRyG7EUAeW0Vp+ItJm0PWLmwuOWib5W7Op6H8RWZQAUUUUAFFFFABRRRQAUUUUAFFFFABW74Q0iLV9VC3khisIR5lxIOoX0HuelYiKzsFUEsTgAdzXpElsdF8PxaJCImvJ8S3TDnk9F/CgCSK4m1vWUtxlrMYjhTttHAx+FeoWNnHp8MMdkFVSB5kD8ZPtXKeDNPisdOa4miQSgYCMevvmus0yQ6hIXffCYl+UOcgn+tAGjF5MKpGm7zXJZlLYK1S1Kd7giPfmNeR6iora/wDtSXVxcwlSW8uM7fSop41VUcAlHONy8gflQALM8a+XcoJI3+6xHNQRq1vc/KAY2HKg4FTF3UnyyZYD1UjkfSmIFDtJA7dcGKTr+FAD5ZBNHkKGccI2OfpUO4T7lXck2fmVxyD6AelOEjiNfJMTK2flfgg+mabLtKBlDkocMO6/j3FAEbbQUWQZD8MFPK1ZhlVA3zNND0Azyv4VC7IyHzANpOPMJ5FIZHUpFLHmNTlXHUj6+tAGB4htDp9+L22I8s8qc4IPpT9Jij1C6tdY1HTG1KC2PzRvyFPtXa6fBFfwyWlwqzQSjcjEDP4+4rz25v8AUdCuJrSynKQ7mG0D7+PX3oA9o8MeI9H1GbyoVWOWQbUiMWCntn0qx4j8QJ4esvN1oRQWobCMVBb615T4F1aOHX7S++ZJydkm7nb+FWvj3BqurWH2sK8kIwFKDII9/SgBuq/FS71LVI9N0xwu+P8AdyQyg5+tZXja+hsvC8V1rJ+1XM8oRrWQ8kdSQa818MaBNcX8ReZra4iIkCsvUA17jL4GXxhdaaNQJEUIBeMggnP90+hoA8Q1XQptW1uOPwxpFw0UsaFIowX5I9a7jU/BnjXw74UsrzxKMWJASKFpA7RLno4HT2r0S08M2nhrxXJCj3CWVxtcuuS6+X/CoFdD4tuTrfhZtaha4sNLVHR7a7i2NOAcBsH86APn5dKvzeRwGFUkmI8t8ZzmvdfBvhOHQdGjkuFSWfAMmRx+Fef2tyJLi0eSRTHEAV9x7V3OpeNYrLTwVZtzcbDyDQBz/i7Tf7YuZRp6LsTnA/nXmd5bG1vJYZo/MPcJ0Y17ML+30/wvJfkDfKd5ZeTz2/CvPtPga7kkufJMshJYOo5H1oAoaLo8eo3aQCAwRD5icdfY13aRQwWsUdsGhigOFHZsU3SrSZYTNb5lOMMdv3fWr0YkCICo8n+B16H/AOvQBTRHd1khYhy3zxgcc96xPF/hC18SLLPKxivlG2OYdz6EdxXpPhiOzS4Y367oskvnhh9K6jT4PCTzyTF3LD5dpIOKAPkOX4X+Mg5+zaDeXackPbJ5gYeoxzVRvh74wWQI3hnWA3obRx/Sv0G0ObTLezigtbiEoOI3TAx7GtyN4pF2+arkevUUAfnEvw28atnb4V1k7eD/AKI/H6VA/gHxcmd3hrWB9bR/8K/RnV9WttJhSW5lCqTgLnJb6VPDqFtPbJNHOgRxkbjQB+bEngzxNH/rNA1Rfrav/hVZvDWur97RtRH1t3/wr9Kpda0+JzHJdRBx1XNWbK8t71C9u6uAcH1FAH5lL4d1pn2rpOoFvT7O/wDhVm28H+JLlysGg6nIRyQts5/pX6YTPHBG8km1VUEk+1YUPiizMe+VSqk4Up82aAPhnwh8FPHHiO+SL+w7qwteC9zeJ5SqvsDyx9hXs1t4aOkmKxefdDagRIhPTHTmvo2HXbCYIfN27+AGGDXE+KfDqRSS38YZQ53AswwDQB414l0lZLN5HRG28YPrVDwz4i1DwdKkLpJqWmffwTloD3/D2rudd0hL6BLZwoVGEjENkk/Wsy8hj8swQpGIg+5gB1P9aAOw03XtE8W2CeVLAzNhnWQYY+2O1Sr4V0WK1mRoI5zKhJ5J/CvNZdEUPvVDBk7maLgj2FX9P1fWdNheBLgy28YwodckA+/rQB5t8S/DOn6X4ieLSzKIWAkVOgHtWLpxMcBieNHjyS6EZBHpXb+J9Il1O+N5LJKJiB8j9/8ACual0jULe5SMwqUbqV7igDLl8J6HrRY6fJJp9ztyVPzR/SuJ8SeHb/w9cRpqEY2SgmKRDlXHtX1d8OfCWnz6arzQQy7sArjOCau+LvhJp+paYbaDhOWaAnPzeqt2NAHxZXX+GZgfD06uNximyv8Asgir/jH4eXmmX1z/AGXG8sEQy0TsPMT1471S8G24Ok6iZVdQzKgY8AH/ABoAe6mVgYcs49O1d94J1k3CNpt6wf8AuM/P4Yrh4432+WnlxQrkFieSakMk0c8MkTBNnQg8k0AetvPNDObVjsRQCp7tXH+ONEWOYXVqm5jy7sckGtuC7Gr6ALi2GLu35dR1PvV2xlj1TThviBLDbJnsaAPONfgXxR4XFwmW1bTFw/rJF3/Lr+deZ16ncyT+GvEKywRERFsFCPvL3rk/HWkrZagL+yjI02+JkhOOFP8AEv4H9KAOYooooAKKKKACiiigAooooAKKKKAOt+HunrJfy6rdKv2PTl8w7+jP/CPf1rvPBWg3nijXHmRRcSztlEVeQPauZtrMWPh3T9NDOlxfkTyhl+U/3Qfw/nX0t8LrW08I/DebWWZFvpz9mtyAMoenGaAFPhbSIIZbCZY7u7ihzKYjxGfQ+9cBrUj6XoRNoyGYkrtfuPavSNJszD4Y1HXjK63d4/2dQf4zn5ia8a8Z3Uk18sUbgJEdp5+Un/GgDd0u5W50CCN4xFIx3E9V3U1PlaRoi8R6NGeRn1/Gs3wtO11ZXFqQfNjbMZzzWgyNIpPVlyHCnnIoAQSqwILMucAYGKbOjq2wlS2cqT/jSXELqqrKrmJ1wJI2GVPuKYgMIUOJfLJwknvQAs3mMFcANsyTxkYqOKcq3nK4jYc7W6NViRXWE7J9hGMP0B9jTCxXclwqsMfPtHAoARMIzkRh/MO04/nSs/7xRGWZDwQRynanPDCCjxTGHJ2gH7pI9+1AALmKSRQ2OD0z+NADtOuTb3paKQxuDtdCMjFY3jTS5Apv44JPLbkPGNw/KtgrhXMhYyIuCUIGf8a0LeRZbM2vnShWXO1hyD9KAPKbJ0gPmbnEbHcQQRXrngvX7XU9Mew1WR8gbFkK5DL7iue0DwXfatfybwqWaHaTIRtc56V6jpHwsitYN2l3EMxf5WhduB/utQBX07QfBMOpRXaQm5u41/1T/KsnsDXSDXtFhmM+n2DQOg2mJm+4R2//AFVw+uz2eg38um3MZa+iPO3nitjw54t0bUNAvHvtJSeQEwrOgwRjs3oR1zQBcl8Vqb976LT2WV/lzKmcfjWdruoXeu6Ncw6pG5jZCIk8v5Yz7Vl2HiLVI55YFW0nidRsR8Alc8Y960ZdWk1CZS1vHIqMU2CTAzj+dAHjMUgtZZLcSoWXlN5xsOeRUJlie62SZYAnAbjaexz0qXxlpcljrEsr28iwSMWCsQfqAa3Ph14VOrmaSRJ5UY4ETentQBJFDJqunBYpQVjY7lHQ8das2Op6NZ2slrJrFlbTsMETSAHP19K9Ev8A4J2euW1nFFq2o6VGo+dLbgknuQe1ZMv7L/hdvlTXtURuhkcIRkde1AFTSotwjuYLiGe2ePhoJQyOR16Ut1bLbybrTy/JY58pWJGfWuq8P/APTvD7W5svEuriCN97xMymOQd+AOKh8Y6JY6cjxWdzIZSeVwBgZ7UAcfNJmAKSzc8HdyQajikRCi+WGYHG5W7+/vXT+HFsItLYlYZpy/VvmX3wexrI1HTIpNTlms9luH5wTkN9PQ0AQnUruFisk7xkD5QvGAP605Ndv0kLJf3aSfeVnJBFaENrCsaxFfNdBkM3X6UjxpI7LcDYCccsD06c0AZGo6vqWpiNby+acpyGJIx7VO9/fRqFF1M5jGVCkgYqz9ntoZ45fJzgYbLZH1xV0LH5Y+ygbychV5OKAKt3cTyRR/bLhn4GFAIOfqKs6TqOoaBKLizuZPMlydrtmmyaf5m1QXSMnJY9RTJrG0VcJMWbPypnJI96ALmreKtR1Nz9sLPkbcqcAe2Kjt9bvobf92u1UJySMgj2rJuUdCwSB23cKTwKyL+8mtJUhmkKbRnaG+WgD2bwPrmmaq3k3zBbw4VWPau0ura0j8u01Ng8DnEJY459K+ctKvYw6eS4DpyhQ5yfeu+0nxX9rkt4dYk+UHCuBkqKANHxDoxs7i4SFQ8K4IbPGKwRaB4WmSNdiHn5cD867a7huLUefazQXFlIOAzbiqnvj1qtBBBqFibaIqJHYh3m+VcUAcLNHPcAbETYTgKv86tXVpbxW/l4wwG012dp4dnknYRW0ckcA2BgeG9xWfrmnTW0p3W5Rjj5m5xQBy09nuRUVEAGN3GWb/Cq1xp0TAxySJ5uOiLnA9K22BWbzF3MWG3k9T7Uy7XawVUVCw7dT+NAHJW9/qnh+ffZTqIAfmhcE7vwHSvRNP8AGlvJYRm4BimZeYwucfSuUvdPllhYhI4gvJdxzUOmW7XfnzKgWGKMr527vQByHxCvo5tbW+tCTj5WAXj8a878Q3U2pKI7WFILdfmJAxW3Cr35udKhDSXs0xVWJ7k12eo/CHU7Xw/573ouLhYywhReBjrQB45b20OxlYo7KOhOT9au23kWZE2xJD935uQKypcQXUispypIYAd6ltYnmAj8sbTyA5wTQB1vhjW3g1gwosUVvOdr8etdJfxT6VqQ8sFbSY5GBjcfWvPYhPC29VjhIb7zDn8K9Zt7A6zpdo9wxlnQDJ9KAOf8S6Yms6WWjf8AfRDKhVya42ztjqWnXOg3xk3MN9sXONko/oa+grfw3Bb2kNrEpjlfn7v3j7mvN/iJ4RutPvzOVnS5gYSYUYBH9aAPnq5gktriSCdCksbFWUjBBFRV3HxKto7qW31u1QhbkeXcYXAWUf4j+VcPQAUUUUAFFFFABRRRQAVf0KwfU9Ys7KIKXmkCgMcD3qhXX/DeJV1S6v5ciOzt2YFTghjwp/OgDs9PuYdW8YiN48JENiqRwAvHH5V9B3Phq81/wB4ZstMAJW7ZnYdFHqa+f/h5H9ov7m6kAO1ux7mvTdF1zV7OWey068mt7STl03ED8D2oA6r4m6lBZLa6RYSOItNjESMDkPIev41w2lfD59Qc3eqSNFuyf3fKv7kdjXU6bpr3xSW5VZljOV3Hkt7+tdRCpB2BGXjDL3H0oA4U+ArTT7gXGmzXEM2QzAnKN/hVTXLFUuGL27RkD5yBnA9a9JWZo0KKokRhhkbr+FU5Le3vFKwu8MnTbJyD9DQB5ZHK0sphPlsi8qwHDD396RFIRwsiCNucE5x9K6rXfCzxxNNEQrryjRnv7iuWntp45ZIZEXBwQyDvQAyPcVPmKjAcEN0IpscTLOAJBtfgxt0pzxXCnDEnaPvbMZ+tHzs4eRdxZercAH69qAIY4o1aRlBXzG+6/TNOS2VY2jeMDLk4ByuPx6U4ZeJkZYo3VfkJfBP+NQs8kfMi4J7E8HPoaAHiJVPlbPMhIyUcdPcGtDTJobe6jN1+8iGQMN0H9apxiYoHhWN4vukEEkeozSyAwxo0RPlIcMGHOT/MUAdzpUMsVtLHYSfaEkbzCgwdw9veu7+HVtrmnm6/txraLTjzZYfdIxPLbvevM9AmTyBNYl0uYiG2YwGHcV6FpGtTXLxx3lqrqFLtKSMoewoA8k8eW0lz4qm1GxkVnQsfJboz5556jNZl9rC6FbteyxJaW8oHm24bcFf1zWx48gittbufsEk0b3GZFPGFHtVCztItUeGC9UvHHhvmH+sPpjvQBLYQi4mF7bpGxIV0ByD8wq3rBl8h4BbTKysshniOGBB5HvVTVLr/AEt4p4J4Ay7FVEwAB0NSpdXB0G4vVYiO2UuvPzlR14PWgBviq5s9ZsjakhiYxK0x4ZD059Ca9b+EGjGw0eBoGaQhAcsBz61xHhm5s9Q8KiSztRKNWQLKskYLOAew6ivcPDWnrpWjW8MCsCiDchOcfSgDQMod2IBDoecDtTHCtksEeNm5G3p6095dmH27Vzyy84+orE8Q+ItP0S28y4dZixJARuRQAzxPro0XS3nXa8hBEKrxkY7ivKJpY9SeSe7VzIw5JGNp60zUNYfWNRe9kkxbEcF+VA9q5vWtclumFvaPFHCPuvk89sfSgDRe9s7TcsIjVwfmCdHPfNQPcxT4WKAnd8+AMFPx9Ky7fS3Nu015kEtyAvvVpLjY7xRtuRuAWHzZ9PpQBp+ajeXHcK5kPG5OCRSySERhSnmWxbaHjUblqrDKrRhZWwnRlJII+laVrCLVDHEC0eMjDbiM+tAFdVgkmRYnLc4/ecBqu3P2eFSGKhgB80a5/WoLlxBcBpAi8ABCucmrNs8HmbJF4zyjcYoApm6lmVzK0RgU4+UHePpV23tIXt9sEqnIzvkGCPYkVFdPBFDKyJ5pJwcDAUVGXuYI44xKsayfMqhecetAE1tCFYyXMQKj5eOjD2qjq3h1Lu2eSQmPf8ysBuIFbNnbyM6Sm481wOQMfypTMrTyJJN5ahOS7YA9sUAeYalDdaXMk0OSiEAbR1rs/D8mlahp80UzfZ9X4KmU/LjrTbiUvqPlvNA8ZACFV7e56VynifSvJl+0RuX+bL7QVOO2DQB3Ftf6npczIZVKAcAHduH9BXR6VqjTIss0oLDgkg4H0rjvAOvWTWkun6jvkeZcROANw46ZqaFprLU/KUuYCeC/INAHt3hK8kuYwgcGNRz8vX3rb1Kwg1GDyphx2YdRXneg69/ZNrJuxJuGQY+34U/TvFlxEsqRrPKJCWMjjG36CgDfuvCYjCm2mA/vFwK5Ke1hRJhcuizREhgD+RrZufFU91pctuin7UGAMg6AZ/nXOahbG5b92VM7D5xnqfXFAFCEWV4xguJJZNw+8G7egFZVvClrJLa5dbNXLMFHUVsRWUULgSyKXX5iB1J96yFlms9R3SW8slu5Jx2NAGP/AGfpVv4kS/Nltl3gx+W/OfUiu58QeMbTSPD15IghMzxlQJZfmYkYAAridaiGpSXq6YkcUwXcMPk59PavNNYjnhMsNzBNLKi84BYKfXNAHKTJJ9rnnlMfmEliB90Z9KerMuTGyDcoG7GTUslxa7SPLDyMMFN2PwNViRJEqlDGgOMIvNAGhaXYSP7OsCyup3M8h5Fd94E1yZriS1mKBVKuBGM5H1ryx1iUhh5xUnkAcmtHRLySz1WCeB3RA3zBjzigD7mhsLa+0+3vof3aPArKCPu8ZzXH/GGwh1Pwsk3mItxDD5m/OC69CPeqnwr8WK2hva3ZEtrtLId3zY7rWF4q8UWuu6vcR2Ns66fZ232dTJkbzn0oA+eIbVtQ0rWdHA3qsZuIsjJDr/WvLSMdeDXrsivZeLYmEZSLzMMA3Y15v4qsf7N8RX9qFZUjlO3d12nkfpQBk0UUUAFFFFABRRRQAV6D4dB0/wAB3E6pukvp9o3DHyr7/jXn4GTgcmvUNWha1s9I0yDDiOFMjBBLnk59+aAOx+HlmY9JVpLPypZDnceQa7Wzt90hjcJEzcAouQaytDtBBp8Ub74iEGDt4z3FdHoUE63Gcq8ankk5FAHQWlu0MCiN9rpg7cYzU5llEih2YAk/MRyP8RUQjVw27apPCtnNCQ5Tcr7JFOBg5B96ALFtc4V/MkUuOUK8Z9hS+ZFK8rAbACCQyYArMmniZPJnjcSA5DrjFWYJkViZS5+XqGyCPQigBt7mazdDAJM8gxvzXOavpMLEsBIGCgjB7+hrq5IgypsyrcvHtGBn61HIn2qMK9uyzN94HjBoA8wnSS2JylxFKOdwJZT7YpiolztcSyIecxkd66nXLCa2l8udCIJcbXGW2fX2rmb2G6s32Sx74A3DxncHH8xQA0xy26ImN+5hhWXr/hT5UlMb+YNyg7Sm4DHpzVdmiWNvKuZsE8IzYKn057U+J4pUbfJtBPUc8+4oAaokR5BG8rMTlkUfNtx69DSNPFGqKXdoyeY24fn+tTIZF2MNxkXlZE4H0NKytcnzQQcHJYnr/hQBJp95cWShra4yp5Bccgf1rqtO1jzYI2mhA38M6sOfwrjzEwkkhikbn5kR2BAPtV/Tnt0uRDO4EZILAjaw9eaANfxLoi3tm11Zzb7yJSYty5QjuprE+EU19qOs3VxJp0sNlZxsxWVMAyD+Fc11t29rYKDaTymDOHUPkEetZem+KPEU/ip9J07QfP0MKDJeK4GwH+L3+nWgA8X6zrI1Gxl0fQPOsbkmO6kfDGEfT9c1n/Z/7QuLbTblprfT8lppwhO0+memDXYeIL/+wdNjuYyZzcTCJo1Hzc98elVLeJ9R1NIfOeWzbnywowD6EUAdF4M0MT6tbXNsiwW9r8kKr2H94eleuKCRzjeOhHes3w3psWn6fGI42jOPmDDHNabbxz8o/rQBz/i7WG0mxjZH2ztk7V9P8a8R8QXcl/NJcSz7JXPyh1wGP8q6z4i6mLrxELSRvLiiHzHGMH6153q+pK2oCKRg9sHChgMhffigDVlXbpP2dYhFMRkKpyGP8qiSyjt0SaSFWduny/Kp9xVi0hdGjM0by2pGQw5Kn6+lbmiaG8hM93MbqJvnSJhsTb/9agDmpI7y6SUXc3mqDlVjTHHtiqUtmTGro8aEHIYryfY+9epW1paTYaziSPAyecg/Q1S1bw7ZzowhDROmGZ8Hp70AeYma387yJZHDqclZDjA9qbFevZuSGLRN93APbsTV7xNaizkEbK0o/hZhgiufNy0K7GeQxtwVA/UUAXb3UHu5/MC5UcFN3zN9KSe6eR4mOyPC44bLr6VUZRInzjg/d5AZv8KVInhk2q4RQPmQDlT9aAN6wvo5p41vpPmUZSXOBn0YCukWeNin72MMgAYBeG+lcDHNLGAyFHVW5/vMfStq0uZ2iLMjhVPRj94+maANq71WCOUWsIlWRzkvtx+VSRwxzYliceWRhnc5JP0qjZyATHDIZH+UqxyVz3FWbtRZ2jNNPD8rYDL/AEFAEt/BC1sryRiNIztUquAT61lXTRlcPCl0Qv8ADztHvVF9UkZgZpxszkRsPve4qxHexTgJAwEh+6iJw/tQBy+qQETF7BYbeeNg22M5xXovhWa08R6VEZpFjurf5ZEbjcfrXn/iaGbTnadEaMycOqnFMsdbFhLHOisJiQGgPPH4UAeoXeqpYzr9ntfJCj7xOd34elPivJXjW4iTJc/N5dT2ZsfFOlRtbmWK9VSWU4AB9PcVhXzz6Tvt7hjFjGACcv8AT0FAHVx3UU0LlseYcZiHB+tRvcQkhYMWpUYE0rAbj3FVdMEU8AmjbFzxhG4H506+RGhb7TGshQ8SyIML9B3oAfEU5Kgs7HnfxkeoNYmuzTvAsVvA43HG7fx+FO1S5cW4QSxsMZyPT3rmbjV3huYHKho0cctnn6CgDbi8GX2m2DapLKEm2ksh4ULXG2er213rsWnQXAeeaQK0gxtwa9l13XLafwxKzvJNK8BCxxIOMjgGvl6QfYro3JuBBMjhlwvIINAHtni/4UaQdCub22yb+Nd7OiBRx1rwBIikrmRmiAJ+Yt2+lelar8T9R1LRhp+8L5g2ySquC1cjN/Zt55UaFxOikBWHDGgDLt7eQKJ0EksRPVF61FKwicKYXiZjnDfeP19K3IJhaFYZboKYvmCRkYJ7CsIrLe3r3D3RDuSzE+lAHU+AvET6dqkdo8Ukiuflw33TXpGp6qq3Sxm1jgEvLPuHzV4ZIyG43W3mHacsy9fzr07Q7y31HR7YEtJNEdrbl6enNAHJfEaXyNTS4iVUJIwEGcmuL+JcIe/sdQVXH2y3UuW/vLwf0xXo/wAQbZp9L86PYTGckDqBXDeIYjeeALaeWUvLZXGxVA6K/XP5CgDz+ilpKACiiigAooooA1fDFoL3xDp9uxwrzLk+w5/pXfYm1XxmTBcJJEsvyqwKlcVzPw1jxrst00Jljtrd3b2JGBXU+AbeCfX3ul8+B1yRgZANAHrFte7CsVySSPlBUZFdLo6xhGnYb1xglAf1qnL4K1nR7K31O92SW8xBYKc7QeQTWxpcCpAXjjxu7rwfyoAuLHFMvMqIzDK9s1FNFIsDESK+OPk+8DRNLCR+9i27ehC859aaZDGV43HrkDqPX60AJG6nLP5bq3GfL5H1FMVwjFcvGvbZhl/Wia683JMcsiD5gcBWHsamQpcwsIoArHk+o98UASwuYYNwJaNj1HGPqKfljbrM0jsM9jz+FSWMeRsni3PnAwcK34etRyGSGSQrE6r0CdQPpQBDdWgulIbeUkOdxOTXKatbXFu02+NZoI/utG22RR6+/wBK7CF84VXyv3mUDoabJYGTzFjRJfMGAD8rZ60AeaSRzR/8e8UNxGzZxLHytZ7SAxS7oJQm7oE3Feefwr0fV7F503m2eJVG0hEzg+9c1eWC2rxvE0gYA5A6H0+lAGAlwo2jzCUzgYXHPuO9Nliti7hZblWY4MaoRz6jNW3h3MX+zKrP3Qgbj64qvLKFUwyna2OCTxn69aAHLam4YGNiZU6hh82PpVmCOdUffEJQeqswziqZlgdYfMGydBkNk5H496l8jZdmQyPhRlW6de2e9AGtpu+0ZohIiRSdVdtxWt/T7i0t2jlnEsMsbfL5DYDt2z7VxzNneQs4lHIZSAPy71oW12LtEiu0MnGFdDsMZ9SO4oA0dV8UWFzqEvlmVRIMSLKNxDeoI4210vw7tHsdW+1XSvOkgHzKM5HbivPtN0SSPWBHPDHJ5jcPuxjng19IeFoE0vQoATGVC75Qp+4fb2oA6BQJFVhkDGRVfU2mSylNsAZMfkKyb3xLbqwS2ZXc9GLcVx+v+M9RitZYpIY4pEzvKc4HqKAOG8bXVrpt+32hpDJK3LY3AA+o7VzNpFG14ZHnAglHO1eD7ZHQ0uvavJqE7yNCl1bkD99FkuPXNGnahZWKFI/PnZ8Kyn7q+hoA6zw/DN9rjieRnt8ZClsEemR3rvXtt1uAiCVv9nC4FeSaLHqFxqm6Egsr4BGWGPTNd7b6wlsga4iaAgnKyAqCe+KANSG3gm3xMGS6U8Mvyg+2apatqMGnQ+ZqVyqtAuXO7p/jWZ4h8V6eukCYOqE5/dnrXmepaxc6t5iwSi4tZAFaHbyp9R3oA6LxLqltrsou7GXYyDbhhkP6HPauaXCtsP7ucZLK3f6HpVW3lktVYiJQQcESHnHt7VflMtzbJN9kjliUjaV7H15oAgWQKu6MxOJehCZYHuD6VGoBbD4zg7ST39KlcHdK0ToJSfmOD1qGGc+WA0hlIOCPL4agBYUZVXytvmo33MZP4nvV+HVJbfdCowP49y9PcVWjC3W2O4Pl4OVKnBWr89jmKPc1qyL8zFXyVA9fU0AasF39mRJZXtmXqxUc/Q1BrMsVzZxyRkR78sExkY9M00NEsaGMLHs+6wGcirQhQ2x3PndypxwB9O1AHNsIZVV5oY0bGFJJzn0Fanh62cXyMiJ5akFmJIqnc4E3mKiqMYOGDVJbalNbAwxyId/VHOfp+NAGt4801NUsTcFofNVSV2HH4GvGriae1K4Z4mY5VOp4969Shv3jk3NCXus4JIyo9qo+JPDiX6m7tGYXPUxg5OO+KAMbw342l0W5t5HjaWNjiTEm0n/61ep674i0bWdJgnt3Bl2jcEG8L+Pevnq+SKCYh/PDRZGHbIWrmkapdQSiS127PR+g+mKAPa9Kv7tB5NtLHJGo5JGNv1Hc1Zv7+5mmRcDaRgPKeFHeuM0DxPDsWJdkTsCTuHGfrVu41AXv7yaQEKflSM/qRQBp3twq5SZlYKCUBPDfjXF6zfzS3CBZUVV5ChhxWnqLRXyLE85HOCzgAAegFZNzosfzeTKZSnRSnGKANi08Rz2OjgfaEdD94E5JrktTZb2LzI4i0pJOCAA1Xp4IVjEByHxkrjAFV7l7cWsak7ijfJsHSgDBvLSSFAJV2nruB4+lVRAi7WR1BGcsxroJ7kNH5bhJAf4X9KqQxRlGbykQZ+VsZx9KAMuHeCT5VuhJx749aSVVDCVnDBeNsY4NbUOhahcW8k1vCs0agkv0GP6msu6SVoBIi+WOh8w8n6CgCP7PPPIVjiZd391ecV2ngqJYI/LEjuGPKtxyK420vJ7K482OXylZcEk5P4Vs6Fqc02s2o/eYzjCjPWgDstdtku9Ou43O0Mp+4vA+przfTx9q8Na/pvmRswiLoQOm3k/yr1ifG14ZBgEYavLNHPl+M57QiAQzB4ju5yCMUAeVmkqa7jMN1NGRgo7Lj0wahoAKKKKACiiigDtvALm10nXbrLAmJYkx3Oc12/wikZ9WhZxhWuEV45F3AjcPxrjvCiLH4E1WWcMEkuEVWXrwK7X4ZTTpIkyPHMIWEg3Jzwc4OKAPrfUbg6jreraBdW6mwjsEmQg4JYkj9MCvNrITRQRmASOgb5g/OPxr04XFg1hJ4nEmDPZCNsfXOOe+TivMrc3FuAUdnjbJ2ueATQBYad5MBY5rcj+GRcqfxquY2LfLuXB4liOVz9Ke0kx6zFGY7ggGcH2NRTiZUZpIpHQHlo1wxoAMu7MJJAzZ+8vUexFSopikcK7S8YXYcMtRRtBcHfDMY51X/V3A2k/jSuZUIZjGzEc7Wxkex9aALvly3TsgmbBIcLJhWBx2PpSSeYqbXeUoi/fjbdtNVo1DpGZJlZcHnO5h7Gogq25Mm87yACc4BH0oAtTr56gW5YyrzuV8FvrTUlmkkzcxSR4wrCRv1BpIFdrgSxRqZEU4K8DmmNMSFndlDK2GT7340ANa4uI57gO8jL1VSD932PelW4hmTOXPqhTFCXLyqTK6tu+WN8ZA/wADT5XmK7Cyy9wqD5qAMu60iylRGRBHKRuDZwBWLqeiXCzMbaCKcBclAPve4NdjDHAZFMrbGAwQx3fmKUW/kSkzl1VgcMgyCO3HpQB5cYEMO7LRTRth4mHzKPStOysriWEKBLKjH7h6H6V2Go2dnqJ8yP7Ksg+UliVZv/r1HY2UmmQKrl5oSx5bqvt9KAOJ3OoMbQGJwckSjp9KLe3e6GC8gl6OV447V1F5pclxqfmXAAsmGcwtkn2rPu9LFs2/T2mSORsBX5Kn1zQA2WTzLYiMPKIRgShSrZ9Kv6drCz2klpcXPk7B8nmM2WPpkVFcSiytI4p+L13CyP0Ur/jXC+I51t7uf7JKZos4YAbcUAehW180qAYLiJSXYn5R7881yHinXt1yI7eZbqUH91J5nDj+4SO/1rmZrue6gt/NklSYDaignbj3Fbek+FLu8xNKkcEYIIlIHzD6etAEGhx3mq3BX54dwJZM447119rpMTQQKmEZT88sWSXpkPh+KC6R4ZpSoH3gMgNWnp6XYZgkbSRg4YH60Aa+kSjSFDRMFbrtC5GfU1jeNdauWtS09v8AaOc+YB909q6SSO6FueruABl+CAelc14h0PV7i1UW86BT8xgJ4U/zoA4EahEXzcsRK/3UfnP0ra8J6bBe3Lzs3lyA4ibGDn/CubvdOc3qpK2CASzsQfLYdlHpXdeBn+xwFrsCRcksEPI9CKAGa3YSQkG7mESsDgy42k+ma5S31WW0vGtyFER4KSN0/wB31rtfHqvfW0cUO6UL84R8cfhXnFzJ5ayCePe8fChxvZW9Vx0xQB1TSRpI0jRgIw+X5Ttz6Y9an8sPFukVlgK8+WvzL9fasLTdZuY/L8+bzCVH72TAJ/A1uRXG+dZoLkFdvMacqT34oARCIwqbVkVh8pCZI/GnhDHcEuoIUZ+fGasZO1o2SQAjBAGOT0xTtjC3OQzlOCxwNp9PxoAjjljODaMVySc7shh6H0q0DdCB2BVs87e4/wDrVFGQQ8rhYQMKTsxhqLLXrFZY7d5luGmk8oLbqZIw2C2CwGFbCk4J6Ck2luBlSNMGy6mJ8E+WUxuHtVVJbXZgpJAck5fHX6V0l/pwu7g/ZoJHTOVnkbCqf7vFRNptxI2yUDfkKwZMZHsaYGJseNlwrAH7pzkc12FnAbe0Rp4wSWHMRz+dUbXRTAFu7h5dpOFi25JHv6CtGWcqfLtoeg4QNg0AZXiHRLK/h+WCAOAT86cP7V5VqGnm1d/KxGgbpuA2fQV7RbTSnzHliYx4wOQdp+lcd470OBke7hCRSMAcZ5P4UAcDbQta3KSsImDNt3Byce9dMs6QN5UUiqpOCX6N9K57S9NmcyMEjCDkykHr9Ktajqk1tHHbW5iI/iYpyaAOhikIcs0sf7vkK46fSon1KNS/kXChi2GJHeuQSe5YyMZPlfkgtk49qE8pSxlYkE8qTzQBuahOfM3qBKf4mz1rNna0ZPMjuWD9TGvQUyO5sljYrcbMDGxxyaikWJDJIzJGBjaV6mgCRJ0t5VjlyUcb1ZucA13Hg3QG8UOiQfuo1baXxgAe1ebw20l9qVvGDOzSOApJ4A+lfSujXNj4X0KJnzFtAySoy1AHV6boGn6b4fa0G2RYojvOB6V8kayYJ/EF4lvH+5WQ7SCeOe1ew/EvxjearZx2WjyKsE3+t8skMR6GvMG0XU5ImMNgUXPLg9aAMVowq5k3YH4k1c0eZ/7QtjErJucA/SovKksp/wDSLSZm9GPFX7C8F1qVtFGo+ZgSpGPyoA70PIt20YCyAcHfmvPNTHkeNYpZCsTbxyqjAGa971fwW9p4NTxDAz+Yih5IGTHy/wB6vB/GjTDXraVYgobDAj+KgDz3xrD5HivVEyCPPZgR3B5rDrqfiSoHiqYjPzxRuc+pUVy1ABRRRQAUUUUAd94fRG8BSEPtYXJ3ZXIIxXc+BLKyt7R5QJcMvLRt/LFcT4NmY+C9QRVDMlyuAfQivQPBE5XSZX8rGBj5aAO70WbUpbFbU3ss1qkm8Ju4X6iutgIWKPfG0g77Tg1w+jsVjSWKcRNIRkMNtd3EI/3byboXPy5bOD75oAiuPsrgxkT5PRs8A/WmJ9qj2bW3xDvuyTVxoW8tlhG4E/MSwPFVJbCVWKptbgH5jjB/CgCIRrM5S5iRwoJBPUU1lt3t8OWQYz8y9T9amS38yXZL5ZI4faSGxUc1sqt+7n3K2V2zEDHvQARrarErwSsdw5yMCpYpXTeUNuyY438CovskaozsYjIo6LyDTBJGjLGYUaJjnJGSp/woAcqgSNKqNG+OSjED8qFRAshtj5jOMsG4wac6kspbhWOC6NkLj27UAJvkEsbsvqP50ARheoaIIMEsoGA3vU8VjL55a0T92Rn73I4pgt3ISOS5DrkjZJ1x/skVcs5XtEJiMVxIn8J4+tAFWVGaZy1m25l+dVGNw71ErNFABb+b9lBwI5Bkp7fStKfVknhMPlrBJ1VW4Bz2BrLMs9vKwWefcRwoUH8PegBZ54p5/LDoflwSuAyn2poTbL+5Mo3Dau85H5UiGQsCtuxIPLbQDS+aW3LeWkqtnhhw35UARldzFPK3Sg8kMRj3xUF9bvOrxo8kU3BUhsLirkjN9meNrkSdklGQVHofWq6wpGdxiLEcBgeg9/UUAcB4lvNXsLvbeTKbUcxyKuR9Ca5/zYpXS5aSOQMfnRGG5ffFd74xls4NO3zQSomRui4dT7ivN9T1C3sJ4ZtOiVWYjkKMsPQ+hoA77wVpS3CG5vZXnthJwyL86j6V2hUz7BGFG04QMDl1/wBodqm8H20kegwubW4jeRA4l2YJ78j/AArbm06OaKSZw0V19444LY70AYsK3McskUkSsGHyrCRhfwPNWbKFmu4JBEBJGwAZjtBPoazZYZribczx21xG3Du4w4PrWglpckhrm9SNUfBKHdkev0oA31vba7meMyeTIpO8L1HvjvWD4luNP061lcysZV4xnDkeue49axfFviB7ZkitPKmuTlPPjAGQPU+lcHb2eoalMJ9RljMKsSpiYkH6+lAGFqGql7+QW0YlL5wMZXHqPT6VZ0K6udIulfVLWaBZZAsTOhZJSegXHU+3WvR/Cej2ryB0tjJEW3SAfL+XtXr/AIm1TStM8KktbWtyXCxwWDRhzPKfuxqnc9/QAEkgAmpnJRi5N2sB43p/h/xL4hjjAsUsrfP/AB9agpQ7e22L75+jbPrXO/E3wfpPhyLS7V7m4vtYu5TO8rt5ccUUfXai8cuUHz7jgNg16P4c8R3VhrEemXwlu/PuSl1NG5a102VgNlqjtlpGzt3c4BboAcDzPxtOfE+uanrcMqvGHNtagHIEEZIDH2Zt7g+jCvisvxWaY/M0q0rUYrmXKmlJXtHfXV62ejS2szplGEYabnLb7eW9Eqz7pE4aJl4HuO1bNjJJbJmK3LJu5AGQv41zunie6nWKVlkmPDqBlMe9btuf7JlMEsUvmTjBZcmNh6AGvtzmNk6pJM6opZQBzGxwPz7VFdtcS3UEDmO3t2bEk5UyFfdUBXeP+BDHoelUnjwVTaIlbkhsHPsWqS3tLafTjq+uXVxD4YXMcMUb/vtRkH/LK3HUJwdz+mcEDLDlxmJhh6TlNtX0VtW29kl1f9PQqKbZ6v4U8F+F9UsYtQe7l8RJkoHum/dAg4KmEALweMMCRXMeL79b/wAYmGyiEWlaNGbOHygAgmODLgDsMInsVf1rE0L4iahpt3d3bQLHbPa/ZbDTLfm2tWx+5UYx/FwzY5z2AApmmwWkFosUlz5sp+eSVT80kh5JYepOSTXy2TZPjIZhLFY+Tlyr3bu9ubfyulo7K2uhtUqR5OWJtPNcxA/ZkwJDnIx/Kp7e4ht2VZpP37c8ZJ9+vSsy1mcy7ZlcDGS4HGPaqupef1iV4oieWIy4HqPUV9mc5uX+sIpVYrqJT0ZmJBx6VSbUII1QLGBuPJJ3A+4PpXOsrcqVQIfuknk/nTP+PcpHEMeYdu0MCM0AdfZyW8l1h5kaZ+EPTH19ak1jT7o2ySSQwyRAkHkEtXLRBoGBkhB7AtlTn2rsNNKNpy3FxMjuByjDpQB5r4xN3Yg+Tazx2j8CRB8h9qy9B8L6t4hkUaZt29zIegr1PXbFdT0xdi5hY7twOdpHbFdz8LfD+n22iqbeKFrpkJ3ElWzQB4V/wrzU7HUEtZnWVpCACuSAf8Kr+I/DjaJfm1vWjkXG4FOSa+hvHkFxY2tvdghJYjn92OvsfWvEPGWoyanqTLdYyo4xFjH0xQB59I8azumnW+UT7zsMn8AajhtvtN0qxXGC3BLjAFXbmK3ScrN5sahvlEiFB+dU7nbHcNG8qna2UIHAH9aAPQfBfh6K9t51+2QQXkI3iYsBgD0zVfWdZl1byrNi9zMrbFKE4IHfiuQtXDSBbRpWLcFlbgn0xXqfw08IlC17fmYEZKeXgYFAGh4b8LsFSbUUKyR4whYENXX2/kwFFjt40IGSWHWrSwbEVklBjHZl5oVCQcuH5PJ7fhQBxvxD8Pwalo89/JaYmiG/MfBxXjfh/wAyPxHBscKN+BuxmvpS4VPIkR/MYMhBK4xXzvYWyR+JZEntnUpcHbMemM0AfXN08lxcDQldil3o7bdy/KG+7k+/NfGnxCtJY722D+YjRHy2IPynBxxX2rA0P2Kx8QvNmG3sG3AfxAgH8+K+N/iTKs94Dbq6xuxbnqMnOaAOJ+JkPl6tZsRjfaIc5zntXHV2nxMVVn0cDr9iXPv8xri6ACiiigAooooA7vwW2PCWrjDjM8fzKM44Nei+A1I0+SNJ1bBzwcH8RXnPw/n/AOJNrcAkCkBJQCODziu18DX9kzTQP/rBzxkE/j3oA9Fkjf7OgkjiZdwynU12VtKWt1AlKqFGUkBwR9a4yBtyKwMvGMN6D1rs7YFLdFB38ZIxndQAKVGJBFIu3OTG2f0phvmX5SGUMOAy4NTzzqXXaBG2MAsuKjlKNOTKvnY5JI4/OgAW9m8pUeNTkYMoHIqApLKwOyBznaGkORmnrHHuBXciMNoAIxUGwoZA5O08NuxtP+FACyLJBM/mJ5cwziEDAI9jViUAJ5ksDohXOYiNy1EXRI8TxyGIDjndn0wakRUVcmXnIIZhkj2IoAglNpMQYp2aNRnZKmS59eKFMixkNAzCQYDE4wPpVxoGMKSZtWXJ5U7WIpkimMoDKoXbnD57+9AFO3lUmNBC4kUkg4qdpoQTJMsyo/DY5XP17VL9pkWVoRtOBhCi4Bz61B9pRpNksKBCAeuASPagCyIN8aRrMHgJztI3YHtUKJNASEYFc5POCPpmmkNI5Mcxifsm3+ZFMdFUADc27O0jlcj60AWNzwOhBExIxy/A+tLcTyO7iR/vAEfMCh+g6iq8bNE7CONMbOUJypP9KYU8xPmkRWByEUcEen1oAVWdC5SFHTGQQMqaSRoo4/3yYwM7Wfof8KR0lEMixbyo+7nC7R7VxPjPxHBpcEkEShLl1wGPzhj3460AZPxE8RRSqLWOB7iLkbEwNh9R/eFcVZxR3iStFPFFOgBNvIOXArPu7yW7nzIYwSdxCg4/PtTLeRkCm1BS459y/wBDQB9Z+Er6XUPDenTQxSqQgTaeRwPrW9b2UUzkyRgFvkLCXBU9iK8C+HHj1PD0AttQt3a2Y7z8x3A/T0r3WwvrHVrOLUrOVmszjlsAJ+PWgCK50wRQ486JgSQwlwS3tmuT8RatDpciWS3ADOMorDOT6EipfGvxG0fRbK6tbKRbu+AK7HHQ9iDXz9cardalrC6rM8iMxDbWmJYN0wB2FAHpN9M91ftAogEcinzZCPu/QVteE9FSaUFZGe0XiMn7rc4w1cb4da8uGudQ1Fo5kbgDcAV9MDvXp+iPd2nhee5EErhEadbaFcSSYHRQeMnsKAL2qapFpNgsNxA4nMnkwQWigvcyH7sajue+egAJOACa55/7Uv8AUZ4LWdf7ZRPJvdQjbdFpaEDNtbk8NORjc/bjphVFXSZLrWZUnsr+OXU7iIJc6nE2U06FgCba2z1mPG+Qjg9eiqOz0exs9O09LbTLYGCAFBErfdzySf7xJySepNePySzOV6itRWye833f93svtbvTR6X5NtzPTTIf7APhyIywWSJxHko656srf3snO7rnnrXL3+irpEiWsMSxWO0KhdcggDAWvRWlkuYokmLKyDKk8qB6MfSsDxbbrNZZlIbyiGwmDGV/2fevXsZnlBs00fWLmRYD5b8MpOAnuDVK4eK4lkkNwYSnUM5+UAZznpit3xbGJtElNmRLGRghgVcH/CuSNjc2ljYXX2T7Q8DpN9nu03QyhedrjuppTbUW4q7A34VtrLQoNY8VxFNMcj7FpsJ2zaseuWz92HoST94exAfLuNYs/EmqC+8QXnmTohSKG3BSK1j7RRr/AHRxk9TjnsBh+IJ73Wr+TWtZu2u76TCuoGFVR0SMfwqM9PxOSSaoWjXEUwxa8A7g7AKa4MLg58/1nEu9T8IrtH9Xu/JWSuUtLLY6waXqZtjdacmy0zyE6Be2M881f0NxIhM3m2wBwTtHzfjWhoGqWTW0Iu7oCZh9zbjYf7p7N+FWNRkuI5XntVjjtjwQyZ5+navRIL+lz29xJ+6UQzL8oW4IXzB6j1qlqF25Lwsg8ssRjd8y/TFXdJEMyp50cU7OOGDZK+4/wrGuolSaTCzbt5ywOKAIlAmhmOxnjjI5cZKH+lOTKDLRROOoOcFvxNQ3SGQK1yXQr0YHGf8AeA61LDGCwlNvHcR+uTx+FAGnYxNPOu2F3tx94u+4rWnelZVSO3t9kCAEtg/N9a0tDEf2RPskMSBDuYA5GPQ/4VLrNr9qH+jsIlYfOkR6j+lAGeuqpFAY7eJUfpjsR7V6J4EdZNGcz5Kp0YDa2D7V5Hc2TWcg+Z3bIxITnHsK9h8DtOLCMzyW8mRtMg7D0NAGhr0rQaW8/wBqJt0TkONwx/jXmeiajot1qEs8phZkYgjZkmvRPHRMfhm+2CONZEKox6bvWvBNCskhl82a5Ftdb+CowH/GgD0jxfo+ia9pEjlbYSL80bEdxXzzrSeTcMscSiFOpZecetep65rpt5lSBkDRL85Yg5PrXnch1HW9T8gxCTzGyT0IH16UAXfAlhBquox+Wh/dDdlBjd/jXutmlvHGIjKVQYByuBWN4T0iHSdOhUJEsgXGWPSuhmLj7/zKOmcYH0oAeQu4j945z8vOB+VEcS7g0qtGo4BxzU0bRqA4ZpG6ckcVNJNHEFBblup9D/SgCo0aYIVGz0znr9a+ePE9o9t4lvCHwVmJO2TPfpX0ak2FKyOHAPY5Jr55+IUOfFd/5EUiuz7squB/9egD0/TPEd4fDB0i0u91rLhhnkgd1+ma8f8AiQXF9DtKM4P3cYBrsNJimjs7EyTKyBOVjTn8a5H4iuy30SxsRExGeeRQBx3xTdmu9I3xeUwslyoPua4eu0+KE6SatYxxtIxitEVi4xzya4ugAooooAKKKKAO0+GstuJtVguVVvNtvlBHocnFdR4eEEl7G1vtAIP3B6etcR8PLsWniyy3eXsm3QMZOgDDGa7jRwlprzphCUkKkA/rigD1DTVS909JCpJxtyCT+ddhpbFbaIghGC/wnkVweiu1vPIhlYEnpnHHtXa6IbdtyTyPuI+73oA0WXMZL3DY9e+ah3JnlnZwMAr/ABVcJjZsIYwMYKyj9agdpCUWKKBoR1wefwoAgOJPlmJyeSdpx7VHFANjpDKrkN8ys3FWj5chVZT5YHUg8596rzqMoLdVYE8sgILUATh54ZQI12hVwFYZB+lNcK4jZ0aL5s9s+9ERkjZHmlKfNkKRmpbsTpAJRjIyVLdPy70AUQIzPtQ+YzDALZX9KcxWNmikkfdjj5cml+0GcBJIQzA7zIqYapW+1LIjCMmHrubDfkaAJIoHm8tPtBXOSrngj2PtVzU9Pght4vMaGU9CY+tUEk6uEZQDwGNIg5eN41WdjwykjeD2FACosuOXIRfuCRxmoEkCykmF9/QYOVNP8oWsym4juGJ5243fUVIbiHewWFZIz91VP3fegCOFM7Q3kAfeVSCDTWy05kXZu5HoMU5IYpFDwuZQe8hwwOa5zxRrkOm2exrmOOXJUxlCSffI4oAz/HHiddMgjijSJLtTtcs+eOxAryqfXln1U3N9byXE3JDcYPuvpT9abzppWkVbhg28JFyfzNZhRWUhSGYDeFfjZ7ZoAdfStcT+faDdGx+4qAY9zVb9+zHccEDdnGFI9qfKAyDy5miONzjGAT6g9/pQxHlx5m3vH0yuNwPqBQBYtru4t/LxJtbGcE/IffNd34d+Isllo0mkX9sz2kilXEL9c9wad4H+Efi/xboMGu6VdaGmm3TSpHDc3EquNkjRkkCJh1QnqeMV0Fx+z940mjx5vhpJOzrezjA9P+PegDy7WrvT7u6c2rTeUwxHuOGBHVSfWnabp8l7bzXNtJ5yqBgHGQfQHua9GH7O3jhRhbnwwo74u5+f/IFbGjfA/wAcadbpbs/hmW1375Ilvp0Dnt/y7nFAGT4Ys30/QFM8480fN++T5Rn6V2/g/VJltQnmM9qy7o/+Wig9/cU+9+GvjS4tXhjs/DMW7+IapOcD0/49qoaL8KPHujzpJZv4eA53g6nP849P+PagDtSimNZIoiS38EeOQTkt9c06XyTPGPOMkwT5ip2FR/dPvVa28M+OoTj+z/DflkYZV1idSR9fsvFX7bQPFEECxf2BoL4OWZvEE2W+v+hUAUrgTW9x5ceyWIjdgAkn2PrXO+KdSjhiW3CB7YgswkX7h9R6V1Gs6H46u42j0/S/DFipHB/te4dlPqD9lFcHrPwl+IeqqVuLnw6FJ6DUbjn6/wCj0AZ+p2cNzZOjSec/l5J7AdsEVys2o/aLWz+2RPHPbNtDI5wyj0Fel6R8NfH2n2Edqy+Gplj+4TqM4x/5LGs7Ufg/42vLmWQJ4aSOTqn9oznB9Qfs3FAHm18La+vc2sLJETw7DaVP+73FZerx29mrLLl1PV2f+Qr0hfgb8QFZSL3w7wec305yPT/UcVx/jjw5qfhzXTo3iP8As77QLWO9RrSZpAVZ3QDLomGzGe3cUAUfDdlBqd/biFbp7EHdIA2D9c+n0r1K4t7YaQzQySER5G05BI9q4/wfpXlzxre/aA8q77eZG+Ur6HHFd4IopIikkuZwOBnG4e+KAOU0qweDZcQTNGGOQzjKt+A70/Vlbzh8hAI4+bhj3Bq3FdG3jkW4eTO/aCqhcf8A1qkufs10uy7kmXHPmRgEfjQBgyMjkLcxSxkjAIIKD61PpVq6XIntFjkRTjYzZI9a0GsLGzbzZHnnjJG1mPGPp6VpafCJU3rHhTyrxLgr9R3oASOTzLoJHbyxM3OEGE/Suks9I1C4gS5CCIj7pCjOfxrFhtw7sonVwvQo3LH09jXofgvUQli0LoJ/K4U7s4PoRQBzN3pc9mPM1K3YJnJkZMhhWjF4y0G009Y7GMPdDgwxNzj3zXdarHHf6bcW80samRCAjj7px2xXh0+k33h+1uYrjSDdzM5EcvVSD0HHNAGP478a3utXRt4fNtraH7kOc7m9T7VxTQTy3CS3Eiq2c53kH6Ve+wa3a6gJr/TpbK2ckqRGZEx7N2rOvoXilMvOx2KiSQ4U0ARahfoMwRIt2rHlZD84/Gu4+GPhp3X+0JJbi3AOUhDgo31rnvDejJcxef5qSSs2I3iYFcZ717Fpuniz0+OOOESsqglQOp9QaALLiKMIxZDj7w4IzSQtIzExRBgOMBcfpTm8ycpmBYQCCMjJBqcW5ZG37yCc8EDP40ANjYoAFIDEZby16VMZ1ZFZbnfg5ZSoyRUaxNFETMFxnhgSAB6HFOUnbmNY49n3nC5yPp3oAesqsTs8raeR5gAavBfiPJcSeOJ4maJxuUbcYr31FlkcMPIkUfxBcYrwvxQn2zxxPKpQBbjYcnPSgDogDBbxxZHCj7jdT6V554+8ttXtvNjJzgZQ5IPvXo1wUVSrRFgeN0Y/WvMvE4e48WW0cUK7cgFjnPXuKAOL+KTlvFbqXZwkESjcOfuCuQrf8d3D3HizUTKwYxymIHGOF4H8qwKACiiigAooooAkgkMM8cqgEowYA+xr07WJbdpbLVUiMcV3EJC0eOG7/rXltd94Ini1PQb3R5EX7ZEDPbMTgkfxL/WgD1Pw9qKax/Z8FooN9KREFkGATXpd5pmoaBNFb6lbiNpRhZEwV/A1458LNbh07X9OM0ZaWCZWycNg5wcmvsDXbKPW9PmsXYATx77eXGdp9f8APagDzCJDJGWG3ceB5gzkVG4aI7okMJA4IG5T71Aba7trp7a68hZbf5GIOMH1oLSRRkNch8+3GfrQBJ5jsqiVEIJyXKYIqKSV13N5jrH0HHAp0ckskaOOSMjA70kguJAqAhHPqufzoAjGY3WSHczYwzM3Az7VLEXRY0aVnC/NyORT7YMxb90jk8Oc01onZiqyoCrD5G6fnQAsk7S4MaHcTt3oO3bNNijkaRiJSgI+7EdwJ9MdqXzCGBOBPnkL0xVV3tvtWUfax+Y7QetAFmdpNvzvGABgGRCMGmSPKCS0yTHgja3C02ZpXmQsCzAfcUg5/CpwjSRyMv2dVHzFSAGPtmgCFZP3DSxN5iMScMSR7/Snws6oHiS0jhYBh1DL7Gm/adkLNBJtlxnyyv3PwqrfXQlt5VBcBF3DPAJ9qAIfEGq2trYTfaLhQ2MoAuRu+vavGdW1HUNSluPIAePvHnOK1taE99es1yrLaOcbWPX8ulS2mqRaDYrHbQQXPz8rKmM/jQBzGm2Elxd2/mzLHApy2Gw646jFL4qmgW78nTGia3UE72cZ9+PWrsl7JdXUs1vALVD8xDDIHuDVO+tYZJFzD57dTLGgxz1OaAOaR4GZ40kkjYcANJhSfXmrJIdSs6FgRtLKOn41tyaLbrbb4JVkyMgSqCR7VmTSJbHZCWErcCFlIVj7UAfX/wCzaAvwa0MA5AlvAP8AwLmroPHfim78O3GgWmnabBf3esXv2KNZ7o26Rny2fcWEbn+DHA71z/7N7Fvg3obMoRjLeEr6H7XNxV/4oeGLzxLqfg4W8M72llqn2i8kgujbvFF5Mi7g6sr9SB8pzz6ZoAXTPiRZpJqtp4ltX0vVNOvUsHtrcve+fI8fmJ5PlpvkymTjYCMcgVrP468PrpkF8bu42TztbRQiynNw8q8sggCebkAZI28Cuc8VeBtMstHs7bRPDmo3ZW+N69xp2peTfRTFSDMJZnBkYglTufoe+BXLyeD/ABfc/wDCO6trkeq6o2m3N7F9ii1QWt+tnNs8stNE6I8q+X8w3gEMBk4oA9UbxboY/sz/AImCMdSuDaWwVGYtMFLGNgB8jAKchsYIwcHimXnjPQLJNZa71FIhpEkcN7ujceW7qrIo4+csGXAXOScdeK89ufCN9BZ6Lqeh+F7+2nsPEX9qXFhdaotzdXUbQmJpTJJKyiTG35DJjC9cmqNx4U8U32o65rr6C0M//CRWGs22nyXcJe5ihhWNl3Biiv1IBIG5epGCQDrtD+I1tfeKPFcN4y2Oh6LZ2tz595azWkqmTzN/mLKFOPkXHyjOe+RW/pHjbw/qq3xt75oGsYRcXKXtvLaPHEQSJCsyq2zAPzYxx1rzbXPCPiXxVf8Aji8bR30r+0INMNjFeXMTGZ7aZpGR/LZwueB1I+YHJwal8XeEPEXxBu9avZ9Lbw/v0F9Kt4bu4ikeeZ5UlJYxM4EYMYXk5O4nAoA7aL4l+FnVHa+uoY5PKKPcafcwq6yOI0dWeMBkLMo3j5eRk1p6x4v0LRru8ttT1BLeaztVvZwUciOJn2KSQMZZhgL949hWBfLf+L/DGqaJ4l8Nz6DYTacyy3U13A6xy44MYjdjtUjcGbb90fLXIeENJvvFPwr1LXte0Y6vqviP7PK1pDdfZ3MMOxYjHI2NpyrTLkjl+SKAOo8UfFbSdH0pbu0s9Su5VvraymtpbC5t5YvObAco8W7pkgY+YjAOTW1e+PtAslg+0yaiss0DXItxpd008cSsVMkkQjLxrkEZcAHtXnF74U8Z3/h/VIWTVbizttR0++0yx1i7t5b1hC4aZTKjFADgbQznockZrX8daVq+s6imr6X4a8T6drDae0EV3YaraQyKwdisVwhlKMgJ3AqXOGPAPFAHqllcw3tnBdWriS3njWWNx0ZWGQfyNfMH7ScmPi5Zwtb+ckmj22ecAET3OK+lfD6ajHoWnJrcsU2qrbxi7kiGEebaN5Uem7NfMv7TV1c2vxZtfsyoVfRrcOzdV/f3OCP1oA3PB9nDDpjKQsMKLveNnAWL1PPQU64t9S8R5g8MWivBkD+0FPlW5Hc7yCZP+2YYepFcf4avUSeC5u7OPXLyUrHZWMqF1lccgIuQqtxkuwbaBngA17jfeLdPtvDmtalHNDLJpKMlzDG+QsyqD5QYgZ5IXI78dQQPkuIs9xeXzjQw1K7ls279bbLXfRN6X7m9GlGavJnzN4ltb7TPEeo27agdQitpRAzqoiQOAN+3knAbK9eqk8V1HhK+uJbV4WdZMHAQnOPoe9cPJqdy0rrc26XLZLsx4aWRjln/ABYk/jW74W1BJLUoD5EkLFiWGAM19RQjONOMajvJJXfd9WYu19DrLTULS71gW7QSqsWEeOdSMH147VurpkraoJoZpYVJ+RFI8th6Z7H61z/gO0in1y4luLjzGc4Xcc7h7+1d9HBBBIwwn2MHa0anLfhWoitJHdRz5EaRNt53en4VZ8DxXcfiBpMMkbDB29H+tbNhaWDRfaLcthOqzYVq1NAiju74XEIm2DqoYZoA2lkgfcoy7H7r4xj65p+0MkkNwQyD+MY3KfrXnPxN8SRaTrlo9nNcMY1PnW4IO/Pqv9araZ8S0kstz2aqT1L4JX2oA9JhgsxGYw0xQjBSXmM+wNcV478HaffWLtDYJG3O1SvH1rPtPifbFJFa32lW6rFwf6U2bxrJrCtDbkRoylWYrjcPSgDlPC+ibLsQxKsMEBG5gAHrvvJ2Ff3jybep8z/CqGh2S26PgB3c5Ky5AA9qvRM8bECGMI33lIyKALVvAs8ip523K8I7YH50pRLKf7PNKkhbkYByKjhtyDujlRyPuoBnA+lPleWQMGijk2rkMByP6igBUS1w3lxSZBwTmomIAxHMhUdQcqaBJIPLCK+VALb3GPyqXfK8e4FPLP8AdXmgCCYxGGaQ3UqlVJ68E47ivB9Pnt7jxTc7oAqrIzlySQTmvbvE8y2/hu+kkZ8iIhCB37V5D4PDRW0909sC8r4YT96AN2eVSrMrIgVc4LYzXm0DxX3jBZWlAWIM5dzgDHr7V0viyZo7ZhGscDP6N0+lcGbhbPwzq+otDFI0g+zI5Y5DNx/LNAHnup3DXWpXU7kFpJGYkdDk1VpaSgAooooAKKKKACruj6hLpepW97BgvC27aejDuD9apUooA9bu0tVnttW0p1gtbxQ+Ceh7ivpj4J+NYdR0eLRr+4CzwgfZ5Xb7w/u5Pf0r5N+G2oC9tbrw/dbCsgM1qWXOJB1H412XgzUbmw1CazuoRu/gIbBUjuKAPpz4l6QIZI9YtocyHEVxtwMjsx/lXHw7vs37vcVJ+VcZGad4R+IyanZX+heLWBZoz9mnIxvwOFPv05qnpckzwbCoA64Rs96ALjeaRueVFIB+RDyaijd0Xc5K56Yyc/WrO5siJFVBgsMr83503ZIu559jKo/1YON1ADVeKZ48j5weWHygH3qKcRyPgp8vqDw1STSwyopeJ4zjIZRg/T3ojiT7OItxLsCctwRQBFGfJJ2KBtHUtyB6VZgAuSPLkCOAfTJ+tUArbCsbRu65UszZOKdLNJFEuIIiygYfNAFoLH99tkrrzuIwV+h701pIpGzbPvT7z7uSfwpqXEwhIPlSuPmwQRgfTvT9/wC7IuoBCWwQYj94e9ADJpVdN6lCxU7sDkgVwXiLU4ZpvLs2aScckM3C+oFdN4kOEkaV1G1M8n5QPpXI+GtPW/1QJEFLs4OW+6B7etAFex0+71q7ysUm0KAy4xkCuk0v4eGW5Ec88iLjKsV3Ffwr0PR9Ka1OxmgZ4zhQTtBHtjvW6DKXRWhbcDguRxj60AcFF4HggUR3cpuVI27iozj6Vk6r4Qt7Bt0VmxhcZyhwPqBXqhS9hZ0iaMHtvHA/Ko5ylxZNFM8cuDtLxjLr7fSgD5d8YW1zFeFI5MWr/e80BTgdhiuWN3bwW8kEStI4PclgB6A123xntQvidkil+aNcBZG6ccGuCindSYwyo+MbmXdu9vp70AfU/wAAPG/hbS/hPo9nq3iTRLC9jluzJbXN/FHJHm6lYZVmBHBB+hr0P/hY/gf/AKHLw3/4NIP/AIqvhbyHmJaPar43BVHykelaGk25u57ZJLVY4nkCEIep9xQB9s/8LH8D/wDQ5eG//BpB/wDFUf8ACx/A/wD0OXhv/wAGkH/xVeRfD3RpLnUS1u8DLEojCE4P0r6AtEMdtCjKFZUAIHY4oA5z/hY/gf8A6HLw3/4NIP8A4qj/AIWP4H/6HLw3/wCDSD/4qullYrGxUgEDjd0NQ216ktqkr/Lk7cHjmgDA/wCFj+B/+hy8N/8Ag0g/+Ko/4WP4H/6HLw3/AODSD/4qtPULyMoJIYfO8s4L+ma557CS5uWupzKVIwUXhXHoRQBZufH/AICu7aW3uvFnhea3mQxyRSalbsrqRgqQWwQQcYNLb/EDwFbW8UFv4t8LxQRKEjjj1K3VUUDAAAbAAHaqqQwtA4e2KYADIq5DfXPT61Zsbz7y+QXkB5Zc4K+jUAS/8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVb1vdKLQTTuAPXGAKq68LS60eRrgh7fg5AzQBl/8LH8D/8AQ5eG/wDwaQf/ABVfPXx013Sdc+Iq3GhXdhranTLSBBZTrPuk865/drsJy3zLx7j1rq/FbaXZpciZxNbx5LYbg9gPXPoOprzsxQ+BC9+LdP8AhMr5PMtYJwH/ALJt2yPMfPWZh0Hbp0zu4sZi/q6UILmqS0iu/m+yXV/q0ioxv6Eer348DW8ljFPGPGV7EFu7heV0mFhnyI2HHmsMZYfXstcQdV1BNLuNHgmMdlcLH50Gcb/LYshDf73NP1ZUt1LMLyZJiXlYjzCSTkuW6kknJJrNX9252ssnGFV89Papw2AjTi3V96cmnJvq1qrdkvsrp63YOV9ie3jKzweYzyd3TpyPQ103h3ULdLqaGQJ5cp2gSD7vtmsG0kULDmISFW5mHJx6Yq9Y2y3V15iM7AOcCY7SK7yS3rNxqGj3LT2cJurRh8zQN9z6jrWzpHiPUBZoIH8udugPLEevNYuvWFzDcrPp5ePcAssRXcsv0NVEJgvY2ZZI3wNhk6D2BoA96+H1rd3cKX17di4m3Ze3lXjFdpr3jPRtCsZDFCq3u07YoMA59xXjnhnUdY1SNYWXyFAIWWJDhxXT6V4bht5DdTlZ7jJyXHK++KAOIfSNc8WXsuoO2JnfcfMbawX0FQat4W1iEqkiXBTG3agHze9etrsKBLhRG+eJ4xgAe4q55dxbQqyXMVxAMHemHyPr2oA4dfD8mi+H4bfTwLiZ2Vn8xfvZ7U+DRLhrc+aSkRODGw5z/s4rs5JkDsPKH0zx/wDWqSV7cxrII5YJO+7lRQBXsrQi3j+xagSm3aY35OfTnkGrMKSOw3EOq8MknA//AF0zIDhpSjqcDz15C/WrF9bsEkKPuicgrJ2z70AQiBIjvhbySCRtB5/A08FgQArEjnco+aoy6Ip3yJF2BReCfrUg8sM+9y3pgHB+hFACvO+9H2k4+UOADj6mmq7hSrxYUnIKA8+4pqTw8pFIqH+KNshvqPWpll57r6EDFAHEfE6WKTSYtMt58z3MgJw2GCjqCO9Q3Xg27sPCtteNGUs+BtcfMc9Ce9bGneE08V+OPtN4dum6eBI7q20kjnGfwrqfivr4t/hte3ihUSaZY7QMDyv9715wTQB8z+Pi/mrDCzIU6Hrz7Vxvj2Z7HSNM0jzlcsv2mfaRyTwu4eo5/Otyyuftmrs900/kR5lm3Zxge9ed+I9RGq63d3iKUjkf5FJztUcAflQBm0lFFABRRRQAUUUUAFFFFAFrTbyXT7+3u7dissLh1I9q9b1pzIlhrmmyt5Fwoc57HuPzzXjVemfD2+l1HwxqGkF9z2p8+BCOoPUfnQB6BpJa8srS73DfE+DxkGuvtdWS2uIpYwGG7nB2gfWvMfA2pbi9lqm9FU5VemDXc2bWDRTRLCZC3QhsYNAHf2l296peFkQscFnH9afOhMe1Ckkik8hqwfDupeZH9la1liwflf1rcWVW3L5ZUY7jkmgByNukCqzN5nViPlB9KiJWCdt7CV14AA4H+NNaDfIFY+Wnd4jn9KgLIII5ImxhsM0i4JoAnQ27OTMiKX6uVx+FKqTkbbZ0CoeV2bs/jUL3TCQmP5mweg3fnSW92ocK5MbP1Gdo/wD1UAOIlM7lUZieMk8D6VBLmAbpJCrk8EkFT+FTxSAuVbAwflPUVWmtsRyEQGSXrlT059KAOW8SqNzicPKpPzqhxzT/AAfYyE7kgZVV8ghscemK5Lxpf3MF+VEXlp0B5D5z0zXU+CtZtVZJWnkWYDhWIJxQB7Hpk0KInmxLtA+91x9auvMsz71kyAMFUGA4rj4PFNjGzHaG3Lkb8Ek+pxxWgfFcEjRmeWBjj7nQY9RigDe+aMyxoypJtB2gFt1Z+p6rYW9nJLdSW9gfLKEH7zmsTUvGVlbpH9mujuwTnGCvsK8q8e6/qmouXjCyFjmMkZ6+tAHnvjy7S88S3UpzNASAG8zn8qpw20bQpILhC4GNrDaCPTPepRazRzMt1BHEx5aQpnH0NO1q0tUljFiHnTAJ3n7p9R6GgCjMskDsYwzqflGw9B9OwrpfASyTav8AaSwK243BVPVu34Vy0ZA3RpLJg53k8/8A6q7rwPYwWmhT6lNKVY/IqqvLj2oA9l+GDtfurTRRO/mbZAg2tjPrXuhOCor508E35t9RtZrUvEyFW8tzjjuDX0ShSUJIozlcg+xoAewB681RvLEygiJ9gZtzAjPPtVwyIHCFgHYZC9zTsc570AZ1vpqQzedLK7uPU4X8qllhkZxsUEtyZD2HsKufWloAytUHC5kCEnlW4DfjVW1nW0bPlkh+qgYP5d61rqFnAaPbuUEDPP6Vy8drP9taJi+F+dfMBBPtmgCTW9XaGJZFLCNWwdy5P5dK5W/1jdYztbPKgySAo7/StOVLhriZ0Ia3fnY53bfWuc10xspUrJHtPDqQBQBzOr27X0UBLQpcQSpc20kIBdJl+6xQ8NjPIP8Aga8g8VWbW+v373dzO91K264lmYN5p7tnHf0HA6DAFewv5a7onhkDuxZJO+fXNeZeNdOdYZJZH/ebiFd225yehPao9nDn9pb3rWv1t2C/Qr+H7hZ9Ens5487VJ3o2AU/mK5uTSWWNnsmEkLHgA5K+1JptxJ5zxB3adUIDFs/QHHUUxbl4rjOGWQ8EqMBW9x6VYFi2sf8AR2OPKnB4dc4/EevvV7RrSRopJ3mZmi5UycrUY1VtOkCXkAlMg5dO/wBK6jTNX0m306Zo7fzbmSMqIsHIP06EfSgDStkju7WFmR/mG4eWQApx2re8N+HLW9mE1wGO07suu3d9QetZPgrRvtsKeX+6XO94Qx+T6Z5FelqFjtkjWJLhR8vP3h75oAt2oazgEVpaRyR54Cvyv0HakMommYqF352sHG01E0bwqrKQsL8eV/GDUkkJKhnDshbKk9RQASRMrKxnKgL1VeGB7GoUVIGLW7uvPCk4DL9KkEAkBH2xBgZ2uaQ+TzBcI5RuVMLDg+xNAFyIGcbsoAOpXqBUQQRynEoK/wB5Fzj60ioVVigV4c4VnbDD605iu9wDtY4DgYxigB0cZRcRiJS3LZON9aNgECBYpNrxnDRSDcuP61lhLZpAJIJXVeGy21gOxFT2W23vomhlEkW7hSOQPrQBJf2sUVyfJhVo+rRqckn1Aqkht2QFXmjDcgOCCp9DWprTiS4Lqqg7eSjYJFZ5ZjHJ+9DRHHyyLnPtmgCOSOSJsTKWU/dcDOKjupJI7ZsscMML65q7EoZC0cc4THODhfw9aw9R1VbW/t3UpNHA4mbPHQ5waAPRdP0vTvDvhN4tTmWOOX95cybiC7HnHqfTFfO/xz8cy65eJb2DyrYwHy44VXp/tGrHiHxnrWv3d7qV/lLJMrBbA/u8Dpj3rzrTbgS3d/q+q70tLZS78c+w/E8UAYXi27m0LQY9O8x/tt+u+UEfdi7YPua85rQ13U5dX1W4vZ+GlbIUdFHYD6Vn0AFFFFABRRRQAUUUUAFFFFABW34P1htE162ugxWInZLjuh4NYlKOtAHrms2k2j6tFf2bb7SZt6sRuDA13um3qPHBLGEJYYZimPyFebfD7VE13SG8PXrk3MIL2rFsZX+7+FaPhXUbjT9Qk0/UJZMq2QM54+tAHqKyFiH82QbDkAV0un3YuYIhFkMANxbtXFaZOqrJid5N3TJxitaGWWCUzW+B/sBuDQB1fliICRQglHO4HAomDYBUxztyxUn5VqrZ3kk1ukfl25B5bDcgVNtcTcRqkTcF24/CgBWmO5dscbO2OU4wajYAxyGdI/kJJfG5vpTyQ3LIxUPinqybNkZ2uG4A7j3oArQALsZlfyDjJC4x+FR3nMR+zErGc467j+FT7ptzENIQO27r7VEzh0bgHaOMDoaAPEvHsk0V60J85pl+8rjBAPQ1iWl59kRUkbMh5Hv+NdF45nCas7kvIyNtdgeVH071yc5QyZfaIhyA55oA2Y9VuIVjEUsi4PRPuj8auya1qbKxga3QrzlFLZHfPvWNE0IHIUxgZC44HvipIrtRc/uWcDr0AoA3YLuVlWa4kby3OR2BNVNZ1Z7mNUtnI8uQMSo5x71iy+dq8kkEbgxnrvbbj6UGzkEfyztIyfKWUc49PegCTUHvHPyySPC3zbZF+U+/0qm0aGQ7Ww38Sf8ALNPep4bsxxypH5pVhglznd+HamR2s9zKiRIxd+AH6D8qALvh/RrrVdVWBvntTy7KAMD3r0rVY7a0sYbaGb/RgQvlxDDL71B4d07+x9LcxGBrhhube20H2rntdvpZLl3YbGXlWA4x+HWgDtLCKTT7iKSHzrq2PzEv94e49a+gvAurnVtEjL+WJosIVU87cfKSO3FfMPgnVG1R00+cTvMW/dPHkqM+voK9W+Hr32ieJ4LaaX5LkhHA5Vh259aAPWtSkulaNrK3SXPys2cMo9qm0/zhCROGBU4+bvVsY74rh/GXj630ZWh0uNb69DbGAf5Iz7nufagDtXkCKzSEIi8licDHrUMF/bXDslvcRSSDnaG/lXz7rvjHVNTkC3swY4IMUWQAPwrHtNTuYrhEjurk87keP+H/AGaAPqPIzz1pGVXHzAEe4rzDwV8TLW7MdnrJMdwPlEzDB/4EO1enQMrxh0fejchgcgj2oAw9T0ZpLlJLfYsTH96jDg+9cF4xsTHeERyqBnG3qMfSvWJpEhieSVgqKCST6V4X4t1ODVb+4l8rEIcrG6MQ2PUigDnL258vVBBqav5AX91cRHhSD0xXDeK7rF2wklWexn6iUY2H1ror3UUtZIlhulkbOFjkXr71R8Z6fNfWq3VnDHKSvzwuuFP0NAHnZtYxcmW1mB2ncFUgDFOuBNDcy+Qg2kcNI+SM1GymCRSv7oKclGHT6VcF+s1g8c8MW8HDunXFAFHc0i+VK/mxqeGIx+FSWN49jewxs4Rmb5Cy5IqxJa2stqux5SSMK6+n9aqsjh12F52JxkjlcelAH0H4PjMWnR3K20jO45kTsK6TykkKlm5Zc5xgg1heDyE8P27W0u+AoCUzyp71rkhpC1ld7TkfK45z6c9qALMcURmBt5ZUcDa8cxzz6rTCkcNwrv5qq55WTJP1FSS3l2WAntbeaROhC7WoMkjrsZyjnoGGQPagAeOLf5haNmIwBIvBHqKrSRnazSFXVjgeo+mKn2PI+5UG9RkLGdxOPQU2EAMhj3R7jk7RlT9R2NAEcfkgGFVlBztMnY+1TiNIyY5IvlPOXOCKZJBL57bnjbB7fKSKntzJEWwjXK9SrHdgUAI8ckWAN8yN91sZOKktnljZ3iAkQcMp+U07dAm0I88ffZjp9D2pWYSyHDFwDtWQdR7H1oASCRpCQkZJPVSQR+dG6NU3LCXIbDDHI+opPKZpCEZlI4YdMGnTyTwxB7qNMDOJQcce+KAKes6itlZNJ+9AIIjZARz9K8s8Q6xI9rLBthle4IQyI+HH1FbviW/+2SC4Wd4kiPyKX+U+9cVe3ltB5moXaLHMB8rBcq1AGN4ukaG0t9NtriRt4+bHODXI/Ei/bT7Cy8PwXbzDYs9zn+8fuqfp1rpdMkhn1C61y9kP2S3UyMVII4HTBryPWL6TUtTur2X788hc+2T0oApmkoooAKKKKACiiigAooooAKKKKACiiigC1pl9PpmoW97aPsngcOh68ivXdXt4tf0S08Q6ayebt/fIDyrDqMV4xXTeCfES6JdvDeRmXTrnCzIDyv8AtD6UAeoeHtd+1W6wNHGZcBNxx1ruIWEMgE0ys20Y4wK8o8QaaNNZbmyk32Eo3xtE2V/MVd8N+JCI/LvYQ8RAAfPIoA9gWVIysqqQcYG0VrWmpQC3V8J5o5zICTmvPLbWUYwiHG0nh1PI+tdp4Ags9a1tbK+kmgaUExyls7mHagDWWSS4UyIsUbMd24twRUcsLkK8jhWIOTnAP4V2WpfDkpGj6RfyLMv8E+Cp/IVwWpS3Wj332bWbOZSCUEnl5Dj1U9DQBYWEsFdtuE5LZ4zUMytHIS8nB52xfdx71HHdLcD7kJUDKpu5B+lVNa1A2mnGSSREwMHB60AedfEyCe4vg1u8IA4IYY3ewNcJDtgkUzRDcv8ACBuAra8Ra5JeXTFVjMIYfITyw9c9qypzAjq8YyMbiB/CfQ+tAEl/cxypHLaxuqbCr8YqlGolx5MfQ5welLJcKJosxbFfq2MinMEkRmSMxEdNh5agCQyRxRASoUGSChGNx9qla42xkRpsycgA/e+vpVOBllJA3lg2T5oycjrit/QvDN9qMqEzPHbZwxK8euKAKemWEuoTBYPkk3fMX4Cn29RXo2haLb6Pb7pQbu7kBy4GNp9vSrcekLZRotvaR+Yv8Zbn6VcRGiikUxtulzvIPzH2+lAFeW2EqOt0d25cAg5K+9Yt7p7WaFLSJJM4JaduB64raR4UGJjtdDj90MkD3Fczr3iW0t7otb2xdUBXM2cA/wC7QBv6Bd6fp0rSxHDkZLDgofQV03h7xA9z4x0Rdm6SS5QIG+9j3ryZHv79fPBt4LbGclcHPtXt3wW8BJJ9l8Q6i0m+CTdDuOd/ofpQB7dfwvc2VxBHIY5JI2UOP4SR1r5s1LQNR0OcW2s2b+bES3mpkxSc9Qe5P6V9N9T9K5bx5Y3+o2UNvp1v5jq5fcxG0cYxQB4FBZExs8BEEbE53vmjUbYSmKWMSIFQKRDyc+tamtv/AGZq3kajELO6df3hYcMR+g/rVOO4S7mZY2d5w2VdcoAPr0oAyIoobXUTcs0zqfllduuD7V7B8EPEs+ox6hos0ExhsSHhuW5V0J+7n1qh4d8H2XiL9xqLOHRNzNGwB56c16poWkWOg6ZDY6bAkFtEOAO59T6mgDyn4w+N7yx1VdJ00SKkSgzkpw5POAa8eutV1S6lkeO1dbWRsB1P3WPr7Vq/H6xvdN+I1zN9ru/sF2qzeXvygYDpjt0rG8N+I4jBJZyxiAOcZZSVkNAGPrUV5YajE94ybmHytH6+tdhpUlxdWKR8neABngOPr2qtdRWjKsjRRTW5J5dDuQ+xPardnpoEAWynygG4R7hn8KAOK8VaYLW7kaIsiKcGPO7H41y9uFgkHl7ZHznDHqp6ivXrm0gvLZoLlE+cHIK4YfWvOdb8P32kOY5IVlt/vRTo2So9KAKyMBcfZ0lVrbO5Cg+ZM1DdRyFlFtMwcNxtbkeuabbobguJ5JLZ24DAbR9DU11aTwCGaLO9erKQCfc+tAHuXwykWXRAkYDSKckchgQOvNda5gklLSIsc+7ox+XHt715L8JtYRb0W08snzDKn73PcV609zbYCyKH3ZwXToaAJCsjI4kJljxlWzgqKWRoiQrKyKcKWUHOe1RiAlZJIJvOIUMUAwwHp70qS+XlnuJVWQcoydvf0oACrPMoSTzXTIBI2k/4VKsFzcsSYfuLlgGxu/GpJpYZWjHmuHwAjMvBqLcZMwlJWmU9jgMKAHQyrjYjSBHU74Z+WQ/7J9KdDlZElRlAUYwR1/CmRPE1yUaNhKvVHHP/AOqniRA+1UO4NuwP4R/hQBNBeokrFo9kvZtvBps8iPE8gjCEkZMT7QfqKmM8rjzNqyjH3Dis++vLe0zMYjA5HGBkfiKAJbq5iQl3uAsXBYSdT9DXGa7qMzTsElcWTZG0n5X/AMKdqOrNfIx2xK0Z5Re49a5+4vZTuWLIib7ysMrigDNvriOdjEzPGp5XK8A/jXK69qD3s0Ol2xaYg7WjjGc+49q1Ne1Gfyja6esVzn7yE8j6Hsaw7mW28GaSdQuzHNqcy4t4CfnQnufYUAc98Sb63061h0CwC5XEl0wGCG7L/X8q88qW7uJbu5luLhy80rF3ZjkkmoaACiiigAooooAKKKKACiiigAooooAKKKKACiiigDuPAPiuDTkbS9biWbS5CSrEZMTHv7iuj8Q+F2tUOoac0s1tIAUKchV6jFeSjvXW+EfG1/oI+zS5u9NPWB2Py+6nt9OlAGvZ6vPZyMVkQoO7jn8q7jwt4oJWMhxG0eGEzHGDnr61lxWeheKbNp9JukS4xzAcK+fp3/CuWu9P1HT2ka8t5UjHyggHDUAfW3gn4qwzqtrr3QHaLtM4I/2h/WvRrqHT/EVgEdILyxlHySIc7T6+xr4P0jxFNauY55JVg4O3GBXqHhDxpc6ZcBvD2oNHJImHjdd6n6g8ZoA6bV9Gl0zXbnT2jZHic7ZE43g8g5+lc/quiRanKxknn3KNpy3A96xtd8ca0dcE2pJJdtIfvAbAfpj+VbQmvLxFYW7K7fN5ecZHvQByN94Eml8x7S6VmU4+fByPesqXwjqtvnyBHJtGcjoB7V6DZNcG52yIIg/BVjgH6VeEJV2VgAqn7rNkY/CgDzBdD1VozHLFtyODwSav2Hgry3EmpzeWxwyhDyK9BUQwsfMcluxiHH0phfr5sG4A8M3JIoAr+Dvh5F4gvHSySbci72LnCkH3r1nRvhSsUQF9eiFsD5LbPGPc/wCFcl4Y8e/8IbEFvbbdZStkqijIHtXd23xb8J3JR4WuXvGXIh8k78fyoA17fwJ4fsLCbFuzNsJM0rljnH3ueM14nr32yK78mDEqkkMQBnb612XivxrNraulsZYLNFz5a8Et/tHv9K4y3t2XbLFHtEvVnfvQBRe28yPb8oK8EluSPeqt34d0y8Dq8UZnxiPPIP8A9etd4yAxXaY8fMinGaLdftMQWL5M9Ac9frQBxE3mw20tlLGyCPJCkZYY96+kPB+o2uj6F4c0WSQ+fdWyztuGMKRxXhviO0lMCzIoeaA8qerH0PtXr/hfXPDurW+lXmt27adqdtbpE0R5jGBxgjt3oA9YXGBjp2qETqzyRphpF/hzXKX/AMQdEsWkTe8mwfKUHD/SuZh+MGjS6i8MNo8dxKMJI54c+hoAT426Fb6lFbsYohLMCplfoCOn86vfDDwlbab4dWS605Zblm2gSrzs45Gabpvjyz1i8e11myhW3R+GIz+ODzjNdXp/i/Rr25e3julRl4Uv8qsPY0Aaen6XbaaJhZxKgkbdgDGPYe1WEYT2+50wSOVNMj1CzkJEd3bsQcELKpx+tWARjjHNAHlnx30PTrrwx/ak9uxvEZYwydWB7EV8y6hpM9tdgaU7TK4y8RblGr7D+J09vbeAtXe9KhfJITkD5z93Ge+a+cvDGlR2MEdwymWWf5/MJJPPY0Ac5pesalaXEdvdwvJBs2jcO9a9rcPBKjMksbE/INuM99ua6O9t4p4GVpIwg/hKHcD9aybqwuJokc3KnYdgJbg+59KALcUsl9KNkTwyMcmRjnB9KuNAs6tb3rqwAwUcbT+dctbXes6dIxniimjQkEIe3r71taL4jtL29W1m2xyPyDMMr+fagDl/EHgiaGNrnSrh5gRloZGzgdxXKNNLaOI7mE/ZT0bdu2n0I7V9S2Pw4i1OGK7tdejkyMnyhvUH04PSqesfBZbpJGiu4HkYZz5ezJoA+f8AQZbSGRbmC5NvKjgsUHzH3x3FfQejap/aenwy5WVdg+eJRt+uO1eX+IfhJ4g0xy0MA8tWzuCbsj6im+E9Q1DwvcvDeRHyRyVbII9qAPWREXuvlB3Z4ZDgg052mgkEN4ZULE4JAIb61mxX+m6pbxz2c6KemC+CD6H0q2lw3khVmgmC9d75OP8AZNAFg2/zg/aMEDIcLx9MUpildBvKl1GVdeGIrHuNbs7KOUm6RCDllL5I/Cs3UPGtumw2AnuMrkGI4x+dAHYJLHcCMyAxzJ91wOSPemXl1DA6m6SNXK/LKjc/Qiuc0O28beLWQ/Ybex01jzcSjDEeo716VoHgbTdJiMuoytfygbme4xsX6D/GgDz++1W4tgGtiVgOQd6Yzn0Nc/eX0oUyxzFkAyS33oz/AFFdp8VPFOm3Fk+jaf5bqmDLPHjag/uqf8K8Q1bxPBpP+sH2hCMCRTkY96AN/V9RtZJBJOXgmCZ8yIfK4rljfXOs5tdPdyjZBI6/j6VRt7O+8VTx3AHl24OR8+OKwvEvjWy0iCXTvDcCi65jluz/AAnvtx1Oe9AGnrmqaZ4HjeOJ/t2uOvTPEee7f4V5RrGqXmsXz3moztNO/VjxgegHYVVnmkuJnlnkaSVzuZ3OST6k1HQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACilpBS0ASW1xLa3Ec9vI0U0Z3K6HBB9q9G8PfE+68v7H4lQ3loRgyoo8wfX1rzWigD2m403StethP4euBcOynMQ4Mf1rmHTUtGvJImVom4wQO/1rh9Ov7rTblbiwuJLeZTkMjYr0fQ/ibHPF9m8TWSXBbrdIPmz6kf4UAaFrrRuYyl8Gd0xiTOcV3ml6pZzpEI7hXkAOV3YOMd64y90CLVIjfeHLmO5RhlghyB9fSufzc6fdebcoUYA4Ow0Ae0BlmYiFF+Ug727DHrTQ0bAgH5c87edx+tebaZ4xWCSJLkPMDwFHAxXY2Ov2lw58shdy5Cn5QKAN2RZAqqWjVAeAe3uaYB5RUySCXzMhcjAB7YqKZ4mjRo2DFhuPOacJFcwfxD0A4oAjuLJb4n7XFHwc7QelRwW1vaSB7Zk3q3DL2/Cra/MkhYo0n8CjsabBCokeV3R5XHzKVAVaALLx4UOZZJHLZdcADnuKUQSTOQ8LBOiqSAD+NNKJ5QY4IJAOG60xkjKsjFyYwWKluM0ATTxg5VmMTE42xAc/U0yMzJKE6bTxzk475p0aExGSMZJ6Y5FEipIyCKM7wOecHmgCtqdpHdqywCXnlmiPU0+xiaG0S2BlPl8Dc3f096nUSCMqqxRFOPlbg+9Oht03NIvllxyTknPsKAIfMfzFWWJ9wHGT938ayNWNmslvMYxC4+UTKP4q3pPMgiD742GMHeOB7Vyt2YQqtfmQPI+IkC5U+1AGilzEsz/KWnWHcXQ5yKtaXCHsAlzPJuDZUIuDj0rFSZGgvnCSooXaoI+8AeRW3bOI7CEWzAvtBznJB+lAF3TgkAceTMybiAxPQ+9Xxf3lvKksVzPFKpwhWTjH0NVHuFVPMKFYmHzrjj61DMokXytzFEO9SvO7PagCbxBrOoeJdMtbLVHNwtpLu2Ngeb1wSe55qigW3lRVEyqSPkHG32FDeW0ofe5AGJAB92nIXCP5iDk5RscD2oAnDmQlvmz2QgZpUeJ5WwRGW77QNp+lIXiwrSB0cfxryGonSFGVYQ20/Mrtxk+maAILm0tJruJlkgM6d1YgNWVrWlpMXWCAQSL+8Lp/F9K3ftEUmUWKNmXoTHgrUUkmAzFF8rGd3cUAc54Zste0jUhe2moTW2DuRUPDexHSvWtI+IusxoF1BLa5P8WRtYflXHQeaIQEdXbGSuPvKaaIxdBWhOxl4ZDyQaAPV7f4mabuIu7aeNAQBIhDqf8K434oeIbTXfIi0uFR5ZIe4kTBbPQDFcviRZFLrGecbWBw3+Bp0rIm0LFmMHqeSgoA5HUFm0+f8AjUY+YxjKNVWDWUbZteFkj4YgkMre9dfqdzBa2u64jBjP3SvI/GvMLpUN1cSSR7WY/KEHDCgDsNP1XTLy9YXMaFhjzGXnd716B8P7HR9Q1lpLya2j0uL5xHMwUMw6c8V4nbTB97QW0duYsZL8HFSRahbxyGNJzcyMN3lyEhSfY0AfWet/EHQ9KD29tMlzdIvyRxjCfTd0/KvD/GnxYvdRlnhnci227TbW+QvXqT3rym81e8vJVhCS7S+BGrcKfrW9a6XY6dY/2h4guvIi6E5+97Y7n6UAZdzqup6nO6afCs0LjmEcMv8ASrmlaAsFpLea8y2cKKSyyONp9vWsLU/iRZ2iyQ+HtP2OvEdzIcfjt7/nXBa/r+pa/defqt088gAAzgAD6DigDpfGnjU34/s/QlNppqLsYqcNL9fauGoooAbRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACijNJRQAuaM0lFAC5ozSUUAXNO1K802bzbC5lgf1RsZr0C1+J/2i1jt9b0uKfb8plhwpI7kj1rzOigD2jTY/DniGyY6LdrbagDxDMAr/gO/wCFZd/4e1WyPmGRnhT7zivLUZkYMjFWHIIOCK6rRPHmt6ZGIjOt3bjP7u5G4c+/WgDr7DX77TpljUOUC5COOMeprfsvG8s+yC4hgR88bDxmuZs/Hvh+9jxr2l3CsB/ywIIP8q249H0TWrL7T4ZO2Nx8oY8q3cEdqAOti8QaXcRbY5Y4nPBIHOalttStZYH27WKHazDrmvO5fB+r2sgMiB1B3bYzzUUsWpQky/Z5lwceWoPB7UAeqJcRPasIsjaM7jxinxuZE3bVYMMsM4zXkMev6hEylklQ9MNkZ/CraeIr2R/NNyVK8bRQB6ql0jMTv2REbQFPC1L5ztHkOFA4DY5B+teTNfXP2ncs+Yk4ZWOM+9XbXxBqNmMLNDIh5IPIf6UAemoJSFZZA5H32HU0hacFmVSqnnPr71waeKb9ZiVRTGwwpPHPuKg/4SHWZn8qR0J64UY/CgDsB4kt5ZJYW4dCBl/un/69advHb3N2gSUTKVyoC5Cn6155D9vmYMYURicgMuc1cW+8QWjedZWqjYfnTHGPWgD1aK0txFGAisScMpXBNZMem+RcyrE6fvD9wnDLXOS+KdSk08NJbCM44dRnn1rDfXr0TK944kkPG5QQxH1oA9EkRY7WVWfeQcE5GcVSE5BYf8swO4xXG6V4itoJGgcTkFuC/VT9anuvF9qriJolmQH5TyMUAdSHJO5o2AxnJH609XO9ckmNhn5ugNc9/wAJRZPGuxzGmMkEk59vamXPjDTREuxtp+8FI/SgDppbgQWrzSugQcb0Gdp9CKhtrtblQrbvKbo69D7iuFi8T2UryRGUu79Ub09au2HiyztbLBjeUoSVC+ntQB2ajyn8p2GT9xs4pyQvdo8ayCO5Xna5G1h7VyUXjfT7iIKY5lKn75HWm/8ACYWRYPFDO0w42noaAOtj82IhSvlzxdRn/PFSZaeUyoNshGeBjJ9K49/GNuylGt5Ax+9v4IrNuPGMnlNGsIhYjBcPnI7GgDvJ75WQRythgcAjgk1k6l4jt7IFXlVJV+Uqw4P5V59fa1dXa7Xn3KTkKvUD1rNWGW9lJSCR5cdWzyPWgDc1jxPHcuTBHIzDrjO0D1xWRe3NzMgCyeWcjapGAfxpINJ1YzGKKxdZgNpzxuX1Fbkfh9dNtzN4jv47aDG4LI/Ofb1oA5cSyFjHMZpHI5HXNa+g+HbjUwGiSRLboT6fTuKUeM/Cuit/odvcahKFOx/ubW+p7VyviL4iatqqGG1Kafbcri3+VmU9mbvQB3Op+K9C8GiS0s4I9Uvejru+VT/tN6/SvJ/EOuXevahJdXr9T8kan5EHoBWXkk5JJPXNJmgBaKTNGaAFopM0ZoASiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoq7baZeXVu01rbvMi/e8sbivuQOQPeqjqyMVcFWHBBGCKAG0UUUAFFFFABRRRQA5WK9OnXFT293JbvvhLRy5yJI2KkfTFVqKAOpt/HfiC2AWLU53Qc4mw/6kVv2nxY1NGX7XY2kygfMRlWY+ua83ooA9bX4oaRO0YudBZADuLrIGOfxFWbfxl4NnDq1pLbsRkNJFkE/gTXjdFAHtp1Lwbfx7YryGM/9NMqfpU/2Tw1fW6quqWaL6eeoOfxrwuigD6Ei8K6Z9nEq3251O0fvAQRVucaT4dtGvLwxgREYdjnn6d6+dBNIBgSOAPRjQ8sjjDyOw9Cc0Ae8n4leF4wBF5vP/TE8Vrad468N3tuobU4ImbhkcFf5182Upx2oA+uLY29zCDbyQyROvytGQdw9sVV1HS7eQIoCbV6gjqa+WLa6uIHUw3EkRHQq5GPyrRi1vVbeZLiPVZjKpyMyMensaAPctT0WZ2ZoUi+XhmbuKrf8ItPNAmBHGmMkkfdPqK80/wCFkeJHt3BuICAOWMa5rn9V8R6xq0itfX9xLt+6obAH0AoA9kuPC9+mwO0Mrt0Cjt7+lY1/oN5bqymzEkSnJYfyzXm2neIdb0+Qy2l/dKR97LFh+INbdr8R/EsSsrXcc0TfeSSJcGgDof7Gu7i382000yND82AMNj+tSw6XqguVh+wbFK7lJ6MDXOD4m+IVkR45LZCvQCEdPSmyfEnxGVGLqBRkkAQrxQB2ln4Y1efewjhjAGFRv46dJ4O1jawZ0BAzkDkfjXnV5468R3QIbU5o1PaLCD9KoN4k1pmLNqt6Se/nNQB6hb+BtRnnUXdyNoXjOaut4UsNPESajqVvHGThTI4GfXrXj82v6tPEY5tSvHQ9jKcVRmnaVgWJOOzEt/OgD2m6uPA+gQNPDfRXV1HysMZL7/oegrAuPitdKwj03SLOKDGQJiWb8+K8zjlePcEYqGGDjuKZQB6BffFTXrtVSJrezA6NFHuI/wC+ia4rUtSvNTmEt/dTXMgGN0rFsfT0qnRQApOaSiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAu6Pql7o98l5ptw8FwnRlPUehHce1dtD8SJ9Qfytf0PR9TDjYXaARuPcFe/4UUUAd34P8I+FvEun+eNGNq0jkECcvj6cDFXtX+B+hNYm4s728tmBPy8OP1oooA8a8XeFv8AhH9pF59oDOV/1W3H6muYoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAXJ9TSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oral and intravenous contrast enhanced CT scan of the upper abdomen demonstrates an enlarged pancreas containing multiple cystic lesions within it. The findings are consistent with acute pancreatitis with pseudocyst formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J Pierre Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37381=[""].join("\n");
var outline_f36_32_37381=null;
var title_f36_32_37382="Prostate anatomy PI";
var content_f36_32_37382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Prostate gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 579px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJDAiADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAJwM03ePeiU4jY1XD0h2LG8Ubx71BupdwphYn3ik3j3qLNLQIk3j3pdwqKloAfvHvRvHoaZSUASbx6GjePeo6KAJN496N496jooAk3j3o3j3qOigCTePejePeo6MUDsSbx6GjePQ1HRQIk3j3o3j3qOigCTePQ0bx71HRmgCTePQ0bx71HmjNAEm8e9G8e9R5ozQBLu9jRuFR5ooAk3CjcKjyKTNAEu8UbxUWaNwoAl3igMDUO4Ub6B2Js0ZFQ76N4pXCxNkUbqh8wUhk96LhYm3ClDAniqxlFLDIGlA9aLhYs0UUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEV0cW8h9FJrKW5B71q3Q3WswHUoR+lcDHqXA5rOcrGtOPMdaLgetPE/vXLJqQ/vVMmoj1qedFezZ0yyj1p4lFc4l+PWplvh61XOhezZveYKcJB61hi+HrS/bh60c4uRm55gpPMFYv24Uv20etPmQuRmx5g9aPMFY320etH20etHMHIbPmUu+sYXgPepBdj1o5h8hrB6N4rLF0PWl+1ijmFyGpvFJ5grM+1ikN2KOYOQ1DIKaZBWWbv3pv2r3o5g5DW8wetHmCsn7UPWl+1e9HMHIa3mCmtIPWso3Q9aQ3Q9aOYOQ1PMHrSGUVlG6HrSfavelzD5GawlpRKPWsg3Q9aabsetHMHIza80etBmFYhvR61G16P71HOHIzcM4ppnHrWC18P71MN+PWlzlKmdB9oHrSG4HrXPG/H96mnUB60ucfszoftI9aQ3Q9a5ptRA71DJqQ/vUvaD9kzqDdgd6Q3o9a5F9U/wBqoDqvvS9oP2TOya9HrUbXwHeuP/tT/apj6n/tUvaDVI619QH96n6fqG6/hUn7zYrh5dS/2qbaat5V7byFuEkUn8xS9rqV7HQ9fooorqOIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooACMjB6V4fcXTW93PCTzHIyfkSK9wr588WsbbxRqsXTFw5H0Jz/WubEaJM6sKrto1E1D3qzHf+9cel0fWrUV2fWuZSOz2Z1yX3vVhL4/3q5KO7PrVmO7PrVc5LpnVLfH1p4vjXMreH1p4vD6mq5xezOk+2e9KLw1zgvPeni7J70c4vZnQi7J6077VWAt0eOakFz70+YOQ3Vuzmni8rAFwc9af9p96rmDkN8Xh9aDe+9YH2k+tIbo+tHOL2Zvm996T7b71z5uj6003R9aXOP2Z0P233o+2+9c79qPrR9pPrRzh7M6I3vvSfbveue+0mkNwT3o5w9mdAb/nrSfbveufNwfWk88+tLnDkOh+3e9H233rnxOfWlE59aOYXIb32001r33rF8/3pDN70cwciNZr0+tQveH1rLaY1E0tLmKUDUa9PrTDen1rKaU0zzDU8xXIapvT61G16azS59aYXo5h8qL73p9aryXjetU3c1C5NS5DUUW3u29ai+1H1qoxNRsTU3K5S99qPrSNdHHWs8saQsaLj5SzJdn1qtJdHnmq8jH1qq7H1pNlKJ9JeHbwahoVhdA582FGP1xz+ua0a4j4QXpufCQhdstbTPGB6A4YfzNdvXpU5c0UzxqkeWbQUUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXg3xXg+z+NbpsYE0ccg/75x/7LXvNeO/HC226vptyBxJA0ZPurZ/9mrDEq8DpwjtUsecq3PWp43PrVUdanjrzz0y2jmp0kPrVRKmSquBaWQ+tSCQ1XWnigViwJDUgkNV1qRaYiykhqUSGqqmpFNUmFiwJDT/ADDiq2eKdmncRMJDQXNRZpCaLhYkLn1pN59ajJpM0DJd5o31DmlBoCxMHpd/vUQNLQIeWo3UzNFAiQPTg9RClpATBqUtxUIal3UxWHM1Rk0E00mgYE0maQmkzSGONNNGaSgBjVG1SmomqWBE1RNUrVGaRRGaaaeaYaAIZBVaRauMKgkWkykd18GdR+z63dWDthbqPeg/20/+sT+Vex181aJfvpWsWd8mSYJQ5HqvcfiM19JQyJNEksbBo3UMpHcHpXbhZXjy9jzcZC0+buPooorpOQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzj43WvmaFYXIHMNxsP0ZT/AFAr0euV+J9r9q8E6iAMtEFmH/AWBP6ZrOqrwaNaL5aiZ8/DrUsdQ96ljrzD2CylSp1qFKlWmBYWpBUS1IKZJIKepqMU9aAJVqQGolNPU0xEopQaYDTqoB1FIKM0wA9aSiloASlFFKKAFUU7FIBS0ABFJTsUUiRtFLSGgAzRmkptAxxNITSZpCaAAmkpDSZpAOzRVmKzdlVpXSFW5G/JJHqAOakNnBkBbz5j0zC2P0p2Y+VvoUDUbVeksZxG8kYWZE+8YzkqPUjqPyqkaTQETVE1TNURqRojNNNPPWmtQBGaicVMajcUhorsOa9y+GGrf2n4XhikbM9mfIf1wPun8sD8K8OfrXXfC7V/7N8TJBI2IL0eS3s/8J/Pj8a0oT5J+pjiYc9N+R7jRRRXpHkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWLq/izw5ot6tnrGv6Rp94yh1guryOKQqSQCFZgcEg/lUtj4g0u/12/0e0uhLqNhHFLcRBGARZASh3EbTkA9CfegDVoorA0zxhoWqeEJPFFjfeboUcUs7XPkyLhIiwkOwqG42N25xxmgDfqhr9qb3Q9Qth1mt5EH1KnFSaRqNrrGlWepadL51leQpcQSbSu9GAZTggEZBHBGat0mr6DTs7nymOgz1qRKu+I7P7Br+o2mMCK4dR9MnH6YqileS1Z2PbTurllKlWoUqUUxlhKkFQpUopiJBT1qIU8UCJVNPBqJTUsatIwEas59FGaYh4NOBq5b6NqU/wDq7OXB9RitCPwnrDjItgPqaExcyW7MTNLmt3/hENZxkWyn/gVQTeGtXiBLWbH6EVWwueL6mTRVl9OvI+ZLaRB6txTBayH+6O33qFqaKLeyIRThUotJOzJ1x1pRaSk4AUn03Uw5JdiMU6nG2nXkxNj25phyDhgQfegh3QtJRmkJpCFpM0mabmgBTSZpM0UDCkpaQ0gENWtPhDO0sgBWPGAejMeg/mfwqqa0rX5IootoO4bzn1bgfoP1prcuC5mSttUuZ8SM3JfJ6H0qs+o28M6wz3KeYD91pFVvbAzmue8c61JpsEVtZSFbmfPzZyUQcEj3J4H0NefpaiYlm+ZjySe9NysehSw/Ors9pjmTzS6M3mgghwcOPQU27smugGWNUu8fMqfdkPsOzew4P16+ZaRqt7pckal2mtgf9W5zj/dPb+Vei2F3DqFqk1tMD3G7IIPpx0NCaZnXw7juZbVG3WtjU4jcRNdqoEinE4Hf0f8APg++D3rIaoascVrOzIzTDUhphpAMNRv0qU1G3SgZAwpqO0civGxV1IZWHUEdDT3FMNSxn0R4T1hdc0G1vhgSMu2VR/C44I/r+Na9eQfCDVzbarNpkr4hul3xg/8APQf4j+Qr1+vSoz543PIr0/ZzaCiiitTEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwb4t+B/EeuePdbvdO07VLjTL/AMPDTlaxns0EkwlZwkomYMI/uklMN6HrUa+EvHOmyeIbu10WGa8vNN0i1QWmotbKXhQibyyksb4U4+UugYdz0PvtFAHz/o3h34mxadp9vrLa3dadDr1xLcQQaosV5NZNGvk4l+0FgqvvyhmLdOWwDWJpnw+8f2fgHSdCubDUGsl0nUreSwsdSih2XksshieYiVRJGVZfl3MOuV6g/TdFAHzhJ4N+KFvDottb3mq2lja6PYQQJpk0bm0mijUSq6NdwxvlgeSJQVOBjrXovww8MeI7HxH4m1nxTqutsZtSu49PsJ78TWos2dGjkVATtbgqASMDI2jNelUUAfOfxgGrWPje6kbSInt7hVkiaG7BLqPlyQyrg8cjJ+pri11mSP8A4+NJ1KL6RrJ/6AzV7h8cLINaaZfAco7QN9CMj/0E/nXkq9a86slGbVj1aDcqadygniPTFx500tv/ANfFvJD/AOhKKvWes6Zd/wDHrqNnN/1znVv5GrCVHcWFnd5+1WlvPn/npGrfzFZ6G3vF9KmWsBfDOjj/AFVhHb/9exMP/oBFSjQVT/j21PVYP+3oy/8AozdTshXfY3RWjpWk3uqPttISy5wXPCj8ab4f8Ba5cQ/apvEBihHKre2SSZ+oQx/lWxqOs+JtDiS1gOgXmeEjhimtHceuN0uKT8mZuprZLU29P8J2FntbU5jPL/zzXp+Vah1nTdO/dWkECMO33iPwHSvM73XvEszMb7RCYc8xafeo35lwhP6VWPiL7NhLrRtZtgB8yraCYKf+2RemoSNI4dz1qOx6PeeMLknbaRTynt5aqi/mT/SsafxL4hkz5VnjIz8932/Ba5mPxboeGN1qC2aA7na+iktwD6YdQc+1Uj4+8PyfLYXUt6wPBhVQG/Et0/CtLae9+p0Qw1Fu0dTql8Q+J1OTbQ49roj+lTweM9egI82xmYf9M51f9CBXBXvjTUZVCaZbwWQ/56N+9kP4ngfgKox+JfEKNubVHkPpJGrD9RSvHobfUU1sj123+IULHZqNrKh6HzYCP1XIrVS48P6vH5mwRk/xpyK8MvfFOuXMZje9WJT18iJUJ/EDNY0cl2s4nS+uRKOjiQg0m+xCy62sXb0PoG68M7gX064WZOuM4NY89nLbMFmRk2t07/nXB6J491TT8Lc4ugP487X/ABI4P5V6LofjvTdZVIbrAlPG1/lf8Ox/Cp5mtyZRxFH4lzIqNHmNmj+6Dzn9aSVWLYZSVzkg9Pyq7q2h6hJHJc+HNQhnzyba7iDD8GGD+ea5ODxPLaXv2LxLYGwmBx5kYJj/ABXqB7jNUpJmlOSqr3dfzNVraOU/IpjYngA9voaqT20kQLEBkHVl5x9fStlFjljDw+XOp5VkcOCPbFQoWj3BTkjjpzj/ABpsiVKMtjDJpN1aVzZrNuaICNx2PAJ/p/Ksp8qxVgQwOCD2qXoc8oOLsx+aUGowaUGkSSZopuaAaYhcFiAOp4FaZVlklJQMCdqtnpjgVT09d19CD0Dbj9Bz/Sn6pcNZ6VNMGDFI2k9CMAtVRN6KuzzDXbo6jr93MDmNX8qP/dXgf4/jVm2h+QcVk6apJXd1PWumtovlFRue18Ksis8A29Km0S/Ol325smB8LIvt2I9x/iKtyR/LWXcx4OaNiVaSsz0+OY/64bGG3JA+7Ih6/mDWJqEH2a5eNSSn3kJ7qeQfyo8GXDXOkmBh5jQPsweynkfyYfgKv6hGJbPzFH+ocpn/AGWJI/I5/OrequeTXhytrsY5phqUimEVmYEZFMYVKRTGFAEDiojVhhxUDCkMfaTy2tzFcQNsmicOjehByK+itB1OLWNItr6D7syZI/ut0I/A5r5wr0z4PayFludHlPD5nh+vRh+WD+db4afLLl7nNi6fNDmXQ9TooorvPMCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5f4l6f/AGj4NvlVd0kAFwn/AAHk/pmvn0da+qJY1lieOQBkcFWB7g18y61YPper3li45glZB7jPB/LFcWKjqpHoYOWjiV0qZagSp0rmO0kWuz8C6Ct7Ib+8GLWE5UH+IjvXKafave3kNtF9+Rgo9vevUdZuodC0NLeIACFAAv8AebsKTZlUk9l1KXivxD9lVYLUDzj9yPqEH94j19BXOxxvblpZn33j/NI7cn6CqWkB7q/kuJn3SD5tzd2Pf+Z/Cr5O6bZjaTwqjoD9fSrjG2p04akl7zEXczSs7mOJEMkkhwQiDkn68cVyM/jNPOYwacHjP3WnnIJHYkKBj6VV8QeJptQhksLACHTt2GI+/cY/iY+ntWJ5K+WGJAxTb7HqU6V9Zl3VtWvNaaNbhkS3j5SCIYRSe/qT7msi50exuM/aLS3lJ/vxhv5ip0D/AMJOKtQxgDLnJpXZryxta2hir4esUIaKEw4OR5MjR/8AoJFa8cZPBYVMy9849qXy0K8k5ou3uKMYx2Vhv2dGABP5UjwIg4OTUdzNFaQtNczrDCvV3OB/9c+1V0ub262nTLE7G5+0XuYlH0T75/ED60JXJlOMXbqWhAOpXFNZBHhiwX3PFMOj3NxzqOq3L5/5Z2uLdP0yx/76p0fhzSlIb+z4ZG/vzZlY/ixNOy7i5pPZfe/+HOk0DxtdaTKu+6SeEcYMo3D6Hv8AjXo9tqWgeNbBUvGgkfosisA6H09jXjq6TYp92ytV9hCv+FQyaRp5kDtp1i5BzzAp/pU2RzVsL7R80NJdze8b+Cr7w/MZk3yWZOY50yMemcdDVvwf4jYp9j1y4xxiC7lPT/Yc+noT0q14WttGvUNnHc6ppEjqQ0dpev5Z9xG5ZCPYrWL458G654ZhF3a3EOtaUxxuKCCZM9M4yh/JaaZlGu7+yrr3ujR3bLhEYnJP8SYIP0I61BeW63MO9MmZRwQOo9D/AErzPwBr0dr4ntrGR3t1u3EUtpONu4HgMvYkHuCa9TceVM4yQVyDnjocVVipxUvdvcwAacDU2pxiO53qMLKN+MYwe/6/zquDU7HA1Z2JRS0wGnA0El7S+JpnP8ELH8+P61meMZhB4bvhgqzxhef9oqP6mtXTgPslyT/GyRD8yT/IVzvxEmC6PsDZLzImfpuJ/kKvodeFV2jjNNTpXS2g4FYGnDAFdDZjIFQj1Zlkx7lrMu4/atxF+Q1m3y4JqmZRepZ8FyFL65iBwJId34qwP8s110qkJNGzBo5YWGf9oDcP1FcV4YbbrkOejLIp/wC+DXajY9zHHGcAnG0HgZU047HNi173yMAimMKkHQU1hWZ5xEaaaeaaaBkTCoHFWWFQuKBlc1b0q+l03Ube9tziWBw49/UfiMiqrU0Hmp21Ha+jPpqxuY7yzguYTmOZFkX6EZqeuB+EWrfatGl06Rsy2jZQH/nm3P6HP5iu+r1IS5opni1IcknEKKKKsgKKKKACiiigAooooAKKKKACiiigAooooAK4zxZ46h8LeLtG0vVrRYtL1K3uJBqTTYWKSFd5jZNvdeQc8njFdnXH/FLwPonjzwz9g8STz2tpbSfavtMEixvFtVgTuYEBdpOcjpQBl6F8U7CbwTYeJPElhfaNa3kbzp5drcXkccIYqrySRxbU3DBw2OCOTW7Y+O/D2oaz/Zem3c99dgRFzaWU80UQkXcnmSohRMjn5mFcz4m+FnhXx5aaXdLqFydOh077DaiykhltzCR8roHR1DgdJEw3vVa0+HPg9fG2kA680+u6LHDLBZb7OO4WONFRDIY4lmdMY4Zipz6cUAerUUUUAFFFFABXivxk0/7P4lhu1XCXUIyfVl4P6ba9qrhvi/p32vwuLpVzJZyh8/7LfKf5g/hWNePNBm+Gly1EeJpVhKhAqZK849Y7b4Z2Ql1Ka7kGVgXA+pqHxzetPfxwZ4UGVvqen6D9a2vhwoTw/qEo+8XIz+Arj/EEhk1u7J/hfYPoABR1MVrN+Rc0PH2K5+UnLDOOwwatQMPtIKncNrbcd/kNZ2hSEGeMMQCoY4GSccf1FX0kaJ1kTB8ohgB6+9aJ7Ho0dadjyazceUMYyKkbe2ORg1reLtD/ALK1Eta/8etwPPhB/hB6r+B4rFRn2gOOKlqx6UZKSTReSNgqgHNOKl1JBwBUSSlQNp61Mh3cZ4pFBFED0JPuaq3WoOLo2OmwrcXa4MhY4igB6Fz6+ijk+w5qG4uZru6bT9OkMbpg3Nyoz5IPRV7bz+g59K0dPs4bK3ENrGI4wSeuSxPUknkk+pq0rbmLk5u0du/+X9f8CpZ6XHHcrd3rm9vh0lkHyx+0adEH6+pNbkQ3DJqKKPLc1oRRAgYFGrGkoqyIlt93XipVt9o45qfy8Cnx4zjFArlVrcN7VVmiMf0rXdeAQOaqzqDndQNMylzHKssTFHU7gR2PrXp/gvWY9ZsZNOv1Vg42ujdOe49jXnDRZVh6VY8NXxs9Yt2DYVm8tvxPH64qJIxxNJVYPuil478NwWF5cafcRrLADvj3jnB6EHsR6j0qXw5qWs2ujfbLl5tXsoZTBIuM3USAA7gf+WwA7H5+OrdK7n4p2S3uj2eqKPnjG2T3B/8Ar/zqppNiLLSrG1tlGfLEzYPJkf5iT+GBVU5XRhGaq04yfxdyvd3dtf6fZXllPHPby7jHIhyGHFVAaz/E9m+l3xv9DhLM4828skOBcZ/jQdFlwAe27oecGprC8gv7SK6tJBJBKMqw4/AjsR0IPSnJa3Rwzd5NMuqaeDUQNTQRtNMka/ec4+lIk0YEP2KFNpJctJgdT2H8q5P4kb3gsl2kASnj6KP8a7RdrSb0J2L8ir/siq97aW19AY7qFZU3gAHgg+oPatLaWOyjJU2r9Dy6zbaBWzZzgYqTVtJgs9QaGByVKh13dQD2qqLZ05U5rPY9O6kro20uV8vFULtw2aq73Xg5FDvkU7kqFmX/AAyM65AR2Dn/AMcNdyPluoPuHDE/L9K4rwmu7Vmb+7C5/PA/rXYSIEkVkJ+47nJ9FPNVHY48X8XyMJeg+lDCgdBTsVB5xCRzTCKmYVGRSGRNUTip2FQuOtAys9R1LJUJqWM6j4e6mdM8UWb5/dzt5Eg9m4H5HBr3uvmGF2VlZThgcgjsa+jvD9+NT0SyvQeZolZv97v+ua7MLLRxODGw1UjQooorrOEKKKKACiiigAooooAKKKKACiiigAooooAK8n+NF34nN9a6bpa6nHoN3p12LiXTbD7VJJcbMRwv8j7EbP3sDv8AMOo9YooA+ZLDUPihonh/w5pWlW11pNlb6NbGF302acNMCPMSdI7aaQHGQF/ddc5PSrj2/j/Qbz4g6xoFvqcl3d6xbKd9op3WxQbpoR5JZynCDCsApJKMwr6PooA8Dg1H4p6knhywt9XuLR7vUL2K51IaHI/kW4iRoTMs1vD8wYsAyqisfXBWpU134op42ura7MkNnDfSQpH/AGdNJDcW23CSI8dqyq5PzZecDPBQDk+70UAeBeHde+J0dtpUupzamzX2hXM1wbvRCy2d4rkR/LDEHyRtOwhieSB2rt/gzqviXUrLU08WRasZrd40jub2JYo7j5fnaJPs0Eirns6ntgnmvRqKAOd1C78Wpeyrp+iaFPaBv3ck+sTROw9SgtWCn2DGszVW8aajpl1Zy+HvDYSeJoyf7dnOMjGf+POu1ooauCdtT5JeTX43ZH03TA6kqw+3ycEdf+WNKtxr3/QN0z/wYSf/ABiuw8bWZsfFepw4wDMZF+jfMP51irXlvR2sezHVJ3O5+G1xrp0KdbvTdMisS7b5otQkkkB7ARmFQRnvuFc7rP8AyGL3/rs3867b4fnd4UvFHVZD/SuK1oY1m9/67N/Oo6kQ+JkVnObe4jlAyFPI9R3H5V0EmyRA6DepXhs8n0Nc0Kv6ZeLA3lzcxE5B/un39qs66NTkeuxY8Qad/bGlC1i+W7tmLW5Y8Nu6ofTJ6GvN50uLed4LiF4pUOGjdcEGvVXUM+1lRjjI2/xfjUGp2MOq2aw6hnzV4juQMtF6ZP8AEvqD+FO1z0IT5PQ8xVSU4GGFQajcSqsVrZnF/dZWPjIjUfekPsoP4nArR1OCfS7yS3vk8qWLqT90r/eB7j3rO8PAXLT6rMMS3YAiX+5CPuAfX7x9z7UJdWbTle0Y9fyL+nWEenWqW0APlrySxyzMerE9yTyTWgg4FNU5HSpkUFeKRVklZEyKCARV2LhaqwqQOKnhyTgimSywCDxUiqBUaRndUsY3Ng0yCF87TI7hIwcZPrVe4VvmU9RWnKECKpXcAc/jWfcnkn1pMaKDsVUjvUCRlMseD2+tTOSW4FQXBmkIht0MszcKijn/APVUmh62YotW8JGGZtsUwAZh2Bwax5DH5ksw+WFeAOhVQOP0FXvDWV8GWis287UXPrWJq8+yJLSMZlfG7A5x2H4/4VNN2ujxqUlBSt3Mq4lM87yt1ds49PaudvmOhak2oLgaXdMBeqB/qZDws30PCt+DdjXpOi+FfMaNtQYgN/AOg+prO8X6RaW0rwxKsls6mOSM8hgQR+RFNTVzBtSdluZIOK1NNidYmmVfnlzHH9P4j/T865bwcsjy3GjXJYyaaVHmd3tyP3b/AFwNh/2lNdrlXj3KdgHCgdFUdAP881olZmlNc2pFdSR2Nq0spESou52Y9F75rz3V/GF5cXDLpyLDbgnDOu5m9+eBUvjnWXvLv+zYG/dREGYj+J/7v4fz+lYVvb8DIolLoj1aFFW5pEMt3ezzPNNK7yMclietSxXt0n8RNXUt89BTzZ+1QdWgsOoMwHmDNTl1cZU/hVQ22DUsSbRQFkdR4KjUzXksmdqoq8cdTn/2WukkYrHct/AsBVf+BED+prG8HRgafIzdJJufcAAD+ZrUvPk05sABZJtoA9FyT/MVotjy8VL3pGUBTh0pMU4VBwDCKYRUpHFNIoGQsKhcVZYVXkFIdypKKgPWrMo4qs1JlCoea9m+EF95+gXFoxy1tMcD/ZbkfrurxcHmvRPg1dbNdu7ctxLb7gPUqw/oTWmHlaaMcTHmps9gooor0jyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPHfjHaeT4gtbpRgXEGCfUqf8CK4NRXrfxntt+j2FyB/qpyh+jKf/iRXkq151ZWmz1cNK9NHo/wzcPpWoQ98k/pXM69au/iKeGJcvIwIH1ANbHwxnCapPATxIg4rXubFV143BHJQRfiCc/piopw5ppE1J+zbkY1h4chCg3BaZz2BwP8amuvDtqV+WOSE9iCT+hrqbePYiKvDydW9BStG5Y7CzKOuea9D2ULWscLrVL3ucBIl1pDCO4zLZnhXX+H6en0NWNiSrviYOjAbSG/Mf8A666m6t0kjdWUFG4dDXEahbT6NeZgYmGT7pPIYeh+lc1WlyarY9LCY1v3ZGX46xf2lhokscUpvpxb7iPnihX55drdR8gK/VhVbVvDs9l+/wBHheeyAwYlG54D/dIHUehq3aXCar40lkfEf2KxWGNGPBklcs+P+AxoPXnvXRtD5RD7WXDHbtH5jPX1rN7WPTozu3KP9f0zzmCRmdllBRx1Vhgirce0HG7Ndjf2tvqSeXqCNKqgskyELLH7bj94exrNm8NWiwf6BqEn2gjcq3KgK3tuHA/GpsdXtV1MmFcPlW49KuR4By1Ft4f1ljukhhi54DzqN305psiva3DW2oRtDMB91h1HqD3osx88XomWJiY4/MX5lHXFWIIg8PnA8Gst5fspJV98DDDD096bZ6gY7RoActvKr9KBNNrQ0Z2AGBWVdSY6gmtGaWC3tgXbLkZNNl0XUZoI5VWC3SQZUzSBSR6460rNgpJbmIZmeSOKBczSMERfUngV1eqJDo+kXUFomHSEiW4H3pW789hnjFWdO0uz0yKJrUCe9IO+7cdD6ID0+tSy6Yb26tbRY9sXmCSfnIKjkD8T/Wh+6jGrUTV+hrWg/s7wlZowAZIgxH+6v+NZvhKzN7fveXILlWyOOp7mr+vt9smjsbY/eAUkdlB5P54FdNpWnx2diuzCsi4A9qwT09TyJSsvUesqzid5B5UUa7VXGOa851yZ57pY0DEE/KByTzgV0mvawyRskmFUHB2nlvasGxikD/a5RieUZQHjy09fbPQe3PcVdOLk7jpQZh63bDR9W0bUIVJYSCxv2HRklOFz7JJt/wC+m9as+Mda/srTx5BH2qX5Ih/dPdvoOPxIqXxm6nwnqkEkix/6M21h0D9UI99wGK8xj1GbxBNHqVxwZo1ZUHRARnArok7I9DDUrz12JLK3J+ZslicknqTWrFF04plvHgDitS0gyQSKzR6UnYbBBxnFTNFx0rQjh+XpUcseKqxjzXMidAKrdKu3WM0/Q7P7bqcUbAmJT5kn+6O348D8amxrzWjdnYaXbm10q3Tau5I8uD3LfMf50mpHbHaQ9NsfmEe7HP8AICrmzztqxsfMlOCT05rNvJRNdyupymcKf9kcD9AKuWx49aV/mQYoFOxRioOcQjimkVLikIoAgYVXkFWmqtJQNFSSqz9atSd6rP3qWUR11Hw3uvs3jHTjniRmiP8AwJSP54rlzWhoM/2XWbCfOPLuI2/JhSi7STCa5otH0rRRRXrnhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfOngPx7421AafqYutS1e2jn1D+1YZ9OSC0hgiDeWY51iXLkrjAZ/cCrvir4wXOteDru2sNPm0y6vvCcuux3cF6d9uwkMexcKDnjO4EemK9T+GesaF4h8Iw6h4Z0wadpc00yi3MEcPzLIyuSqErywJz3zzVu38FeFbYTC38M6HEJomgkCWES742OWQ4XlSeSDwaAPJbj4sX2n+GZrC7triLU9Os9LnN1aXySNcJcMi5cywttf5skbWznhh1r0TwR4zvvF9/qEljpNtBollezWD3E16wuS8fBPkCLABOOsgOOcdq2bXwf4ZtLGaxtPDujQWU7rJLbx2MSxyMpyrMoXBIPIJ6VPH4b0OLWjrEejaYmrnOb5bVBOcjB/eY3cjjrQBrUVX1BLp7OVdPmgguyv7uSeEyop9WQMpI9gwrnfsPjj/oYfDf8A4IZ//kygBnxTg87wXeN3iaOT8mA/ka8PTmvWvGWneMpPCuqi417w9JCLdmZU0SZWIAzwTdnHT0NeGRQa8QCNS0z/AMF8n/x6uLEL3kz0MJL3GjuPCN19k122fsx2mvRNYTZdFx0yJB+NeHW8XiGORJE1PSwykMP+JdJ1H/bevUDbeLb3TLa6GuaAVZQuBo02QD0z/pVYxajJSuVXXMtjponwquOdh3f8BNXFyYZVQ4J+YY71xmlxeJ4rmL7Xq2jS26N88celyo7r3UMbhgD74P0rqYJPLKhT8v8AAT/6DXpnmjZl3jd/F/OsPW7AXdo0XTPzI3o1dK6B1Lx/8CX0qlLGrfK/Cnv6H1pNJqzGm4u6PE9Iy2o66zjDLe+Tg/7ESD+ea6S01SeABX/eoOmeo/H/ABqqunOkuvXSDIXV7hJMdsbcH8sVFXn1IuErHr0anNFSR0cF1aXihA6xvnlXABP07frUstp5bEnMe/5SMYJ+ntXL9etT295c267YZ5EX+6Dx+XSo0OuOIktzZe2KEEKo2rgjb29akwrwLDPHHcQg7RHOu8A9OD1FSeGvtmrTOjrD5EYHmzsCCoPRRjqTzgYrp30K3HEU0wX0aFT/ACYU9F1KeLp7M4y60zTbpfI+yi0c8LLCxIBPqp6j1rkfC1h9o1+7tLzOLMOZFU43FSFwD2ycc163/YTFkUXIxkjLRkdT14zXA+E41l+KOu25YKs8l0gYjIyrbun/AAE01ZmsMRFxlyvZXNgWtok7NDp1ss0Y3Ifmk/mcZH0q15ckmZJH8yTruxnP+FdKmjRDiS4kYf8ATOIL+pP9KuWtnbQuohgRpCMBpDvJ/kP0pOUVuznli4L4df68zj8eVIsWC9wwA8oDBUerHt/OrjyLYwtucGZhztH3fYCsS18Qx3XjLUbW0OnW2lxxtFAMKjTzAgbw565O7jOMD1rfigSzYT6kw37sBM5IPvWdW+3Qyqym2uf7hfD9mzTvdXmI3fAC9dqjoPr3rQ1u8SGNhFNyR0xWTquqoziSAmGBRy2P0HqayCz3i+bKrLbt9yI/fm9z6L/P9aiMHJmKg5O5HtFzKk8q+ZCGPlqf+Wrdz/uj9enrUs8oBllupMBRvck4Ax3J9BSysg3GQqTswGIwEA7DsAK858WeIX1SU2Ng5/s9MB2HHnMP/ZR29etdKSirHfQouTsip4j1qTXL4LFuWxib92p/jP8AfP8AQdhWV4Sh2aUkfeKSWL/vl2A/QCrltb7QPWk8Mp+4u+OPtk+P++zU3uj0eVQkkuz/AEN61hzWzaw8CqdmmAK1IOKaM5snCAL7VnXjAZq7cTBUwKwr6fJIBptkU4tsp3D5Y12HhfTmtLD7Q3FxPhgp4wnYfU9fyrD8NaUdQufOnGLSNsHPSRuy/wBT7fWuxZWkHlAjzdxyx4AH8RPtRFdRYippyL5kc8ojtpbjpJJmKMDjt8zfkcfjWUoqW9nE8oEeRDGNsYPp6n3J5qNRUt3PLnK7HAU4ClApwFBImKYwqQ1G9AEL1Wlqy1VZKQ0VZe9V261Yk71XapZREadG20hh1HNIaB0NSUj6gtZPOtopP76BvzFSVn+HZPN0DTX/AL1tGf8Ax0VoV66d0eE1Z2CiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPnrwr8FfEmnnTllvdH0qWytNSgOo6bJI9zdG6DCMPmNMLGW3D5m5HGOogvfgh4juvDmrWNtLoWmNc6XZ2H2a1mlMF1NDOkj3cx8oESMqEfdY/Ny3evoyigDwvXPg7rM6eJbfR77T7DTb7WbbU7awiO2GSNEKyRSKYmRdzEH7jqdoyp6V6H8KfC1x4P8K/2XdEgi4klRPtguVjVsHarCCEKucnaEwM8HsOxooAKKKKAM7xLH5vh3VE/vWso/8dNfN1qcoPpX0xqq7tMvFPQwuP8Ax018y2P+rFceK3R34PZmhH0r0TwHeC506awkPzKML/SvO4ulbPh++bTtSimBwmcP9K5XsdU1dWOpuZzY6j5FydsUxzE5/hfup/mPrWpbTLyknRuo9ff60nirTk1XTN8ONz/Mh/2wP69K5DRNa8vFrfkgD5Vkbt7N/jXVQrW9yRw1KPMuePzO9jZgQQeR0b1+tLIBIM4we4rPgnZOvzKavJIrKGU/jXYchzfhq2VdR8UWkmMnUvOXPcSQRHB/EGsDxFor6fM8sKk25PI/uH0+ldJCTb/EW5tzgRappqTxj1kgcq4+u2WM/hW/c26XUbRTAFiMc9HHoazqU1NWZrSqum7o8horV8QaQ+mXHy5MDH5Seqn0NZVcEouLsz1YyU1dHofgNFGghgPmeeQsfoFA/Qn863/vlsE46YxjmuX+H1wG0+5tyfmjmD4/2WXH81H511D9cM2c9F6VhU3OeW7JLf5poz8wywBB+teL6IzxfEBbsHax1l42Hs0hU/oa9mHyurYxjuTXkiWpg+LLWWDg6stwP90/vauideDa99eR60RtfAU8HH596wPFE1xP9n0DTHEV7qCt5sw/5drUcO/1P3R+NbdxcQwW011dy+RbwoZJnP8ACo5JrL8OpPNFc6zeQmK81LayRnloLdf9VH9f4j7tUwVlzM54ae8+n5/1r/w5ieJtF0HStEt0g0a0lVZVjUyhg7jaSSzAgnoPasC61aaeR3CKkjkksOT+HpW78QLnMllag/dDTN+Pyj9Fz+NYWl2SyD7Rcj9wpwq/89G9Pp6/lWtnKyZrByktXcfYW2/FzeZkHWONiTu9z7e3er0s/kiWa5YKQN7OWwAP6CmX1wkMcks7Igxu3E8IBXm3iPXJ9anaGIslkG4HQyY6E+3oKvSKO6jQciTxV4ifWJDa2W5LIHLN0Mx9/RfQfiazbWERqMinWtpt5I5q8Yfl6VD1PSjFQVkLAFcgKQTVPwkd2kRyn/lvLLMPo0jEfpiqmszyWWnXc0WfMSNtn+9jA/UitLRdkWl2tqow1vEsf1wAKa2IlrP5fn/wx0VtIFxVe58UaLayvDcatp8MyHDRyXKKyn0IJyKqmVoyVYFWHYjBprzse9NMmVNvZkF34u0RshdZ00/9vSf41Bp+s6He3O2bX9KghHLu95GDj2Bbk10mi6DNf7ZrrdDakjBx8z/T0Hv/ADrrIlihhS1ghUIDtRFHP+OffvVJJ7mE6soe7Fq/p/wTEh8XeFbaERRa/ovlIoVAL6Lj/wAe/M96g1Hxn4bWMww+INIZ3wZXW9jIx2UHdz6n8K3b28S1BjiIe7xtLg8Rew/2vft9ayVFEpLY86cpPr/X3mQvivw7/wBB/Sf/AAMj/wAalXxZ4c/6GDSP/A2P/wCKrXQVMoqdDHUxh4t8N/8AQwaR/wCBsf8A8VTv+Et8N/8AQwaP/wCBsf8A8VW2BS09BamEfFvhv/oYNI/8DY//AIqon8W+HP8AoP6R/wCBkf8A8VW+1ROaWg9Tn28V+Hf+g9pP/gZH/jVeTxT4fPTXdK/8DI/8a6FzVWQ80tBpSMB/E+gE/wDIc0v/AMC4/wDGoD4l0H/oN6Z/4Fx/41uv1qFqTsXaXcxD4k0LP/Ia0z/wKj/xpV8S6F/0GtM/8Co/8a1jQOtRoP3u57F4T+IfgyLwzpcdx4u8PRSpborI+pQqykDoQW4rrdD8Q6Lr6TNoOsadqawkCQ2VykwQnON20nGcHr6VV8B8+DtJ/wCuArer1YfCjxp/Ezyr4v8AxE1Hwb4k0CwtZrG1sb22u7i5urjT570xCFVYYSJ1ODk5J4HU4ANUYvjfYaL4V8P3XjK0MOt6lp51KS1sZItiQ7iFcGWRQdwGQilnzkYOK9L1Pw1pGqa3Yavf2Sz39hHLFbyM7YVJV2yArnawI45BrCtvhf4TtLexisrC6tPsIkS2kttRuYZYkc7mQSLIH2E87M7QSSBzVEEWm/Emw1vUHtfDWk6trZigt7ieW0ECJCs6CSMMZZUySpzhc4+tc58O/i7Jq/hLwvf+JtJnt73XdQfT4JLRE8h3DuAwBlLqoCYOed2cAjBruF8EaGmsR6rFFew6iqRI88Oo3MbTiIAJ522QedgDGZN2R1zmqEfww8JRaZBp8OmzR2lvd/breNL64X7NNkndERJmLlicIQCe1AHPwfG7QbmK2az0nXLh50vJFjSKAMFtf9aTulA6ZI55x68Vu+DPiTpPizWk0yxtNRt55dNTVoHuUQLNbs2zcu12IIbghgD6ZHNPsPhh4QsPJ+y6QU8mO5iTN1M2FuBiYcvzu9T07YrR0LwT4e0HUbW/0nT/ALPd2unrpUT+dI+22D7xHhmIPzc7j83vQB0dFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBX1I4066PpE5/Q18xWHMYr6U8RyiDw9qcpONltK3/jpr5rsBiMVx4rdHfgtmaUXSrCdKrxVYWuc62d94G1Jbu2fTrlvmUfIT6dvyrA8aaW1nqBnVMRynD46B/8A6/X86ybC6ksryO4izlDyPUdxXpV2kGu6J5v3ldMMR1HofqKh6GT9yV+h59pWtz2W2OXMtuP4T1X6H+lddYX8VzH5trIGHcdCPqO1cBdwPa3MkEow8bbT7+9Ngmlt5RJC7RuO6mumnXcdHqiKuHjPVaM6zxrLJZ2Vj4gt1Zn0S4FzKoGWNuw2Tj/vglvqgrr5biK4t1lhcNkBgynII7GuJ0/xHE6eVqUYwQVLKMqwPBBFJ4E1GBI7jw7O6vPpgH2Z1P8ArrMk+U31UDy2919xXXGcZ7HDOnKHxI6TVIY9Rsf365DfK317H615xdQNbXMsL8tGxUn1r0i+uobe2Jkby4V5JbvXnF7Obm8mnIx5jlselYYm2nc6cHfXsaPhXUBp+sRtIwEE37qQnoATwfwIB/CvTmzjspBwc9q8ar0DwZrQvLZbG4b/AEuFcISeZUH82X9R9K45R5kdNSPU6MFdwb14HHWvP9SVYPjbp8jkKJreNsk458p0H8hXoPXDKc59+MV5Z8R7FtS+IWl2KEI1zaQRZPO3MjjNTR3ZphUnNp9UzrRNH4r1aS3iHmeHtPkBmkH3b24H3UB7xr1Pqce1dLIxZy7sFGMlm4x6k+w5NQ2dpb6dYw2Vgnl2sC7EH9T6knk1zfjbWBBC+mW7AzScTkH7i9dn1Pf0HHrR8TstkYyfM7R2/rX+vQ525f8AtvXbic7hbZznusY4UfUjA+pq7JIoG4xhY1G1AOFQDtn8+fqahtEFvZwx8ZciST8eg/AfzNcn8Q9VKQpp1s2wzcyBf7g7fif5e9brRXPQw9K7SRheJtafVrowWzn7DGcD/pqR/F9PQfjVeztunFQWUGAOK6Cxt844qNz1bKCshba2yBxVl7UBM4rTt7UgA4puoGO3t5JZnWOONSzsxwFAGSTVWMXU1OB8RL5+pWFgn8TfaZvaNDwPxfb+RrZ8GzLB4nthIoIbcq57Ng4NZdgjSi51OcES3zB0U9UhH+rX64JY+7Gtfwnp8t3rsE6qfKt3Ejt9DwPqTxQ97FLWEpS6/l0/rzO+1TToNSQG4X94OFdD8wH1/oais/DthaFZD/pDqc5kbOD2wAMfnmrxCRxDIYdiCc81HNJFaRo1znJXKxA/O/uf7o9/yqtNzg9pKMbX0JQ+8vnakacu0hwqn69/oKzrrUdu5LEsqkbWmYYd/p/dHt19T2qpd3ct2ymTARfuRqMKv0H9etRAVLl2OaU2wUVKopoFSqKkhj0FSrUaipBTEOFKTTc0hNMQjGoXNPc1CxpDI5DVWQ9ankNVpDUlIhc1E1Pao2pMoaaB1opfU1Iz6G8ELs8I6SD/AM+6n8xW3Wd4ci8nw/pkfdbaMf8AjorRr1o6RR4c3eTYUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc18R7kWngjVnzy8PlD6sQv9a8Es0+QV6z8br7y9DsbFT81zPvYf7KDP8AMivMLROBXDiHedj0sIrQuTIvFTLShcClxisTdsSus8Cat9nuDZTHMcmSuf1H9a5OlikeKVJIztdCCp96T1E1dWZ1njzSfLcXkQ+7gPjup6H8On5VxuK9Vhli1vw8rsNx2YYDrg9R+FeY3tu9pdSwSfeRsZ9R2NJCpvSz6EFZetWczmC/07I1OyJaIBtvmqfvRE+jYHPYgGtQmkzVJ2LaT0ZBYanHq1lFdwyyOjZG2QncjDhlYHowPBFTVi6haz6fdyanpUJlMhzeWinHngDG9O3mAf8AfQ4PODWlp95b6haJc2colhfoRwQe4I6gjuDyKH3En0ZYpyO0bq8bMrqQVZTgg+optFIo7HTfGZVFXU4Gdx96aHGW9yp4z7gisjVryG7+MWiyIW8lbaCVSRglQrvnFYp6V3WqMbHRrLakQnFqyeaY1Lqm37obGQMn1q4JatjpR5W3HqmihqXjKaWJo9NiNvn/AJbMcuB7Dop9+TXM20RuLuKIkkyyBST15NRCrekuE1SzZvuiZM/mKldiFFR2NkzMTMyoNhPPpj/9VeU+KJDN4ovM9IysQ9gAP65r1YqI4ZUYYZSRnNeUeKYzD4pvs8B3Eg+jKDVy2PVwtuZliyjziul06LpmsHTiCimugtHxjFTE6KhrjCpXE+Ip/wC29QfTkIOnWzg3jA/61xyIfoOC34Dua0NX1Wa+mfTNGm2OnF3eKMi3H91exkPp/D1PYGPR9Kjklh0+xXyrdMlj12jOWYk9SSep6k1o9DlhHnbvst/8v8/uF0zSptYuCBlLdTh5Pf8Auj1P8q7e1tYbKCK3s4zgHCxrzuPr7mnRxpZwx28MOB91ExnPv9fequo3f2MNbW75nI2zSg/d9UU/zP4VPwmdevzeg+9vVs2aNdk90OC3VI/b/aP6fWsZ3eSRnkYu7HLMTkk0wU8CobucbberFUVIopq1ItBLHAVItRipFNAiQU+o1p9UIKYxpxqJqQCMahc05jUTGkUiOQ1XkNSuagfvSGiJjUZNOc1GetSyhRUsMZllSNersFH4nFRrW34QtftfifS4SMgzqxHsvzH+VCV3YG7K59BwRiKGONeiKFH4Cn0UV654QUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZviPVY9E0W6v5sERJlV/vMeFH4nFJuyuxpNuyPG/ihqQ1TxlJFG2YbJRAP97q36nH4VjW4xVVC880k8x3SyuXc+pJyauRCvNb5m2exGPLFRJxSGikNAhDSClPFMZqQ0db4B1HyL1rOQ/JJyv9RTfHun+RNHcKOh8tvcdVP8xXNWFwbW9gnHGxwT9O9ej+JbcaloO9OWZOPqOR/KoejIl7skzy+kozxRVGoVkahpcwu2v9ImW2vmA8xHBMNyB0EgHQ+jjke44rXopp2Bq5lWetQyXEdnfRtYagw4gmPDn/pm/Rx9OfUCtWoL20tr62a3vYI54G6pIMj6+x9xWfbaTqVrKsej3z3EZ4W0vQZceyyD5x+O6noxarzOl0Oya/1SCBRkFtzewFb/AIxvFcSRoe4iX6Dk/wBKydM1O+8K2sv9ueH76K7lGftFkVu4lX6Lhx+KVzd94w0W9uz/AMTKCEL8qpcEwt7khwDk1fK4xsWpxUdy7RyDkHBqmuq6c4yuo2RHtcJ/jUM+vaPB/rdVsF9vtC5/LNZ2ZHMjtxKJglzgMs3zZ/uuOo/P9CK4j4jaZIVh1SNSSg2TAc4UnKt+BJH5VLpnjCyjLxWtvf6lBJ1FtbNgHswdsL+vStOb/hIL9ZImtrHSo5VwrTOLuVlP+yuEGR/tNWlrrU6KFdRaa1PP7bUreztzLdTpFEP4mOM+w9T7CrsU19rA8tPN0/TWHzSH5biYeij/AJZg+p+b0A61DrHgr+wLhb+Ey3yqPmmlwzwn2AGAv0A96sWF4HUc1Pwno2dVX6f1v/XzNYJBZ2UdtZxJDBGMLGgwBXS+FIFg04zSKd1y3B77QcDH45Nce8uRXe6ZIYtKswnaJCB68f8A16FqyK65YWQ68uBa2zTLnzpSY4Qeqj+Jv1wPcn0rArQ1wkXUUfZIUA/Ebj+pNZ9KT1PMk7sUU8CmjpTx1qSRwpwNMzSg0CJAaeKiBp4NMRMpp2aiBp26mIVjUbGlJpjGkMY5qFjT2NROaRSI3NQOalc1Xc0MaI3PNMHWlJoUVAyRBXc/CS0E/ihpiOLeBmH1JC/yJriEFeu/B7T/ACdJu75h81xIEX/dX/65P5VtQjeaMcRLlps9Aooor0jyAooooAKKKKACiiigAooooAKKKKACiiigAoorldR8c6bYeJtT0OaC8a70/STrErqilGhDFdqndnfkdCAPegDqqK5bw/498Oa3YaVcR6paWk+pQxz29ld3EcdyRJwgMe4nJPAxnPaoNf8AiR4V0fQ9X1P+2rC/TS03XMFjdRSzKd20Lt3DDFuACRzxQB2FFebWvxe8Pz+LbbTZLvT7bSbnRl1WLVZ7+NIyxmMXkY+7uBDZw55UjHGa7C58U+H7W/ayudd0qG9UBmt5LyNZACpcEqTn7oLfQE9KANmisvQ/EWia+JToWsabqYiwJDZ3STbM9M7ScVqUAFeQ/FzWTearDpED5gtgJJgO8h6A/Qfzr0vxLq0eiaJdX8uD5S/Iv95zwo/PFfPiySXE0k9wxeaVi7se7E5Nc2InZcqOzCU7vnfQljTAFWEGKI04qQriuVHa2NqSCCW4kEcEbSOeyjNXtF0qXVJyqfLCn35D2roL3V7PRLf7NpqKDjBkx8zH2/xqlG+rKjG5m2/hScoJNQuIrVD2JyasromhQ8TXc0rewxXOXerXVy5YuUz6dfzqkWZzlmZj7nNLmitkX7qOz/svw4wwJblT6810mleU+mTW8DmVIQGRj1IFeT4xXZ/De723k9s54cZAP5H+lTJp9DKrZx0Gz+E7R5GZNRSIk7gjD7ue1Qnwdk/JqVuR7/8A66Z4zM9rqq+XI6IyYwDxkH/DFYa310P+WzfiAacZRtqi4tNXN4+DLj+G8tj+NNHg64z815bAfWsYajdD/lr/AOOj/Cmtql3/AM9R/wB8D/CneHYr3f6/4c6KLwtYwkG81INjqsYqd7zStGQ/2dEqSkYMsnLH6DrXIS311KCHnkI9AcfyqvT5ktkF0jR1TVZr1iNzbD1J6t9fb2rNkUSDbIocejDNLRUPUltvcqNplgxy1hZk+pgT/CpYbW2h/wBTbwR/7kYX+QqaigVkKST1Oa0NOvFAW3umIhH3JMZMZ/8Aifas6ihaDTtqdM0eWSCUhcnORyGBHUH0IrhPE3hxrWSS80mM+WMmSAdvdf6j8q6TTr4RKILkM1sTkFfvRn1X+orZKgRKqsHVxvWQHh/cf4dqvSSOmlWcXoeSW12JVHNel+H5lm0O1ZW/eCLbj1wcH8eK5Dx3oZtANWtUAjY/v1XoMnG/8+tbHw9uTNpLrGAzxykEH0IBH9aS0djsrNVKXMuhoa4Mz28naS3Q/l8v9Kzq29ahLafDKQN0MrRNjsG5X+TViUpbnlS3Y4U6mZpQakQ6ikoFADwakBqIdaeKBEgNOzTBSk0xCk1E7UM1RM1A0DGoWNKxqNjSGMc1A5qRzULVLKG09BTQKlQUgJYkaR1SNSzsQqgdyegr6K0DT10rRrOyT/ljGFY+rdSfzzXkPwz0c6l4ijndc29niVz/ALX8I/Pn8K9truw0LJyPPxk7tRQUVFdyGG1mlUAsiMwz0yBXz54U+MnibWNPs5NQj06BdS0i+uoZY7Ce18q4gViqRvK7JccKGOwfL36c9RxH0RRXjdr8ZbHw54H8L33jBbm4ur/Tra5nuYZLQFmkADN5PmrIQCcnZGQB+ODx98UZ/wC2tJ07woL2JIPFNno+o3zQxGCTfnzLddxL7sY+YKAMcNyMgHslFeJaj8XRe+NvCEmlPeWfhKZ9UF7dXEMXl3i20BYtHy0gVGUnkJnPfnFyL9oTwhLpuo3iQamy2VtHeNHGIJHkieZYQQFlIUhnXKOVYA9KAPYaKy/DGsDX9Fg1EafqWnCUuBbajbmCddrFcshJxnGR7EGtSgAooooAKKKKACiiigArz/xf8P7nV/E95rmkaxDp9zfaQ2jXS3FmblWhLFtyYkTa4z1OR7V6BRQB5XpHwW0Wx1mO6upUvraDRYtIt457ZTLAyZ/fpISdrnJ6KMetY+l/AeC00i+06fWEnSbTJdLguvJuPtEUTPvUHdctFtB5KrGmTyNvNe2UUAeSaj8IrnVGu5dR8QQNcXHhr/hHC0OnlFAE29ZtplbkAAFc8kE5HQW9L+ElvY6xq2qnUYn1K5022sbK7+wp5unvDB5XnRsxbluDgY6YyeteoUUAebfDf4a3fhLxNf63qPiGTWLu8sorSVpIpQzsh/1haSaQ5I7DCjsAOK6fUPB2mX97NdT3OvJJK25lg12+hQH2RJgqj2AFdFRQB4V8WtC0y1uLHTLa611iQZ5RLrt7KPReHmIB+9zXFweGrI4/f6r/AODS5/8AjldF4tvzqvi/UrndujEpiQ/7K/KP5Z/Go4BxXnzm5SbPVp01GCTRmx+GbHGTPq3/AINrr/45T4fCtpcTpDFNq5dztA/tW6/+OVtDha6Dwdbqj3OoSj5IEwuf71KLbdrlqCb2IZbO08Iaa9hYS3jvLtaYz3ks+Wx0HmM23rzjGePauXlkaWQvIcsepq54gvTcX8jM2dpOfc9/8+1Yc1wdpO4Ko6kmpnK7NXp7qL1OWse3vVlYiKdJCOwbNaVvLvHPWpEWMVreFbj7Nrlu2eHOw1kip7ZzFPFIOqMG/Whq6EztPiFbB4UnA5VwfwYY/mBXD4r0rxJF9s0DeoyWiOPqvIrzY0omdP4bEbUw05jVeSZVpmpLRVcTg9qlWVWoAfRQDRQIKKKKACiiigArR0i52yfZZWxBM2ASf9W/Zh/Ws6imtB7HSzwieFrSe3JjfdE6nvwdw/nXC+B430nxLqOjzEvgHYRwWC8qR9VJruI5jJFBOzH99H85Hdgdp+nTP41yPjBRpXinStUiYlG/dSN67Tz+jGrfc7aMrpx7nYlVlgu4MsfOjJCt1DryP5Y/GuZFdQSUKSxhFMZDq/B3H/69Ymr2y294xiH7iUeZF9D2/A5H4UpHLUWtylSjrSVG0qqwXPzelQZk1LUKsSakGTQA8HNPBpijAp3XoOaAH7qazVUu7+0tFJurq3gA/wCekqr/ADNY8vi/Q1JWO+89h2t4nl/9BUinZsV0b7NUTNXOt4utD/qrHVZfpa7f/QiKibxWM/Jo2qEeuIh/N6LF8knsn9zOjY1Gxrnx4pB+/pGqJ/wCNv5PR/wlNkP9ba6nF7tZuR/47mlZhyyW6f3G4xphrJh8S6NM20ajDG/92bMR/JgK1YJIrhQ0EkcoPOUYMP0pNPqJNMeq1MikkAAkngAd6RFrv/hf4dF9eHVLtM21s2IlP8cnr9B/P6VUIOTsiak1TjzM7vwPog0PQooXH+ky/vZjjncR0/AcVvswVSzEBQMkk4AFLXA3jt8Q7ybT7Z2XwbA2y7uUODqcgODBGf8AniCMO4+8flBwGJ9OKUVZHjyk5O7Oo0LWLLxLps11YrK9g0jwxzOu1bhRwXjPdDyA3GcZGRgnntM+Ffg7TY4I7bS5jFbwywW8c9/cTJbpKCsgjV5CIywJyVAPPWu1jRIo1jjVURQFVVGAAOgAp1Mk4O8+Efgm8tvs82jyCA2kVi8cd9cRrJDEQY1cLIN+0gYLZPA5q5dfDbwpc6udTl0x/tRvY9SIS7nSI3Mf3ZjErhC/vt575rsKKAOMtPhj4QtNRt72DSSJLd55IY2upmhiM6lZdsJcxqGBIIC49qa3ww8Kvos+jyWl/JpEyLG1lJqt20Cqrq6hIzLtTDKuNoHGR0JB7WuT8d+Lz4RuPD7XFgJtO1LUE0+e68/Z9kZ/uMV2ncpIIPIxx60AdZRXn3hz4nWWq6Tqer3Wn3sGjwX81na3Nrbz3v2lIvvTFYoj5adcZyODzWhbfEvwreS2UWn6hPqEt5bi6ijsbG4uW8ott3uI0YoN3HzYoA7GiiigAooooAKKKKACiiigAooooAKKKKACqWuXf2DRr677wQPIPqFJFXa5X4oXP2XwPqZBw0irEP8AgTAH9M1M3aLZUFzSSPCdOywLNyTyT61sQjArM09cIK1ohXmo9hkhPFdXdn+y/C1vH0d8yt/n6muYtk827hj/AL7gfrW78QZ9kQiXooVP6/0q46Jsun3OBu5t8mAcnvXJatdveXJhQkQIcAA/ePrW3qMxt7K4m/iAwv1PFYmnW+VDHmsiX2KbRPbsskbFXU5Ujsa7bTZ/Pt4JwMb1BI965vUI8Jmt3w8uNKts++PzNCBG4vapVHFRL0FTJTBno/hucXvhwKfmeLqPp1/SvPdSg+y3s8OMbHIH07fpXTeBr4QXr2z/AHJOR/Wq/juxNvepOo+V/kb6jp+n8qlaMyjpNrucZdy7eB1NYWpam0E/2e2RXmH3mbovtjua2ZRuuBnpXLKM6vdbuvmt/OmassrfamvJaMj0MYqeLWXU4urXj+9Gf6GrMce7nFSG1RxyKAFh1SzkICz7G9JBtrQjkDrlWDD1BzWRJp0TDG0VX/swxnMLuh/2TigDo88UbhWErX8IwJy4/wBsZqZb26H34I3+hIp3A2Mj1ozWQNSdThrST8GBpTq2OttN+lAGrkUuax/7WU/dtpyfwqRNSnfiOybP+04FFwOv0xi2nRqOSsrrj2IH/wBeuc+IuHtbCEAK4lZsegC4P86S0vtThVwBaxRtzhgXIPr1FUZYZb+6ae4keQKMbm7+wHYe1U5aWNFOysjW8PeIrZLJLa/cpNGAgZkLBlHTp0NWdU1a1e1EVu7XDh9y7EPHHPJ/CsJLGMII5xyPuSDg/Sp44JIxgSsR7ilzO1hObasxjyXU3QCBPrlqfBCFPGfc9zU6wlsbiSax7/xFa2s0ltYI19eIdrJEcJGf9t+g+gyfakkStXZG+iegrLvfEem2c5t/Oa4uV6w2yGVl/wB7HC/iRXNXr3uqMRqV0Rbn/l1tiY4/+BNnc/5ge1SW8UNvEIreJIox0VFAH5UuZI66eDnLWehbuPEOq3O4Wdnb2KHpJcN5sn12LhR/30ayriC5vM/2lqV9dA9U8zyo/wDvlMfrmr3JpQlLmfQ64YSlHdX9f6sULbTrS2/497WCP3VBn8+tXFUkY5xUyx1KsVKze50JKKsit5frThGPSrYip4hFPlApGMGoSpBrU8kY6VE8FHKFygBnhuR71BLpOnztve0hEnaSMbHH/Alwa0GixQiYNJXWxM4xkveVypHHqFnzYarcbR/yyugJ0/M4Yf8AfVeqeE/jD/ZttBY614dMVtEu1bjS5fNUe5jfDD8C1ed7A3SsC/klv7yTT9PkaNYyBdXC/wAAPOxT/fI7/wAI98VrTqSi7o4cRgqFRWas/L+rH0FD4x074n6k2g+GdUEekxpnVJQxhuZAf+XeJGw6553vgYHCnJJX0yxtLews4LSyhjgtYEEcUUahVRQMAADoAK+P00q0WG3iS2VTBjyGjyrxnsUYfMDnuDXvNq3ivwdoVvPJqa+IUCIHs9QIiuFY9RHOBhsejrnj71dtOspni4rL5Ye1ne56dRXMeEvG2keJne2t3ltNUiGZtOvF8u4jHrtzhl/2lJX3rp62OBprRhRRRQIKwvG/hfT/ABn4YvdC1fzRaXQXLwsFkQqwZWUkEAggdq3a4P4raj4isF0BfD5vobGe/Eep3en2X2u4gg2k5SPY/UjBOxscUAZQ+GXhDxF4P8OaXpeqTT6RoZeOB7WaC4jmbo/nKyPG7bsk/KCGJxisq6+Engi3/wCEe8N3/iGdZrVQbC0mkskupQsjSEpJ5InxuJzsYDj61wPhyT4k+G/Bmjado1jqWmWk01+81y2nyPMkxkYxeZGLaZghGG4jG7puWtdrf4gw+KfEXiXT4by51z/hGrQQ/wCgmO2nmJHmIoliV8rlpAhw27AbI+WgD6Nor55i174qTaDi2u703U2rWEMcraLK01tBIricyiS0gR0DBTlB8o4LDIJu65qnxV0rxX/Zovmns7VbUQ3w0uV4b/j98ZFgtpijE5GN8QXr83UAHvNFeF6PrvxJTV9Lub46rJZza3fWlzbS6Svlx2irmGX5Iw+M9G3Ybjr33Pg/rPjC/wBc1C18WDVbmGODzEvZLT7LaO5fhI4pLWGYMFx1aQdec4oA9YooooAK53xN4z0Pwzf2Njq1xcreXqSSW8FvZT3LyLGAXOIkYgAEE57V0VeeePfA2p+JfHvhfWLHVn0y00yC7hnlt2X7T+9QKPLDxunY5JwQDxzQB2uh6vYa9pNtqej3Ud3YXK74po+jDOP5gjHbFXq8C8WfAmWa9sYNAnSTQLXThZRWU94sElvIJDIZY5Gtp8MxJJKhGyfvY4qbU/g5rN3qer6klxpv9oz6vYX9pdSTOZoo4UCygyCMHc2O3B4Jx2APbdOv4dQikkgS5RY5GiIuLaSAkr1IDqCV9GGQexNWq8C1j4O69daVLBGdKmuhq+oalbvNeZgTzyNnmwSWsqSkAHIO3HZucj2rQbC4sfDOn6dcSwrdQWkcDy2cKxRhlQKTGmCqjI4XGBwMdqANOuA+NUuzwnDED/rbpB+ADH+grV/4RfV/+h78Sf8AfjTv/kWvPPjHoWpW2m6aJvF2uXYedsLNFZALheo2W6nv3rOt8DNaH8RHK2YworRQ8Vy9vpN7gY8Q6oP+2dt/8ZrobKJ4baOOS4luXUcyyhQzfXaAPyArgtY9RvyNrw5H52u2ins278qZ49mLXBGerM39KueDF3awzn+CMmsLxpNuvQueij9STTfwGsdInE+IX/0OGMH78mT+ApdPXbCvFQa8cz2idtpP6irdv8sINZkdSrqmXZY4+XYhQPc11djbrb2sMK8iNQua5mwxNrKk/wDLMFh9egrrU4AoQEgqWOtPT/Dt9dgMUWFDzl+v5VrxeEOBm8O4/wDTPj+dHOkS5I563ma3njmj+8hyK9A1WBNd8P74sFygI9j2NcreeGr2IZgZJ19B8p/WrfhHVHsLtrC7DIGONrjH1FJtPVES1V10OGuUaOX5lIZTgg9jXM6qn2bVzIPuTAN+PevXfHWhFGN/bLuRhl8dx/erzjVrH7XDszhl+ZT6GmaRkpK6GWb7gOeKuCsHSbnkxvw6nBHvW+nzLTQwx3FLSgUY9KAE+opCqntTsGnbaBkDRA0zyQTVvZTglKwFRbcZqZYMDipwtPxinYLkCwDPzkt7VIV4wMBfSn0UCGlQeDVPVNRtNKthNeSbAx2oigs8jf3VUck1T1vXUspWs7NBc6mVDCL+CIHo0h7D26nt61g29qy3D3d5M11fyDDzuMYH91B0VfYfjmnotzajQlVem3ckvLu/1XJuWksbIjAtYnxI49ZHHT/dU/UmmRRRQQrFCixxKMKijAH4VPtL/Sjy6zbbPUpUYUlaJCFyalVKkVRmpVUelCRsRqlSqvFOVakVatIBqpUypT40zVhEp2JbIRHTglWAlIVxTJuRbcU1o89BUyjc2KhlvfLuUhjTcCeTQBA8XPIpDFxnFaNwgKgjrVdWxwaGgvcz5oy8bxh2jLKV3pwy57j3qG1sYLK1SC2TZGg45ySe5J7k9SavzgdRUI5GKnyHZN3N34e6UdW8XWETDMULfaJP91Of1OBXovjzUZpLvZbv+5tmwVxw7d/8PzrJ+EMK2Wna5q7gfu1ESE+wLH9dtVdRvEeLaXyc7mPqT1raPuw9TzKr9piH2jp/mUdT0u11YJd3KkyxYe3ljYpJC395HUhlP0NbXh7x5rPhyONPFO/VdFPTUoo/9Itl9ZkUfvFH99Rkd1PWsRBdxWoVo9sZGcsas2yXJePT4VaSWRgsOO+acJuOxFfDQqrX7z27T7211GyhvNPuIrm1mUPHNE4ZXHqCOtWK8sj0a78P6nLeeBhCGjAS806RylvqDgfO4PSOXPAcDBxhgeCC28TS/FKafSfD0txpuj2reVrNyWCXG/kG1iwTg8HdKDjHCEk5XrhUU9jwJw5Wa13qt94z1h9M8NXUtpoVnNt1DVoThpnU829u31GHkHT7o5yV72q2mWFppen29jp1vFbWdugjihiXaqKOgAqzVkBRRWV4rv77S/DWp32kae2pahbwPJBaKcGZwOF/+sOT2oA1aK8U0P412tnpt9ceMLu3S6tY4zLp8emz2N1FK7bfL2TOyMuc/PvUDuF61uad8afD+pxWX9m2OqXd1d6hLpiW0Jt2YTIm/wC/5vllSCMMrkH1oA9PoryiD41aLqWk/aLC01S0Nzpd5qNnPdW0ciP9nDeYuxZgSylTwSoOOG70T/GrR9P0zz73T9Xuvs+m2WpXlxbW8SJHHcBdrbGmLDlhlQXIz1bBNAHq9Fef33xW0Kx8Z2Phu6huVu764W2glSa2kUsw+UsiymVAemXQc1L8E9e1LxL4Bg1LW7n7TetdXUZk8tUyqTuqjCgDgADpQB3dFFFABRRRQAUUUUAFeYfHP/jy0f8A67P/AOgivT681+OKZ0jS3/u3JH5qf8Kyr/w2bYf+IjzO2HAq+o4FUbX7oq+vSuBHqSOi8GLiS9k9I8fzrjvFUm7VZh6ED9BXZ+Evls79u5wP0rhvEJ3apcn/AKaH+dVL4Ua7RRy2t/8AH/bD/pnn9atbsWwxVbXBi+tW7GMj9f8A69Tf8uzfSsjMXw/Gz3M0/uEx+teo+CtPjuJpLqZQwiICg+vrXm3hXJimyOPMx+gr0fwrqJsIZA+NjNkEj25/pTcW1aJE3aJ3+1IlzIcAjIwaikvreMnCnHGSf1rnnv5dQl8q3dghPL9CfYegrUtfD6yLudQT6nmtaeElJXehxSqpPuXo7i3mXglCzYGen51X1TSIr6EFgAy8pKvBQ+xqpPpD2zFocofVf8OlLZ38ttIsVweCQAT0P09D7VNXDSp6rVDhVTeha02VmiOn6jgnokmOG/z6VwHivRjpV6yhT5D52n0PpXo9zClxAHj+6eQe49/aqV9bLrOly2tzg3MQ4b1HY1jGRvGXK7ngWswi0u4biMYDnDY9fWtiwm8yMGp9btMpcW0qDeoI+hFYehXBZQp6jg1Z0HQ+9GKE5FOA5qgFUcU4LSilApDEApwpcUoFAhVFLtpVFPAoAjK1zuv6zLDcHTtKCtfbcyzOMpbKehI/ic9l/E8dZvFGrS2zJp+mug1KddxcjIt4+hkI7nso7n2BrJsbSC0h8uPcSWLu7tuZ2PVmPcmnsdGHoOq7vYr2dmlpGVj3MzMXkkc5eRz1Zj3JqwELdqtArimM4XpUM9ZKyskNxtGKaFyaQsWpVBoGkPVMU9RQoqVRVIYKtTolIi81MgqkS2PjSplGKanSpKZm2AFI4GKcFoIoEQgYpI4EEm/GWqQ9aTdigdwmbjFVGPNSyNVZzk0mUkMl71XVyDzVtk+TJrV8G+GpvEmsrCFZbKMhriXsq/3QfU//AF6STbsglOMIuUtkd5okI0/wFp1rIMNfFrqUf7JOQPx+WsF0gj1IkIqqFJxitnxLqLyX0iWNvm0gUQxEHChVGOPbOaxEsmlSSa5c+YR8qoelay7djzaa3nLr+ot1eiaZVIPkggM3Ye1dH4XXF1e6vx/oqeVB6GV+B+Q/nWKyItisKxAs+BsA5LHt+ddrZaclr9j0yEfJaASTkHO+dhyfwHH41LfKrmOJqJQ5V1/Lr/kZeq6Nq+pJb6TbTNY6I8Ze/vo5MTyjP+pjxypbks/YHA5ORQ1DR4bG4g1Dw1LFot3pUAhhkjjzFJCOfIlQY3xk9O6k5U569trE4tbPYn3jxWZp2npdbYp13JkO6nuewP8AP8q56lV0kuXoedGKldyNPwH4wtvFdhJmI2erWpCXtg7ZaFj0IP8AEjdVccEehBA6iuH8SeHWupItT0B0tPEVghFtOeEkXOTBKB96Jsc91PzDBFbfg/xJb+JdMadIntb23cwXtlKf3lrMOqN6juGHDAgjrXoYbEqtHzOScOV6G4zBVLMQFAySTgAVTvbWx1zSjBcCO7sLlFb5X+V14ZSGU9OhBBrj7+RvH+pTaZasR4StJDHfzocf2jKpGbdD3iBBEhH3j8g43V0fizR5tW8J6jpWm3c+m3E1u0dtcWsjQtA4HyEFcEAEDgdRkV0kGQ3w08KS299FdabJeNeqizT3l5PcT4Q5QLLI7OmDyNrDB5q2ngbQhPp080V/dT6dcm7tZLzUrm5aKQrtJBkkY4x/CeO+M15NH4c+LN54Omvb29urfXp761SfT477IFnDHtfyisyKryPl2xIhPTetN1Dw38R18NaZDbXPie9vbWa4fyLieK3jlVseWk0sWoCbCncQwkc46rxyAehaZ4A8AyRjStOtLaX+yYLiwa3ivpHe2juQxlRxvJBcMx+bkZ4xUE/hD4fXGt3fhSax3ahdaNAs1r51wN1jBIEi+fdgbWUDg7jjnIrk7zQPiS51dg9+tpJqGnSm0t9W/eSWqQYuYreVpMxkyd2KFsZzzyzXfCPjCfxBf6p4Rs9R0iV/Cz6fazapqCXFxHcfbfMKF/NlbJj3FW3ELlRkYwAD0JPhj4Rj1hdTj0uRbtb5dSG28nEf2kcCXy9+zd6nbz3zW/4b0HTfDWlJpuiW32ayV3kEfmM+GdizHLEnkknrXE/BrSfFGlLq3/CU3Gruk3ktBBqDJIIWCkSeW/2q4dgTtJ3FcHoMEgelUAFFFFABRRRQAUUUUAFcJ8ZIfO8KREYLpdIwHc8EHH513dePeP8AUDe+JLiKaTbBanykUngcAk/Un+VY15WhbudOEp89ReRxEAkAA2GrSu4XlTU5uLZThST+FBurc+v5VwHsOmjovCDg6XeEnBL8Z+grhdVffe3Gf+ejfzNdpoUkLadMRn79YN3bQySyYZclj/OqlshuOljiPEK4ksn/AN5f5Gnjm0J9q2db0f7VaEIcSRneh7Z9KwrV91kwI5HaoMXFxZe8JPhZQRwXOPyFdraHFmg9Sa4jwwAyOucFXJFdnaAmzB7qxFb4f4znxC9w6rw0B5q16PZbBFjivL9Bn2yJzXe2d1lBk16DPMZbvkVs4Fc/qFqkqsrAEGtuadStZtwc5NIRl6TdNDO1tOSV7E9x2P17Vdus208dwBgKcN/umsjUB5dzE44+bB/Hj/CtuYfaLEEgfMuDXl4mnyT0O2lLmWpwHxAshFemaMYWYYz7j/61eYW7eTq9xGePmz+dex+NB5uh28x+8uP5YryPVoxHqdvIOGdcH3x/+uoi7o64bHQQnKCphVSzbMS1bSqRY4CnigDinAUAAFPApAKdQAoFZ3iDVV0mw3oolu5m8q2hJ/1khHf0UdSewFX5JEhjeSV1SNFLOzHAUDkk1xVu0ur3ravcggSLstIj/wAsoc5B/wB5+GP4DtTXc0pU3Vlyogs7ZoEkaWQz3czeZPOwwZHPf2A6AdgBVoKe9WSirTGIJ4qXq9T2YpRXLFaEfNPWItz2p6IKkdwq4Uc0FNkQRV60oYdhUXLHmpEWgLEyYx0p4FNUYp4qhD0qxGuagFWoaaJkSItSKtCjFOzVGbFwAKjan9acEoFcrstQycVcdcVVnUkcUikynI2TSIueTSSqQaksYJr28gtLYbpp3EaD3JpGuyudl4I8JJrcT3+pu0emxkgBW2mUjrz2UetdDrmox2elPZaLGlnYYICxrtaT1J78/n61Z8RXEei6RaaJZK7pDGolKjr7H6nk1zEccmoNvuZAkP8AdHJPtWz91cq3PITdaXtJ/D0X9dR91cj7GoyACvAFM8qc2yLtMRUDk4Oar3EC29whYloAcqD2PYfSrULTahcQ2tpGzSzMEX059T6Dr+FQa2srrY2PCNn5TzazdlZY7U+XbpjAknPT8v6+1dlpUJt7ZppjmQ5Zm9WPJP51n29nF59tY2p3WlgCm7H+slP32/mPzq3rFyEiEEXXpWc5a36L8zyas3Vnf+rGXqd2jSSXEx/cwjcfc9hUvh+5K27SzsFldjI3PTNY1/BLqV0un2pVIbch7mZugbHCD1PetS10iFNpeSSd17twv5Vwzi6hWiVjZjvlRiysTnv615j4zlu9W8R3D+DI7o3dnCINcmtJRG89sWDfZozjm4C7mUjBQEjILitrxVqN1Je/2B4fkC6pIge5usblsITnDkdC7YIRe55PAOdHwhp9rpcsOmadGUhjiJJLFmYlslmY8liSSSepNXCPsP3ieqIklO6Oz8JzaTceGtNl8OeSNHaBfsohXaqpjAGOxHQg8gg55rWrz20lTwT4vW12hPD2vXBKHtaX7dR7JNjI9JAf79ehV7dKqqsVJHBJWdgooorQQUUUUAFFFFABRRRQAUUUUAFFFFABXiXxR017LxTNPg+TdqJUPbIADD8xn8a9trB8aaEuvaJLbgD7TH+8gb0cdvoelZVoc8bG+Gq+znd7Hg0Sqe1SmMegpjRvBO8UqlJEYqykYKkdRU45WvOPdTOk8MwK2lzcc7z/ACrn76Ly724U9nNdV4VX/iVt7sawfESeXfFv7yj9OK0a91FGMXYMQGxXK6fh4pz2LMR+dbepXHk2d1L3CED6nisbTIytqPpismYT3LHh0qs86ZxIGDD3FdrpThklib+Ibh9a89tWWDVULEgOCufftXZWEzRsj5DY7+taU5cskzCceaLRt2M5inAPGDXbaZdeYg5rz65YK6yIflPOaseHvFNpcahNZ2zPKbcYlmUZjV/7m7u3qBnHfHFeotVc8uSPSi5NMflTWZBqcboPmFPlv0C5yKRmVNcwIW9RzWvYnOmqWx1OK5LVL8S5UHrxXWxHytLOf4QTXDjfs/M6aGzOe8TgHw0M+o/9CryDXSDqFtt9G/pXrvjRlt9Ct4G4ZguR+teNai/ma0gB4VOB6c1ywWh3w+E3bD/VCryCqlkPkFXkFWWSKOKkApqipVFAMAKXbTlFRahdwadp9xeXRIggQyPjqQOw9z0HuadiTmfFUzX1/Fosefs+wT3x/vJn5Iv+BEEn/ZXHeldgq16p4E8GaRf+EVOqRpJrl4TdXsiHEkMjdEH+yihVHY7c964nxB4T1LSryWKW1meFWOyZEJV17HI6fStZ02kjtwNanZxekvM5d2ZjxTooiTk1pxWW04YEH0PFStBtHIrLlPRc1sigsdDRqBzVpgqcmqU8244WgE2xMLTgVA4piRs3NS+Q3pQi9BoOakFRbSDzViML3piegLVuEd6YsQYccGmeYYG2uOD0NBD1LyAkUuMGhHUQbs02M/KZH4HaqMx+cGnBwBVVpS5wnNNbeoy3FFx8pcA30xoR1zTY3+Su78A6DE8J1nUgot0BMIk+7x1c+3pVRjzOxjVqqlHmZz2leCdU1pFlVUtLY9JZgct9F6n9K6qw0HSfBaSXXmtfasEIjyv3M9wo6D3JzVrXfEU1wjiylaC2HAI4eT3z2HtXLW16YbXc5OHZiT1zzVe7HY5OetWXvOy7L9WSX2ppcRMTJvZjknuTVWEXNvCu6F9p5H096jQym4a6ht2KYxkDFWYLqW6B+XCjgljUbmtuVWWw3cztHLIoCKd2G7ntXTeHYJLe3+3ZxeXeY7b1jj/ik/HoP/r1iaDpv2u8nluXP9l25DTHux7Rr7t+n5V32mQtI7312oRmAwo6Io6KPYUm7LTdnHiqqXuL+vIljjj0ywGAAccVgyzsQZuPOkby4Ae7nv8AQck+wq3qU7X11sU4QdT6Cuc0jVE1TWNSuIcG2slW2tvfdku/47QPoK5ZyTdkcsIu12dLplpHGiww5KKSWY9XY9WPuTWm3lQjBxmoNMKrGPcU3UIA4J3FT6ihWSuS9WYk0dhpovHs4Uia5ma4nYEkyOepJPJ4AA9AABgCrvhGPJa+lGDMcJn+4P8AE1nW2lRXepCO4lZ0xu2f3uelddcQrAiJGAOOAB0rCtN7IvRe73Kmu6XaeILO70/UIzJaXCbGCnawOcqynswIDA9iBR8PtZn1LSp7HU33azpMxsr0kAGRlAKTAekiFXHb5iO1W5mFuil3ACAtIT29f8K8y/t2XTfiFZ+IhhNNvGXS70E4zGzfuZf+ASHGfSRvSu7Ac0L32f5/1oZVKLnFyj0PaqKKK9Q4gooooAKKKKACiiigAooooAKKKKACiiigDy74s6AImXWbVcB2CXCgd+z/AND+FefwPuWvoq+tIb6zmtbpA8MqlHU9wa8B8R6PceHtXktJgTH96KTs69j/AI1w4inyvmR6uCr80eR7o6LwnKDZyx91fP51k+L8LPGfY0nhe623zRZx5i/qKh8YsTeQRrydhY/n/wDWrNv3T0L9TiPELkWCp3llA/Ac1JaKFtlHtUvi7Tru0TTJbiJooZgzR7uC2MAnHpzTIeIl+lZvTc527u6M3V4CEDp1ByK2NN1CD7GZ2mSFFXc5kbCrjrk9qoavd21pZ+ZcsfmO1EUbnkbsqgck1zMVncG8S51eH/RtwdbIHKqR0Z+zMPToPfrTS6shu2x2UNxd+JQIUaWx0Q9ZuVmufZe6If733j2x1rcg09NMgjt7OJYYIxhEQYAFZ9hexzxq0UwYeh7VrwXJVQr4dOwz0+ldNKvy6PY56tDm1W4sWpPDwT0p82tsy4BpHhtp+Q4U+jcU3+zbcdXT/vquv2sXrc43TknsV0vmklU4JIINeqaVf2s2mqZWG3rg9xXmai1tj8g8xv8AZH9ajlupyrDzDFGf4FPFceKcalrPVHTRpS6ml421YaheMEb91HkA15pFmfWLiTtu2j2ArZ1zUFhj4PPRV7ue34VS0O2IXc3LHkn1NcyR12tojoLJcIuauKOajhXaoqdBTGSKKkUUxRUyCmJiqKyNYg/tXV9P0pWO1P8AiYTqBkMsZAjU+xkIP/ADW2q5IHrWH4alZrq+118tFfTmGE+kMRKJ+BO9v+BVce44R5pJI6Wy1Yw/fzHOvRg2GU+xro9N8c3gl8i4WCcDG1zlWI9yOP0rmrVLdmklcJLubcAw6VLLb291Gpt40hk6qy1Sk1szpqU6c9JI7sa5p14NmpW8cQb+JwJEP444/KuN8b+HUsIhqWmgPpz/AHgh3CM+oP8AdP6VmxrI100V62NmCEHRveugsdQms4ytvIVU/eQgMjD3U1TlzaMzjTdBpwfy6HlV9L83yniobMqzZbn6V7HZ6hoc9wwm8O2fnKcF440wT9CK1l8Q6TbyJAtlJDu4wkaYH4A1CpJ63Ol42UdFB/eeNx+UUyhBpkk2OMV6/q3hjRvE1u8tkY4bwDiaJdrA/wC2nGR/nNeTa5ouqaPcPFf2kqqpwJVUlHHqGolBxNcPiYVtNn2ZmSOSc1JGWqGPB5JGKuW8scZzkGoOt6CiV48FkO31qVmjuYSARmrUckUwwSKoahD9lbzIencDvTM07uxHHKyRtEx6H9KnV5LphGnCjgmsuef5ldejCtTT5PJgDZAJ5JqUypKyua0NvFbw5YjNU7maLnAya7HQPBk+pWy3ut3DWVmRuVMhXYepJ4UfrWx/ZfgrToy/2Z75k5z88gJ+uQtbcja7HA8VCMrayfkcL4V0S51/UUghRltVOZ5/4Y178+voK7fxdfJPpws9NIjsLfCrt/5aY6Y/2R+vWo9S1m61DThbaUkGm6eV/wBSijLD0JHT6CuYP2iafyJZMgLn5RRdRVkR71WanLS3QfFFd3tv5m8KmO1MgvBDbmNwModoqx5kqx+RawOdoxnHA/GqkMwiPlm1L3JOSWXPPtUGq1LlpcyRx7pmKJIflX2qbT9MbWtVS3s22DG6aX+FE7saLWzutVuI7CJFa4fk+kY7kn0FdtY6fBDb/wBl6Xzaj/j5uP4rh+4z/d//AFeuW3ZXZy166p7bv+ri6fYQ3Bhhs0Mel2xJjB6yt3kb1J7e1W9YvAkYgh47cVYvbmLT7Xy48AgY4rktRv2tY45nAa7uZBDbRt3YnGT7DqawqTt6nnRTk7sbq9veXlu+nWMi24kH+lXTc7FP8CjuxHX0H1o0Hw5b6RHKLaW4laVQrs+Apx0OP/r1q20AEgiUllXlmPV27sfc1vW8KhQCKyjG7Kc7KxkWlvNF/wAtPlqS9nxERnkVoXUYQEiuS1K4ka6EUYLFuAB3oas7MI+8XPD++bU5JFBPlpjj1J/+tXS7zg3D5wpwB6mqmhWLabYlHUefL8zMTUeu6kLCyXyQGnclIVPr3Y+w6/lWEYOrU0/r+v8AIr4nyow/GeqBVFirFRgNOw6n0Qe9cXe6X/bdjcxXZVLWSJoQvoCMZX3Hr6ip73zHmkKl55M7pZM9M9ce5pbmWMWgnt5JECDGwngY7V6SSirLoelCmox5Uej/AAs16fXvCFu2oMG1SydrG+PrNHwW/wCBja49nFddXkXw3kl0nx3JBNIkcHiCxN2kBOGEsBVN2P8Abjcf9+q9drvi+ZXPn61P2c3EKKKKoyCiiigAooooAKKKKACiiigAooooAKqanptnqluYL+3jni64cdD6g9QfpVuihq+402ndHGr8PNIjukmglvIijbgokBA/MZrXtfC+kwXgujbCa4UAK8p3bfoOlbdFQqcVsjR16jVnI8S/aHGdR0Qf9M5P5rXk99qn2d0tLOL7VfuuVhBwFH95z/Cv6nsDXd/HbW18Qa1YWvh2QSx2wkinvwu6FHyMpGejuO+OFJ554rjNM0+CwgKQBizndJK53PI3qx7muGvZTbZ34e7ppIbpOmeTOby/kF1qDDBlIwsYP8Ma/wAI/U9yav3duJV4FPj7VNtzWLdzoSSOclspLecTQZVwc+x+taFrrSR8XUTI3qMkVqeSrDkVUuNOSQnAoEW7XVEuFzAUK+parLXO3rKn0AzXNTaKNxZcqfY4qAaQ4PEjj6MaYHSXOoJCu6SUIPUkCsW71h5Pks0MpP8Ay0f7o/xpkGijducZPqea1LfTwuABQGpj2ljLPOJJyXc9WNdPYW2wAYp9vahAKuqMDAphsKox0qRRTQKkWgB6ipkFRLUyU0SVNdlmh0W8NqcXLJ5UH/XRzsT/AMeYV00fhG/0fT7W0sFiv7G0iWIeR9/CgAZQ89u2a58Qm+8S+GrBTgSXwuX/ANyBTJ/6GIx+Nex/2cJ08wMwlHRgcGs6lf2clFK5CqunK55POln5bgRyQTr1XlcfUVJ9nma1imtipKqMxdD9RXo13aC6Bj1CC3vscATJh8ezDmsefwpbEF7S6ubFv+ecw82MfiOQPrVQr057P79P+AdKxK+1p+P/AATirX/T7hlucpsGB2IPrVxbSRCUS4yOxIp2raPqmlSi6lg82HoZ7f50I9eOn41RW4nuZY3gUAD1bGa22Om/OrxehZ+yz2UhZdsyNyxQ9DUSzj+0VZ/l2qcfWluWuoyiTL5Yc43A5qdrO1MYO1mbHLFutAr/AMxZfUvLTfv2unKupww+hFb2meJ7+O1X7WsF0Mchjsf8xwfyrmIdPiuLb9zIEYHI3HPNQt9rhIRlyc4BB61Sk0ZypQmrHTrrWmX7CX/hHrJ5c8tIEz/6DVk+KbG2XZNpEKJ02xFT+mK41re5t5lQsqeZlsHoKdc2r2oScuJyDzt/hp88ifq9N6fqzrbrRfDPidGFoq2d8RkNGvluD7r0avKfEmnX2g6m2n6oBkjdFKv3ZV9R/Udq6sanDhT9yRTlXXgg1b8buvirwFJeLtOpaRIJXwOWjPDH8ufqtTO0ldbmlFzoTSbvF6a9Dyabj5ewbiu5+G+mpq3iiL7Tj7DYR/apy3Tj7oP48/ga4lR5q7gOa9H8CBrTwVrVxCQJ7y8jtC2PuoF3f1P51lTXvHdi5NUmlu9PvN7xfqx1BGcsRFkiKM9h6n3NY80kz2awxKzHGMCm3Ni7xhmuS7DkLtwKbPetHtigG6ZhgKK1bbd2cMIKMVGPQV1uo7dI4osbVxuPApmnyRRQPJK4808MT7elNuLu9KrHJCVzhfmNPENpaWzG5CvKTnJ7Ui7aWfXsWdNnd4C6kgFiAfUVDZ2V3qervDYpvYr8znhYxnksewqax07y7B7/AFW7Gl6W33N4zJKfSNOv411lgivYx2djAbOzfDNGTmST3kb19qTajuc9Wuqbahq/yJNJ0+CC0NlprM6P/wAfN5jBnP8AdX0X/PvWzcTQ6XabVwGxgAUnmRafbdsgVzl1M95P5suSucIg/irKU+vU853m7sjv76OGJr6/JEQOI4x96RuygetUodFlutQj1TU5Ha+jw0UCHEcA7L7n1961bfQHu7uO+uoZLiSP/VDH7uL/AHR3PuatrBJHMQCSc8hhgiseV7svmS0QzTplExDcN3BrbjuVVeorOe1Gd+35qzLy4MIPzH6VWsdUTbmNbUL1dp54rH0K3N7rT3B4hgUnd/tHoKqW0Vzqk/lxttjH33PRa6yC2t9G05iW2RqNzyP/ADPv7VnK83yrcfw6Ik1K5SztWuLl8KnLnv7KB6mvNtT1K41G5mZMeew59Ik7KP8APNP13Wp9al3orRWanbAp4Ln1x6+/as/TsWk80UrASHDZPfiuunBQVkehRoezjeW5YtbmKO1iRTtRjg/73fNRxrBC17f3pVdMtNsko7yP/DGvueKmjtxqEi2dttAwWd2PyxKOrE+grifGWux6lNHYabldKtCRGe879DK3ue3oKpy5Vc6acOeVl8yhceJ7qPxnpvim8ch7W+jll29Egb926j2Ebt+VfWdfG89qt5aT2z/dmjaM/iMf1r6g+F2rtrvw88PahKSZ5bONZif+eija/wD48prfCyummednFFQnGS6q33HUUUUV1HjBRRRQAUUUUAFFFFAFbUnvY7GV9Mgt7i8AHlxXE7Qxsc85dUcjjP8ACf61554Q+KP9p+HbnX/EdhZaLpMV09jG0d7JdzSzq+zYsQgUnJzjaSx/u16ZXnlx8IvDlx4Kk8MXL3s1ib9tSSWRo2kjnZi2RlNhHzEYZSMEg5oA0B8TvCTQWskWpTTSXVxLaxW0NjcSXBliAMiGBYzICoIzlRjIrDn+LlnH4h8S6Z/ZtxDHpGnpfrdXcNzEjhoy5EoEDNCAB1IJJ4AJ4pb34M6FeeHxo0t5Mtl5kkrCLTNNjJZ1VSRttQEYBeGUK3PU4XFqf4S6K7X4g1DV7aG/0pNHuokmjcTQpGURiXRmDgHqCASBkHnIBs6X490PUb630+3nmudQeOF5Y7KzuLiOAyqGTfIse1AQc5fbxyQK5XwT8X9MufAOi6z4vuobTUr6G4uHgsbWaUJFFM6GQqodkQBRlmOM55rf8P8Aw7svDmrNe6Fq2rWSTCAXVshheK6MSBAXDxFlJUclCufauePwJ8Kiw0W3SW8MmlQy28M88Vtcs8bytKVdJoXjOGdsEICM9aAPTI9Rs5NKXU0uY209oRcrPn5DGV3b8+mOa4/bqfj3PmC70jwk3RTmG71Jff8AihhPpw7DrtHB7HSbGLTNLs7C3x5NrCkKYRE4VQB8qKqjp0VQB2AHFWqAPJfixpFvbx6NbWFtFb2tvC8ccMSBURQRgADgCvOXsmUdK9+8XaZ/aAgOM7QR/KuFvPD7Jn5a4q1NuTZ30KqUUjzcQkDpTlSurn0ZlJ+Ws6bTXUn5awcWjqU0zJVcVJtz2q4bRh2pvkMO1KxV0VPKz2oW3HpVzyz6UojPpQFysIRUqxgVMIzThH7UBcjC08CpAlOC0xEYWngU7bTgtFgBRUq0irUiimhFnwXGLj4huxTd9i0pmX/ZeaUDP5RH869YtLjYSr8A15l8L2X/AISrxPM3UG0txn/ZjZz/AOjK9JuljLKVON3WvPxTkql/Q53aTaZJEVN4xOD6GrUjRuGVgARVCO38zaySBSDyDT7i3eIBt4Y+hHWsYykk7ImUYtrUrCDbO32XMTsMlkOP/wBdUr/Q4JQXvbGC4kP/AC0QeS5/FeD+IrQWTbJuQlsgZ46VZkuDJHtI5qqVaUFo/wDItuUWmjiL/wAKwTRlLS9mt2blY7pNy59nXp+IrFv9I1jS4g09t5kHQywt5ifiR0/GvTLJVeRtxzzgU29s1jlEkLvE/wDfQ4JHpXTDFvlvJfcbRxMoy5Xr6/1/meRW5ljU+XJHgnO3d0qSZ50mhknx5f8AsnPPvXous2toUSS+srO93fxFdkhz/tL1qungyxuojKqXumZGQryq6/keR+NddKcaukH/AF+Rv9cgtZq39ff+BwtxMbydI45MMozuPP4U+SC/jXgRsPUNXUy+C7ISAjXoVcd9i5x/31SHwhb7TjxFF/3wP/iq15WP61R6P8GcdbTC2uGWdUJJznGa6Hw7cQvrcUMoVra9RrSZMcMrDp+eKvxeD41Vlj1yyfdy25Qc/wDj1Fp4LaC/tp4tWs8RSrJtBPOCD60KMkTUxFGaa5vzPDLa1ksNY1HTJyTJZ3EkBz32sQD+VejeEUaT4czBX2M2tMN2OgEQrlPHMYt/i14ijXgPIknHq0an+td78JILLUfDesWV+JWS2v1udsZIJ3RhR07cGsaSs2vU7MTVvh41H5MoXMMMS7WvZCx9xUui6ZqcsjHT7Cacnjzyu0H8WwK9FtI9PsG/4lmk28LnpJKQWP8AM/rS3upSB4kurtkMzbESIbAT6cc/rVucI9b+h57xkmrRj9/+SOZHgnVLtkbU761tEyCVB3sB+grTuPC62sK/8I7Pp8moDrcXzeaw/wB1R8oPvirRljTUI7ZIdzMhdn67R2znk5omYtfRW4gjeMoXkZh0HQY/Go+sJbR/EwnVqz0ctDiG8N6vc+KrU+KRM0SZnmumbdH5afMQCOB9OOtcvpfxb12+8ZWyxwW50G4u1gWzWAbvLZtoO7rvwQeuM9q734taw2i/Du8t4pnE+puLKBC2cA/fI9tuR+Irz34bWek6RcRa/wCIrqK207Tj+4Vjl7i4A/hUcttznjvj0NS3qlB26s6sNTi6UqlRX6Jf5Hr+o20jahJbqry4fbGg6t9fQepqeWXRfDU1gPEd7bw3d65jgEmQmRzjPQdRyfWvG/GHxJ1nxDcvD4eMujabuz5qttuJ/dmH3R7D86lbwZ4w1qx0+81Jb3VFZSsBuZgzRqfUMcgHA5PtVQtduKv+QlgZWTrSUU/vF8e/ETxdb+MtUTR9QWDTrOby4Y0iRlYKBkkkEnJz3r2DStT/ALb8L6Lrc0Agnu4VaRB0BI5x7ZHHsazbP4f+GNP0ixGr2cTXMca+afMbEj45+UHBGfarWqask5jigRYbWEYRAAPYcdvpVzTgnzyvfoYVp0ZqMaMbW3e1y5e3KrF8tc/b2kmragFJK26NmRx2Hp9atWsU+qSbIMiP+KTsPpWxc3VloNiozgdFUctI3sO5965Pem7RM0raLcsM1tpdiS5SGCP5ueAv19T7V5/4k1s6lMPN3i0B/d2/8Uh/vN/hVLXdVvdVvMOyjaf3VunIT3PbPv8AlVEW5t5I5WffKrYck9M10wpqmrI9Cjh1D3pbloW1z5i3Ekkeegi/uD0FU7SGe/1I28UInmOVTd7nqfQD1q5JDc3Opw29h88rZ4zhQO5J7AVgeKPENvZWUuj6DP5jSfLe3yceb/0zQ/3PU96ptLVnTBSlot/yI/GGuRWtvJoWiTB4Cf8ATbpOPtD/ANxT/cH6/wA+OjXNIi1ahjzWLbk7ndTgqash8Mde1/s9TOfBV9Zv92y1S4iQeiuRKP8A0aa8hijwK9S+Acu1/E9r2W4gnA/34gv/ALTrqw2kjy84jein2Z63RRRXafNhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2RBImDWbcWatnI5rUpGUHrSauNOxyt3pKNnArGutGHPy13skAbtmq0loD2rN00zWNVo84n0fr8tUZtJIPSvSpbAH+GqU+nDH3aydI3jXPOX0xh2qJtPYdq759N/2aibTB/dqPZFqscJ9hI7U37IfSu4bSx/dqNtKH92l7Mr2yOLFsfSkNufSuxbSf8AZqNtK/2aXsx+1RyJgPpR5J9K6htL/wBmmf2Z/s0uRj9ojnVhPpUghPpXQrpvtTxpvtT5AdRGR8O4D/xU86ffGqhf++beHivQLKSO5jyxIPQg9jXHfDmPZdeLbZ+P+JuxHtmCEiuibdazlwDtPDgfzoxeG9rTTj8S/qxxwqcs2nszRXcW+QZx/Fmn5kdcYJzT7WZVhK8HIyDSW8uxs9a8Ky7nW29dAgcwSHcvfvTbqRZiNq7T7HtV/wAxJsBk6+tV7hI1YqABVSjZWT0IjK8rtakaRZjDw4yOq0y5ugkDPMcKo5zTrUSFTsHI6c9qhnX7ZPBayqMSuNw9VHJ/lilCLk1FdSurv0EtG+zW8NzLGHu5hmKNuka/3j+n549ahuZBtae7k3heSz9B9B2qe4l8+7mk7bvLX/dXj+eTWbHe2t95ts4ZSSUKSDbu+lejNqP7uGyIim/ee5bgljmjDwuroe61Ta+lj1P7NPCFifHlyA9eO/48VClhcWU3mWjiRT95G4JFaEsS3EIWRSO4z1U+tQXoiPUZDb2cs6RJIyDOG+vNWLNY5mgZUTDlSPlFRXEqw2kkk6l1RfnCrnI+lWdGWMvbCE5i6qfbrTgrySJk7RPnjxRP9r+K3iWXPC3RjH/AQF/pXV/Ce/Nl44l09/8AV6nasgGf+WifMv6bq4CymNz4y1i4c5Mt7Mx/FzXTaWxt/H3huZDtIvolz7Mdp/Q1rB397zPeqU74d0/7v5HsV3Du1iwmPQB0+hxn/Gnz2/navbyMPlhjLD/eJ4/lV+5iX7SQf+WchI/Uf1rJs7q5m0ie4fHmnf5W0fgP1rF6aHhJ3Vy46pbtc3cnPyD8FA6fnT9LMl7FDIYfKllHK5zgZOOf1qvBp6xaeloWZgSDKWOS3OT+dcr8WfE76Lp0eh6VMI9Xv0zM6dba36E+zN0Htk+lVGN9XsVCDqSUI7s4X4l65F4l8YqlnJv0rR1NvE2flklz+8ce2QBn/Z963/B3wqXVHg1DXJDaQzfNFAP9bIOuefuj9fpVv4aeDLSy02PWtaiUQIN1rbyDAbH/AC0YenoO/wCVemWFz9tvbOdWLB2JBIxxtbt2reKipLmV2ztxGK9hD2NB7bv+vxMvSdMtrO2CaHpVlahGILOm+QkHHLHk1ZlbWXYh7tV7YXNWrdpY/PdOEM7hcd/mNTzI0TIznLHnFcE8RVTaucL953lqZb6DNJ+9vLpmHXavBP41bg0ayi2k2wz1zId2fwNXZGY/fILgfd7D/E+1cz4i18xO9vZOPtA/1kvURe3u38qunTlUer/r+ugQjOeiLWv6/Bo0JhiUSXDD5YE4A9Nx/pXnd5qU+oX37yUyXMh2mT+GMeiCo1kN5eO7mQxj5sn70mepz/Wn3c2WgaO3aJY2H8BAArujFRVonp0qMaWltSwtsloH+yuxlAydx6n1qtZQTX6G1gXfcSMWlZjhUHdmPYCrixG7ugYZI4440LzTSHCRp3LGuP8AE3iNJYpNM0Jnj00/66YjEl23q3ovov5020tWa04ym7LcueJvE8MFpNo/h5iYX+S6vv47j1VfRP5/z4tEzSomasxR1i25O7O6nTVNWQkUWTV+CPFNijx2q3GtUkU2ORa734Evt8VeKYuxtbJ//Hpx/SuHjWu3+CC/8Vr4lI6Cwsx/4/PXRQ+I8rNX+4fqj2iiiiu0+aCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEKg1G0INS0UAVjbD0FMa0B7VcopWHdlA2i+lMa0HpWlRijlQ+ZmUbQelMazHpWvgelGxfSlyj52YT2Q/u0z7EM9K3zGp7UhiT0pcg+dmELIelL9iHpW35K+9L5S0cgc7PMtAhMHirxpAOCL2CcfR7WIZ/NDXTZ+0xcj98g+Yeo9axpQtn8VNYjH/L3pdpckeuySaNv0KVqzo0EyyxHIHI9x6VZmxLeb7MQr/6ong+h9K0XfeAGXr04qnIkc8W9OUbqPQ023laJ0hlPA+43r7V4+Owru6kPn/mdVGp9lmjGkoAwgBPpUNx5ikb/AJQT161NJdswUcAjuDTZZ3dAJVxngGvLfLbRnRHmvdojhWULmMEr/SpLGJjqsMjYwqMB654pYZXjBCcjoaZBI6anaE8I7Mpz6lSR/KtsNZVYeopttMp25JhQnqRmqcl7YzO0c+AynafNQjn6mryLs3R/3GZPyJFUp9SgWd4DHLI68EBMiup6NoI6k8qyfZSLF03j7pc7l+lNguXwFuomhk/NT9DSwCNsMls8We5QLVnoPakBVhkuInK3QV0J+WVBxj3Hb61f0pEgu4wgwpYnA6DIrNlN+bhhCbZYf4d2ST9au2rPHJG0hQsGB+XOP1qoO0kxSV1Y+YdNjMHi3VYX4aO7lUj6Oa6aLLeKtAC/eOoQY/7+LVHxna/2T8WNehIwslx56/SQB/6mtTwtbtqPxH8OwJ91LgXDewjBf+gq4KycfO34n0LmnR9p/dv+B7ve/wDH3N/vGs21fyZo7KOMlIotzyZ4BJ4H48mpNUjN3NAvOwz+Y+PQZP8APFSxLFbRXNzdypDbpunnmY4CKB/QCoa5padT55aIoeKdftvCugTateYeQfu7SDvPMR8q/TuT6A15v8M/DFx4g1W58ReJS08bymWZm6Ty9ox/sr+XAFVoRe/FTxutx89vodmCsCkcQw55c/7b4/zivYgtvaWkNraIsFlbrsjXoAPU+9apqKv93n5nY39Whyr45b+S7ev9diDVr6BXVrlTI/VIkXcfbAq5pcge5jnYMqRxNKQwwRwBz+ZrNsri3lu3WCKVmIyZ2Xg+2a0WkEOlXcrf8tmFug9ex/mfyqab97nfTU4prTlQyxMrafBLINuctg+/NXRuVhJKSX/h9v8A69NUkxqxHyIPlB6E1y/i3X5LVXtbUn7Swwzg8pnsP9o+vYVyUKXO7/1/Xb7zWMHUlyoh8TeISpksbCT99jbPcD/lkvdV/wBr3rknbdAG2EWi44HVh6/SoYTCwIklAiByRnlz/hS2t4phlR2wdxwfavSSUVZbHpwpKCsh0l0Gu1uLaNjGF2nC4FXEuHubeaeZxbWMA/fXEn3UHoB/E3oBUMQiXTHuby4NtpVv8sk2MtI39xB3Y/pXDeJvEM+tyRxIn2bTYOILVTwv+0x/iY9zSlLl3NIU/aOy6f195N4m8Q/2mi2OnRtbaTE2UjP35m/vyHufboKwkWhFqxGlZayd2d8YKCsgjSrUaUkaVajSqSBsWNamWhEqZUqiGxyDiu++BsWdf8VTdvLs4s/QSt/7OK4VVr0j4Eor2PiS5HVtT8nPskEQ/mTW9Be8eVmsrUbeZ6fRRRXYfOhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeZ/tG6jfaV8KNRutLu7uzuluLZVltJmikAMyAgMpBGQSOvevTKKAPAr7WfHngcmS0twltr3iC00zSbDxDeveSWyPE+9nlSRyAzhSBufAzxVjVvir4r0jXp9LvrTRDqVncWNq2lRRym41IyqPNltWLjEatnGUfgfMQeK91ooA+dfFnxQ8R6j/wl+hWV1p9vcx2l7JZPpCC8ZY4lyGa4iud0MhAbAaFcHHXpSap8YdS8OeBPDjWWsaTq+qy6OLxzJZlkl2ABlaZrtf3q4IZVDuW52DOK+i6KAPnTQ/iF4jtfFXjrVJLhL0nSLDU7DQm8zMge23H7ODIcBCf3hVTuxn5a7v4L+PtX8aSamurJo7RQxwSwTWFxCWO9TuWSJLiYoQRwWIyOwIIr1CigDwGx+Luu6l4lsdMnTRYIr7Ur3T5tN8pzeWccSEo7t5mMtjj5AODjPbj9B+K9/wCBvhT4Ys9GNnNcw6V9re1u7PAdftDqSsxuIyeP4UjkI2knAzj6Mi8GaIniOLXZILu41OFpGgkur6e4WAyff8pJHKR5HHygYHA4roqAPCdU+LniO21TV5ILXSDpmn6vYWBheGTzpI7hAxPmCTaGU/7BBz045wdX8Y33ir4neFIdQfTrU6b4qms49MRGF3GiR4WWUl+Q/OMIBx1NfSlFAGbrk2sQxRHQrDT7yUt+8W8vXtgo9QVikyfbArH+3eOP+he8N/8Ag+n/APkOuqooA8e8V3Piy08e+HL+fQtBjlu4LnTVVNZmZHOFmXcxtQVI8p8YBzk9O+sbnxjjY2g+HtrH5T/bc3yn/wABK2fitAB4bt9TyVbSL631DcOyK4WT/wAhvJWhGQwKNigDjje+MrWRidB0HH8S/wBszc+//HrVk3Hi+4iyNB8OlDyCNbm4/wDJSupKCRfKk++Put6+1Vot9nMd3+rJww9PeplG40c9bal4yt59kug+H2bHBOtTDP8A5KVafVPGM0ZU+H/DvHf+3Jv/AJErprq2W4iBQ89VYdqrWmJpljnULInDY7+hrxsVQ9n70Iq3U6aclL4tzAtNS8Yx/wDMA8OsMd9bmH/tpVfUtU8YRRi5Og+HwInEny63Meh/69K6q6jMLHYe/wCdP+xie3JlG5cdK4ozadlHb1/zN7R+Jvc5W7vPGAvJCNB8PDzQJRt1uYgg8ZB+ye1Z41nxk07xJ4Y0jKnG86xKFP4/ZeldhBG39mqjHdLYkqfVoj0P4f8AstQ3lytrbmZ1d1GAAgyTmvQqSTfOlo9SIq2nYztGn1+Wdxren6Vaw7co1nfSXDFs9CGhQAYzzk/Srd1Z2s0/mXLsTgAIZMAfQU2Ke9uOVto4Yz3lYk4+gqWzs4LKM7FUEZJc9fzNZMvYPLtbKF5RGkaKMlsZNPtp2uF3+S8cZ+6X4J/Cq8V+t222zjMq95G4Qf41ezjAZgWP60A/M8V+O0CweP8ATLxBg3dghc+rKzD+WK0Pg5CJ/G9/csM/ZNOYqfRnZR/IGnftDwgReFrwdQ08JP8A3yR/WrHwJXfd+JJcfN5Fuo+m561T99/f+Fz0+f8A2D8PxsepRo0jqqDLHgV5b8RNWu/FevR+DfDjebZxyAXkiHieUHJUn+4mMn3+lbvxO8USaRbDQdFkJ1++ULIY+Wtom9P9tugHXv6Vp/D7wtH4Q0QRuijVLhczMOTEvZAfXuff6CnGKinf5/5f5nJSSpR9tLf7K/X0Rp6Pplj4Y0WPTbMqqqAZ5scyvjk/T0FL9oW6LCymtpGTkq4JxTmvoVmEBJSdjhFcFdx9jimG4uUmUHT2IY4Z0dTgetZyk5O7MNW7vdkttJcmJ/tUSI4bagRshvT6c1cuULahaWSYKWieZIR08xun9T+NOtdiNJdTnFvajeT6tjgf59RUVoTHaTXV18jTFpZCf4R1x+Qx+FNq0OVby/Iz3l6FHxRrA0uwzHj7Q5KxA849W/D+ZrzETNNc+fdFvIZiNxOcnvk+/rV7Xr59QvpLmbKiQ7Y1/wCecXY/U/1omuYRaiFSDgYVQK6IxUVyo9ejT9lHbVlPUJbbzopbZU+U5IA6irka2t8st7fsLfTbUZnmxyfRF9WPpSaXCLwrb26xx7EL3EzDAiQdWJrkPGviJNXmistNDR6PaE+Sp4Mrd5G9z29BQ5cquzeMXN8q+/8Ar8Cn4o16XXLtNkYttPgGy1tVPyxr6n1Y9zWUiUka5NWEWsdW7s7oxUFZCotWYkpsa1bhSrSG2OjSp0WlVamjTPaqMmx0SZqYLipI0wtJIuKqxF7sYCCR6V6p8CrbyvhvY3bKRJqM09+2e4klYp/45srxnxBJLHot2LUE3Uyi3gA6mWQhEH/fTCvpjQ9Oi0jRNP023/1Nnbx26fRFCj+VdGHW7PFzefww+ZeooorpPGCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4/R/HtnrOr3FrpOlaveWNvdmxl1SKFDbLMOCPv+YQDwWCFR3OOa7CuB8NeBNS8M3F5baH4iFtoFzeSXv2VrFZLiJn5ZEmZ9uwtzzGTjjPegDfs/Gnha+jupLLxLolxHaRma4aG/icQoOCzkN8o9zxT4PF/hq4sby9g8Q6PLZ2ZAuZ0vYmjgz03sGwufevHtf8Agvro07WtRbxHP4h1ubRrnTYknR0ecyNuXLyzsqYORhQi+wOSdOw+Dl1fadNc6/qGnzand2djbGCSxkENstuowB5VwrtIGA/eCQDg4XB4APTbbxh4auoxJa+ItGmjMUk4aO9iYeXH998hvur3PQd6ybTx9YXPjW60VDanTodIj1caqLpTE8buV9MbcDO7diuPuvg5qVxBatP4yuLu+TT73TZri+tWuN8VyDwuZdy7M8bmem3PwNgu9JksLrXpjG+g2ui7orfYQYJRIJfvnIJABT/x6gD1bRtZ0vXLU3Oi6lZajbBihltJ1mQN6ZUkZq/XGfDnwSfCB1WWW5t7q61CRJJp4luQ0hUEZcz3ExJ56gr+PGNHUPB2mX97NdT3OvJJK25lg12+hQH2RJgqj2AFAGrremw6xo1/pl2M295BJbyY/uupU/oa4TwFqE994YshfHGpWm6xu8/89oWMb/mV3fRhW9/wgekf8/niT/wo9R/+P1wFz4GsNK+IF5YrPri2GqWv262263eL+/jIScEiXLEq0TZbJ4PYUAejbxIMNwf1FPY+dESwy6cH3HrXHL4P0oHEtz4gyPXX7/P/AKOqwng3RsEi88QjI/6GC/8A/j1AHVafLscwt0PK1HqS+TPHOOP4W+lcpF4L0t7qNUuvEBJbtr9/wP8Av9U+teCdKSDCXfiEsxAGfEF+3P4zVjVgp6PqVF21Oo8mWaPeMYp0Vy6IUcY9jXLr4M0+2Uia68RbR1ZfEOoY/Sbin2XgrRpyT9t8QE9iPEN//wDHq+flTUJWd0/T/gndzXV2ro6ASm3Y3irkL8rr3ZO/+NRyxrbyKkbBoXXfCw6FfT8P5YrIHgLSpmci78RAdP8AkYb/AJ/8jVLo3hmx0O7eFbnVHWYbYGu9SublYm9AkkjKPqAD1Gea6aDTj7Nv09f+CQ5a3Ee8nnvZLW0j2+WcPK44/Cr0UW1cMzSMfvFu/wCFP+ZXaOUbZEOGX+o9jWfHHdXN1MbomK1VsJGp++PUkUNW0Zpe+xNdNLBDHHYQKxZtvGAqD1IpbaNYX2vKZblhlmPXH07CnxXET7/LK+XHwz9FHtmorAwO00lqCVdstIf4j6D2oA4P9oCDf4K0u4Az5OpBfwaNv8K4fwf4i1PwxPcXOlC3c3UIjdZ1JCkcqwweoyfzr0f45Jv+GU5/5530DD88f1rivhboseua3ax3S7rS3jNxOp6Mq4wv4kj8M1tFNzVuyPVwjh9Vl7RXSv8A5nZ/DHwtLbO/ijXC1xqF2xkg84ZZiesp9PQDsPwrtpLj/ShHIH3yAsrYyG9eexqS7uVaQea4j3cJ2A9h2qmRdvujEgXA3JOoBDezL/hUTknotjzalR1Zc8v+GQkt0WkKwMhmX/lhKNrH6GrFtJJPDEfJaOaQ7RE/UN/h3+lV0g+0xxyalBGs8L5Vlb06Nx/KtFmksrYXCxlryb5LeMj7uerH+f6d6IRUtXstzOTtotx80Ks8dijbooWEkzf89JOuD9Ov5Vh+N9QWCwW2B/4+Dhuf4Byf8K2bGJre3IkJaUElmJyWY8k/59a878a3Ul7rckMRB2YiGeg55qqUvaSdT7v6/rc3wtK87PoZ0OBby3NwgZpeAp9Owpk9uLS5hkto97P8oUDJyemKmW0nE8fnyLJEozhRjBpIL5dI0271i4w5s2MVorf8tJ2+7+Cjk10ep6V+q1Mzx5q40qxbw7ZODcy4fUZlPU9REPYd/wD9defqKdNLJcTyTzuZJpGLu56sxOSadEuTXPKXM7nfSpqnG3UljWp0WmotWI1qkiySNauwpxUEK81fhXirSM5MVE5q1FHyKIox3q1GmKpIxlIQKAKglHNWn4FVX5bFNiiWfCemjWvH+gWbHMVo7apMvqIgAn/kSRD/AMBr6Fryf4FaZ5/9teJpVyLuX7DZsf8AnhCSGYezSmT8FWvWK7KUeWJ81javtaza2WgUUUVocgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXAeKtf1Ww+LvgfRra5Mek6nDfG5iMakStHGrJ8xGRgnOAR70Ad/RXgPgr4ueJptP0CxOiN4m1jV5b9o5FuorMLHBMVH8AUgL3znjua1rb4x6jrk2oRaF4UvzZr9sgi1JhNsglhQlTN+4MaBiMDDuRxuUZoA9oor5t0nxz4xvJvhPqV1LHc3N7aarPNbpfNBDfrHApVpgkW1WB3YUKwBAOeTjsdK+Md9reoeGrTQ/Cb3b6vpo1OUtqMcX2WMTmKQncuGC4LZBBPAwOcAHsNFeW+DPi1H4j8a22gjToPs95bzXFrqNpPNJDKI22sAZYIg3Q8oXGeM16fKzRxO6xtIyqSEXGWPoMkDP1IoAfXHfFHT7qfQIdU0uNpdT0Wdb+GJesyqCssX/Ao2cAf3ttT/8ACUav/wBCJ4k/7/6d/wDJVH/CUav/ANCJ4k/7/wCnf/JVAFbTdWs9Rsba6hkSe0uI1mhfH3kYZB/I1oxLZtg7uPTNeY6Lqd74e1268Ov4Q14QTNLqGnW5lstyQFgZIwftG3CSMcAMSFdcgADPTtqeomLcvgXxCo65E+n/APyVXDPFuEnFx280bKmmk7nXC5tbcHYVB9upqG1dL28Ert8kJ+VB1z6n2rlrbX9RiPzeCNf3ZwSJdP8A/kmrU2tak+JE8EeI1dejrPp4I/8AJqsFjZOXMo6eqKdJLRs65wc7hhl9RwR9apz2sMrMVLQS93iGD+K9DXOp4r1eNGafwR4hGzq6TWH6j7Tx/KpG8T6mwVh4I8Qsp+6Rcafj6g/aq7lKliI9zNc0GdDapcwR4DLOB/EvBP1HWql1PDeh7eVlDkbducEH6V5v4p8bawmsmE+HPEVrGiqVhSe0Vjnqx2zn+dV7bx7rfnLHceFdUvowMj7Q9oJU+jicH868+rgot2g7HoQpSa52vzPVVjd44re/lUXK/LBc9pB/db3/AJ/WqGpWjXEMlpM728hwW285Ge3qDXFXfjl7iBYJfCviGGRuTH5llIn/AH39oGPxrWsPE2uNYgX/AIK129tV/wBVcW1zYySL/wB83HP1/PNVGnOfuzWq6/5mTTp6/p+RvSWdv9gNtKB9nA+bJx05yTSWlzDIrCAYgiGN+MD6CsK51XVrmykEngnxFLaMvLLNYBj+AuT/AJ7VUOtX81pHDbeD9fWFXBYLNYHcB2P+k1lKlKPxAppjfjX/AMkuv/8Ar6g/9DFYvwJGG1U+lmg/8eqP4u69qFx8O7yKfwprdqjXMJ86aWzKA7hx8lwzc/SpvgKWktdXleF4W+zxKUfBI+ZvQkdvWtYqzv5f5nfSkvqc15/5HoN9cRwowvIibZurgbh+I7VVsdPSK5ju7S5b7KyE+X2YHoa1GIPyFS7NwEAyW/CpykVnGsl8uZD/AKu1TBJ+v+cfWsowclfZdzhcraBCixoLu5B8lT+7jH3pW7cenp+fSkge4FzLcXiqJ5BhVzkRr6VPaM00n2u9x5g4jjHSMf4+9Mm/esXPcgL9c1hXrJpQp7fn5kxWr5hl04gjLueFUyH8s/4V5Iwa8v5GZ2R5HZ9w9BwP616T4onMOk3knPKhQPYn/CvL7ZJ2WSWF1Vo1wQ3fqT/OuuhFRhp/XQ9LBr3XIlF1NAHWX5gpKhh3rn/iHcGO4sNJDcWcPmSr/wBNpPmb8htFdRp8YuH0+B2V3nnTcB2ywrzzxPdG98Sapcsc+ZcyEfTcQP0AqqjtE76KvP0/r/Mzlq1EKrJVuOsonaTxirMYqCOrMY6VohMswrWhAvFVIRirsR4q0YSZYQVOOFzUCckVKzcYqjJjZGrN1MTzxw2Fg+zUNRlWztTjO2R+N30Vdzn2Wrzcniuk+Dmi/wBreILnxPcr/odj5ljpoP8AHJkCeYfiPLH0f1q6ceaRz4ut7Ck31ex6xoOl22h6LY6XYJstLOFIIh/sqMDPvxV+iiu0+YCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs/WtD0nXbdINb0ux1KBG3LHeW6TKD6gMCM1oUUAZ0Gh6TbzWU0Gl2MUtlG0Vq6W6K0CHqqED5Qe4GKrr4V8PLrR1hdC0kauWLm+FnH5+4jBPmY3Zxx16Vs0UAYll4S8N2LxPZeH9ItniaR42hso0KNIoWQjC8FlADHuAAasaf4f0bTZrebT9I061mt4TbQvBbJG0cRbcY1IHC7udo4zzWnRQBi6Z4T8OaVffbdL0DSLK8+b9/bWUccnzfe+ZVB57+tbVFFABRRRQBy/j/AEC41nS4rnSWSPXtNf7Vp8r8DzAMNG3+xIpKN9c9QKreHtcTWtEt7y3DIky4eJ/vQuDh42/2lYFT7iuxrzvxDbv4N8SS6/bKP+Ef1N1GqIOlrPwqXQH91uFk9MK/ZjXBjsO6seeO6/I2ozUXZnRxjzSecHpVlYZEXOciq7BwS5AweuOxqVZ3C7Scg14UbLc7JXewsX7yTaWIB4wDjilmt/si/wCikKD1QjKt9R/hUGfmzHkj+VOacyY3HJB6VcKnJqt+5Lg2/Iw/EWjjVWjurPEOoou0I5+WVeuA3rXDSLK2ovb3vm2rx8Ou3DE16zHZebH82Oex5rN1TTLe9QQ38AuFThDnEkf+6/X8DxXdDF3S9qreZ0UK6h7u6/FHn7Sw2RPl3DnI/jxmo9Bk8mS4uI5Jopmc/NFIU/QVrXnha5sbtptOzqEZH+qcATIPp0b6j8qxLiffdpAM22M7027WB9MHpXWnfVHbGUZpqLudBpvi/Wo7yWGSeCZFAKiaPn81xW7aeIbW+WSXVtM8lkbYs0LbjK/dVxhuB17CuIntsTRm0kLTN8g3j72TUuoSl74rbfctswoCcKEXjP1LZb3zVqTtrqYTw9Ob0VvwE+N+pWdx8O4UsGmCz6nHGyyghgVUsRz+FXfgXbD+w9YmaN3DPHHtQ8naCcDn/arhPihJjQvCNhnEk8lxeyL7Fgq/pmup0D/iX+ANLD5X7VfyT5BKnai7Qc/XFZxt7Ru2y/r8zR0rYX2cXvL8n/wD0oXMqF47e2Gm54Mky5dv6fqal09YoXeSZzNIx5lY5J/+tXD3XiTUUS0urO7lZ5g0ZVjuQuhwSVPHKlCcY5zWjB4lUDzNVtYdvQyWhKOvuVzg1jWoTm9JfJ7fh/kcX1eUVtv951qRrPcYGdnUii9TbIiqflU5x6cGq2nSR3dsLjSbtLmFj0bhgfQn19jipkZxOyTxyI20tlxwfpXG6M6TXPHrv0Meu+3QwfGxLaTgjG+ZFI9q89s2H2O4CsvmO7ADPvXpfjlAdK8wc7J42P54/rXmtraRzLcq64dXbBHXrXfS/hxPSwjTpGtoNtBH4n0ranO/B57hTg14/eZN5cZ6+a//AKEa9W0VFstT0273k7J1DgnOAeCf1rzTxFbGz8QanbsMGK6lX/x40Vdkd2H+N+n6spR9qtR1VSrUdZRO0tR1biHNVIqtxHpWqJZcjHFWoqrRGqepvqNvKlzYKtzCq4ltDhWYf3kb+97Hg+o72jCbsrm6r7aC+aztL1G21S2E9pJuUHa6kbWjYdVZTypHoamvruGwtJLm5YrEmPujczEnAVQOSxJAAHUmn5EJq3NfQdJBeapqFloejuU1PUWKrKBn7NCP9ZOf90HA9WKivofRNLtdF0iz0zT4/LtLSJYYl6naBjk9z3J7muP+EvhW40XTrjVdbhSPXdTw0iDk20I/1cGe+MlmI6sx7AV31dlOHKj5rGYn29S62WwUUUVocgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUV3bQ3lrNa3cSTW8yNHJG4yrqRggjuCDUtFAHnehvN4M1W38M6rK0+j3OV0e+lbLcc/ZJCerqoyjfxKpHVeemnRVkIQ8EZ4PSrviDRbHxBpU2narAJrWXBIyVZWByrKw5VgQCCOQRXEaVf3ui6wnhvxPcGa5lydO1Jl2i/jH8LY4E6j7wGNw+YDqB4+PwrS9pBaHTQqa2Z11qYywD9xxTJlEcxIP0NLPb+VGGUkr/KkiRJGAdt1eZr8J0K3xLYnS62Jgr070xYmmkDNgAnJqKePyn2g/L1qK4nFtGZHlUIOSxOABRd7MFFbx6li+to8AHkHp6g+orD19dJnjRdWe2lbb8rSSBJk+j9T+Nc54h8YSS5g0tiq9GnPU/7vp9a4JdTinv54S0jSpks7cgkdea9rB5dVfvyfKu3+Y43XXVHfLoQNzBdaDqUV88LhvssrBJCAQcA5wTx7Vj+JLKTS9SuoSZoWZ2eLevyyBjkY/PBHrXI6bq8d7dGOKKRONyOe+P5V6B4N1a/a+Iu7520u1ia5uRNiRVRRnjPTn0rvng+WO5vHEzg7y1OB+KjhvHtpp64xpOnQ27Y/vkFz/wChCu21cGxtNEsY494s7BN6k4xJJ8x4/L86878JpL4w8cteXKndqd8ZGH92POcfgox+Fe1ax4bF/rE91Dq0cYmk+dJYeUAAGFOcHgVwUYualJdWddapCh7OnUeyv8/6ucxJNDHplkJhGvmSzuFAwMDYufzU/lWdJtup9sLOsY+/zkYro9f8NanPdsbW2trizjQQ26xzKWVBzkg4+Ykkn61mvpGuxFRBpFwmOqqgIP5Vcou+wqdWm1dSX3mj4Uvxb+ILSODBhuP3MiKevHB+oP8AM16S4+UqrEjujjtXD+EPDN5Dq0eqarbR23lA7I+pZiMZOOBjJrt2KsMLwB6HcPy6iumkny2Z5OOlB1FyPoYuuWJuNF1CKNmJ8olUbkgjkYNeV210Vup1jjaR3+YKPTFezSZ3g55xj1BHpXkV5EdL8RXa42qrbP8AgByVP8qwqU407KOx25fU5oyiypCkrxS/MUfduKf1rnPiXEp8SC/iGI9QgS5+jY2uP++lP5118jrLdCKOQICMu49PQVR1/Szqnh6a3hzJeacWuYPV4j/rF/DhvzrGSvGx6VOfLNSf9XPNkqzEaqip4zXOj0C7GatIapxGrSdK1QmXImq3HzVGOrsRAXJIAHJJ7VaMpIoarpIaZtSsbhbG/jT5pj/q5FHO2Ud19+o7Gum+DNvD4k8SWuoeIo1s57WMXOl6dMrD7SSP+PxCyrvQZIUAcZ3HBK1Y8A+EpfG1yl/qMbR+FImykbDB1Ngev/XAEf8AA/8Ad+97J4i8Padr9glrfxMPJYSW80LGOW2kHR43HKsPUfQ5BIrrpU7ayPncfi1JunS26+f9fia1Fct4fute07Uk0fxBC+oRMpNtrFvHhZABnbOg/wBXJj+IfI3bacLWJ8S/iT/whWv6Jpf2TTW/tOK4l+1ajqX2KGLygDtLeW+S2cD3wO9bnlnolFeeaX8WNDbwro+reIUudGudRtHvfsLQS3EsUKEgysI0JEeBkOwAwRWy/j/w79uWztrq6vrkwxTldPsLi72RyDdGzmJGCBgQRuxxzQB1VFeb+Afi1o/ibw3oupahDPpFzq121jb2zxTSK8oZgAsvlhWyFySOFPBORV7/AIWz4LMMMiatLKsyzsgisbh2Ig/1p2rGThe59MnpQB3VFc14b8deHfEmpGw0bUDPdC1S9CNbyxh4GOBIhdQHXPGVJweDzXS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWd4g0Ww8QaTPpurW63FpKBlSSCpHIZSOVYHkMOQRkVo0UAeaR6hqXhS4h0zxbK9xp7yCGx1k/dlycLHc/885Og3/df2JxXWOqhAVY7x97jFbF9aW+oWc9pfQRXFrOhjlilUMrqRggg9RXlPirw34j8L6cw8N3F5qugKebDdvu7VPSJycyoP7h+YDoW6V5lbLVOV6btc6ada2kjota8SWemBkZjPdAcRL2+p7V55rmtXOob5ruTEMYLCNfuqB7dzXJzeJbZlB09ftYP3mDbQp7qc8hh3BGRUkl5c6jaW82mqVIk2zxtjpjoc9RXp4XL6eH95avv/kdWrI7TVrq71NFihH2VuNpHzAf3iaebpLLVvstpZJtYhXbJ3HPPGe1ST6fE0MkelSrDPkbwshOF7jPUf8A1qdBcC/s54LSb/S44whuCvf2PX1rv0HoS2AnW8uA1pFBbKdqFVwzYP6itb4hznQPB0Ph+I41nWmWW6UdYrYHhT6ZP/s1W9Hig8NeH18Qa+5kt7Xi1ibhrybnaoz2B6n29jXCrcXmsapd65rD77y6befRB2UegA4FeZj6+nso7vf0OrB0HVqc72X4s7b4NWKWmtTXchCQ2Fm8jOegLcD9N1dbceL7OJiIIZZv9r7o/XmuYjjk0fwxDZONl1qRF1OO6xDiND9eW/EVz0l7HN59vZTRm8QEKrf3q1wtBKmrnPjLV6zl0Wh6GnjOAnEllIB6hwa0bXxRpU2AZZbdj/eBH6ivItIk1EXLx36uybchimNp+o61CurXVtqUlvfwoIt3yunZT0PuK6XRRzPDxex9AQXbyRh7a7Z0PQh8g1OL64H+tCSj/aGD+Yrx/T7+5sJhJaSlD3HVW+o713vh/XItVRkK+VcoMsgPBHqKxlTcdTnnScdTqkuI7jgHbIegY/171x3jzTdyJfBfujyrj2QnhvwP863zjux/4EKlMkdxGYLvEkbgoxPcEYwawnHmVi8NX9jNM8strSBonidds6dwcZ9DVrT1kszHdwuy3cLEgschh7/UUzxDpcuj3hgkLyQL80MgOC0foT7f4etVZEURRywyyPaEjepPIHfmuLZn0N+dXT0ZgeO/D4tJF1nTUzpV42SB/wAu8p+9GfbOcGuTU4r1tLiCwikRo/O0m7XZc2zHIZT/ABD0YdQa4fxb4YbRdl5Yzi90ec4huV6qf7jjs386ynD7SOihW2hL5f13/Mxonq5C2azI2xViCaSS8gsrK3lvNRuDiC0gG6ST39FUd2OAO5pRu3ZHROUYRcpOyNSS4htbeSe5lSKGMbndzgKPrXZ+Bfh/c+Kmi1HxJBLa+Hhh4bCVSkl93DSjqsXohwW/iwOD0HgL4WfZLq31fxe8F5fxYe3sIxut7V/7xJ/1kg/vEADsO9er130qPLrLc+cx2YureFL4e/cbGixxqkaqiKAqqowAB0AFOoorc8kK5fxN4G0jxL4g0zVdXWaZrG3ubVbbK+TLHOmxw4IyeOmCPxrqKKAPKpvgd4cmt9JSe91K4m0uBrW3nu0tbphAWLLEVmhdCqknadu4ZxnGBXQaR8PbPRdZ/tLRNU1LTpJY7aK7htkthDdiBQib0MJCfKMHytgweMcV2tFAHm1p8INHs9D0vS7XVtait9J1D+0dOYSQl7SQlmKqTEQykuThwx96j0r4MeHtM+zGG91ZzBFewqZJYzkXQxITiMcj+H075r02igDivCfw40jwxrVhqdhc38lxZaOuiRrPIhUwLJ5gY4UHfnvkDHau1oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4Hx18L9G8UTS39uz6VrbgA3tsAfMx082M/LIPc4b0IryDxNpuseE7Caz1mw+yAjZDqNtl7WUnuX6xMfR8D0Jr6dprosiMkihkYEMrDII9DVxm4mkKsobHyp4f0loJVuWXy0KlQM58wH+ldpDpmj+EtJGqeJFMED822noT5103bg8hf8/Xu734a2NpqB1PwfOug6jktsWETWjn1aAkAH3QqfevIPFXg3xrb6tc6n4msZtaY8/bdOPnLt9PJ4dQPQAgetTiMRU5f3a1O7Dzp1p2qS5UY+r6pqHivVF1DViEhiG21tE4jt07Ko/LJ7123hHRYLa0XXdfi/0CM/6JbNwbqTtx/cHr3/AJ1vCcfhyG3W+u7+11S/Ubo9LgfmJv8ApuDyMf3SPzqHxT4hnlnNxeF5rhwRGijCKB2HYCufDYRyfPM9HEYuPL7HD7d/8v8AMXXdTbUL6Vru7EV5d5KsOo7DH06Cud/4R+aErJbyxtIp3A5Ktn15q/8AZRqelIdSjSOdlJDgfc9D/Km6Tp8lhHO0cyzKy/IoJI3dq9ZaHnrRaE9yl/LDamCRIZAwMw4ORVLUtS0436wXFu8zRna0gGAnsfWoNOh1iO7glumuWRm+dTyoz/KrGLC612a3+zuZQN0kgbClhjjH0oGJ4hnuYbiz+yytHHgt8vRiCMCugtLiW2njmhbZMmGGO1c9a6zLNqL20kEaRiQxqQcspHAJFJp1rdWF9c3epSqUZTvmLjaRkY47UmtBNaanumlXqahYRXERIDj5l67W7irRA/2f5VxngG8UyT2bN8rjzYyP1/pXaYI6SD8a45x5XY8+pHllYqatYLqVibdztkX5oZOuxv8AA+lebXEE2nm4ieIoyHEsPof7w9jXqexm4AVj7VyHi7VdDlnWz+2CXXYxiK2so2uZmH910jBIHucYrmq0+bVHfgsX7P8Adz2OZS1u5LWN2MRiXDbC3J9qnl1W00+xlu5pbSCzlXZcQXJHlyj0I9fTHPpU+meC/F2sPtWCHQNObB828YTXGD/diQ7R/wACbj+7XoPhL4daD4buRepFLqGrYwb++bzJR/uDAWMeyAVnCjJ76HTXzCmtI6/keTad8O7zxdqCXWixXfh/w/IAzTX8eZ2PcQRtzt6YeTH+6a9p8H+DNE8I20kejWYSaXHn3Uh3zTkd3c8n6DAHYCuiorohTjDZHl1sTVr/ABu4UUUVZgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGD4j8IeH/ABIAdb0izu5B92Zo8Sp/uyDDL+BFcXffCGKM50HxFqdkM/6m723kQHoN+H/8fr1Kimm1sNNrY8F8UfCzxhPAsdnd6NfRo25gXltWk9sYcfrXIf8ACFeNdGnST/hF7/arAsbO5hnVhnn5d4J/KvqmirVWSNVXmj5Pvo9Zs9fa+/sDxIkDIAyPpsxHHGPlUj8asLc6fHffa2ttXhlY7mD6dcLyRjkeXX1RRVe2kP6xI+UdM1eea7lNxpWpupYmN49JuCwGeASE54qDTtO8SX0d1FceH/Es6XKnrYOgVs5BHmbRX1rRR7aQfWJHz/4P0DxvZPaPF4WZPKyM3t/FCCp7YQu3f0r0NND8Y3ceJr7Q9KJH/LGGS8YfixjH/jprvaKzlJyd2ZTm5u7OFj+HFpd8+JNY1fWs9YZZ/s8Gf+uUIQEezbq6vRtH03RLQWuj6fa2NuOfLtoljUn1IA5PvV+ipJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the male anatomy and a close-up of the prostate gland.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37382=[""].join("\n");
var outline_f36_32_37382=null;
var title_f36_32_37383="Occupational asthma Light";
var content_f36_32_37383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Occupational asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchial biopsy of a patient with occupational asthma after removal from exposure, showing partial desquamation of the epithelium, thickened basement membrane, and some cellular infiltration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lemiere, C, Malo, JL, Boulet, M.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37383=[""].join("\n");
var outline_f36_32_37383=null;
var title_f36_32_37384="Differentiation (retinoic acid) syndrome";
var content_f36_32_37384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differentiation (retinoic acid) syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/32/37384/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37384/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37384/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/32/37384/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37384/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/32/37384/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37384/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37384/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/32/37384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation syndrome (previously called \"retinoic acid syndrome\") is a potentially fatal complication of induction chemotherapy in patients with acute promyelocytic leukemia (APL). It is characterized by fever, peripheral edema, pulmonary opacities, hypoxemia, respiratory distress, hypotension, renal and hepatic dysfunction, rash, and serositis resulting in pleural and pericardial effusions. It is a cytokine release syndrome, sometimes called \"cytokine storm,\" and all of the pathophysiologic consequences result from the release of inflammatory cytokines from malignant promyelocytes, probably independent of their differentiation to segmented neutrophils and hyperleukocytosis.",
"   </p>",
"   <p>",
"    The differentiation syndrome occurs in approximately 25 percent of patients with APL during induction therapy that includes all-trans retinoic acid (ATRA, also known as tretinoin) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO), but it is also seen in untreated patients or after other cytotoxic therapies. Early recognition and aggressive management are essential.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical presentation, diagnosis, and treatment of differentiation syndrome will be discussed here. The pathogenesis, diagnosis, and treatment of APL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12888?source=see_link\">",
"     \"Treatment of relapsed or refractory acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiation syndrome occurs in approximately 25 percent of patients treated with all-trans retinoic acid (ATRA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO) as induction therapy for acute promyelocytic leukemia (APL). In addition, it also occurs in patients with relapsed or refractory APL who are treated with these agents. The risk of the syndrome is not a function of the dose of either of these agents, nor is it proportional to the WBC count. Differentiation syndrome is not observed when ATRA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ATO are used as consolidation or maintenance therapy for APL, nor does it complicate ATRA or ATO treatment of non-APL malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/1\">",
"     1",
"    </a>",
"    ]. This syndrome depends on the presence of malignant promyelocytes. For example, APL is the most common acute leukemia to present with non-infectious fever, and this is thought to be due to the release of cytokines even before treatment is initiated.",
"   </p>",
"   <p>",
"    While the reported incidence rates of differentiation syndrome have ranged from 2 to 27 percent in patients treated with standard doses of ATRA and 30 percent in patients treated with ATO, this variation is at least partially due to the use of different diagnostic criteria among studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The incidence may be lower when ATRA is administered concurrently with induction chemotherapy or prophylactic glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Prevention'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'ATRA plus chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the largest studies analyzed 739 patients with newly diagnosed APL treated with ATRA plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    for induction as part of two prospective trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6\">",
"     6",
"    </a>",
"    ]. Differentiation syndrome was diagnosed in 25 percent; 13 percent were severe and 12 percent were moderate.",
"   </p>",
"   <p>",
"    As yet, no factors reliably predict which patients are more or less likely to develop differentiation syndrome after treatment with ATRA or ATO. An increased incidence has been reported in patients with an elevated white blood cell (WBC) count at diagnosis, a rapidly increasing WBC count, expression of CD13 on APL blasts, or an elevated body mass index (BMI), although only a high BMI has been confirmed as a risk factor in subsequent studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. It is important to recognize that the syndrome can occur in the absence of an elevated WBC count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of the differentiation syndrome is incompletely understood, but is thought to be due to release of inflammatory vasoactive cytokines, causing capillary leak, fever, edema, rash, and hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/15\">",
"     15",
"    </a>",
"    ]. It has also been linked to the maturation of promyelocytes induced by all-trans retinoic acid (ATRA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO), followed by tissue infiltration by the maturing cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/16\">",
"     16",
"    </a>",
"    ], but this may be a secondary phenomenon.",
"   </p>",
"   <p>",
"    Acute promyelocytic leukemia (APL) is characterized by the presence of an abnormal PML-RARa fusion gene that encodes a protein, which functions as an aberrant retinoid receptor. This",
"    <span class=\"nowrap\">",
"     PML/RARa",
"    </span>",
"    protein heterodimerizes with the retinoid X receptor (RXR); the resulting",
"    <span class=\"nowrap\">",
"     PML/RARa-RXR",
"    </span>",
"    complex binds to retinoic acid responsive elements in target genes. This interaction blocks myeloid differentiation at the promyelocytic stage. ATRA and ATO induce differentiation of the malignant myeloid clone by dissociating the",
"    <span class=\"nowrap\">",
"     PML/RARa-RXR",
"    </span>",
"    complex from the target genes. This leads to a sudden increase in differentiated myelocytes and neutrophils that is believed to contribute to the pathogenesis of differentiation syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=see_link&amp;anchor=H2#H2\">",
"     \"Molecular biology of acute promyelocytic leukemia\", section on 'Retinoic acid and the retinoic acid receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients treated with ATRA or ATO who develop differentiation syndrome demonstrate interstitial edema and infiltration of the lung, lymph nodes, spleen, liver, and pericardium with maturing myeloid cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/2\">",
"     2",
"    </a>",
"    ]. Three general theories have been proposed to explain the infiltration of myeloid cells into the lung and other tissues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ATRA and ATO may induce release of cytokines from differentiating myeloid cells that cause a capillary leak syndrome. In vitro studies have demonstrated a strong upregulation of chemokine production by APL cells after treatment with ATRA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ATO [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/17\">",
"       17",
"      </a>",
"      ]. In addition, the administration of vasoactive cytokines (eg, interleukin-2 for renal cell carcinoma) produces a number of features of the differentiation syndrome, including fever, generalized weight gain, and episodic hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12522?source=see_link&amp;anchor=H2#H2\">",
"       \"Immunotherapy of renal cell carcinoma\", section on 'Interleukin-2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ATRA and ATO may enhance the migration of maturing leukocytes, with subsequent organ infiltration resulting in respiratory and renal dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ATRA and ATO may induce upregulation of the expression of integrins (cellular adhesion molecules) in leukocytes, resulting in their increased adherence to capillary endothelium and consequent capillaritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/20-23\">",
"       20-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These proposed mechanisms are not mutually exclusive, and it is likely that some of these and other, not yet identified, mechanisms contribute to the pathogenesis of differentiation syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of clinical manifestations of the differentiation syndrome follows a bimodal pattern with 46 percent of patients developing clinical manifestations within one week and 38 percent developing symptoms between the third and fourth weeks of starting all-trans retinoic acid (ATRA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical symptoms and signs of the differentiation syndrome include fever, hypotension, dyspnea, weight gain of more than 5 kg, and musculoskeletal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/2,4,6,7,24,25\">",
"     2,4,6,7,24,25",
"    </a>",
"    ]. Patients with more severe disease tend to manifest a greater number of these symptoms and signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6\">",
"     6",
"    </a>",
"    ]. Diffuse erythematous rash may also be present. The following list shows the range of frequencies of the more common manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dyspnea (59 to 95 percent)",
"     </li>",
"     <li>",
"      Edema (53 to 81 percent)",
"     </li>",
"     <li>",
"      Unexplained fever (53 to 74 percent)",
"     </li>",
"     <li>",
"      Hypotension (12 to 39 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary hemorrhage is a well-described complication; however, its incidence is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/3,26\">",
"     3,26",
"    </a>",
"    ], and it may reflect concurrent severe thrombocytopenia. Sweet syndrome (acute febrile neutrophilic dermatosis) has also been reported as a complication of differentiation syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40905?source=see_link\">",
"     \"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of hematologic abnormalities are noted in patients with the differentiation syndrome, including anemia, thrombocytopenia, and coagulopathy requiring plasma transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6\">",
"     6",
"    </a>",
"    ]. Some of these abnormalities may be due to the underlying acute promyelocytic leukemia (APL) and concomitant chemotherapy.",
"   </p>",
"   <p>",
"    Patients with APL are monitored daily with complete blood counts. Although an increasing WBC count may be a risk factor for differentiation syndrome, no exact WBC count is predictive or diagnostic. In one series, the median count at the onset of the differentiation syndrome was",
"    <span class=\"nowrap\">",
"     31,000/microL",
"    </span>",
"    (31 x",
"    <span class=\"nowrap\">",
"     10(9)/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chest radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph is typically obtained to evaluate dyspnea, cough, or fever. The main findings on chest radiography are an increased cardiothoracic ratio (87 percent), septal lines and peribronchial cuffing (87 percent), ground glass opacity (60 percent), parenchymal consolidation (47 percent), nodular opacities (47 percent), air bronchogram (33 percent), and pleural effusion (73 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Radiographic opacities often mimic the patterns seen with pulmonary edema or an infectious pneumonia in a febrile neutropenic patient. Ground glass opacity tends to be diffuse, involving most or all lung zones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/3\">",
"     3",
"    </a>",
"    ]. However, approximately 40 percent of patients with differentiation syndrome have a clear chest radiograph at presentation, although only 11 percent of patients with severe disease have a clear chest radiograph, so treatment of the differentiation syndrome should not be delayed by waiting for the radiograph to become abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest computed tomography (CT) findings associated with the differentiation syndrome are nonspecific and may include diffuse ground glass opacities, subpleural nodular opacities, septal thickening, pleural and pericardial effusions, and patchy consolidation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66511 \" href=\"mobipreview.htm?22/8/22657\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6\">",
"     6",
"    </a>",
"    ]. Among patients with documented pulmonary hemorrhage, poorly defined centrilobular nodules, areas of consolidation, and diffuse ground glass opacities may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT pulmonary angiography may also be used to exclude pulmonary thromboembolism. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bronchoscopy and bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy and bronchoalveolar lavage (BAL) are rarely necessary, but can be used in the setting of suspected differentiation syndrome to evaluate for pulmonary hemorrhage and infection, rather than to make a positive diagnosis of differentiation syndrome.",
"   </p>",
"   <p>",
"    Approximately 77 percent of patients with APL have a platelet count of",
"    <span class=\"nowrap\">",
"     40,000/microL",
"    </span>",
"    (40 x",
"    <span class=\"nowrap\">",
"     (10)9/L)",
"    </span>",
"    or less",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a coagulopathy at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6\">",
"     6",
"    </a>",
"    ]. While thrombocytopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an uncorrected coagulopathy are relative contraindications for endobronchial or transbronchial biopsy, bronchoalveolar lavage can usually be safely performed. The contraindications to bronchoscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=see_link&amp;anchor=H3441165#H3441165\">",
"     \"Flexible bronchoscopy: Indications and contraindications\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The BAL technique for identifying pulmonary hemorrhage includes three sequential lavages in a single site. The effluent typically shows increasingly hemorrhagic fluid with each successive sample (",
"    <a class=\"graphic graphic_picture graphicRef61103 \" href=\"mobipreview.htm?42/31/43508\">",
"     picture 1",
"    </a>",
"    ). This is confirmed by cytologic studies showing hemosiderin-laden macrophages. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=see_link&amp;anchor=H12#H12\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lavage samples are also processed for bacterial, fungal, and mycobacterial smear, special stains, and culture. Samples can also be sent for viral culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung biopsy via video-assisted thoracoscopy or an open procedure is rarely performed, due to the increased risk from aberrant coagulation and the prompt improvement that most patients have with the institution of systemic glucocorticoid therapy.",
"   </p>",
"   <p>",
"    In patients with the differentiation syndrome, the main pathologic finding is interstitial infiltration with maturing myeloid cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with fatal differentiation syndrome may also have evidence of septal edema, diffuse alveolar damage, intraalveolar hemorrhage, and capillaritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/3,22\">",
"     3,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-mortem studies have revealed extensive infiltrates of myeloid cells in other organ systems, including lymph nodes, spleen, liver, and pericardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of the differentiation syndrome requires a high index of suspicion, but the diagnosis is typically made clinically based on the appropriate setting for patients with acute promyelocytic leukemia (APL). For patients who develop fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dyspnea following differentiation induction for APL, oxygen saturation should be assessed and a chest radiograph obtained. Funduscopic examination may demonstrate papilledema from brain swelling; this is a medical emergency.",
"   </p>",
"   <p>",
"    The differentiation syndrome is a clinical diagnosis based upon a constellation of findings within the context of remission induction treatment of APL, most commonly with all-trans retinoic acid (ATRA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO). Any three or more of the following signs in the absence of other causes are sufficient to make the diagnosis and institute glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Weight gain (from capillary leak and soft tissue edema)",
"     </li>",
"     <li>",
"      Respiratory distress",
"     </li>",
"     <li>",
"      Radiographic opacities",
"     </li>",
"     <li>",
"      Pleural or pericardial effusion",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Renal failure (usually from hypotension, although disseminated intravascular coagulation may also be present)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of patients will have a combination of dyspnea, fever, and radiographic opacities. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Symptoms and signs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pulmonary hemorrhage is a rare complication of the differentiation syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/22\">",
"     22",
"    </a>",
"    ]. As glucocorticoid therapy and transfusions are the main treatments, an invasive procedure is not usually warranted to make this diagnosis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Bronchoscopy and bronchoalveolar lavage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A rapid improvement in respiratory status with initiation of glucocorticoids supports the diagnosis of differentiation syndrome. A lung biopsy is rarely needed, unless the patient fails to improve and noninvasive studies are unrevealing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of the differentiation syndrome includes lung infection, sepsis, thromboembolism, and heart failure. Occasional patients may have a combination of these processes, and the documented presence of one of them does not exclude a concurrent cytokine release syndrome in APL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lung infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of concomitant fever and leukocytosis in patients who are immunosuppressed requires the exclusion of infectious causes, such as pneumonia due to nosocomial and opportunistic organisms. The evaluation should include peripheral blood cultures, sputum smear and culture, and often flexible fiberoptic bronchoscopy with bronchoalveolar lavage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with APL have an increased risk of thrombotic events, including pulmonary thromboembolism, although the incidence of differentiation syndrome is much greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Pulmonary embolism should be suspected in patients with evidence of peripheral thrombosis and in those with hypoxemia that is out of proportion to the extent of the radiographic opacities. A computed tomography pulmonary angiogram would typically be used to exclude this diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of brain natriuretic peptide (BNP) and echocardiography may be helpful in evaluating left ventricular function. The echocardiogram would also identify a pericardial effusion, if present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link&amp;anchor=H21#H21\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without glucocorticoid treatment, patients treated with all-trans retinoic acid (ATRA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO) who develop the differentiation syndrome have a mortality rate as high as 30 percent, principally from hypoxemic respiratory failure or from brain edema. With treatment, most patients demonstrate improvement within 12 hours and complete resolution of symptoms within 24 hours, although approximately 5 percent will not survive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/2,7,31\">",
"     2,7,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach to the treatment of differentiation syndrome depends partially upon the severity of the symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with suspected differentiation syndrome, we recommend prompt treatment with glucocorticoids. We typically use intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      10 mg twice daily. The dexamethasone is continued for at least 3 days and until the complete disappearance of symptoms and then tapered. The syndrome may recur after the glucocorticoids are discontinued, but this is not common.",
"     </li>",
"     <li>",
"      For most patients with differentiation syndrome, we also suggest the continued administration of the implicated differentiating agent (ATRA or ATO), rather than its discontinuation.",
"     </li>",
"     <li>",
"      For patients with severe differentiation syndrome (eg, patients who develop progressive renal failure or respiratory distress), we also suggest discontinuation of the differentiating agent (ATRA or ATO). Once the symptoms of differentiation syndrome are completely resolved, the differentiating agent is restarted.",
"     </li>",
"     <li>",
"      Cytotoxic chemotherapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      and an anthracycline) is typically initiated one to three days after initiation of ATRA; however, patients with hyperleukocytosis (eg, WBC 30,000 to",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      [30 to 50",
"      <span class=\"nowrap\">",
"       x10(9)/L])",
"      </span>",
"      may benefit from simultaneous initiation of ATRA and cytotoxic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=see_link\">",
"       \"Hyperleukocytosis and leukostasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is consistent with that advocated by both the National Comprehensive Cancer Network (NCCN) and the European Leukemia Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/5,34,35\">",
"     5,34,35",
"    </a>",
"    ]. The data to support this treatment approach are presented in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of glucocorticoids in the treatment of differentiation syndrome is largely based upon clinical experience and data from case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6,25,36,37\">",
"     6,25,36,37",
"    </a>",
"    ]. We recommend prompt treatment with glucocorticoids for all patients with suspected differentiation syndrome and typically use intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    10 mg twice daily. The dexamethasone is continued for at least 3 days and until the complete disappearance of symptoms and is then tapered. This recommendation is largely based on the following observations:",
"   </p>",
"   <p>",
"    In a series of 44 patients with differentiation syndrome, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was initiated at a dose of 10 mg twice daily in all but two patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/7\">",
"     7",
"    </a>",
"    ]. All-trans retinoic acid (ATRA) was discontinued at the earliest signs or symptoms of the differentiation syndrome in 82 percent in that study. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two deaths occurred that were attributable to the differentiation syndrome. One of these patients did not receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      until three days after the onset of symptoms; the other had prompt administration of dexamethasone.",
"     </li>",
"     <li>",
"      The syndrome resolved in all eight patients continued on ATRA with the addition of glucocorticoids.",
"     </li>",
"     <li>",
"      None of the patients who subsequently received ATRA as maintenance therapy developed differentiation syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retrospective comparisons have noted a decreased mortality rate after the widespread use of empiric glucocorticoid therapy compared with no glucocorticoid therapy (approximately 5 versus 30 percent mortality) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6,25,36,37\">",
"     6,25,36,37",
"    </a>",
"    ]. This evidence suggests that high-dose glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    10 mg every 12 hours) are beneficial and has made it impossible to conduct a placebo-controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ]. However, some patients will have progression of their symptoms despite dexamethasone administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential toxicities of short-term glucocorticoid treatment include hyperglycemia, insomnia, depression, emotional instability, and immunosuppression. Severe toxicity is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Differentiation agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether the differentiation agents, all-trans retinoic acid (ATRA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO), should be continued or discontinued when differentiation syndrome develops. Based on the retrospective study of 44 patients described above and our clinical experience, it seems likely that ATRA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ATO can be safely continued for most patients with differentiation syndrome as long as prompt treatment with glucocorticoids is implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While ATRA and ATO are clearly implicated in the pathogenesis of the syndrome, they are an essential component of the curative treatment for acute promyelocytic leukemia (APL). It is clear that patients with APL who receive both ATRA and chemotherapy have superior rates of complete remission and disease-free survival when compared with patients who receive chemotherapy alone. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'ATRA plus chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many clinicians will stop the ATRA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ATO if the differentiation syndrome symptoms are severe (eg, requirement for high-flow oxygen or mechanical ventilation). This practice is largely based upon theoretical concerns regarding the pathogenesis of differentiation syndrome, which may not be correct.",
"   </p>",
"   <p>",
"    When ATRA is discontinued due to severe manifestations of the differentiation syndrome, it may be resumed once manifestations of the differentiation syndrome have resolved. In a retrospective series, differentiation syndrome recurred in 3 of the 19 patients in whom ATRA was discontinued and then reintroduced; two of the three were taking concurrent glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/7\">",
"     7",
"    </a>",
"    ]. One death occurred due to recurrent differentiation syndrome.",
"   </p>",
"   <p>",
"    Once patients have obtained a complete remission, ATRA can be incorporated into the consolidation and maintenance programs without recurrence of the differentiation syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/7,25\">",
"     7,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with differentiation syndrome, we also suggest the continued administration of the implicated differentiating agent (ATRA or ATO) rather than its discontinuation.",
"     </li>",
"     <li>",
"      For patients with severe differentiation syndrome (eg, patients who develop renal failure or require admission to the intensive care unit due to respiratory distress), we also suggest transient discontinuation of the differentiating agent (ATRA or ATO). Once the symptoms of differentiation syndrome are completely resolved, the differentiating agent is restarted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the differentiation syndrome often require specialized, symptom-directed supportive care including empiric antibiotics, cautious diuresis, supplemental oxygen, and sometimes, mechanical ventilation for respiratory failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of these patients will have a fever in the setting of immunosuppression requiring the prompt administration of broad-spectrum antibiotics and a rigorous evaluation for superimposed infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28552?source=see_link\">",
"       \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An attempt may be made to diurese the patient as tolerated by hemodynamic and renal status; in some cases this has led to rapid improvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/39\">",
"       39",
"      </a>",
"      ]. For patients with renal dysfunction related to hypotension, renal perfusion should be supported with red blood cell transfusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vasopressors, as indicated.",
"     </li>",
"     <li>",
"      Many patients will require supplemental oxygen and some will need additional ventilatory support with noninvasive positive pressure ventilation. Patients with severe respiratory compromise will need intubation and mechanical ventilation. In one series, mechanical ventilation was needed by 26 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"       \"Overview of mechanical ventilation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatment modalities have not proven beneficial. While leukapheresis may blunt the leukocytosis associated with retinoic acid administration, this procedure is not recommended because of its potential to worsen the coagulopathy in patients with acute promyelocytic leukemia (APL) and lead to catheter related thromboses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the potential severity of differentiation syndrome among patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO), there has been interest in whether prophylactic glucocorticoids should be administered either to all patients with APL or to a select group at higher risk for differentiation syndrome. Based on the following data, we suggest treatment of suspected differentiation syndrome when symptoms develop rather than the use of prophylactic glucocorticoids.",
"   </p>",
"   <p>",
"    A single arm prospective study examined the use of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 87 patients with APL and a white blood cell count above",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    (10 x",
"    <span class=\"nowrap\">",
"     10(9)/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/40\">",
"     40",
"    </a>",
"    ]. Differentiation syndrome developed in 16 percent of cases with a 3 percent mortality rate.",
"   </p>",
"   <p>",
"    A retrospective analysis of two prospective studies, one that administered prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) and one that did not, reported similar rates of differentiation syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/41\">",
"     41",
"    </a>",
"    ]. An \"indeterminant\" differentiation syndrome was present in 23 and 26 percent of those that did or did not receive prophylaxis, respectively. A \"definite\" differentiation syndrome occurred in 4 and 5 percent, respectively.",
"   </p>",
"   <p>",
"    Despite the absence of scientific data, some experts administer prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , 10 mg intravenously twice daily, to patients with a white blood cell count over",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    (30 x",
"    <span class=\"nowrap\">",
"     10(9)/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37384/abstract/32,33,40\">",
"     32,33,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective, randomized trial of glucocorticoid prophylaxis is required to determine whether this approach decreases the incidence of mortality associated with differentiation syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation syndrome (previously \"retinoic acid syndrome\" or cytokine release syndrome) is a potentially fatal complication of induction chemotherapy in patients with acute promyelocytic leukemia (APL) characterized by fever, peripheral edema, radiographic pulmonary opacities, hypoxemia, respiratory distress, hypotension, renal and hepatic dysfunction, and serositis resulting in pleural and pericardial effusions.",
"   </p>",
"   <p>",
"    The differentiation syndrome occurs in approximately 25 percent of patients with APL during induction therapy that includes all-trans retinoic acid (ATRA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with suspected differentiation syndrome, we recommend prompt treatment with glucocorticoids, rather than waiting for diagnostic confirmation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We typically use intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      10 mg twice daily. The dexamethasone is continued until the complete disappearance of symptoms and then tapered. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with differentiation syndrome, we also suggest the continued administration of the implicated differentiating agent (ATRA or ATO), rather than its discontinuation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differentiation agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe manifestations of differentiation syndrome (eg, requirement for high-flow oxygen or mechanical ventilation), we suggest temporary discontinuation of the differentiating agent (ATRA or ATO) until the patient is stable, rather than continuation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Once the symptoms of differentiation syndrome are completely resolved, the differentiating agent is restarted. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differentiation agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with APL, we suggest treatment of suspected differentiation syndrome when symptoms develop, rather than the use of prophylactic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with hyperleukocytosis (white blood cell count over",
"      <span class=\"nowrap\">",
"       30,000/microL)",
"      </span>",
"      may have a lower risk of differentiation syndrome when given prophylactic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      10 mg twice daily intravenously. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/1\">",
"      De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998; 92:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/2\">",
"      Frankel SR, Eardley A, Lauwers G, et al. The \"retinoic acid syndrome\" in acute promyelocytic leukemia. Ann Intern Med 1992; 117:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/3\">",
"      Jung JI, Choi JE, Hahn ST, et al. Radiologic features of all-trans-retinoic acid syndrome. AJR Am J Roentgenol 2002; 178:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/4\">",
"      Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/5\">",
"      Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/6\">",
"      Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/7\">",
"      Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/8\">",
"      Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84:3843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/9\">",
"      Jeddi R, Kacem K, Ben Neji H, et al. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia. Hematology 2008; 13:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/10\">",
"      Jeddi R, Gh&eacute;dira H, Mnif S, et al. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res 2010; 34:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/11\">",
"      Gallagher RE, Willman CL, Slack JL, et al. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997; 90:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/12\">",
"      Santos FL, Dore AI, Lima AS, et al. [Hematological features and expression profile of myeloid antigens of acute promyelocytic leukemia patients: analysis of prognostic factors for development of the retinoic acid syndrome]. Rev Assoc Med Bras 2004; 50:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/13\">",
"      Fenaux P, Castaigne S, Chomienne C, et al. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992; 6 Suppl 1:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/14\">",
"      Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood 2012; 119:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/15\">",
"      Luesink M, Jansen JH. Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. Br J Haematol 2010; 151:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/16\">",
"      Huang MJ, Chang IY, Lin WY, et al. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia. Leuk Lymphoma 2000; 38:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/17\">",
"      Luesink M, Pennings JL, Wissink WM, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood 2009; 114:5512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/18\">",
"      Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/19\">",
"      Gordon, M, Jakubowski, A, Frankel, S, et al. Neutrophil (PMN) function in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) (abstract). Proc Annu Meet Am Soc Clin Oncol 1991; 10:A761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/20\">",
"      Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994; 120:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/21\">",
"      Hickstein DD, Hickey MJ, Collins SJ. Transcriptional regulation of the leukocyte adherence protein beta subunit during human myeloid cell differentiation. J Biol Chem 1988; 263:13863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/22\">",
"      Nicolls MR, Terada LS, Tuder RM, et al. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Am J Respir Crit Care Med 1998; 158:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/23\">",
"      Larson RS, Brown DC, Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 1997; 90:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/24\">",
"      Flombaum CD, Isaacs M, Reich L, et al. Acute renal failure associated with the retinoic acid syndrome in acute promyelocytic leukemia. Am J Kidney Dis 1996; 27:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/25\">",
"      Breccia M, Latagliata R, Carmosino I, et al. Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. Haematologica 2008; 93:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/26\">",
"      Raanani P, Segal E, Levi I, et al. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA--a manifestation of the basic disease or the treatment. Leuk Lymphoma 2000; 37:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/27\">",
"      Cox NH, O'Brien HA. Sweet's syndrome associated with trans-retinoic acid treatment in acute promyelocytic leukaemia. Clin Exp Dermatol 1994; 19:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/28\">",
"      Park CJ, Bae YD, Choi JY, et al. Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid. Korean J Intern Med 2001; 16:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/29\">",
"      Breccia M, Avvisati G, Latagliata R, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2007; 21:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/30\">",
"      Tallman MS, Brenner B, Serna Jde L, et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 2005; 29:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/31\">",
"      Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J Clin Pharm Ther 2008; 33:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/32\">",
"      Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol 2009; 27:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/33\">",
"      Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114:5126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/34\">",
"      Frankfurt O, Tallman MS. Strategies for the treatment of acute promyelocytic leukemia. J Natl Compr Canc Netw 2006; 4:37.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/36\">",
"      Cortes JE, Kantarjian H, O'Brien S, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994; 73:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/37\">",
"      Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/38\">",
"      Smith-Whitley K, Lange B. Fatal all-trans retinoic acid pneumonitis. Ann Intern Med 1993; 118:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/39\">",
"      Yokokura M, Hatake K, Komatsu N, et al. Toxicity of tretinoin in acute promyelocytic leukaemia. Lancet 1994; 343:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/40\">",
"      Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia 1995; 9:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37384/abstract/41\">",
"      Sanz MA, Mart&iacute;n G, Gonz&aacute;lez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103:1237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4351 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2143548A13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37384=[""].join("\n");
var outline_f36_32_37384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chest radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bronchoscopy and bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lung infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Differentiation agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4351|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/8/22657\" title=\"diagnostic image 1\">",
"      Chest CT differentiation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4351|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/31/43508\" title=\"picture 1\">",
"      BAL in differentiation syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=related_link\">",
"      Molecular biology of acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40905?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12888?source=related_link\">",
"      Treatment of relapsed or refractory acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_32_37385="Pathophysiology of seizures and epilepsy";
var content_f36_32_37385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of seizures and epilepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/32/37385/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37385/contributors\">",
"     Carl E Stafstrom, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37385/contributors\">",
"     Jong M Rho, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/32/37385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37385/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/32/37385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37385/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/32/37385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An epileptic seizure is an episode of neurologic dysfunction in which abnormal neuronal firing is manifest clinically by changes in motor control, sensory perception, behavior,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autonomic function. Epilepsy is the condition of recurrent spontaneous seizures arising from aberrant electrical activity within the brain. While anyone can experience a seizure under the appropriate pathophysiological conditions, epilepsy suggests an enduring alteration of brain function that facilitates seizure recurrence. Epileptogenesis is the process by which the normal brain becomes prone to epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The aberrant electrical activity that underlies epilepsy is the result of biochemical processes at the cellular level promoting neuronal hyperexcitability and neuronal hypersynchrony. However, a single neuron, discharging abnormally, is insufficient to produce a clinical seizure, which occurs only in the context of large neuronal networks. Cortical and several key subcortical structures are involved in generating a seizure.",
"   </p>",
"   <p>",
"    This topic will review the cellular basis for focal and generalized seizure activity, with specific attention to ion channels, the essential currency of neuronal excitability. The pharmacology of antiepileptic drugs and issues related to the assessment and management of patients with epilepsy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy is not a singular disease, but is heterogeneous in terms of clinical expression, underlying etiologies, and pathophysiology (",
"    <a class=\"graphic graphic_table graphicRef75633 \" href=\"mobipreview.htm?11/42/11948\">",
"     table 1",
"    </a>",
"    ). As such, specific mechanisms and pathways underlying specific seizure types may vary. Epileptic seizures are broadly classified according to their site of origin and pattern of spread (",
"    <a class=\"graphic graphic_figure graphicRef76510 \" href=\"mobipreview.htm?6/9/6295\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal or partial seizures arise from a localized region of the brain and have clinical manifestations that reflect that area of brain. Focal discharges can remain localized or they can spread to nearby cortical areas, to subcortical structures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      transmit through commissural pathways to involve the whole cortex. The latter sequence describes the secondary generalization of focal seizures. As an example, a seizure arising from the left motor cortex may cause jerking movements of the right upper extremity. If epileptiform discharges spread to adjacent areas and then the entire brain, a secondary generalized tonic-clonic seizure ensues.",
"     </li>",
"     <li>",
"      Primary generalized seizures begin with abnormal electrical discharges in both hemispheres simultaneously. Generalized seizures involve reciprocal connections between the thalamus and neocortex. The manifestations of such widespread epileptiform activity can range from brief impairment of consciousness (as in an absence seizure) to generalized motor activity accompanied by loss of consciousness (generalized tonic-clonic seizure).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While there are differences in the mechanisms that underlie partial versus generalized seizure activity, it is useful to view any seizure as the result of a perturbation in the normal balance between inhibition and excitation in a localized region or throughout the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CELLULAR PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;At a basic level, an epileptic seizure may be understood to represent an imbalance between excitatory and inhibitory currents within neural circuits of the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Neuronal circuits are composed of excitatory and inhibitory neurons and their dendrites and axons, synapses, and glial cells. All of the following circuit components function via ion channels:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuronal dendrites and somata, which convert incoming synaptic current into propagated electrical activity which is integrated at the axon initial segment,",
"     </li>",
"     <li>",
"      Axonal conduction, the propagation of action potentials along the neuronal axon, and",
"     </li>",
"     <li>",
"      Synaptic transmission, which occurs between neurons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ion channels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ion channels are membrane-spanning proteins that form selective pores for sodium, potassium, chloride, or calcium ions. Movement of ions across the neuronal membrane determines the electrical membrane potential and generates the action potential. A gradient of sodium and potassium ions (in relatively high concentration outside and inside the cell, respectively) is maintained by an ATP-dependent",
"    <span class=\"nowrap\">",
"     sodium/potassium",
"    </span>",
"    pump which maintains the resting membrane potential in a polarized state (about -70 mV) (",
"    <a class=\"graphic graphic_figure graphicRef74749 \" href=\"mobipreview.htm?40/39/41587\">",
"     figure 2",
"    </a>",
"    ). When an ion channel is opened, the ion moves passively into or out of the cell along its electrochemical gradient.",
"   </p>",
"   <p>",
"    Two major types of ion channels are responsible for inhibitory and excitatory activity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Voltage-gated channels are activated by changes in the membrane potential that alter the conformational state of the channel, allowing selective passage of charged ions. Voltage-gated sodium and calcium channels function to depolarize the cell membrane toward action potential threshold and are excitatory. Voltage-gated potassium channels largely function to hyperpolarize the cell membrane away from the action potential threshold and are inhibitory.",
"     </li>",
"     <li>",
"      Ligand-gated receptors mediate signals from neurotransmitters such as glutamate and gamma-aminobutyric acid (GABA). After release from a presynaptic terminal into the synaptic cleft, the neurotransmitter binds with selective affinity to a membrane-bound receptor on the postsynaptic membrane. This in turn activates a cascade of events, including a conformational shift to reveal an ion-permeant pore.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Passage of ions across these voltage-gated and ligand-gated channels results in either depolarization (eg, inward flux of cations) or hyperpolarization (eg, inward flux of anions or outward flux of cations). This is discussed in more detail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Voltage-dependent conductances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Depolarizing conductances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depolarizing conductances are excitatory and are mediated by inward sodium and calcium currents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inward sodium conductances include the rapidly-inactivating current that underlies the depolarizing phase of the action potential (",
"      <a class=\"graphic graphic_figure graphicRef74749 \" href=\"mobipreview.htm?40/39/41587\">",
"       figure 2",
"      </a>",
"      ). A noninactivating, persistent sodium current can augment cell depolarization (eg, produced by excitatory synaptic input) in the range immediately subthreshold for spike initiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/5\">",
"       5",
"      </a>",
"      ]. Augmentation of noninactivating sodium channel activity may promote burst firing in neurons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Each sodium channel exists as a complex of polypeptide subunits; there is a major alpha subunit and one or more smaller beta subunits, which influence the kinetic properties of the alpha subunit. The shape of action potentials is determined by the types of alpha and beta subunits present in an individual neuron [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/7\">",
"       7",
"      </a>",
"      ]. Genetic alterations in the structure of sodium channels are believed to underlie the syndrome of generalized epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome, a severe myoclonic epilepsy of infancy as well as other epilepsy syndromes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3226?source=see_link&amp;anchor=H6#H6\">",
"       \"Febrile seizures\", section on 'Genetic susceptibility'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=see_link&amp;anchor=H5#H5\">",
"       \"Epilepsy syndromes in children\", section on 'Myoclonic epilepsy of infancy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Many anticonvulsants act in part through interactions with voltage-dependent sodium channels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/9\">",
"       9",
"      </a>",
"      ]. Examples include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"       lacosamide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H2#H2\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Drugs that affect voltage-dependent sodium channels'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Activation of voltage-dependent calcium channels contributes to the depolarizing phase of the action potential. Calcium influx can also affect neurotransmitter release, gene expression, and neuronal firing patterns. There are several subtypes of calcium channels, with distinct electrophysiological properties, pharmacological profiles, molecular structures, and cellular localization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/10\">",
"       10",
"      </a>",
"      ]. Similar to sodium channels, the molecular structures of voltage-gated calcium channels are hetero-oligomeric complexes which form the pore as well as other subunits that can modulate the kinetic properties of the channel.",
"      <br/>",
"      <br/>",
"      Calcium currents in hippocampal CA3 pyramidal cells underlie burst discharges in these cells and may contribute to epileptic synchronization. Alteration in calcium channels also play a role in childhood absence epilepsy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Primary generalized epilepsy: Absence epilepsy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyperpolarizing conductances",
"    </span>",
"    &nbsp;&mdash;&nbsp;An array of voltage-dependent hyperpolarizing currents, mediated primarily by potassium channels, counter balance depolarizing currents and function to inhibit or decrease excitation in the nervous system. Potassium channels represent the largest and most diverse family of voltage-gated ion channels. The prototypic voltage-gated potassium channel is composed of four membrane-spanning alpha subunits and four regulatory beta subunits that are assembled in an octameric complex to form an ion selective pore.",
"   </p>",
"   <p>",
"    In hippocampal neurons, potassium conductances include a leak conductance, which is a major determinant of the resting membrane potential, and an inward rectifier (involving the flux of other ions), which is activated by hyperpolarization. (Rectification refers to a situation in which the direction of ion flow through a channel changes according to voltage; rectification can also be secondary to \"blocking\" of the pore by other ions.) Other potassium conductances include a large set of delayed rectifiers that are involved in the termination of action potentials and repolarization of the neuron's membrane potential; a dendritic A-current, which helps determine interspike interval and thus affects the rate of cell firing; an M-current, which is inhibited by activation of cholinergic muscarinic agonists and hyperpolarizes the resting membrane potential, reducing the rate of cell firing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/11\">",
"     11",
"    </a>",
"    ]; and a set of calcium-activated potassium conductances, which are sensitive to intracellular calcium concentration and affect cell firing rate and interburst interval.",
"   </p>",
"   <p>",
"    Facilitation of hyperpolarizing conductances may be anticonvulsant. While none of the anticonvulsants in clinical use today act principally on voltage-gated potassium channels, part of the anticonvulsant properties of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    may include such effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The anticonvulsant retigabine acts by opening and activating voltage-gated potassium channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in the KCNQ2 and KCNQ3 genes encoding the potassium channels responsible for the M-current have been linked to a rare form of inherited epilepsy, benign familial neonatal convulsions as well as to families with benign partial epilepsy and idiopathic generalized epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link&amp;anchor=H9#H9\">",
"     \"Neonatal epileptic syndromes\", section on 'Benign familial neonatal convulsions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/921?source=see_link&amp;anchor=H2#H2\">",
"     \"Benign partial epilepsies of childhood\", section on 'Benign epilepsy with centrotemporal spikes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Synaptic transmission",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Excitatory transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amino acid glutamate is the principal excitatory neurotransmitter of the central nervous system. Glutamatergic pathways are widespread throughout the brain, and excitatory amino acid activity is critical to normal brain development and activity-dependent synaptic plasticity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/18\">",
"     18",
"    </a>",
"    ]. Ionotropic glutamate receptors are broadly divided into N-methyl-D-aspartate (NMDA) and non-NMDA receptors, based on biophysical properties and pharmacological profiles. Each subtype of glutamate receptor consists of a multimeric assembly of subunits that determine its distinct functional properties. Glutamate receptor channel subunits are currently classified into several subfamilies based on amino acid sequence homology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The NMDA receptor contains a binding site for glutamate (or NMDA), and a recognition site for a variety of modulators (eg, glycine, polyamines, MK-801, zinc). A voltage-dependent blockade of the NMDA receptor by magnesium ions is reversed when the membrane is depolarized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. At this time, activation of the NMDA receptor results in an influx of calcium and sodium ions and generation of relatively slow and long-lasting excitatory post-synaptic potentials (EPSPs). Calcium entry also initiates a number of \"second messenger\" pathways.",
"      <br/>",
"      <br/>",
"      These synaptic events can contribute to epileptiform burst discharges. Recurrent excitatory circuits produced by mossy fiber sprouting in mesial temporal epilepsy are associated with increased NMDA conductances [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Synchronizing mechanisms'",
"      </a>",
"      below.) NMDA receptor blockade attenuates bursting activity in many models of epileptiform activity.",
"     </li>",
"     <li>",
"      Non-NMDA ionotropic receptors are &alpha;-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) and kainate receptors, which are both coupled to sodium and potassium ion channels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/22\">",
"       22",
"      </a>",
"      ]. Activation of the postsynaptic AMPA receptor by glutamate is responsible for the fast-rising, brief EPSP. In addition, the depolarization generated via AMPA receptors is necessary for effective activation of NMDA receptors. Consequently, AMPA receptor antagonists block most excitatory synaptic activity in pyramidal neurons.",
"     </li>",
"     <li>",
"      Metabotropic glutamate receptors (those not directly coupled to ion channels) represent a large, heterogeneous family of G-protein coupled receptors. These activate various transduction pathways and are important modulators of voltage-dependent potassium and calcium channels, non-selective cation currents, ligand-gated receptors (ie, GABA and glutamate receptors), and can regulate glutamate release [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/23\">",
"       23",
"      </a>",
"      ]. Different metabotropic glutamate receptor subtypes are specific for different intracellular processes and are differentially localized within the brain. Knowledge of the role of metabotropic glutamate receptors in epilepsy is expanding rapidly and this receptor may eventually provide a therapeutic target [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alterations in glutamate-activated channels may lead to their increased activation, as is observed in animal models of epilepsy and in human epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/25\">",
"     25",
"    </a>",
"    ]. NMDA and other glutamate receptor agonists induce epilepsy in animals. Glutamate receptor autoantibodies have been identified in Rasmussen encephalitis and other focal epilepsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/26\">",
"     26",
"    </a>",
"    ]. Upregulation of a vesicular glutamate transporter in patients with temporal lobe epilepsy was identified in one pathologic study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inhibitory transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synaptic inhibition in the hippocampus is mediated by two basic circuit configurations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Feed-forward inhibition occurs when a collateral projection from an axon of an excitatory principal neuron synapses with and directly activates an inhibitory interneuron, which then provides simultaneous inhibitory input to the same target neuron which the primary neuron activates.",
"     </li>",
"     <li>",
"      Feedback or recurrent inhibition occurs when an excitatory principal neuron synapses with and excites inhibitory interneurons, which then project back onto the principal neuron and inhibit it as well as surrounding principal neurons. This circuit functions as a negative-feedback loop, controlling repetitive firing and limiting recruitment of surrounding neurons (ie, inhibitory surround).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both of these inhibitory circuits utilize gamma-aminobutyric acid (GABA), a neutral amino acid, as the neurotransmitter. After release from axon terminals, GABA binds to at least two classes of receptors, GABA-A and GABA-B receptors, which are found on almost all cortical neurons. GABA-A receptors are also found on glia, although their functional significance on these cells is unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GABA-A receptors are macromolecular complexes consisting of an ion pore, as well as binding sites for agonists and a variety of allosteric modulators, such as benzodiazepines and barbiturates, each differentially affecting the kinetic properties of the receptor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/28\">",
"       28",
"      </a>",
"      ]. The ion channel is selectively permeable to chloride (and bicarbonate) ions. At least seven different polypeptide subunits have been described, each with one or more subtypes. In theory, several thousand isoforms of these subunits are possible, however, a limited number of functional combinations are thought to exist. The precise subunit composition of native GABA-A receptors has yet to be identified. Because individual subunits may be differentially sensitive to pharmacological agents, GABA receptor subunits represent potentially useful molecular targets for new anticonvulsants. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H13#H13\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Drugs that affect GABA activity'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Activation of GABA-A receptors on the soma of a mature cortical neuron generally results in influx of chloride ions and membrane hyperpolarization, thus inhibiting cell discharge. However, in immature neurons, GABA-A receptor activation causes depolarization of the postsynaptic membrane instead [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. This reversal of the conventional GABA-A effect is thought to reflect a reversed chloride electrochemical gradient, a consequence of the immature expression of the",
"      <span class=\"nowrap\">",
"       potassium/chloride",
"      </span>",
"      cotransporter, KCC2, which ordinarily renders GABA hyperpolarizing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/31\">",
"       31",
"      </a>",
"      ]. Outward flux of bicarbonate through GABA-A channels also contributes to the depolarization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Susceptibility of the immature brain'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      GABA-B receptors are located on both the postsynaptic membrane and on presynaptic terminals. These so-called metabotropic receptors do not form an ion pore as ionotropic receptors do. Rather, they act to control calcium or potassium conductances through second messenger GTP-binding proteins. Whereas GABA-A receptors generate fast high-conductance inhibitory postsynaptic potentials (IPSPs) close to the cell body, GABA-B receptors on the postsynaptic membrane mediate slow long-lasting low-conductance IPSPs, primarily in hippocampal pyramidal cell dendrites. Perhaps of more functional significance, activation of GABA-B receptors on the presynaptic terminal blocks the synaptic release of neurotransmitter. It is thought that some GABA-B receptors are associated with terminals that release GABA onto postsynaptic GABA-A receptors. In such cases, activation of GABA-B receptors reduces the amount of GABA released, resulting in disinhibition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The summation of individual GABA receptor mediated activation produces a largely chloride mediated membrane hyperpolarization that counterbalances the depolarization generated by the summation of EPSPs. Impairment of this inhibitory activity can lead to seizures and epilepsy. As an example, drugs such as picrotoxin and bicuculline bind to the GABA-A receptor and block chloride channels and are proconvulsant. Infants deficient in pyridoxine, a coenzyme required for GABA synthesis, are prone to seizures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41335?source=see_link\">",
"     \"Etiology and prognosis of neonatal seizures\"",
"    </a>",
"    .) Angelman syndrome, which includes severe epilepsy, is associated with a genetic defect involving a GABA-A receptor subunit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversely, enhanced GABA-mediated inhibition is an important mechanism of antiepileptic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    and the benzodiazepines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H13#H13\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Drugs that affect GABA activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Role of glia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contribution of glia to the regulation of epileptiform discharges is increasingly appreciated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/34\">",
"     34",
"    </a>",
"    ]. Among other functions, glia play an important part in maintaining extracellular levels of membrane permeant ions and neurotransmitters.",
"   </p>",
"   <p>",
"    One important role for glia is the restoration of ionic homeostasis, particularly extracellular potassium levels, after neuronal activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/34\">",
"     34",
"    </a>",
"    ]. A variety of inwardly-rectifying potassium channels mediate potassium uptake. The location of glial end-feet on brain microvasculature provides a convenient \"sink\" for potassium release. Glial membrane potential changes are directly correlated with changes in extracellular potassium, and blockade of glia-selective potassium channels results in neuronal hyperexcitability.",
"   </p>",
"   <p>",
"    Transport of glutamate out of the extracellular space may be an important role for glia in the maintenance of neuronal excitability. Glial cells have at least two powerful glutamate transport molecules in their membranes. Rapid and efficient removal of extracellular glutamate is essential in normal brain tissue since residual glutamate would continue to excite surrounding neurons. Blockade of glutamate transporters or \"knockout\" of the genes for these transport proteins results in epilepsy or excitotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glia can modulate neuronal excitability in a number of other ways. First, they play a critical role in regulating extracellular pH, via a proton exchanger and bicarbonate transporter mechanisms. Even low levels of neuronal activity create significant pH transients. Furthermore, pH modulates receptor function, particularly the NMDA receptor, which appears to play an important role in epileptic discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/36\">",
"     36",
"    </a>",
"    ]. Second, glia are also now thought to release powerful neuroactive agents into the extracellular space. Glutamate released from glia can excite neighboring neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/37\">",
"     37",
"    </a>",
"    ]. Other investigations have suggested that other glia-related factors, such as the cytokine, IL-1beta, can have profound anticonvulsant efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an epileptic seizure, neurons transition from their normal firing pattern to interictal epileptiform bursts, and then to an ictal state; each of these stages in the evolution of a seizure is governed by distinct electrophysiological mechanisms. Much of our understanding of the mechanisms regulating each stage comes from cellular electrophysiological studies in which microelectrodes record intracellular potential changes from individual neurons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Focal epilepsy: Mesial temporal lobe epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most prevalent form of focal epilepsy is mesial temporal lobe epilepsy. Ictal onset in mesial temporal lobe structures can produce a seizure aura, such as an olfactory hallucination, an epigastric sensation, or psychic symptoms. Progression of the seizure is often associated with loss of awareness and motor automatisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=see_link&amp;anchor=H8#H8\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Mesial temporal lobe epilepsy'",
"    </a>",
"    .) As a consequence, hippocampal pyramidal cells have become one of the most intensively studied cell types in the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hippocampal formation consists of the dentate gyrus, the hippocampus proper (Ammon's horn), with subregions CA1, CA2, and CA3, the subiculum, and the entorhinal cortex (",
"    <a class=\"graphic graphic_figure graphicRef76895 \" href=\"mobipreview.htm?37/32/38415\">",
"     figure 3",
"    </a>",
"    ). These four regions are linked by excitatory, largely unidirectional, feed-forward connections. Backwards projections include those from the entorhinal cortex to Ammon's horn and those from the CA3 field to the dentate gyrus. The predominant forward-projecting circuit begins with neurons in layer II of the entorhinal cortex that project axons to the dentate gyrus along the perforant pathway where they synapse on granule cell (and interneuron) dendrites. Granule cells send their axons, called mossy fibers, to synapse on cells in the hilus and in the CA3 field of Ammon's horn. CA3 pyramidal cells, in turn, project to other CA3 pyramidal cells via local collaterals, to the CA1 field of Ammon's horn via Schaffer collaterals, and to the contralateral hippocampus. CA1 pyramidal cell axons project onto the subicular complex, and neurons of the subicular complex project to the entorhinal cortex, as well as to other cortical and subcortical targets.",
"   </p>",
"   <p>",
"    In hippocampal sclerosis, the pathologic hallmark of mesial temporal lobe epilepsy, there is a pattern of gliosis and neuronal loss primarily in the hilar polymorphic and CA1 pyramidal regions with relative sparing of the CA2 pyramidal region, and an intermediate degree of cell loss in the CA3 pyramidal region and dentate gyrus. A form of synaptic reorganization known as mossy fiber sprouting is believed to result from denervation of dentate granule cells; axons of dentate granule cells then innervate neurons of the dentate gyrus rather than CA3 and hilus, causing a form of recurrent hyperexcitability (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Synchronizing mechanisms'",
"    </a>",
"    below). It is not known whether these pathologic findings are primarily the cause or the result of epileptic activity.",
"   </p>",
"   <p>",
"    A wide variety of brain injuries can increase the propensity for seizures to develop. Examples of insults to the brain that are associated with the development of epilepsy include physical trauma to the brain, hypoxia, prolonged fever (in young subjects), central nervous system infection, and stroke. Mechanisms of epileptogenesis in these circumstances can involve any of the physiologic factors previously discussed that increase excitation or decrease inhibition. As an example, mossy fiber sprouting can result from numerous initiating brain insults, confirming a similar response of neural circuits to a wide variety of epileptogenic stimuli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Paroxysmal depolarization shift",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurophysiologic hallmark of a partial seizure is the interictal epileptiform discharge on EEG. The cellular correlate of the focal interictal epileptiform discharge is known as the paroxysmal depolarization shift (PDS) (",
"    <a class=\"graphic graphic_figure graphicRef76134 \" href=\"mobipreview.htm?23/7/23667\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A PDS is characterized by an initial rapid and prolonged depolarization of the membrane potential, followed by a burst of repetitive action potentials lasting several hundred milliseconds. The initial depolarization is mediated by AMPA receptors, while the sustained depolarization is a consequence of NMDA receptor activation. The PDS terminates with a prolonged hyperpolarization phase that is mediated primarily by inhibitory potassium and chloride conductances, carried by voltage-gated potassium channels and GABA receptors, respectively. This constitutes a refractory period (",
"    <a class=\"graphic graphic_figure graphicRef76134 \" href=\"mobipreview.htm?23/7/23667\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Experimental techniques used to promote epileptogenesis, such as blockade of GABA inhibition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    potentiation of excitatory transmission, such as with NMDA, can induce PDS-like activity in cortical neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A PDS is an event occurring in a single neuron. An interictal epileptiform discharge represents synchronously occurring PDS in several million neurons, involving an area of cortex of at least 6 cm",
"    <sup>",
"     2",
"    </sup>",
"    . For discharges of a localized group of hyperexcitable neurons to spread to adjacent areas, the epileptic firing must overcome the powerful inhibitory influences that normally keep aberrant excitability in check (ie, \"inhibitory surround\") (",
"    <a class=\"graphic graphic_figure graphicRef76134 \" href=\"mobipreview.htm?23/7/23667\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Synchronizing mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synchronization of neuronal activity is an important part of normal hippocampal function. Sharp waves, dentate spikes, theta activity (range 8 to 13 Hz), 40 Hz oscillations, and 200 Hz oscillations are all forms of neuronal synchronization that can be recorded in various regions of the hippocampus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuronal synchronization is also a hallmark of epilepsy. This may result from exaggerated synchrony among hippocampal neurons. Alternatively, or in addition, normal forms of synchronized activity may become epileptogenic in a hippocampus that has undergone selective neuronal loss, synaptic reorganization, or changes in expression of specific receptor subtypes.",
"   </p>",
"   <p>",
"    In the hippocampus, synchronizing mechanisms include input from subcortical nuclei as well as intrinsic interneuron-mediated synchronization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/42\">",
"     42",
"    </a>",
"    ]. As an example, high amplitude theta activity represents synchronized activity of hippocampal neurons that is largely dependent on input from the septum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/41\">",
"     41",
"    </a>",
"    ]. Subcortical nuclei, such as the septum, have divergent inputs that target hippocampal interneurons. In turn, the divergent axon projections of interneurons, and the powerful effect of the GABA-A-receptor-mediated conductances that they produce, enable interneurons to entrain the activity of large populations of principal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/43\">",
"     43",
"    </a>",
"    ]. These characteristics make interneurons an effective target for subcortical modulation of hippocampal principal cell activity. In addition, mutual inhibitory interactions among hippocampal interneurons can produce synchronized discharges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent excitatory circuits are another mode by which neuronal synchronization occurs in the hippocampus. Recurrent excitatory collaterals are a normal feature of the CA3 region; CA3 pyramidal cells form direct, monosynaptic connections with other CA3 pyramidal cells and contribute to the synchronized burst discharges that characterize this region. In the epileptic temporal lobe, synaptic reorganization and axonal sprouting might lead to aberrant recurrent excitation, providing a synchronizing mechanism in other parts of the hippocampal formation (",
"    <a class=\"graphic graphic_figure graphicRef56930 \" href=\"mobipreview.htm?25/20/25921\">",
"     figure 5",
"    </a>",
"    ). As an example, while granule cells in the dentate gyrus normally form few, if any monosynaptic contacts with neighboring granule cells, the mossy fiber sprouting seen in mesial temporal sclerosis results in direct excitatory interactions among granule cells that lower the threshold for synchronization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, mechanisms independent of chemical synaptic transmission might synchronize neuronal firing under some circumstances. Such mechanisms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gap junctions that allow electrical signals to pass directly between cells. Recent studies suggest that gap junctions are up-regulated in epileptic brain tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/45\">",
"       45",
"      </a>",
"      ], and that blockade of gap junctions significantly affects the duration of seizure activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Electrical field (\"ephaptic\") effects generated by current flow through the extracellular space. Earlier studies demonstrated a potential synchronizing effect of these ephaptic interactions. Other experiments suggest that manipulations that alter the extracellular volume may affect current flow through this compartment, and can impact the epileptogenic synchronization of neurons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changes in extracellular ion concentrations. Increased extracellular potassium concentrations are thought to affect epileptogenic excitability",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      synchronization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/48\">",
"       48",
"      </a>",
"      ]. Experiments have demonstrated epileptogenic effects of blocking potassium regulation (eg, through inwardly rectifying potassium channels) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Role of glia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Consequences of repeated seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether seizures cause brain damage has been the subject of intense study, but a simple answer has been elusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/50\">",
"     50",
"    </a>",
"    ]. The consequences of seizures depends on many factors, including the etiology, epilepsy syndrome, age at the time of seizure onset, and seizure type, frequency, duration, and severity.",
"   </p>",
"   <p>",
"    The longer a seizure, the more serious the potential consequences. As an example, status epilepticus causes damage to neurons even when systemic factors (eg, blood pressure, oxygen level) and underlying etiology are controlled. This can lead to increased risk for recurrent seizures and disabling neurologic deficits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=see_link&amp;anchor=H4#H4\">",
"     \"Status epilepticus in adults\", section on 'Complications and outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brief seizures, if recurrent, can also lead to long-term changes in both brain structure and function. The process by which a normal brain gradually becomes epileptic as a result of repeated seizures, or even subclinical synchronous neuronal discharges, is known as kindling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. There is growing evidence that temporal lobe epilepsy can be a progressive disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/53\">",
"     53",
"    </a>",
"    ]. Such considerations emphasize the need to suppress seizure occurrence.",
"   </p>",
"   <p>",
"    Further considerations depend on how \"brain damage\" is defined, ie, structural brain changes versus a wider spectrum of cognitive, behavioral, and neurologic disabilities. Persons with epilepsy face numerous psychosocial and medical challenges, including intellectual impairment, mood disorders, psychological adjustment to the chronic nature of the disorder and to the unpredictability of seizures, the need to take antiepileptic drugs with their attendant side effects, and the dependence on others for certain daily tasks. Together, these epilepsy-related adverse psychosocial challenges are referred to as \"comorbidities\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/54\">",
"     54",
"    </a>",
"    ]. Therefore, the consequences of epilepsy are both multiple and multifactorial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2890?source=see_link\">",
"     \"Evaluation and management of drug-resistant epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Primary generalized epilepsy: Absence epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood absence epilepsy is a subtype of generalized epilepsy with a distinct pathophysiological substrate. Seizures are characterized by a temporary loss of consciousness, usually with a sudden cessation of motor activity without falling, and total amnesia for the event. These seizures are generally brief (most last less than 20 seconds), do not include an aura, and end abruptly without postictal changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=see_link&amp;anchor=H7#H7\">",
"     \"Epilepsy syndromes in children\", section on 'Absence seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The generalized spike-wave discharges seen on EEG during an absence seizure reflect widespread, phase-locked oscillations between excitation and inhibition in thalamocortical networks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/2,55\">",
"     2,55",
"    </a>",
"    ]. This network includes excitatory projections from pyramidal neurons in layer VI of the neocortex to thalamic relay (TR) neurons as well as to inhibitory GABA-ergic neurons comprising the nucleus reticularis thalami (NRT). In turn, excitatory outputs of the TR neurons activate layer VI pyramidal neurons in neocortex. This thalamocortical circuit is a critical substrate for the generation of cortical rhythms and is responsible in large part for normal EEG oscillations during wake and sleep states. It is influenced by sensory input as well as several brainstem nuclei.",
"   </p>",
"   <p>",
"    In absence seizures, hyperactivity of this circuit causes rhythmic activation of the cortex, generating generalized spike-wave discharges. Involvement of this circuit is also implicated in other idiopathic generalized epilepsies, including juvenile myoclonic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although multiple ionic conductances are involved in these pacemaking rhythms, two specific channels are believed to play a key role in regulating thalamocortical activity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T-type calcium channel. A subtype of voltage-gated calcium channel is known as the low-threshold or T-type calcium channel, so-named because it can be activated by small membrane depolarizations. In thalamic relay neurons, calcium influx through these channels triggers low-threshold spikes, which in turn activate a burst of action potentials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/58\">",
"       58",
"      </a>",
"      ]. Such an excitatory burst is believed to underlie the spike portion of a generalized spike-wave discharge.",
"      <br/>",
"      <br/>",
"      While the pathophysiology of absence seizures involves more T-type calcium channel dysfunction, genetic alterations in the T-type calcium channel have been associated with childhood absence epilepsy as well as other generalized epilepsy syndromes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. Moreover, anticonvulsants known to be clinically effective against absence seizures (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"       ethosuximide",
"      </a>",
"      and valproic acid) block T-type calcium currents, although it is uncertain as to whether this is the primary mechanism of their action [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HCN channels and h-currents. The second important ion channel involved in the regulation of thalamocortical rhythmicity is the hyperpolarization-activated cation channel (HCN channel), responsible for the so-called Ih or h-current. HCN channels, densely expressed in the thalamus and hippocampus, are activated by hyperpolarization and produce a depolarizing current carried by an inward flux of sodium and potassium ions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/63\">",
"       63",
"      </a>",
"      ]. This depolarization helps to bring the resting membrane potential toward threshold for activation of T-type calcium channels, which in turn produces a calcium spike and a burst of action potentials. HCN channels are also critically involved in developmental plasticity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/64\">",
"       64",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Unlike other voltage-gated conductances that can be labeled either inhibitory or excitatory, h-currents are both inhibitory and excitatory [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. HCN channels possess an inherent negative-feedback property; hyperpolarization activates them, which then leads to depolarization that deactivates them. The net effect of HCN channel activation is a decrease in the voltage change produced by a given synaptic current. H-currents tend to stabilize a neuron's membrane potential toward the resting potential against both hyperpolarizing and depolarizing inputs.",
"      <br/>",
"      <br/>",
"      The relevance of HCN channels in the pathogenesis of absence seizures is supported by the demonstration that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , an AED effective against absence seizures, enhances activation of dendritic h-currents in hippocampal pyramidal neurons, and by the experimental finding that deletion of a specific HCN isoform results in absence epilepsy in mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/67,68\">",
"       67,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other synaptic influences. Antagonists of GABA-B receptors and agonists of dopaminergic receptors can also interrupt abnormal thalamocortical discharges in experimental absence epilepsy models [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/69\">",
"       69",
"      </a>",
"      ]. GABA-B receptors mediate long-lasting thalamic IPSPs involved in the generation of normal thalamocortical rhythms, while brainstem monoaminergic projections disrupt these rhythms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Susceptibility of the immature brain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizure incidence is highest during the first decade of life, especially during the first year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/70\">",
"     70",
"    </a>",
"    ]. Multiple physiological factors contribute to the increased susceptibility of the developing brain to seizures (",
"    <a class=\"graphic graphic_table graphicRef52092 \" href=\"mobipreview.htm?36/59/37820\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/5,71-73\">",
"     5,71-73",
"    </a>",
"    ]. Each factor alters the brain excitatory-inhibitory balance in favor of enhanced excitation. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ion channels that mediate depolarization develop earlier than those that mediate repolarization. Excitatory neurotransmitters develop before inhibitory ones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/18,74,75\">",
"       18,74,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As discussed above, early in development, GABA exerts an excitatory action, rather than the inhibitory effect seen later in life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inhibitory transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrical synapses appear to be more prevalent in the developing brain than in the mature brain; fast-acting electrical transmission can facilitate rapid synchrony of the neuronal network and precipitate seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Structural factors also play a role. During the second week of life in the rat, the hippocampal CA3 region is characterized by an abundance of excitatory connections between pyramidal cells that cause regional heightened excitability and epileptiform activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/78\">",
"       78",
"      </a>",
"      ]. As part of development, these connections are pruned and excessive excitation is stabilized.",
"     </li>",
"     <li>",
"      The ability of glia to buffer extracellular potassium also varies with age and the expression of the neuronal membrane ATP-dependent",
"      <span class=\"nowrap\">",
"       sodium/potassium",
"      </span>",
"      pump follows a developmental time course [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37385/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seizure propensity in the young brain involves a complex interplay between the timing of these cellular and molecular changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise pathophysiologic mechanisms underlying epileptic seizures remain to be elucidated. The pathophysiology is believed to be heterogeneous and include a complex array of perturbations occurring at multiple hierarchical levels of nervous system structure and function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a basic level, an epileptic seizure represents a disruption in the normal balance between excitatory and inhibitory currents or neurotransmission in the brain. Drugs or pathogenic processes that augment excitation or impair inhibition tend to be epileptogenic, while antiepileptic drugs tend to facilitate inhibition and dampen excitation. These currents are mediated via two types of ion channels. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ion channels'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Voltage-gated ion channels are activated by changes in membrane potential. Depolarizing currents are excitatory and are mediated by inward sodium and calcium conductances while inhibitory, hyperpolarizing currents include inward chloride and outward potassium conductances. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Voltage-dependent conductances'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ligand-gated ion channels are activated by binding of a neurotransmitter to an ionotropic receptor on the postsynaptic membrane. The primary excitatory neurotransmitter in the brain is glutamate, while gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Synaptic transmission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glial cells also play an important role in epileptogenesis by regulating the extracellular concentrations of excitatory ions and neurotransmitters, as well as through other mechanisms. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Role of glia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The paroxysmal depolarization shift is the cellular correlate of the interictal epileptiform discharge, a hallmark of partial epilepsy. Abnormal neuronal circuitry is required for propagation of the PDS to other neurons to produce an epileptiform discharge on EEG or a clinical epileptic seizure. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Focal epilepsy: Mesial temporal lobe epilepsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seizures can result from injuries to the brain and by other circumstances that alter the balance between inhibition and excitation. Likewise, recurrent seizures not only lead to a subsequent decreased threshold to additional seizures, but are also associated with psychosocial comorbidities such as impairment of cognition, behavior, and mood regulation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Consequences of repeated seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Childhood absence epilepsy arises from alterations in the thalamocortical circuitry. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Primary generalized epilepsy: Absence epilepsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of cellular and electrophysiologic changes in the developing brain make it vulnerable to epileptogenesis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Susceptibility of the immature brain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/1\">",
"      Pitk&auml;nen A, Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 2009; 14 Suppl 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/2\">",
"      McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 2001; 63:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/3\">",
"      Faingold CL. Emergent properties of CNS neuronal networks as targets for pharmacology: application to anticonvulsant drug action. Prog Neurobiol 2004; 72:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/4\">",
"      Chang BS, Lowenstein DH. Epilepsy. N Engl J Med 2003; 349:1257.",
"     </a>",
"    </li>",
"    <li>",
"     Rho JM, Stafstrom CE. Neurophysiology of epilepsy. In: Pediatric Neurology: Principles and Practice, 4th, Swaiman KF, Ashwal S, Ferreiro DM.  (Eds), Mosby Elsevier, Philadelphia 2006. p.991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/6\">",
"      Stafstrom CE. Persistent sodium current and its role in epilepsy. Epilepsy Curr 2007; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/7\">",
"      Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005; 57:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/8\">",
"      Lossin C. A catalog of SCN1A variants. Brain Dev 2009; 31:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/9\">",
"      Rogawski MA, L&ouml;scher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/10\">",
"      Catterall WA, Striessnig J, Snutch TP, et al. International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels. Pharmacol Rev 2003; 55:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/11\">",
"      Cooper EC, Jan LY. M-channels: neurological diseases, neuromodulation, and drug development. Arch Neurol 2003; 60:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/12\">",
"      Herrero AI, Del Olmo N, Gonz&aacute;lez-Escalada JR, Sol&iacute;s JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 2002; 42:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/13\">",
"      Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003; 45:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/14\">",
"      Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs 2011; 25:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/15\">",
"      Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/16\">",
"      Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci 2000; 23:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/17\">",
"      Neubauer BA, Waldegger S, Heinzinger J, et al. KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes. Neurology 2008; 71:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/18\">",
"      Simeone TA, Sanchez RM, Rho JM. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol 2004; 19:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/19\">",
"      Mori H, Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995; 34:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/20\">",
"      Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008; 7:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/21\">",
"      Avanzini G, Franceschetti S. Cellular biology of epileptogenesis. Lancet Neurol 2003; 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/22\">",
"      Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/23\">",
"      Conn PJ. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann N Y Acad Sci 2003; 1003:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/24\">",
"      Ure J, Baudry M, Perassolo M. Metabotropic glutamate receptors and epilepsy. J Neurol Sci 2006; 247:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/25\">",
"      Rakhade SN, Loeb JA. Focal reduction of neuronal glutamate transporters in human neocortical epilepsy. Epilepsia 2008; 49:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/26\">",
"      Pleasure D. Diagnostic and pathogenic significance of glutamate receptor autoantibodies. Arch Neurol 2008; 65:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/27\">",
"      van der Hel WS, Verlinde SA, Meijer DH, et al. Hippocampal distribution of vesicular glutamate transporter 1 in patients with temporal lobe epilepsy. Epilepsia 2009; 50:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/28\">",
"      Macdonald RL, Olsen RW. GABAA receptor channels. Annu Rev Neurosci 1994; 17:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/29\">",
"      Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci 2002; 3:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/30\">",
"      Staley KJ. Wrong-way chloride transport: is it a treatable cause of some intractable seizures? Epilepsy Curr 2006; 6:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/31\">",
"      Rivera C, Voipio J, Payne JA, et al. The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 1999; 397:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/32\">",
"      Staley KJ, Soldo BL, Proctor WR. Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors. Science 1995; 269:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/33\">",
"      Simeone TA, Donevan SD, Rho JM. Molecular biology and ontogeny of gamma-aminobutyric acid (GABA) receptors in the mammalian central nervous system. J Child Neurol 2003; 18:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/34\">",
"      D'Ambrosio R. The role of glial membrane ion channels in seizures and epileptogenesis. Pharmacol Ther 2004; 103:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/35\">",
"      Meldrum BS, Akbar MT, Chapman AG. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res 1999; 36:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/36\">",
"      Traynelis SF, Cull-Candy SG. Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature 1990; 345:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/37\">",
"      Tian GF, Azmi H, Takano T, et al. An astrocytic basis of epilepsy. Nat Med 2005; 11:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/38\">",
"      Vezzani A, Moneta D, Richichi C, et al. Functional role of proinflammatory and anti-inflammatory cytokines in seizures. Adv Exp Med Biol 2004; 548:123.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartzkroin PA, Mueller AL. Electrophysiology of hippocampal neurons. In: Further Aspects of Cortical Function, Including Hippocampus, Jones EG, Peters A.  (Eds), Plenum Press, New York 1987. p.295.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/40\">",
"      Nadler JV. The recurrent mossy fiber pathway of the epileptic brain. Neurochem Res 2003; 28:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/41\">",
"      Buzs&aacute;ki G, Draguhn A. Neuronal oscillations in cortical networks. Science 2004; 304:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/42\">",
"      Bouilleret V, Semah F, Chassoux F, et al. Basal ganglia involvement in temporal lobe epilepsy: a functional and morphologic study. Neurology 2008; 70:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/43\">",
"      Cobb SR, Buhl EH, Halasy K, et al. Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature 1995; 378:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/44\">",
"      Jefferys JG, Traub RD, Whittington MA. Neuronal networks for induced '40 Hz' rhythms. Trends Neurosci 1996; 19:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/45\">",
"      Li J, Shen H, Naus CC, et al. Upregulation of gap junction connexin 32 with epileptiform activity in the isolated mouse hippocampus. Neuroscience 2001; 105:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/46\">",
"      K&ouml;hling R, Gladwell SJ, Bracci E, et al. Prolonged epileptiform bursting induced by 0-Mg(2+) in rat hippocampal slices depends on gap junctional coupling. Neuroscience 2001; 105:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/47\">",
"      Hochman DW, Baraban SC, Owens JW, Schwartzkroin PA. Dissociation of synchronization and excitability in furosemide blockade of epileptiform activity. Science 1995; 270:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/48\">",
"      Gnatkovsky V, Librizzi L, Trombin F, de Curtis M. Fast activity at seizure onset is mediated by inhibitory circuits in the entorhinal cortex in vitro. Ann Neurol 2008; 64:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/49\">",
"      Emmi A, Wenzel HJ, Schwartzkroin PA, et al. Do glia have heart? Expression and functional role for ether-a-go-go currents in hippocampal astrocytes. J Neurosci 2000; 20:3915.",
"     </a>",
"    </li>",
"    <li>",
"     Sutula, T, Pitk&auml;nen, A. Do Seizures Damage the Brain? Elsevier, Amsterdam 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/51\">",
"      Vel&iacute;sek L, Mosh&eacute; SL. Effects of brief seizures during development. Prog Brain Res 2002; 135:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/52\">",
"      Bertram E. The relevance of kindling for human epilepsy. Epilepsia 2007; 48 Suppl 2:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/53\">",
"      Pitk&auml;nen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 2002; 1:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/54\">",
"      Austin JK, Caplan R. Behavioral and psychiatric comorbidities in pediatric epilepsy: toward an integrative model. Epilepsia 2007; 48:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/55\">",
"      Tyvaert L, Chassagnon S, Sadikot A, et al. Thalamic nuclei activity in idiopathic generalized epilepsy: an EEG-fMRI study. Neurology 2009; 73:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/56\">",
"      Deppe M, Kellinghaus C, Duning T, et al. Nerve fiber impairment of anterior thalamocortical circuitry in juvenile myoclonic epilepsy. Neurology 2008; 71:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/57\">",
"      Lin K, Carrete H Jr, Lin J, et al. Magnetic resonance spectroscopy reveals an epileptic network in juvenile myoclonic epilepsy. Epilepsia 2009; 50:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/58\">",
"      Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003; 83:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/59\">",
"      Heron SE, Khosravani H, Varela D, et al. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. Ann Neurol 2007; 62:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/60\">",
"      Chen Y, Lu J, Pan H, et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 2003; 54:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/61\">",
"      Coulter DA, Huguenard JR, Prince DA. Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett 1989; 98:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/62\">",
"      Leresche N, Parri HR, Erdemli G, et al. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J Neurosci 1998; 18:4842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/63\">",
"      Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol 2003; 65:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/64\">",
"      Santoro B, Baram TZ. The multiple personalities of h-channels. Trends Neurosci 2003; 26:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/65\">",
"      Poolos NP. The h-channel: a potential channelopathy in epilepsy? Epilepsy Behav 2005; 7:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/66\">",
"      Dyhrfjeld-Johnsen J, Morgan RJ, Soltesz I. Double Trouble? Potential for Hyperexcitability Following Both Channelopathic up- and Downregulation of I(h) in Epilepsy. Front Neurosci 2009; 3:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/67\">",
"      Ludwig A, Budde T, Stieber J, et al. Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2. EMBO J 2003; 22:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/68\">",
"      Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 2002; 5:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/69\">",
"      Snead OC 3rd. Basic mechanisms of generalized absence seizures. Ann Neurol 1995; 37:146.",
"     </a>",
"    </li>",
"    <li>",
"     Hauser, W, Hersdorffer, D. Epilepsy: Frequency, Causes and Consequences. Demos, New York 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/71\">",
"      Holmes GL. Epilepsy in the developing brain: lessons from the laboratory and clinic. Epilepsia 1997; 38:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/72\">",
"      Wong M. Advances in the pathophysiology of developmental epilepsies. Semin Pediatr Neurol 2005; 12:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/73\">",
"      Rakhade SN, Jensen FE. Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol 2009; 5:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/74\">",
"      Brooks-Kayal AR, Shumate MD, Jin H, et al. gamma-Aminobutyric acid(A) receptor subunit expression predicts functional changes in hippocampal dentate granule cells during postnatal development. J Neurochem 2001; 77:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/75\">",
"      Raol YH, Lund IV, Bandyopadhyay S, et al. Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 2006; 26:11342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/76\">",
"      Perez Velazquez JL, Carlen PL. Gap junctions, synchrony and seizures. Trends Neurosci 2000; 23:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/77\">",
"      Margineanu DG. Epileptic hypersynchrony revisited. Neuroreport 2010; 21:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/78\">",
"      Swann JW, Hablitz JJ. Cellular abnormalities and synaptic plasticity in seizure disorders of the immature nervous system. Ment Retard Dev Disabil Res Rev 2000; 6:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37385/abstract/79\">",
"      Haglund MM, Schwartzkroin PA. Role of Na-K pump potassium regulation and IPSPs in seizures and spreading depression in immature rabbit hippocampal slices. J Neurophysiol 1990; 63:225.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2232 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37385=[""].join("\n");
var outline_f36_32_37385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CELLULAR PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ion channels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Voltage-dependent conductances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Depolarizing conductances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyperpolarizing conductances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Synaptic transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Excitatory transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inhibitory transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Role of glia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOPHYSIOLOGY OF EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Focal epilepsy: Mesial temporal lobe epilepsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Paroxysmal depolarization shift",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Synchronizing mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Consequences of repeated seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Primary generalized epilepsy: Absence epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Susceptibility of the immature brain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2232\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2232|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/9/6295\" title=\"figure 1\">",
"      Spread of sz by type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/39/41587\" title=\"figure 2\">",
"      Normal neuronal firing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/32/38415\" title=\"figure 3\">",
"      Hippocampal circuitry 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/7/23667\" title=\"figure 4\">",
"      Abnormal neuronal firing in epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/20/25921\" title=\"figure 5\">",
"      Hippocampal sprouting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2232|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/42/11948\" title=\"table 1\">",
"      Egs pathophys epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/59/37820\" title=\"table 2\">",
"      Immature brain sz suscept",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/921?source=related_link\">",
"      Benign partial epilepsies of childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41335?source=related_link\">",
"      Etiology and prognosis of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2890?source=related_link\">",
"      Evaluation and management of drug-resistant epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3226?source=related_link\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=related_link\">",
"      Neonatal epileptic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_32_37386="Overview of the treatment of seizures and epileptic syndromes in children";
var content_f36_32_37386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of seizures and epileptic syndromes in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/32/37386/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37386/contributors\">",
"     Angus Wilfong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/32/37386/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37386/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/32/37386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/32/37386/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/32/37386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with epilepsy, particularly infants, differ from adults not only in the clinical manifestations of their seizures, but also in the presence of unique electroencephalogram (EEG) patterns, etiologies, and response to antiepileptic drugs (AEDs). The immature brain, particularly in the neonate and young infant, differs from the adult brain in the basic mechanisms of epileptogenesis and propagation of seizures. It is more prone to seizures, but seizures are more apt to disappear as the child grows.",
"   </p>",
"   <p>",
"    This topic presents an overview of the treatment of seizures and epileptic syndromes in children. Treatment of neonatal seizures and the treatment of specific epilepsy syndromes are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21912?source=see_link\">",
"     \"Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=see_link\">",
"     \"Epilepsy syndromes in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/921?source=see_link\">",
"     \"Benign partial epilepsies of childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE FIRST SEIZURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child's first seizure may be caused by an acute illness, such as a metabolic derangement or infectious disorder, and be nonrecurrent, or may represent the beginning of epilepsy. A decision must be made about initiating chronic antiepileptic drug (AED) treatment if a potentially reversible acute cause is not found during the evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\", section on 'Setting in which episodes occur'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prognosis after a first seizure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child who is neurologically normal, has no history of a prior neurologic illness, and has an unprovoked seizure with no evident acute cause has a 24 percent risk of having another seizure in the next year, and a 45 percent risk over the next 14 years, according to one large prospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The one year recurrence risk increases to 37 percent in children with a prior neurologic insult (remote symptomatic), such as cerebral palsy, and increases to 70 percent in patients who have had two seizures that are separated by at least 24 hours. Children who have a seizure in the setting of an acute illness (eg, acute infection, acute head injury) have a low risk of seizure recurrence compared to other children with a first seizure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Withholding treatment until after the second seizure does not alter the long-term prognosis of epilepsy. A study that randomly assigned 419 patients with a first tonic-clonic seizure to immediate AED therapy or treatment only after a second seizure found that immediate treatment reduced the short-term relapse rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/4\">",
"     4",
"    </a>",
"    ]. However, at one and two years, the number of patients who remained seizure-free in the early treatment and delayed treatment groups were similar (83 to 87 percent at one year, 60 to 68 percent at two years). A similar study of 1443 patients (38 percent were &le;19 years old) found that immediate AED treatment reduced the short-term (one to two year) risk of seizure relapse, but had no effect on the long-term risk of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/5\">",
"     5",
"    </a>",
"    ]. The benefit of immediate treatment was lost by four years after a first seizure and by six years after multiple seizures.",
"   </p>",
"   <p>",
"    The long-term risk of mortality after a single seizure appears to be quite low. There is no evidence that treatment after an initial seizure has any impact on mortality. In a cohort study of 407 children with a first unprovoked seizure, four had a seizure-related death over a 14-year observation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/2\">",
"     2",
"    </a>",
"    ]. Each of these had multiple seizures that were not fully controlled with AED treatment; none died prior to initiation of AED therapy, and two had been treated after the first seizure that was status epilepticus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predictors of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study, the electroencephalogram (EEG) is the most valuable predictor of recurrence in children with a single unprovoked seizure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/1\">",
"     1",
"    </a>",
"    ]. The recurrence risk was 41 percent in the first 12 months after the initial seizure if the EEG was abnormal (epileptiform activity, focal or generalized slowing) compared with 15 percent in children with a normal EEG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of the 283 children in this study were not treated with an AED. In another study, significant magnetic resonance imaging (MRI) findings, present in 16 percent, were more predictive of short-term seizure recurrence than EEG findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first study, 9 percent of children had an initial presentation in status epilepticus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk of seizure recurrence was not increased in this group. However, in another cohort study of 613 children with established epilepsy, episodes of status epilepticus were more common in children who had had at least one episode of status epilepticus by the time the diagnosis of epilepsy was established (19.6 versus 4.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/7\">",
"     7",
"    </a>",
"    ]. Recurrent status epilepticus was more likely to occur in children with partial seizures and in those with remote symptomatic epilepsy (particularly those with a previous craniotomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Long-term remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study, 594 of 613 children with newly diagnosed epilepsy were followed for at least two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/8\">",
"     8",
"    </a>",
"    ]. Seizure remission occurred in 74 percent; of these, 24 percent subsequently relapsed. Children with idiopathic generalized epilepsy and age of onset between five and nine years were more likely to have remission. Those with a remote symptomatic etiology, family history of epilepsy, frequent seizures, and slowing on the initial EEG were less likely to have remission. Approximately one-half of relapses occurred in children who had stopped or were tapering medication, while one-fourth occurred while on medication.",
"   </p>",
"   <p>",
"    A smaller study followed 144 patients with epilepsy with onset before 16 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/9\">",
"     9",
"    </a>",
"    ]. After 37 years follow-up, remission occurred in 67 percent, 86 percent of whom were off medication. Of the one-third of patients who did not achieve remission, 19 percent were drug resistant (medically intractable), while 14 percent had experienced 5-year remissions. A symptomatic origin was associated with failure to achieve remission and with medical intractability. Low IQ was also a risk factor for intractability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision whether to treat a child after an initial unprovoked seizure is an individualized one. The limited data in children suggest that treatment appears to reduce the risk of a recurrent seizure. However, the interval between seizures cannot be determined at the first seizure, and could be months to years. The risks of not treating include another seizure with its attendant risk of injury and psychological stigma (including restrictions on driving and work environment in teenagers and young adults) and, infrequently, status epilepticus. These possibilities must be weighed against the risks of chronic AEDs, which include possible effects on school performance and behavior, allergic reactions, and systemic toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/10\">",
"     10",
"    </a>",
"    ]. The financial burden of chronic AEDs, office visits, and laboratory tests should also be considered.",
"   </p>",
"   <p>",
"    A practice parameter for the treatment of a child with a first",
"    <strong>",
"     unprovoked",
"    </strong>",
"    seizure was published by the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/11\">",
"     11",
"    </a>",
"    ]. The following recommendations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with AEDs is not indicated for the prevention of the development of epilepsy.",
"     </li>",
"     <li>",
"      Treatment with AEDs may be considered when the benefits of reducing the risk of a second seizure are greater than the risks of pharmacologic and psychosocial side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is consistent with the current practice of most neurologists to refrain from treating a child with a first unprovoked seizure. Even if the child has a static encephalopathy, treatment can be withheld until a recurrence pattern is established. The risk of seizure recurrence is higher in children with a potential remote symptomatic etiology, particularly if the seizure was focal and the EEG abnormal.",
"   </p>",
"   <p>",
"    Many parents elect no AEDs if the seizures are infrequent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild. The definitions of \"infrequent\" and \"mild\" may vary from parent to parent. Children with absence seizures, atonic seizures or drop attacks, and infantile spasms are virtually always treated, since they usually present to the clinician with an already established pattern of frequent seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SEIZURE TYPES AND EPILEPTIC SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial work-up should include an attempt to determine the specific type of seizure the child experienced and, if possible, the epilepsy syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21912?source=see_link\">",
"     \"Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=see_link\">",
"     \"Epilepsy syndromes in children\"",
"    </a>",
"    .) The optimal choice of antiepileptic drug (AED) depends on the type of seizure and the epilepsy syndrome (",
"    <a class=\"graphic graphic_table graphicRef58459 \" href=\"mobipreview.htm?18/1/18460\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The electroencephalogram (EEG) pattern should not be used alone to determine the type of seizure and choice of AED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/12\">",
"     12",
"    </a>",
"    ]. A detailed clinical description of the child's behavior during a seizure should be used with the EEG findings in selecting an AED. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTIEPILEPTIC DRUG THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initiation of therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an ever-growing list of newer antiepileptic drugs (AEDs) and nonpharmacologic therapies available to manage childhood epilepsy. Traditionally, the medications have been separated into \"older\" and \"newer\" groups based upon their historic regulatory approval and availability. Typically, when a medication is first approved for epilepsy, it receives an \"on-label indication\" for add-on (adjunctive) therapy for partial-onset seizures in adults. Then, as experience grows and other studies are done, the use of the drug may expand to other seizure types and younger age groups.",
"   </p>",
"   <p>",
"    The AED chosen for initial therapy should be one that is highly effective for a particular seizure type or syndrome and that is safe and well tolerated (",
"    <a class=\"graphic graphic_table graphicRef58459 \" href=\"mobipreview.htm?18/1/18460\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/13\">",
"     13",
"    </a>",
"    ]. In some cases, seizures may even be aggravated by the administration of a less-appropriate AED. As examples,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    have been reported to worsen absence and myoclonic seizures in individuals with idiopathic generalized epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Also, the AED should have low toxicity and few adverse effects. A long serum half-life allows for relatively smooth serum levels with less frequent daily dosing that can enhance medical compliance (",
"    <a class=\"graphic graphic_table graphicRef68462 graphicRef80434 \" href=\"mobipreview.htm?10/7/10366\">",
"     table 2A-B",
"    </a>",
"    ). Cost-effectiveness is also desirable; as an example, the World Health Organization recommends",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    as the treatment of choice for partial and tonic clonic seizures in countries with restricted resources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/18\">",
"     18",
"    </a>",
"    ]. The pharmacology and specific indications for individual AEDs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In infants and younger children, oral suspensions, chewable tablets, and sprinkle formulations may be useful. Some AEDs come in a sustained-release form (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , valproic acid (See",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     \"Valproate: Pediatric drug information\"",
"    </a>",
"    .),",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/0/25608?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ) or have particularly long half-lives (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/34/2598?source=see_link\">",
"     ethosuximide",
"    </a>",
"    , phenytoin,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/52/25415?source=see_link\">",
"     zonisamide",
"    </a>",
"    ) that requiring only once or twice-daily dosing. These AEDs allow for \"make-up dosing.\" As an example, if a child on ethosuximide misses the once-a-day dose, it can be taken the next day with the regularly scheduled dose.",
"   </p>",
"   <p>",
"    Elimination kinetics also should be considered when choosing an AED. With linear or first-order kinetics, a constant fractional amount of the drug is eliminated over time, independent of the concentration of the drug in the serum. With nonlinear, dose-dependent, saturable, or concentration-dependent kinetics, as the level of the drug increases, clearance declines as the elimination mechanisms become saturated. Linear kinetics is more desirable.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     Valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    have nonlinear kinetics. Phenytoin is particularly troublesome, with linear kinetics at low serum levels, and nonlinear kinetics as the serum level approaches the low- to mid-therapeutic range. Thus, a small increase in dose may lead to a large and potentially toxic increase in the serum level. At high serum levels, phenytoin's half-life is significantly longer. At these higher levels, it may take only a minimal increase in the daily dose to attain the target level; in some cases, this increase is made every other day.",
"   </p>",
"   <p>",
"    Children with epilepsy are at increased risk for cognitive impairment and learning difficulties, at least some of which may be due to long-term AED exposure. However, our understanding of AEDs' affect on cognition is limited, especially in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Drug dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kinetics of a drug determine the initial dose and the interval between dose increments during titration. Most AEDs should be started at about 10 to 25 percent of the planned maintenance dose. AEDs with a long half-life can be started at close to the maintenance dose. In general, the dose should be increased at intervals not exceeding five half-lives to allow the serum level to plateau between each dose increment. If seizures are frequent, the titration may be accelerated to achieve a therapeutic benefit, but this may come at the cost of increased side effects.",
"   </p>",
"   <p>",
"    The AED dose should be increased until seizures stop, unremitting adverse effects occur, or serum levels reach a high or supratherapeutic range without a significant impact upon seizure frequency. The recommended upper therapeutic serum levels of most of the AEDs can be exceeded if side effects are absent. This should be done with particular caution with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    because of its nonlinear pharmacokinetics and with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    because of dose-related thrombocytopenia (",
"    <a class=\"graphic graphic_table graphicRef68462 graphicRef80434 \" href=\"mobipreview.htm?10/7/10366\">",
"     table 2A-B",
"    </a>",
"    ). If side effects appear but are tolerable, the dose should remain stable for several weeks to determine if the symptoms remit. Dose increases can continue at a slower rate if side effects remit and seizures continue.",
"   </p>",
"   <p>",
"    Some patients may require greater than standard doses of an AED to reach therapeutic levels. Low levels at high doses often are caused by poor compliance but also may be secondary to hypermetabolism of the AED (ie, higher than normal clearance because of increased hepatic metabolism). If levels are not increasing as anticipated and noncompliance is unlikely, the child should be given a loading dose under medical observation and levels should be measured over the next 12 to 24 hours. A genetically regulated hypermetabolism probably exists if levels remain low, and higher daily doses are indicated.",
"   </p>",
"   <p>",
"    Occasionally, children manifest slow drug clearance, often caused by inherited variations in the degradation enzymes. These individuals require lower maintenance doses.",
"   </p>",
"   <p>",
"    Ideally, daily AED doses should be given at intervals shorter than the half-life in order to avoid wide excursions in serum levels. The longer the half-life, the less frequent the dosing. Compliance is improved when medications are taken on schedule and prompted by an association with a routine daily activity, such as mealtime or brushing teeth. A variation of an hour or so in scheduled dosing is usually not significant. Children should not be awakened at night to take AEDs.",
"   </p>",
"   <p>",
"    As a child grows, the AED dose may need to be increased to keep up with his or her body mass. However, the clearance of some AEDs decreases and approaches adult rates in adolescence. Serum levels may remain stable as the declining per kilogram dose is balanced by the declining clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7894656\">",
"    <span class=\"h2\">",
"     Drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many commonly used drugs can alter the metabolism of AEDs and vice versa (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80801 graphicRef55399 graphicRef53463 \" href=\"mobipreview.htm?0/4/72\">",
"     table 4A-C",
"    </a>",
"    ). Hepatic enzyme inducers will lower the levels of drugs metabolized in the liver, and liver enzyme inhibitors will slow the metabolism of the same drugs.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/58/43943?source=see_link\">",
"     Cimetidine",
"    </a>",
"    , propoxyphene,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/63/33785?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    are examples of enzyme inhibitors used in children that may elevate the serum levels of some AEDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7894663\">",
"    <span class=\"h2\">",
"     Serum levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum levels should be used only as guides to therapy (",
"    <a class=\"graphic graphic_table graphicRef68462 graphicRef80434 \" href=\"mobipreview.htm?10/7/10366\">",
"     table 2A-B",
"    </a>",
"    ). The therapeutic range is different for each patient. Many will achieve seizure control at levels below the recommended range; others require higher levels. There is no reason to increase the dose if seizures stop when the serum level is \"low\" or \"subtherapeutic.\" If the level reaches the \"therapeutic range,\" yet seizures continue, the level should be increased as long as there are no adverse effects.",
"   </p>",
"   <p>",
"    It is helpful to have a baseline AED level once seizure control has been attained, which can be compared with levels obtained when seizures recur to ascertain whether the breakthrough is caused by low serum levels from poor compliance, interaction with another medication, decreased absorption (eg, during a diarrheal illness or gastritis with vomiting), or change in medication preparation (eg, brand name to generic drug formulation). If a child is placed on another long-term medication, measuring the AED level after the dose of the new drug has been stabilized may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7894801\">",
"    <span class=\"h2\">",
"     Compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of nonadherence to prescribed AED therapy are difficult to measure, but are probably higher than is generally appreciated. One prospective observational study in 124 children (2 to 12 years old) with newly diagnosed epilepsy found that 58 percent demonstrated nonadherence during the first six months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/19\">",
"     19",
"    </a>",
"    ]. A pattern of nonadherence was often established within the first month.",
"   </p>",
"   <p>",
"    The complexity of drug regimens and the occurrence of side effects are believed to contribute to poor compliance. However, in the observational study mentioned above, only low socioeconomic status was predictive of poor adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adding a second AED",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first AED fails in 20 to 40 percent of children with epilepsy; lack of efficacy and side effects contribute roughly equally to treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/20\">",
"     20",
"    </a>",
"    ]. A second AED is added when seizures are resistant to the initial drug. If the initial drug was partially effective, it should be continued until reasonable levels of the new AED are achieved. Tapering the first drug can then be attempted if seizures are controlled. If the initial AED is ineffective, it can be tapered earlier, as the dose of the second drug is increased. The pharmacokinetics of either drug can be altered by the other; serum levels may have to be monitored closely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Monotherapy versus polytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single-drug therapy is the goal of epilepsy treatment. Monotherapy is associated with better compliance, fewer adverse effects, less potential for teratogenicity, and lower cost than is polytherapy. Drug interactions are avoided and pharmacokinetics are simplified.",
"   </p>",
"   <p>",
"    Most of the AEDs have been reported to increase seizure frequency in a small percentage of patients and, in some instances, induce new seizure types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/21\">",
"     21",
"    </a>",
"    ]. These seizures may occur at low or therapeutic doses of some drugs and at toxic doses in others.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    , for example, can precipitate atonic seizures, particularly in children with Lennox-Gastaut syndrome.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     Phenytoin",
"    </a>",
"    can worsen absence seizures at therapeutic doses and cause generalized seizures at toxic doses. These observations explain why in some cases seizure frequency is improved when the number of AEDs is reduced. In many cases, a second AED was added to an initial, ineffective AED that was not then discontinued. If the seizures increased, a third drug often was added. The first or second AED may actually have increased the seizure frequency, and the problem was compounded further with the addition of more AEDs. Thus, the initial approach to the child with intractable seizures on polytherapy is to slowly decrease the AED that the family feels has been the least effective. When a child has intractable epilepsy despite treatment with more than one AED, it is also reasonable to re-evaluate the diagnosis of epilepsy.",
"   </p>",
"   <p>",
"    However, there are instances when the synergistic interaction of two AEDs improves seizure control. Children with certain generalized epilepsy syndromes occasionally require a combination of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/34/2598?source=see_link\">",
"     ethosuximide",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    . A second AED may also be considered in children with several different seizure types when monotherapy is not effective. In one practice, the clinicians found that children with status epilepticus, developmental disabilities, and multiple seizure types were more likely to require polytherapy than those without these features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/22\">",
"     22",
"    </a>",
"    ]. Virtually every combination of AEDs has been used. Certain combinations should be avoided when mechanisms of action overlap and toxicities are additive, such as any combinations of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/11/42167?source=see_link\">",
"     primidone",
"    </a>",
"    , and benzodiazepines, all of which are central nervous system depressants.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     Phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    also have overlapping mechanisms of action and are usually not given together.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory monitoring and adverse effects of AEDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory screening of hematologic and hepatic function is commonly done in children receiving AEDs. However, the cost for every patient in the United States with epilepsy to be tested three times per year with blood counts and serum transaminase levels was estimated in 1989 to be over $400 million annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/23\">",
"     23",
"    </a>",
"    ]. Evidence is convincing that this routine laboratory testing is not cost effective or necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/24\">",
"     24",
"    </a>",
"    ]. With the exception of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/25/28055?source=see_link\">",
"     felbamate",
"    </a>",
"    , which is associated with a relatively high risk of aplastic anemia and requires close laboratory monitoring, the risk of serious side effects with most of the AEDs is extremely small and, in most instances, appears in the first few months after the AED is initiated. Many idiosyncratic reactions related to AEDs, including Stevens-Johnson syndrome, toxic epidermal necrolysis, serum sickness reactions, and pancreatitis, are not predicted by presymptomatic blood test abnormalities.",
"   </p>",
"   <p>",
"    Increased suicidality has been linked to several antiepileptic drugs in randomized placebo-controlled studies of patients with epilepsy over five years of age, according to a January 2008 FDA report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/25\">",
"     25",
"    </a>",
"    ]. The elevated risk (0.43 versus 0.22 percent) was observed as early as one week after starting medication and continued though the 24 weeks of study observation. The effect was consistent in the 11 AEDs studied, and the FDA considers this risk likely to be shared by all AEDs. Patients taking AEDs should be monitored for emergence or worsening of suicidal ideation or depression. An approach to the assessment of suicidality in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38071?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and management of suicidal behavior in children and adolescents\", section on 'Identification of suicide risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Valproic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     Valproate",
"    </a>",
"    is associated with a relatively high incidence of minor and usually insignificant elevations of one or more liver enzymes and serum ammonia. In a study of 206 adults and children taking anticonvulsants including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , valproic acid, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , the serum gamma glutamyl transpeptidase (GGT) was elevated in 75 percent and alanine aminotransferase (ALT) in 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/26\">",
"     26",
"    </a>",
"    ]. Other researchers have confirmed these results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/27\">",
"     27",
"    </a>",
"    ]. Elevations in aspartate transaminase (AST) are recorded less commonly and may be a more specific marker of liver dysfunction. (See",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     \"Valproate: Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of fatal hepatotoxicity with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    have been in children younger than three years and usually occurred in the first six months of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/28\">",
"     28",
"    </a>",
"    ]. These children often develop encephalopathies and are on polytherapy because of the severe nature of their seizures. It seems likely that many of these patients have an underlying metabolic disorder causing the seizures (eg, urea cycle defects, organic acidurias, mitochondrial cytopathies, storage diseases, or other progressive syndromes of unknown etiology such as Alper's Syndrome), which are exacerbated by exposure to valproic acid. Also, in some cases, the liver enzymes remain normal despite advanced hepatic failure with nausea, vomiting, worsening of seizures, and encephalopathy.",
"   </p>",
"   <p>",
"    Hepatic enzyme elevations that are less than three times normal in an asymptomatic child are unlikely to be significant. Higher levels should be repeated in a few weeks and the medications stopped if levels are increasing rapidly or if the child becomes symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Carbamazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia is not uncommon with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , often appearing in the first two to three months of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/29\">",
"     29",
"    </a>",
"    ]. Severe aplastic anemia or agranulocytosis is reported but rare, occurring in 2 per 575,000 exposures. These severe blood dyscrasias are more common in adults. A drop of the white count into the 3000 to 4000 range characterizes the more common benign leukopenia, which will usually gradually return toward normal or may remain at a mildly low level for the duration carbamazepine therapy. I obtain a CBC after the first month of carbamazepine therapy. If the white blood count (WBC) is significantly decreased, I repeat every three to four weeks until the counts stabilize. If the ANC falls below 800 to 1000, the medication should be stopped",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Topiramate and zonisamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;These AEDs are partial carbonic anhydrase inhibitors and may cause a mild to moderate chronic metabolic acidosis in up to two-thirds of children and can also cause nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. The risk and severity of acidosis are increased if there are other predispositions to metabolic acidosis, such as renal disease or concurrent use of a ketogenic diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H406687830\">",
"     'The ketogenic diet'",
"    </a>",
"    below.) Potential complications of chronic metabolic acidosis in children include impaired growth, rickets, or osteomalacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, the serum bicarbonate should be measured at baseline and monitored periodically thereafter. Dose reduction or drug discontinuation should be considered in patients with persistent or severe metabolic acidosis. If the drug is continued, alkali therapy may be warranted as in type 2 (proximal) renal tubular acidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5860?source=see_link\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Oxcarbazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia has been reported with the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/46/16104?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    , but this is a very rare in children. The two predominant risk factors appear to be concomitant use of other \"sodium-depleting\" medications (eg, tricyclic antidepressants, thiazide diuretics, atypical antipsychotics) and excessive free water consumption. The effect is dose-related and usually occurs within the first three months of therapy or following the addition of another sodium-depleting medication. It is not usually necessary to reduce or stop oxcarbazepine; the serum sodium level usually gradually returns to normal or remains at a mildly reduced level and is nearly always asymptomatic. For sodium levels less than 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or symptoms of hyponatremia, a dose reduction of oxcarbazepine or mild fluid restriction is usually successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians obtain screening laboratory tests before initiating AED therapy with a CBC and platelet count, liver and renal function tests, glucose, electrolytes, total protein, albumin, and globulin. In children under the age of three or those who might have a neurometabolic disorder, one should consider obtaining serum ammonia, pyruvate, lactate, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    levels and serum amino acid and urine organic acid analyses before initiating valproic acid.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     Valproate",
"    </a>",
"    should be avoided if there is clinical suspicion that the child's illness is progressive when no etiology has been determined.",
"   </p>",
"   <p>",
"    Once a child has been on a stable AED regimen for several months, there is little indication for routine monitoring of laboratory studies. The clinician should be clinically vigilant and have a low index of suspicion for adverse events in any child receiving chronic AEDs. A seemingly benign illness that lasts for more than a few days should prompt a CBC",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver function studies. Vomiting (the most common early symptom of hepatotoxicity or pancreatitis), prolonged unexplained fever, easy bruising, extreme fatigue or lethargy, flu-like symptoms, unexplained worsening of seizures, change in mental status, and abdominal pain should lead to further investigations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A family history can be helpful in making decisions about laboratory testing. Adverse reactions to medications, particularly those that are hematologic or cutaneous, or a strong family history of autoimmune disorders, should heighten the concern for idiosyncratic reactions and hematological complications. A family as well as personal history of renal stones should be sought when",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/52/25415?source=see_link\">",
"     zonisamide",
"    </a>",
"    is considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=see_link\">",
"     \"Nephrolithiasis in renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Transmucosal AED administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiepileptic drugs (AEDs) can be administered intravenously for control of prolonged seizures in children, but this often entails treatment delays related to transportation to a hospital emergency department and difficulty establishing intravenous access. Such problems have led to increased use of transmucosal routes of AED delivery, such as rectal, buccal, intranasal, and sublingual administration. Transmucosal routes allow for more rapid seizure control and permit the initial use of AEDs at home or in the field, allowing for earlier treatment. The largest experience is with rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    , although accumulating evidence suggests that buccal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    is also safe and effective. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Rectal therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Buccal therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of status epilepticus in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Rectal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal benzodiazepines are an effective and relatively safe emergency treatment, particularly for patients who live at some distance from a medical facility, those requiring emergency therapy while traveling, and those whose seizures occur in clusters.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     Diazepam",
"    </a>",
"    is available in a rectal gel (Diastat &reg;) that is obtained from the pharmacy in prefilled ready-to-use syringes that are set to deliver a specific dose. These have a long shelf life (years) and do not require refrigeration. The rates of absorption and response are slower than those of intravenous diazepam but faster than with oral administration. Respiratory depression is extremely rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/37\">",
"     37",
"    </a>",
"    ], although if concerns about this possible complication exist, particularly in a handicapped child, a test dose can be given under physician supervision.",
"   </p>",
"   <p>",
"    Rectal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/35/24117?source=see_link\">",
"     paraldehyde",
"    </a>",
"    may also be used in the setting of a prolonged convulsion when other routes of AED administration are not available. It is administered as a dose of 0.8",
"    <span class=\"nowrap\">",
"     ml/kg",
"    </span>",
"    of a 0.4",
"    <span class=\"nowrap\">",
"     ml/kg",
"    </span>",
"    liquid mixed 1:1 with olive oil. In a case series of 53 episodes of prolonged convulsions in 30 patients, rectal paraldehyde terminated the convulsion in 62 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/38\">",
"     38",
"    </a>",
"    ]. There was no respiratory depression or other adverse events recorded. Paraldehyde is not available in the United States.",
"   </p>",
"   <p>",
"    Many AEDs can be given as a rectal suppository for short periods (eg, postoperatively) and occasionally as chronic treatment for patients unable to take oral medications. Any AED available as an oral suspension (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11383?source=see_link\">",
"     clonazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/46/16104?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/0/25608?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ) can be given rectally for short periods. Carbamazepine has a significant cathartic effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Buccal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buccal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    therapy uses the intravenous formulation of midazolam hydrochloride delivered into the buccal cavity between the gum and cheek [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Buccal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    is effective for the emergency treatment of seizures in children, as demonstrated by at least three randomized clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In the earlier and smaller trial that evaluated 79 seizures in 28 children with severe epilepsy, buccal midazolam was as effective as rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    at stopping seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent multicenter randomized controlled trial evaluated 219 seizures in 177 children ages 6 months and older (median age three years) with new onset seizures or existing epilepsy who presented to the emergency department with ongoing seizures and no established intravenous access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/41\">",
"     41",
"    </a>",
"    ]. Buccal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    was more effective than rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    for either stopping seizure activity within 10 minutes without respiratory depression or preventing another seizure within one hour (56 versus 27 percent, respectively). The risk of respiratory depression with buccal midazolam was low and similar to the risk with rectal diazepam. The dose of buccal midazolam used was 2.5 mg, 5 mg, 7.5 mg, and 10 mg for children ages 6 to 12 months, one to four years, five to nine years, and 10 or more years, respectively.",
"   </p>",
"   <p>",
"    A randomized trial compared buccal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    to intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    in 120 children presenting to an emergency room with convulsive seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/42\">",
"     42",
"    </a>",
"    ]. Time to treatment was shorter with buccal midazolam; time from administration to seizure control was shorter with diazepam. Overall, there was a shorter time from treatment decision to control of seizures for buccal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Intranasal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intranasal formulations of some benzodiazepines have been developed and are being studied in the acute management of seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Further studies are needed to confirm the efficacy of these treatments compared with other transmucosal AEDs.",
"   </p>",
"   <p>",
"    Intranasal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    was compared with rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    in a study of 188 prolonged seizure episodes in 46 children in New Delhi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/44\">",
"     44",
"    </a>",
"    ]. Intranasal midazolam was associated with a faster cessation of seizures (in 1.9 versus 3.0 minutes) and less respiratory depression compared with rectal diazepam. Seizures were more likely to be stopped within 10 minutes of drug administration (97 versus 89 percent) and were less likely to recur (3 versus 6 percent); these differences were not statistically significant.",
"   </p>",
"   <p>",
"    The efficacy of intranasal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    compared to rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    as an at-home rescue treatment for seizures was evaluated in a randomized trial in 92 children; no difference in efficacy or complications were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intranasal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    also appears to be an effective treatment option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/44\">",
"     44",
"    </a>",
"    ], and in one study appeared to have similar efficacy to intravenous lorazepam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    remains first-line therapy for emergency treatment of prolonged or closely-clustered seizures in settings where intravenous access is not readily available. This includes at home treatment of prolonged or recurrent febrile seizures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3226?source=see_link&amp;anchor=H13#H13\">",
"     \"Febrile seizures\", section on 'Recurrent febrile seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Buccal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    appears to be more effective than rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    , and is suggested as primary hospital emergency department treatment of prolonged seizures prior to establishment of intravenous access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/39,47\">",
"     39,47",
"    </a>",
"    ]. Intramuscular and intranasal administration of midazolam appears to have similar efficacy as rectal diazepam. Transmucosal administration of midazolam will likely become first line therapy for out-of-hospital emergency therapy once a convenient formulation for non-medical personnel is approved and available.",
"   </p>",
"   <p>",
"    Prolonged seizures that do not respond to transmucosal therapy require hospitalization, intravenous administration of AEDs, and may require intensive care unit management. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Stopping antiepileptic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Withdrawal of antiepileptic drug (AED) therapy should be considered in most children after two years without seizures regardless of the etiology of the seizures. The likelihood of recurrence after a two-year period without seizures is approximately 30 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. One meta-analysis of seven studies found that earlier discontinuation (before two years) of AED therapy was associated with a higher risk for seizure relapse (RR = 1.32), particularly in children with focal epilepsy or an abnormal EEG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/50\">",
"     50",
"    </a>",
"    ]. Longer seizure-free periods are associated with only a slightly lower incidence of recurrence and therefore longer observation periods are not warranted.",
"   </p>",
"   <p>",
"    The risk of recurrent intractable seizures after discontinuing AEDs in seizure-free children is very low. In a cohort study of 260 children who became seizure free and stopped AEDs and were followed for four to five years, three children (1 percent) developed recurrent seizures that could not be controlled again with medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/51\">",
"     51",
"    </a>",
"    ]. It is not clear that these recurrent seizures could have been prevented had AEDs not been discontinued.",
"   </p>",
"   <p>",
"    Numerous studies have attempted to determine prognostic factors that stratify children into high or low-risk categories for recurrence. The presence of a motor or cognitive deficit or an abnormal electroencephalogram (EEG) at the time of discontinuation somewhat increases the likelihood of a recurrent seizure. In a large prospective study, the EEG was useful as a predictor of outcome after withdrawal in children with idiopathic epilepsy but not in those with remote symptomatic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/52\">",
"     52",
"    </a>",
"    ]. The EEG was of predictive value in relation to the presence or absence of slowing (generalized or focal) but not epileptiform activity. Slowing in the EEG done at the time of discontinuation was associated with a 54 percent recurrence compared with 28 percent in those with a normal EEG. The overall recurrence rate was 29 percent in the children with idiopathic and 47 percent in those with remote symptomatic epilepsy. Higher rates of recurrence with symptomatic versus idiopathic epilepsy have been seen in other studies as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/49\">",
"     49",
"    </a>",
"    ]. Several smaller studies with shorter treatment periods (6 to 12 months) have shown only slightly higher recurrence rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Other factors that may be predictive of good outcome are a younger age and having only absences as a seizure type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/52-55\">",
"     52-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with neurologic deficits should also be considered for AED withdrawal if they have been seizure-free for an extended period of time. In one study, seizure relapse occurred in 41.5 percent of 65 children with cerebral palsy and seizures after at least two seizure-free years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/56\">",
"     56",
"    </a>",
"    ]. Children with hemiplegia had a much higher relapse rate (61.5 percent) than did those with a paraplegia (14.3 percent). This probably relates to the fact that with paraplegia, the major pathology is in the subcortical white matter with minimal involvement of the more epileptogenic cortical neurons. In this study, the EEG at the time of discontinuation was not of value in predicting recurrence.",
"   </p>",
"   <p>",
"    AEDs should be tapered rather than halted abruptly. There are limited data to guide an AED tapering schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/57\">",
"     57",
"    </a>",
"    ]. Rapid changes (over days to a few weeks) in drug treatment increase the risk of seizures. Slower rates of AED taper, over several weeks to a few months, are generally recommended. In particular, benzodiazepines and barbiturates are associated with withdrawal seizures and should be discontinued very gradually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     EPILEPSY SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children achieve reasonably good seizure control with AEDs. Some are refractory despite numerous medications and are not candidates for or fail the ketogenic diet. Medical treatment failure may be apparent early in the course of treatment. As an example, one study found that a frequency of weekly seizures during the first year of treatment was a predictor of medical intractability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/58\">",
"     58",
"    </a>",
"    ]. However, particularly in focal epilepsy syndromes, intractability can follow one or more periods of extended seizure remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/59\">",
"     59",
"    </a>",
"    ]. Surgical interventions should be considered, regardless of age, in children who have persistent, frequent seizures that are having an adverse impact upon their lives or are interfering with their cognitive and psychosocial development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/60\">",
"     60",
"    </a>",
"    ]. Uncontrolled observational data suggest that early epilepsy surgery, if successful, can be associated with cognitive gains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical approaches can be divided into relatively less invasive procedures, such as vagus nerve stimulation, and surgeries such as focal resections, lobar or multilobar resections, corpus callosotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/62\">",
"     62",
"    </a>",
"    ], hemispherectomy, and multiple subpial transection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The procedure selected depends upon the type and localization of the seizures. Children with a well-localized epileptic focus, particularly if a lesion is present on imaging studies in the same location, do very well with removal of the abnormal tissue (lesionectomy). Children with unihemispheric syndromes such as hemimegalencephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], Sturge-Weber syndrome, or Rasmussen's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/66,67\">",
"     66,67",
"    </a>",
"    ] may have an excellent response to removal (hemispherectomy) or undercutting of the cortex of an entire hemisphere (functional hemispherectomy).",
"   </p>",
"   <p>",
"    Stereotactic radiosurgery may be helpful for selected cases when the lesion is located where a conventional surgical approach is technically difficult or excessively risky [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/68\">",
"     68",
"    </a>",
"    ]. More information is needed on long-term outcome before wider application of this procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Temporal lobectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly performed invasive surgical procedure is temporal lobectomy. Cure has been reported with temporal lobectomy in over 80 percent of children in some case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/69\">",
"     69",
"    </a>",
"    ]. This procedure is done primarily in adults in whom mesial temporal sclerosis is the most common cause. Children are more likely to have multiple or extratemporal foci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only randomized, controlled trial of epilepsy surgery was conducted in 80 patients &gt;16 years old with temporal lobe epilepsy whose seizures were poorly controlled with medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/71\">",
"     71",
"    </a>",
"    ]. These patients were randomly assigned to surgery or treatment with antiepileptic drugs. At one year, the cumulative proportion of patients who were free of seizures impairing awareness was significantly greater in the surgery group (58 versus 8 percent). Cohort studies suggest that children can achieve a similar benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/70,72,73\">",
"     70,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Extratemporal cortical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of resective surgery in children with extratemporal foci are similar to those of temporal lobectomy if a discrete lesion is present on preoperative neuroimaging. This appears to be true even if preoperative EEG recording demonstrates bilateral or generalized epileptiform activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/74\">",
"     74",
"    </a>",
"    ]. In one study, surgery achieved seizure remission in over 75 percent of such children operated on before the age of three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results in nonlesional cases (MRI-negative) are less gratifying, with success rates reported as less than 40 percent in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/76\">",
"     76",
"    </a>",
"    ]. However, the application of newer technologies in preoperative assessment may modify this somewhat. One study found that surgical success rates similar to those seen with MRI-positive patients were seen in MRI-negative patients in whom the epileptogenic region was identified by combination of ictal SPECT, PET, and intracranial EEG monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of early (within two weeks) postoperative seizures was seen in 26 percent of children in one study and identified patients less likely to have a long-term seizure remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cohort studies suggest that individuals with unifocal lesions, particularly low-grade tumors, are more likely to achieve seizure remission than those with no or multifocal lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebral dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Hemispherectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemispherectomy is performed in children whose seizures are associated with a disease that diffusely affects one cerebral hemisphere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=see_link&amp;anchor=H15#H15\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Hemispheric syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common causes of seizures in children undergoing hemispherectomy include encephalomalacia from a remote insult such as perinatal stroke, hemimegalencephaly, multilobar cortical dysplasia, Rasmussen encephalitis, and Sturge-Weber syndrome.",
"   </p>",
"   <p>",
"    Seizure control rates after hemispherectomy are generally favorable across a range of etiologies, with approximately two-thirds of patients achieving seizure freedom at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/79-86\">",
"     79-86",
"    </a>",
"    ]. Predictors of worse seizure outcomes in most but not all studies include hemimegalencephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/79,84,87,88\">",
"     79,84,87,88",
"    </a>",
"    ], bilateral fluorodeoxyglucose (FDG)-PET abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/83\">",
"     83",
"    </a>",
"    ], bilateral MRI abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/87\">",
"     87",
"    </a>",
"    ], longer duration of epilepsy preceding surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/80,89\">",
"     80,89",
"    </a>",
"    ], and early postoperative seizure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/78,83\">",
"     78,83",
"    </a>",
"    ]. Of these, duration of epilepsy prior to surgery is the most consistently reported and underscores the importance of early surgical evaluation in patients with refractory seizures.",
"   </p>",
"   <p>",
"    Contralateral MRI abnormalities are a common cause for concern in selecting patients for hemispherectomy, but their importance is controversial. This is demonstrated by two studies with conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective series of 110 patients who underwent hemispherectomy, 74 percent of cases had contralateral MRI abnormalities, the majority of which were described as mild to moderate, including nonspecific white matter changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/88\">",
"       88",
"      </a>",
"      ]. At a median follow up of two years, rates of seizure freedom were similar in those with and without contralateral MRI abnormalities (79 and 83 percent).",
"     </li>",
"     <li>",
"      A smaller study of 43 patients found contralateral MRI abnormalities (described as &ldquo;unambiguous&rdquo; findings on visual inspection) in 26 percent of patients who underwent hemispherectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/87\">",
"       87",
"      </a>",
"      ]. After a median follow up of seven years, patients with contralateral MRI abnormalities had lower rates of seizure freedom (45 versus 88 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition of a contralateral MRI abnormality has varied across studies, and this may partly explain the discrepancy in results. In addition, the length of follow-up often differs, and those studies with shorter follow-up times might overestimate seizure control rates in one or both groups.",
"   </p>",
"   <p>",
"    Other imaging modalities may also be helpful in selecting patients who will optimally benefit from surgery. In the largest study to date, FDG-PET activity in the contralateral hemisphere was a stronger predictor of seizure control postoperatively than MRI abnormalities; seizure freedom was achieved in 72 percent of the 119 patients with unilateral PET abnormalities and only 44 percent of the 18 patients with bilateral abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motor and cognitive outcomes after hemispherectomy are not as well studied as seizure outcomes. Most patients already have moderate to severe hemiparesis prior to undergoing hemispherectomy, and the risk of added motor deficits is generally low. Postsurgical developmental gains reported in most studies are modest, but development is often limited by severe preexisting brain damage that may involve the non-operated hemisphere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/82,87,89\">",
"     82,87,89",
"    </a>",
"    ]. As with seizure control, the most consistent predictor of cognitive and motor outcomes is shorter duration of epilepsy preceding surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/81,82,90\">",
"     81,82,90",
"    </a>",
"    ]. In addition, patients with fixed acquired etiologies (eg, perinatal stroke) tend to have better motor and cognitive outcomes than those with progressive or congenital etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Corpus callosotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a corpus callosotomy, the fibers of the corpus callosum are surgically divided. Typically, an anterior two-thirds callosotomy is performed first, with completion of the callosotomy done only if seizures persist after the first procedure. The only seizure type that has clearly been shown to benefit from this surgery are atonic seizures, which are most commonly seen in epileptic encephalopathies such as Lennox-Gastaut syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/91\">",
"     91",
"    </a>",
"    ]. However, many reports suggest that a substantive reduction in generalized tonic-clonic seizures and other seizure types can result after corpus callosotomy, and that improvements in behavior, IQ, and overall quality of life are also possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Withdrawal of medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, epilepsy surgery affects a \"cure,\" such that the patient is seizure free off medication. Trials of medication discontinuation after epilepsy surgery in children include the following case series.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one survey of 140 children, 102 had completely discontinued medication, and 90 percent were seizure free off medication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/93\">",
"       93",
"      </a>",
"      ]. Among those whose seizures recurred, seven were able to regain seizure control with restarting medication, three had recurring seizures that were not controlled by restarting medication.",
"     </li>",
"     <li>",
"      In another cohort of 80 children, 44 percent relapsed without medication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/94\">",
"       94",
"      </a>",
"      ]. Relapse rates were somewhat lower, 32 percent, in children with temporal lobe resection.",
"     </li>",
"     <li>",
"      Among 97 children undergoing temporal lobectomy, neocortical resection or multilobar surgery, medication was discontinued in 68 and 57 remained seizure free for two or more years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/95\">",
"       95",
"      </a>",
"      ]. Only 5 of the 97 patients continued to have seizures on medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many centers recommend continuing medication for at least six months following surgery. If the child is seizure free, then each drug is slowly tapered, one at a time, starting with the one that seemed least effective prior to surgery or the one thought to be causing the most adverse effects. Even if the child is not completely seizure free, an attempt should be made to minimize the number of medications, hopefully to monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Psychosocial outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of epilepsy surgery is typically measured by the degree of seizure control. Many make the assumption that if seizure control is improved then psychosocial parameters will also improve. Two prospective studies have had somewhat conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One looked at cognitive, psychosocial, and family function one year after epilepsy surgery in 30 children and compared these outcomes to a control group of 21 children with medically refractory seizures who had not undergone surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/96\">",
"       96",
"      </a>",
"      ]. There was no statistically significant difference between the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 35 children, those who were seizure-free postoperatively (20) had significantly higher scores on a Quality of Life in Childhood Epilepsy Questionnaire at 6 to 18 months compared with baseline scores [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/97\">",
"       97",
"      </a>",
"      ]. Those with persistent seizures had no measurable quality of life improvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another follow-up study, preoperative IQ was not a predictor of postoperative cognitive development or behavioral outcomes at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/98\">",
"     98",
"    </a>",
"    ]. However, it may be that one year is too short an interval to measure meaningful psychosocial outcomes. Several observational studies with longer term follow-up have suggested that IQ and other aspects of cognitive and psychosocial function improve over time compared with nonsurgical control patients, particularly in those patients who achieve seizure freedom or a reduction in AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/99-101\">",
"     99-101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H406687746\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Vagus nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many children who fail antiepileptic drugs (AED) therapy and the ketogenic diet are not candidates for resective epilepsy surgery. Others may undergo resective surgery and still have seizures. Others may have seizures controlled but with significant, bothersome side effects. These patients may be candidates for vagus nerve stimulation (VNS). VNS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=see_link\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H406687830\">",
"    <span class=\"h2\">",
"     The ketogenic diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ketogenic diet can be an effective treatment for patients with medically refractory epilepsy. This treatment, its indications, and potential adverse effects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=see_link\">",
"     \"The ketogenic diet\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H406688021\">",
"    <span class=\"h2\">",
"     Immunotherapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some epileptic syndromes, eg, Rasmussen encephalitis and others, may have an immunopathogenesis and as such may be responsive to immunotherapies, such as intravenous immunoglobulin and corticosteroids. Observational evidence of benefit for these therapies has been reported in epileptic encephalopathies such as Rasmussen encephalitis, Landau-Kleffner syndrome, and electrical status epilepticus in sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/102-107\">",
"     102-107",
"    </a>",
"    ]. Further controlled studies are needed in order to define which syndromes benefit from such treatment. In general, use of such therapies is restricted to the care of children with intractable epilepsy followed in tertiary care, subspecialty epilepsy clinics.",
"   </p>",
"   <p>",
"    The use of corticosteroid therapy in the treatment of infantile spasms and West syndrome is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=see_link\">",
"     \"Management and prognosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H966430\">",
"    <span class=\"h1\">",
"     LONG-TERM PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis for seizure cessation tends to be better in children than adults, particularly those who are neurologically intact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/108\">",
"     108",
"    </a>",
"    ]. In one community-based cohort, complete seizure remission occurred in one-half of children with nonsyndromic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/109\">",
"     109",
"    </a>",
"    ]. Early seizure control, younger age of onset, and an absence of underlying brain disorder were associated with favorable outcomes. On the other hand, status epilepticus is more common in children, as are severely abnormal EEG patterns, including hypsarrhythmia (West syndrome) and slow spike and slow wave discharges (Lennox-Gastaut syndrome). The detrimental effects of AEDs are probably also greater in the immature and rapidly developing child's brain.",
"   </p>",
"   <p>",
"    Mortality is increased in children with epilepsy. In one prospective cohort study with a mean follow-up of 40 years, 60 of 245 patients with epilepsy died, a rate three-fold higher than expected in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/110\">",
"     110",
"    </a>",
"    ]. The risk of death was especially high among children who were not in remission. Thirty percent of deaths were classified as sudden unexplained death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1128?source=see_link\">",
"     \"Sudden unexpected death in epilepsy\"",
"    </a>",
"    .) Other causes of death included seizure and accidental drowning. The increased risk of death appears to be primarily in children with symptomatic epilepsy and is much lower in patients with idiopathic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/111,112\">",
"     111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of epilepsy on the child is determined by many factors other than the recurrent seizures. Patients may have psychological, behavioral, cognitive, neurologic, academic, and social problems caused by their chronic neurologic condition, independent of the seizures that may have a significant impact on quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/113-118\">",
"     113-118",
"    </a>",
"    ]. Frequent subclinical or subtle seizures may also have a direct impact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with intractable seizures may manifest a decline of cognitive function and memory with no attributable etiology other than the frequent seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/117\">",
"     117",
"    </a>",
"    ]. Data, particularly from animal research and human surgical specimens, increasingly indicate that the pervasive excitatory synaptic activity accompanying seizures, and probably interictal epileptiform discharges as well, leads to neuronal injury, abnormal neuronal sprouting, and interference with the normal pruning and complex rearrangement of neuronal connectivity that characterizes the developing nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/120\">",
"     120",
"    </a>",
"    ]. Observational studies in children with epilepsy also suggest that poorly controlled seizures have a deleterious impact on cognition, particularly when they occur at a young age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/32/37386/abstract/121-125\">",
"     121-125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/54/38754?source=see_link\">",
"       \"Patient information: Epilepsy in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/5/19540?source=see_link\">",
"       \"Patient information: Treatment of seizures in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57948898\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision whether to treat a child after an initial unprovoked seizure is an individualized one (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The first seizure'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The child who is neurologically normal, has no history of neurologic illness, and no evident acute cause for the seizure has a 24 percent risk of a recurrent seizure in the next year, and a 45 percent risk over the next 14 years, according to one large prospective study. The one year recurrence risk increases to 37 percent in children with a prior neurologic injury, and increases to 70 percent in patients who have had two seizures that are separated by at least 24 hours.",
"     </li>",
"     <li>",
"      Children who have a seizure in the setting of an acute illness have a low risk of seizure recurrence compared to other children with a first seizure.",
"     </li>",
"     <li>",
"      Treatment with an antiepileptic drug (AED) reduces the risk of recurrent seizures, however, withholding treatment until after the second seizure does not alter the long-term prognosis of epilepsy.",
"     </li>",
"     <li>",
"      Treatment with AEDs may be considered when the benefits of reducing the risk of a second seizure are greater than the risks of pharmacologic and psychosocial side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The AED chosen for initial therapy should be one that is highly effective for a particular seizure type or syndrome and that is safe and well tolerated (",
"      <a class=\"graphic graphic_table graphicRef58459 \" href=\"mobipreview.htm?18/1/18460\">",
"       table 1",
"      </a>",
"      ). Other considerations include dose formulation, does frequency, the relative risk of certain side effects, the potential for drug-drug interactions. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initiation of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A second AED is added when seizures are resistant to the initial drug. If the initial drug was partially effective, it should be continued until reasonable levels of the new AED are achieved. Tapering the first drug can then be attempted if seizures are controlled. If the initial AED is ineffective, it can be tapered earlier, as the dose of the second drug is increased. Single-drug therapy is the goal of epilepsy treatment. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Adding a second AED'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine laboratory screening of hematologic and hepatic function is commonly done in children receiving AEDs, but the value of this practice and a recommended frequency is not defined. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Laboratory monitoring and adverse effects of AEDs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Many idiosyncratic reactions related to AEDs, including Stevens-Johnson syndrome, toxic epidermal necrolysis, serum sickness reactions, and pancreatitis, are not predicted by presymptomatic blood test abnormalities.",
"     </li>",
"     <li>",
"      Increased suicidality has been linked to several antiepileptic drugs Patients taking AEDs should be monitored for emergence or worsening of suicidal ideation or depression.",
"     </li>",
"     <li>",
"      Most clinicians obtain screening laboratory tests before initiating AED therapy with a CBC and platelet count, liver and renal function tests, glucose, electrolytes, total protein, albumin, and globulin.",
"     </li>",
"     <li>",
"      In children under the age of three or those who might have a neurometabolic disorder, one should consider obtaining serum ammonia, pyruvate, lactate, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      levels and serum amino acid and urine organic acid analyses before initiating valproic acid.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"       Valproate",
"      </a>",
"      should be avoided if there is clinical suspicion that the child's illness is progressive when no etiology has been determined.",
"     </li>",
"     <li>",
"      Once a child has been on a stable AED regimen for several months, there is little indication for routine monitoring of laboratory studies. The clinician should be clinically vigilant and have a low index of suspicion for adverse events in any child receiving chronic AEDs. A seemingly benign illness that lasts for more than a few days should prompt a CBC",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      liver function studies. Vomiting (the most common early symptom of hepatotoxicity or pancreatitis), prolonged unexplained fever, easy bruising, extreme fatigue or lethargy, flu-like symptoms, unexplained worsening of seizures, change in mental status, and abdominal pain should lead to further investigations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transmucosal AED administration (eg, rectal",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"       diazepam",
"      </a>",
"      ) is an effective and relatively safe emergency treatment for patients with prolonged seizures or seizure clusters in settings where intravenous access is not readily available. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Transmucosal AED administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Withdrawal of antiepileptic drug (AED) therapy should be considered in most children after two years without seizures regardless of the etiology of the seizures. The likelihood of recurrence after a two-year period without seizures is approximately 30 to 40 percent. AEDs should be tapered rather than halted abruptly. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Stopping antiepileptic drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some children, seizures are refractory to medical therapy. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Epilepsy surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H40\">",
"       'Vagus nerve stimulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H406687830\">",
"       'The ketogenic diet'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A number of effective surgical treatments are available (focal resections, lobar or multilobar resections, corpus callosotomy, hemispherectomy, and multiple subpial transection). The procedure selected depends upon the type and localization of the seizures.",
"     </li>",
"     <li>",
"      The ketogenic diet can be an effective treatment for specific patients with medically refractory epilepsy. This treatment, its indications, and potential adverse effects are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=see_link\">",
"       \"The ketogenic diet\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vagus nerve stimulation is also effective in the treatment of refractory epilepsy when surgery is not an option. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=see_link\">",
"       \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The long-term prognosis for seizure cessation tends to be better in children than adults, particularly those who are neurologically intact. However, mortality is increased in children with epilepsy compared with those without. Causes of death include sudden unexplained death and accidents such as drowning. (See",
"      <a class=\"local\" href=\"#H966430\">",
"       'Long-term prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with epilepsy may have psychological, behavioral, cognitive, neurologic, academic, and social problems caused by their seizures or by their chronic neurologic condition, independent of the seizures. (See",
"      <a class=\"local\" href=\"#H966430\">",
"       'Long-term prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/1\">",
"      Shinnar S, Berg AT, Mosh&eacute; SL, et al. Risk of seizure recurrence following a first unprovoked seizure in childhood: a prospective study. Pediatrics 1990; 85:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/2\">",
"      Shinnar S, O'Dell C, Berg AT. Mortality following a first unprovoked seizure in children: a prospective study. Neurology 2005; 64:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/3\">",
"      Martin ET, Kerin T, Christakis DA, et al. Redefining outcome of first seizures by acute illness. Pediatrics 2010; 126:e1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/4\">",
"      Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology 1997; 49:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/5\">",
"      Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005; 365:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/6\">",
"      Arthur TM, deGrauw TJ, Johnson CS, et al. Seizure recurrence risk following a first seizure in neurologically normal children. Epilepsia 2008; 49:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/7\">",
"      Berg AT, Shinnar S, Levy SR, Testa FM. Status epilepticus in children with newly diagnosed epilepsy. Ann Neurol 1999; 45:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/8\">",
"      Berg AT, Shinnar S, Levy SR, et al. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia 2001; 42:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/9\">",
"      Sillanp&auml;&auml; M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006; 129:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/10\">",
"      American Academy of Pediatrics. Behavioral and cognitive effects of anticonvulsant therapy. Committee on Drugs. Pediatrics 1985; 76:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/11\">",
"      Hirtz D, Berg A, Bettis D, et al. Practice parameter: treatment of the child with a first unprovoked seizure: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2003; 60:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/12\">",
"      Camfield P, Gordon K, Camfield C, et al. EEG results are rarely the same if repeated within six months in childhood epilepsy. Can J Neurol Sci 1995; 22:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/13\">",
"      Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/14\">",
"      Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006; 129:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/15\">",
"      Benbadis SR, Tatum WO 4th, Gieron M. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 2003; 61:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/16\">",
"      Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000; 55:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/17\">",
"      Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine. Epilepsia 2000; 41:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/18\">",
"      Perucca E. Treatment of epilepsy in developing countries. BMJ 2007; 334:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/19\">",
"      Modi AC, Rausch JR, Glauser TA. Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. JAMA 2011; 305:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/20\">",
"      Dudley RW, Penney SJ, Buckley DJ. First-drug treatment failures in children newly diagnosed with epilepsy. Pediatr Neurol 2009; 40:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/21\">",
"      Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/22\">",
"      Sloan ME, Simard-Tremblay E, Shevell MI. Features of a subset of children with complex partial epilepsy requiring combination therapy for effective seizure control. J Child Neurol 2010; 25:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/23\">",
"      Camfield P, Camfield C, Dooley J, et al. Routine screening of blood and urine for severe reactions to anticonvulsant drugs in asymptomatic patients is of doubtful value. CMAJ 1989; 140:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/24\">",
"      Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991; 41:961.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/drug/InfoSheets/HCP/antiepilepticsHCP.htm (Accessed on January 31, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/26\">",
"      Wall M, Baird-Lambert J, Buchanan N, Farrell G. Liver function tests in persons receiving anticonvulsant medications. Seizure 1992; 1:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/27\">",
"      Mendis GP, Gibberd FB, Hunt HA. Plasma activities of hepatic enzymes in patients on anticonvulsant therapy. Seizure 1993; 2:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/28\">",
"      Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 1987; 28 Suppl 2:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/29\">",
"      Seetharam MN, Pellock JM. Risk-benefit assessment of carbamazepine in children. Drug Saf 1991; 6:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/30\">",
"      Mukhin NA, Kozlovskaia LV, Bobkova IN, et al. [The key role of tubulointerstitium remodeling in progression of chronic renal diseases]. Arkh Patol 2004; 66:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/31\">",
"      Takeoka M, Riviello JJ Jr, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia 2002; 43:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/32\">",
"      Kuo RL, Moran ME, Kim DH, et al. Topiramate-induced nephrolithiasis. J Endourol 2002; 16:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/33\">",
"      Kossoff EH, Pyzik PL, Furth SL, et al. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 2002; 43:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/34\">",
"      McSherry E. Renal tubular acidosis in childhood. Kidney Int 1981; 20:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/35\">",
"      Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982; 307:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/36\">",
"      Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/37\">",
"      Pellock JM, Shinnar S. Respiratory adverse events associated with diazepam rectal gel. Neurology 2005; 64:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/38\">",
"      Rowland AG, Gill AM, Stewart AB, et al. Review of the efficacy of rectal paraldehyde in the management of acute and prolonged tonic-clonic convulsions. Arch Dis Child 2009; 94:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/39\">",
"      Wiznitzer M. Buccal midazolam for seizures. Lancet 2005; 366:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/40\">",
"      Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/41\">",
"      McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 366:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/42\">",
"      Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. Brain Dev 2009; 31:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/43\">",
"      Ahmad S, Ellis JC, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. Lancet 2006; 367:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/44\">",
"      Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol 2006; 34:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/45\">",
"      Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med 2010; 164:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/46\">",
"      Arya R, Gulati S, Kabra M, et al. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia 2011; 52:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/47\">",
"      McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med 2010; 17:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/48\">",
"      Greenwood RS, Tennison MB. When to start and stop anticonvulsant therapy in children. Arch Neurol 1999; 56:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/49\">",
"      Sillanp&auml;&auml; M, Schmidt D. Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: A long-term population-based study of childhood-onset epilepsy. Epilepsy Behav 2006; 8:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/50\">",
"      Sirven JI, Sperling M, Wingerchuk DM. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev 2001; :CD001902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/51\">",
"      Camfield P, Camfield C. The frequency of intractable seizures after stopping AEDs in seizure-free children with epilepsy. Neurology 2005; 64:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/52\">",
"      Shinnar S, Berg AT, Mosh&eacute; SL, et al. Discontinuing antiepileptic drugs in children with epilepsy: a prospective study. Ann Neurol 1994; 35:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/53\">",
"      Peters AC, Brouwer OF, Geerts AT, et al. Randomized prospective study of early discontinuation of antiepileptic drugs in children with epilepsy. Neurology 1998; 50:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/54\">",
"      Dooley J, Gordon K, Camfield P, et al. Discontinuation of anticonvulsant therapy in children free of seizures for 1 year: a prospective study. Neurology 1996; 46:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/55\">",
"      Geerts AT, Niermeijer JM, Peters AC, et al. Four-year outcome after early withdrawal of antiepileptic drugs in childhood epilepsy. Neurology 2005; 64:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/56\">",
"      Delgado MR, Riela AR, Mills J, et al. Discontinuation of antiepileptic drug treatment after two seizure-free years in children with cerebral palsy. Pediatrics 1996; 97:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/57\">",
"      Ranganathan LN, Ramaratnam S. Rapid versus slow withdrawal of antiepileptic drugs. Cochrane Database Syst Rev 2006; :CD005003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/58\">",
"      Sillanp&auml;&auml; M, Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain 2009; 132:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/59\">",
"      Berg AT, Vickrey BG, Testa FM, et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 2006; 60:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/60\">",
"      Steinbok P, Gan PY, Connolly MB, et al. Epilepsy surgery in the first 3 years of life: a Canadian survey. Epilepsia 2009; 50:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/61\">",
"      Roulet-Perez E, Davidoff V, Mayor-Dubois C, et al. Impact of severe epilepsy on development: recovery potential after successful early epilepsy surgery. Epilepsia 2010; 51:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/62\">",
"      Oguni H, Olivier A, Andermann F, Comair J. Anterior callosotomy in the treatment of medically intractable epilepsies: a study of 43 patients with a mean follow-up of 39 months. Ann Neurol 1991; 30:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/63\">",
"      Morrell F, Whisler WW, Smith MC, et al. Landau-Kleffner syndrome. Treatment with subpial intracortical transection. Brain 1995; 118 ( Pt 6):1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/64\">",
"      Vigevano F, Bertini E, Boldrini R, et al. Hemimegalencephaly and intractable epilepsy: benefits of hemispherectomy. Epilepsia 1989; 30:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/65\">",
"      Vining EP, Freeman JM, Pillas DJ, et al. Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996. Pediatrics 1997; 100:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/66\">",
"      Vining EP, Freeman JM, Brandt J, et al. Progressive unilateral encephalopathy of childhood (Rasmussen's syndrome): a reappraisal. Epilepsia 1993; 34:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/67\">",
"      Leach JP, Chadwick DW, Miles JB, Hart IK. Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy. Neurology 1999; 52:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/68\">",
"      Dunoyer C, Ragheb J, Resnick T, et al. The use of stereotactic radiosurgery to treat intractable childhood partial epilepsy. Epilepsia 2002; 43:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/69\">",
"      Mizrahi EM, Kellaway P, Grossman RG, et al. Anterior temporal lobectomy and medically refractory temporal lobe epilepsy of childhood. Epilepsia 1990; 31:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/70\">",
"      Maton B, Jayakar P, Resnick T, et al. Surgery for medically intractable temporal lobe epilepsy during early life. Epilepsia 2008; 49:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/71\">",
"      Wiebe S, Blume WT, Girvin JP, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/72\">",
"      Wyllie E, Comair YG, Kotagal P, et al. Seizure outcome after epilepsy surgery in children and adolescents. Ann Neurol 1998; 44:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/73\">",
"      Cossu M, Lo Russo G, Francione S, et al. Epilepsy surgery in children: results and predictors of outcome on seizures. Epilepsia 2008; 49:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/74\">",
"      Wyllie E, Lachhwani DK, Gupta A, et al. Successful surgery for epilepsy due to early brain lesions despite generalized EEG findings. Neurology 2007; 69:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/75\">",
"      Duchowny M, Jayakar P, Resnick T, et al. Epilepsy surgery in the first three years of life. Epilepsia 1998; 39:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/76\">",
"      Fish DR, Smith SJ, Quesney LF, et al. Surgical treatment of children with medically intractable frontal or temporal lobe epilepsy: results and highlights of 40 years' experience. Epilepsia 1993; 34:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/77\">",
"      Jayakar P, Dunoyer C, Dean P, et al. Epilepsy surgery in patients with normal or nonfocal MRI scans: integrative strategies offer long-term seizure relief. Epilepsia 2008; 49:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/78\">",
"      Mani J, Gupta A, Mascha E, et al. Postoperative seizures after extratemporal resections and hemispherectomy in pediatric epilepsy. Neurology 2006; 66:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/79\">",
"      Jonas R, Nguyen S, Hu B, et al. Cerebral hemispherectomy: hospital course, seizure, developmental, language, and motor outcomes. Neurology 2004; 62:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/80\">",
"      Cukiert A, Cukiert CM, Argentoni M, et al. Outcome after hemispherectomy in hemiplegic adult patients with refractory epilepsy associated with early middle cerebral artery infarcts. Epilepsia 2009; 50:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/81\">",
"      Devlin AM, Cross JH, Harkness W, et al. Clinical outcomes of hemispherectomy for epilepsy in childhood and adolescence. Brain 2003; 126:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/82\">",
"      Basheer SN, Connolly MB, Lautzenhiser A, et al. Hemispheric surgery in children with refractory epilepsy: seizure outcome, complications, and adaptive function. Epilepsia 2007; 48:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/83\">",
"      Moosa AN, Gupta A, Jehi L, et al. Longitudinal seizure outcome and prognostic predictors after hemispherectomy in 170 children. Neurology 2013; 80:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/84\">",
"      Delalande O, Bulteau C, Dellatolas G, et al. Vertical parasagittal hemispherotomy: surgical procedures and clinical long-term outcomes in a population of 83 children. Neurosurgery 2007; 60:ONS19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/85\">",
"      Kossoff EH, Vining EP, Pillas DJ, et al. Hemispherectomy for intractable unihemispheric epilepsy etiology vs outcome. Neurology 2003; 61:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/86\">",
"      Schramm J, Kuczaty S, Sassen R, et al. Pediatric functional hemispherectomy: outcome in 92 patients. Acta Neurochir (Wien) 2012; 154:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/87\">",
"      Boshuisen K, van Schooneveld MM, Leijten FS, et al. Contralateral MRI abnormalities affect seizure and cognitive outcome after hemispherectomy. Neurology 2010; 75:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/88\">",
"      Hallbook T, Ruggieri P, Adina C, et al. Contralateral MRI abnormalities in candidates for hemispherectomy for refractory epilepsy. Epilepsia 2010; 51:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/89\">",
"      Duchowny M. Hemispherectomy for epilepsy: when is one half better than two? Neurology 2004; 62:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/90\">",
"      Samargia SA, Kimberley TJ. Motor and cognitive outcomes in children after functional hemispherectomy. Pediatr Phys Ther 2009; 21:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/91\">",
"      Asadi-Pooya AA, Sharan A, Nei M, Sperling MR. Corpus callosotomy. Epilepsy Behav 2008; 13:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/92\">",
"      Cukiert A, Burattini JA, Mariani PP, et al. Outcome after extended callosal section in patients with primary idiopathic generalized epilepsy. Epilepsia 2009; 50:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/93\">",
"      Hoppe C, Poepel A, Sassen R, Elger CE. Discontinuation of anticonvulsant medication after epilepsy surgery in children. Epilepsia 2006; 47:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/94\">",
"      Sinclair DB, Jurasek L, Wheatley M, et al. Discontinuation of antiepileptic drugs after pediatric epilepsy surgery. Pediatr Neurol 2007; 37:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/95\">",
"      Lachhwani DK, Loddenkemper T, Holland KD, et al. Discontinuation of medications after successful epilepsy surgery in children. Pediatr Neurol 2008; 38:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/96\">",
"      Smith ML, Elliott IM, Lach L. Cognitive, psychosocial, and family function one year after pediatric epilepsy surgery. Epilepsia 2004; 45:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/97\">",
"      Sabaz M, Lawson JA, Cairns DR, et al. The impact of epilepsy surgery on quality of life in children. Neurology 2006; 66:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/98\">",
"      Gleissner U, Clusmann H, Sassen R, et al. Postsurgical outcome in pediatric patients with epilepsy: a comparison of patients with intellectual disabilities, subaverage intelligence, and average-range intelligence. Epilepsia 2006; 47:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/99\">",
"      Elliott IM, Lach L, Kadis DS, Smith ML. Psychosocial outcomes in children two years after epilepsy surgery: has anything changed? Epilepsia 2008; 49:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/100\">",
"      Skirrow C, Cross JH, Cormack F, et al. Long-term intellectual outcome after temporal lobe surgery in childhood. Neurology 2011; 76:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/101\">",
"      Viggedal G, Kristjansdottir R, Olsson I, et al. Cognitive development from two to ten years after pediatric epilepsy surgery. Epilepsy Behav 2012; 25:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/102\">",
"      Geva-Dayan K, Shorer Z, Menascu S, et al. Immunoglobulin treatment for severe childhood epilepsy. Pediatr Neurol 2012; 46:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/103\">",
"      Billiau AD, Witters P, Ceulemans B, et al. Intravenous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile. Epilepsia 2007; 48:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/104\">",
"      Mikati MA, Kurdi R, El-Khoury Z, et al. Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature. Epilepsy Behav 2010; 17:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/105\">",
"      Geng J, Dong J, Li Y, et al. Intravenous immunoglobulins for epilepsy. Cochrane Database Syst Rev 2011; :CD008557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/106\">",
"      Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/107\">",
"      Wong-Kisiel LC, McKeon A, Wirrell EC. Autoimmune encephalopathies and epilepsies in children and teenagers. Can J Neurol Sci 2012; 39:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/108\">",
"      Chin RF, Cumberland PM, Pujar SS, et al. Outcomes of childhood epilepsy at age 33 years: a population-based birth-cohort study. Epilepsia 2011; 52:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/109\">",
"      Berg AT, Testa FM, Levy SR. Complete remission in nonsyndromic childhood-onset epilepsy. Ann Neurol 2011; 70:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/110\">",
"      Sillanp&auml;&auml; M, Shinnar S. Long-term mortality in childhood-onset epilepsy. N Engl J Med 2010; 363:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/111\">",
"      Nesbitt V, Kirkpatrick M, Pearson G, et al. Risk and causes of death in children with a seizure disorder. Dev Med Child Neurol 2012; 54:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/112\">",
"      Nickels KC, Grossardt BR, Wirrell EC. Epilepsy-related mortality is low in children: a 30-year population-based study in Olmsted County, MN. Epilepsia 2012; 53:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/113\">",
"      Alfstad K&Aring;, Clench-Aas J, Van Roy B, et al. Psychiatric symptoms in Norwegian children with epilepsy aged 8-13 years: effects of age and gender? Epilepsia 2011; 52:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/114\">",
"      Stevanovic D, Jancic J, Lakic A. The impact of depression and anxiety disorder symptoms on the health-related quality of life of children and adolescents with epilepsy. Epilepsia 2011; 52:e75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/115\">",
"      Rantanen K, Eriksson K, Nieminen P. Cognitive impairment in preschool children with epilepsy. Epilepsia 2011; 52:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/116\">",
"      Taylor J, Jacoby A, Baker GA, Marson AG. Self-reported and parent-reported quality of life of children and adolescents with new-onset epilepsy. Epilepsia 2011; 52:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/117\">",
"      Geerts A, Brouwer O, van Donselaar C, et al. Health perception and socioeconomic status following childhood-onset epilepsy: the Dutch study of epilepsy in childhood. Epilepsia 2011; 52:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/118\">",
"      Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics 2012; 129:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/119\">",
"      Nicolai J, Ebus S, Biemans DP, et al. The cognitive effects of interictal epileptiform EEG discharges and short nonconvulsive epileptic seizures. Epilepsia 2012; 53:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/120\">",
"      Marsh ED, Brooks-Kayal AR, Porter BE. Seizures and antiepileptic drugs: does exposure alter normal brain development? Epilepsia 2006; 47:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/121\">",
"      Berg AT, Zelko FA, Levy SR, Testa FM. Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: a prospective cohort study. Neurology 2012; 79:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/122\">",
"      Vasconcellos E, Wyllie E, Sullivan S, et al. Mental retardation in pediatric candidates for epilepsy surgery: the role of early seizure onset. Epilepsia 2001; 42:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/123\">",
"      Cormack F, Cross JH, Isaacs E, et al. The development of intellectual abilities in pediatric temporal lobe epilepsy. Epilepsia 2007; 48:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/124\">",
"      O'Callaghan FJ, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011; 52:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/32/37386/abstract/125\">",
"      Hermann BP, Seidenberg M, Dow C, et al. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol 2006; 60:80.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6203 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37386=[""].join("\n");
var outline_f36_32_37386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H57948898\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE FIRST SEIZURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prognosis after a first seizure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predictors of recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Long-term remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SEIZURE TYPES AND EPILEPTIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTIEPILEPTIC DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Drug dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7894656\">",
"      Drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7894663\">",
"      Serum levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7894801\">",
"      Compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adding a second AED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Monotherapy versus polytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory monitoring and adverse effects of AEDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Valproic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Carbamazepine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Topiramate and zonisamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Oxcarbazepine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Transmucosal AED administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Rectal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Buccal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Intranasal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Stopping antiepileptic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      EPILEPSY SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Temporal lobectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Extratemporal cortical resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Hemispherectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Corpus callosotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Withdrawal of medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Psychosocial outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H406687746\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Vagus nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H406687830\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H406688021\">",
"      Immunotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H966430\">",
"      LONG-TERM PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H57948898\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6203|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/1/18460\" title=\"table 1\">",
"      Recommended antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/42/2733\" title=\"table 2A\">",
"      Antiepileptic drugs in children part I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/31/2557\" title=\"table 2B\">",
"      Antiepileptic drugs in children part II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/44/32461\" title=\"table 3\">",
"      AED nonAED drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/29/6621\" title=\"table 4A\">",
"      Carbamazepine interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/26/9645\" title=\"table 4B\">",
"      Phenytoin interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/36/39500\" title=\"table 4C\">",
"      Valproate interactions with other AEDs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/921?source=related_link\">",
"      Benign partial epilepsies of childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38071?source=related_link\">",
"      Evaluation and management of suicidal behavior in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3226?source=related_link\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=related_link\">",
"      Management and prognosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21912?source=related_link\">",
"      Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/54/38754?source=related_link\">",
"      Patient information: Epilepsy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/5/19540?source=related_link\">",
"      Patient information: Treatment of seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1128?source=related_link\">",
"      Sudden unexpected death in epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=related_link\">",
"      Treatment of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=related_link\">",
"      Valproate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_32_37387="Causes intermenstrual bleeding";
var content_f36_32_37387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of intermenstrual bleeding",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervicitis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sexually transmitted ulcerations*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Benign growths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical polyps*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometrial polyps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ectropion*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine fibroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvar skin tags, sebaceous cysts, condylomata",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal Gartner's duct cysts, polyps, adenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rarely ovarian or fallopian tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous cesarean delivery incision",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Often cause postcoital bleeding.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37387=[""].join("\n");
var outline_f36_32_37387=null;
var title_f36_32_37388="MODY common gene mutations";
var content_f36_32_37388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F83071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F83071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Maturity onset diabetes of the young: More commonly identified gene mutations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genetic defect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Beta cell defect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of microvascular disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Optimal treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Hepatocyte nuclear factor-4-alpha",
"       </td>",
"       <td>",
"        &lt;10 percent",
"       </td>",
"       <td>",
"        Reduced insulin secretory response to glucose",
"       </td>",
"       <td>",
"        Normal renal threshold for glucose",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Sulfonylureas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Glucokinase gene",
"       </td>",
"       <td>",
"        15 to 31 percent",
"       </td>",
"       <td>",
"        Defective glucokinase molecule (glucose sensor), increased plasma levels of glucose are necessary to elicit normal levels of insulin secretion",
"       </td>",
"       <td>",
"        Mild, stable, fasting hyperglycemia, often diagnosed during routine screening. Not progressive.",
"       </td>",
"       <td>",
"        Generally no",
"       </td>",
"       <td>",
"        Diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Hepatocyte nuclear factor-1-alpha",
"       </td>",
"       <td>",
"        52 to 65 percent",
"       </td>",
"       <td>",
"        Abnormal insulin secretion, low renal threshold for glucose",
"       </td>",
"       <td>",
"        Low renal threshold for glucose, +glycosuria",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Sulfonylureas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Insulin promoter factor 1",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Reduced binding to the insulin gene promoter, reduced activation of insulin gene in response to hyperglycemia",
"       </td>",
"       <td>",
"        Rare, pancreatic agenesis in homozygotes, less severe mutations result in mild diabetes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Hepatocyte nuclear factor-1-beta",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Pancreatic atrophy, renal dysplasia, renal cysts, renal insufficiency, hypomagnesemia",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Insulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Neurogenic differentiation factor-1",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Pancreatic development",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Insulin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf) 2011; 75:422.",
"      </li>",
"      <li>",
"       Ramesh SC, Marshall I. Clinical Suspicion of Maturity Onset of Diabetes of the Young in Pediatric Patients Diagnosed with Diabetes Mellitus, Indian J Pediatr 2011; Dec 10 [ePub].",
"      </li>",
"      <li>",
"       Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011; 343:d6044.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37388=[""].join("\n");
var outline_f36_32_37388=null;
var title_f36_32_37389="Microvascular endpoint and control";
var content_f36_32_37389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intensive glycemic control prevents microvascular disease in patients with type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier plots of aggregate endpoints of microvascular disease in patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study who were randomly assigned to receive either intensive therapy with a sulfonylurea or insulin or to conventional treatment with diet; drugs were added if the patients had hyperglycemic symptoms or fasting blood glucose concentrations greater than 270 mg/dL (15 mmol/L). Intensive therapy was associated with a 25 percent reduction (p = 0.01) in the development of microvascular disease, which was defined as renal failure, death from renal failure, retinal photocoagulation, or vitreous hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:&nbsp;Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37389=[""].join("\n");
var outline_f36_32_37389=null;
var title_f36_32_37390="Contents: Adult procedures";
var content_f36_32_37390=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult procedures",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult procedures",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Airway",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/14/28906\">",
"           Direct laryngoscopy and tracheal intubation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/50/4905\">",
"           Emergent surgical cricothyrotomy (cricothyroidotomy)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anesthesia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/57/33689\">",
"           Infiltration of local anesthetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/51/34618\">",
"           Procedural sedation in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiovascular",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/33/15894\">",
"           Arterial blood gases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/51/26424\">",
"           Arterial catheterization techniques for invasive monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/1/29\">",
"           Complications of central venous catheters and their prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/5/44119\">",
"           Emergency pericardiocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/32/44553\">",
"           Overview of central venous access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/13/6361\">",
"           Peripheral venous access in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/14/3306\">",
"           Placement of jugular venous catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/27/1466\">",
"           Placement of subclavian venous catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/47/3833\">",
"           Principles of ultrasound-guided venous access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/36/25159\">",
"           Technique of pericardiocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/61/21465\">",
"           Temporary cardiac pacing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/35/13877\">",
"           Venous blood gases and other alternatives to arterial blood gases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/22/33124\">",
"           Closure of minor skin wounds with staples",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/7/18553\">",
"           Closure of skin wounds with sutures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/51/31543\">",
"           Dermatologic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/20/40264\">",
"           Skin biopsy techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/32/41478\">",
"           Superficial wound repair with tissue adhesives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ear nose and throat",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/41/1690\">",
"           Approach to the adult with epistaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/47/24309\">",
"           Evaluation and repair of tongue lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/8/9351\">",
"           Subungual hematoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Minor emergency procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/9/30872\">",
"           Assessment and management of scalp lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/22/33124\">",
"           Closure of minor skin wounds with staples",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/7/18553\">",
"           Closure of skin wounds with sutures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/53/16216\">",
"           Digit dislocation reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/47/24309\">",
"           Evaluation and repair of tongue lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/42/38564\">",
"           Fish-hook removal techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/47/13044\">",
"           Hair entrapment removal techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/25/30100\">",
"           Management of zipper injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/51/32567\">",
"           Minor wound preparation and irrigation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/49/8981\">",
"           Ring removal techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/8/9351\">",
"           Subungual hematoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/32/41478\">",
"           Superficial wound repair with tissue adhesives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Musculoskeletal",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/9/23703\">",
"           Digital nerve block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/14/30951\">",
"           Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28564\">",
"           Joint aspiration or injection in adults: Complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/52/23368\">",
"           Joint aspiration or injection in adults: Technique and indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/31/28148\">",
"           Joint aspiration: The dry tap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/9/38038\">",
"           Knee (tibiofemoral) dislocation and reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/8/10378\">",
"           Shoulder dislocation and reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/54/15208\">",
"           Splinting of musculoskeletal injuries",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/6/19561\">",
"           Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obstetrics and gynecology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/11/2232\">",
"           Antepartum fetal heart rate assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/42/13992\">",
"           Approach to episiotomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/54/24420\">",
"           Culdocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/7/26742\">",
"           Mechanism of normal labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/61/36824\">",
"           Ultrasound examination in obstetrics and gynecology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/63/28659\">",
"           Word catheter placement for treatment of Bartholin cysts and abscesses",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/28/44486\">",
"           Slit lamp examination",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/33/15894\">",
"           Arterial blood gases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12663\">",
"           Diagnostic thoracentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/12/1226\">",
"           Placement and management of thoracostomy tubes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/35/13877\">",
"           Venous blood gases and other alternatives to arterial blood gases",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-65E21E32BF-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_32_37390=[""].join("\n");
var outline_f36_32_37390=null;
var title_f36_32_37391="Stationary biking";
var content_f36_32_37391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stationary biking",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The stationary bike provides safe, low impact exercise. The seat height should be adjusted so that the knees are slightly bent at the low point of the downstroke, and no more than 90 degrees flexed on the upstroke. Resistance is increased gradually. Leg cramps during sleep may be prevented by riding the stationary bicycle for a few minutes before retiring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp;Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_32_37391=[""].join("\n");
var outline_f36_32_37391=null;
